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Yeast biotechnology. For thousands of years, yeasts have been used for the making of bread
and the production of fermented alcoholic drinks, such as wine and beer. Saccharomyces cerevisiae
(bakers’ and brewers’ yeast) is the yeast species that is surely the most exploited by man. Nowadays,
Saccharomyces is a cornerstone of modern biotechnology and also a top choice organism for industrial
production of fuels, chemicals, and pharmaceuticals. Today, more and more different yeast species are
explored for industrial applications. This Special Issue “Yeast Biotechnology 2.0” is a continuation of
the first issue “Yeast Biotechnology” (https://www.mdpi.com/books/pdfview/book/324).
Yeast synthetic biology and strain engineering. Recently, important progress has been made
in unlocking the key elements in the biochemical pathways involved in the synthesis of aroma
compounds, as well as in methods to engineer these pathways. Recent advances in bioengineering
of yeasts—including S. cerevisiae—to produce aroma compounds and bioflavors are reviewed in
Reference [1]. This review presents yeast as a significant producer of bioflavors in a fresh context and
proposes new directions for combining engineering and biology principles to improve the yield of
targeted aroma compounds. In a proof-of-concept study, Yarrowia lipolytica was used as a whole cell
factory for the de novo production of long chain dicarboxylic acid (LCDA-16 an -18) using glycerol as the
sole carbon source [2]. The results provide basis for developing Y. lipolytica as a safe biorefinery platform
for sustainable production of high-value LCDCAs from non-oily feedstock. It was demonstrated that a
mutant strain of Y. lipolytica can be used to produce citric acid from renewable carbon sources such as
rapeseed oil, glycerol, and glycerol-containing waste of the biodiesel industry and glucose-containing
aspen waste [3]. The cost-effective production of cellulosic ethanol requires robust microorganisms
for rapid co-fermentation of glucose and xylose. Therefore, a recombinant diploid xylose-fermenting
S. cerevisiae strain was developed by integrating Piromyces sp. E2 xylose isomerase (PirXylA) and
Orpinomyces sp. ukk1 xylose (OrpXylA) in the genome in multiple copies [4]. The development of
a counter-selection method for phenyl auxotrophy could be a useful tool in the repertoire of yeast
genetics. A fluorinated precursor, i.e., 4-fluorophenylpyruvate (FPP), was found to be toxic to several
strains from Saccharomyces and Candida genera [5]. The results show that FPP could effectively be used
for counter-selection, but not for enhanced phenylethanol production.
New developments in efficient biomolecule production. In recent years, interest in the
industrial production of yeast β-glucan has increased since it is an immunostimulant molecule for
human and animal health. The β-glucan yield was optimised during anaerobic fermentation by
evaluating the effect of the carbon source (glucose) and NaCl osmotic stress [6]. A yeast isolate,
selected for its lipolytic activity from a meat product, was characterized as Pichia anomala [7].
Submerged fermentation optimization resulted in a significantly increased production of an
extracellular lipolytic enzyme.
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Fermented beverages: beer, wine and honey fermentation. Nowadays, wild yeasts are explored
for beer and wine making to increase the natural flavor diversity of fermented beverages. Flavor was
added to beer by performing mixed fermentation using non-Saccharomyces cerevisiae/pastorianus
yeasts [8]. For this, a total of 60 strains belonging to the genera Candida, Pichia, and Wickerhamomyces
were evaluated. Several strains produced substantially higher amounts of aroma alcohols and esters
compared to a reference lager yeast strain.
Proline is the predominant amino acid in grape juice, but it is poorly assimilated by wine
yeast under the anaerobic conditions of most fermentation. A novel wine yeast mutant that was
obtained through ethyl methanesulfonate (EMS) mutagenesis, showed a markedly increased proline
utilization and could be used to perform fermentations in nitrogen-limited conditions [9]. Icewine is
a sweet dessert wine produced from grapes naturally frozen on the vine. Since acetic acid is
undesired in Icewine, the yeast cytosolic redox status and its correlation to acetic acid production was
investigated [10]. Yeasts involved in veil formation during the biological aging of Sherry wines are
mainly S. cerevisiae, which are traditionally been divided in the varieties beticus, cheresiensis, montuliensis
and rouxii. A microtiter plate assay method was developed to assure the identification and classification
of veil-forming yeasts during Sherry wine aging [11].
Honey fermentations are usually performed using almost exclusively yeasts in the genus
Saccharomyces. To increase the yeast biodiversity, two strains of Torulaspora delbrueckii were isolated
from the gut of a locally collected honey bee [12]. These wild yeast fermentations displayed better
sensory characteristics than mead fermentations by a champagne yeast, and mixed fermentations of
the wild and the champagne yeast resulted in a rapid industrial fermentation process.
Yeast nanobiotechnology. Clinical needs for novel antifungal agents have increased due to the
increase of people with a compromised immune system, and the appearance of resistant fungi and
infections by unusual yeasts. In recent years, several micro- and nanoscale approaches have been
introduced for antifungal drug discovery. These are reviewed in the last contribution to this special
issue [13].
In summary, this Special Issue compiles the current state-of-the-art of research and technology in
the area of “yeast biotechnology” and highlights prominent current research directions in the fields of
yeast synthetic biology and strain engineering, new developments in efficient biomolecule production,
fermented beverages (beer, wine, and honey fermentation), and yeast nanobiotechnology. We very
much hope that you enjoy reading it and looking forward to the next special issue “Yeast Biotechnology
3.0” to appear in 2019 (https://www.mdpi.com/journal/fermentation/special_issues/yeast3).
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Abstract: Yeast—especially Saccharomyces cerevisiae—have long been a preferred workhorse for the
production of numerous recombinant proteins and other metabolites. S. cerevisiae is a noteworthy
aroma compound producer and has also been exploited to produce foreign bioflavour compounds.
In the past few years, important strides have been made in unlocking the key elements in the
biochemical pathways involved in the production of many aroma compounds. The expression of
these biochemical pathways in yeast often involves the manipulation of the host strain to direct the
flux towards certain precursors needed for the production of the given aroma compound. This review
highlights recent advances in the bioengineering of yeast—including S. cerevisiae—to produce aroma
compounds and bioflavours. To capitalise on recent advances in synthetic yeast genomics, this review
presents yeast as a significant producer of bioflavours in a fresh context and proposes new directions
for combining engineering and biology principles to improve the yield of targeted aroma compounds.
Keywords: aroma; bioflavour; Saccharomyces cerevisiae; synthetic biology; yeast; Yeast 2.0
1. Introduction
An overarching definition for the term “aroma compound” is one that provides a sensorial
stimulus to the olfactory senses and, in certain cases, also the gustatory senses. In literature, it shares
overlapping designations with words like “flavours”, “scents”, “odorants” and “fragrances” and
these terms are often used interchangeably. Aroma compounds have various applications in the food,
feed, cosmetic and pharmaceutical industries [1]. Some compounds have applications beyond their
sense-activating properties, including potential as a biofuel [2], the improvement of the shelf-life of
certain fruit varieties [3] and antimicrobial activities [4]. They can either be desirable or unwanted in
a given product and significant efforts can be made to either eliminate or increase levels depending
on the application. Aroma compounds are rarely perceived in isolation (especially in fermented
foodstuffs) and thus its interaction with other compounds can greatly affect how they are identified.
Although not discussed in this review, a crucial component in the perception of aroma compounds
is the olfactory receptors that recognize odorous ligands. Seminal work done by Nobel laureates
Richard Axel and Linda Buck show the large and diverse nature of these membrane-bound receptors
present in our olfactory neurons which are responsible for the detection of odorants and give rise
to the sense of smell [5]. These receptors can be variably expressed among individuals resulting in
the different perceptions of the same compound by individuals—a key consideration of consumer
preference of foodstuffs [6]. Often neglected and poorly understood are the psychological aspects of
odour perception as it can relate to the associative memory of the individual [7].
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Aroma compounds are structurally remarkably heterogeneous. They can have cyclic or
non-cyclic, saturated or unsaturated, straight-chain or branched-chain structures bearing all kinds
of functional groups (e.g., alcohols, aldehydes, ketones, esters and ethers) and, in some cases,
have nitrogen and sulphur within the structure. Certain aroma compounds are even inorganic
in nature. If made enzymatically, aroma compounds are derived from the pool of precursor molecules
from the core metabolism of the cell (i.e., the carbohydrates, fatty acid, nucleotides and amino acids).
Odour thresholds (i.e., the concentration ranges at which a given aroma compound is detected or
sensed) are key parameters in aroma compound studies.
Most aroma compounds on the market are produced by isolating natural compounds from plant
or animal or by chemical synthesis. However, there is a clear swing away from chemically-produced
aroma compounds and aroma compounds that require extensive extraction from plants or animals
towards the production and use of aroma compounds of (micro) biological origin—also called
bioflavours. This is despite the fact that the chemically produced compounds are identical to their
natural counterparts. Reasons for such a change in market preferences include the fact that chemical
synthesis can often result in environmentally detrimental production processes and in undesired
racemic mixtures. Also, extraction of aroma compounds from plants or animal sources can be
resource-intensive and cost-inefficient because of low yields. In addition, multiple purification steps
often lead to product loss and degradation. Consumer aversion toward chemical compounds relates
especially to food and home-care products. Despite changing preferences in consumer markets,
the financial implication of aroma compound generation remains a strong consideration as those
derived from chemical synthesis are, in general, markedly less expensive than those derived from
natural sources.
In this context, researchers are directing their research efforts toward producing aroma compounds
from microbial sources. This usually involves Escherichia coli or S. cerevisiae as cell factories by
incorporating genes that code for enzymes that are relevant to the production of the given compound
in a recombinant host [8]. Despite the campaigns against genetically-modified organisms (GMOs) in
some sections of global consumer markets, there are numerous food ingredients derived from GMOs
that are commercially-available the world over. However, in the case of such GM food-ingredients
that comply with regulatory safeguards, high yields using cost-effective substrates have not yet been
achieved in many instances.
This review primarily focusses on recent advances in research aimed at the production of aroma
compounds in yeast. This paper is distinct from other published reviews, including those that
extensively covered the use of flavour-active brewing and wine yeasts for the enhancement of the aroma
of beer and wine [9–11]. Here, we focus on the exploitation of two types of yeast precursors which
are responsible for a variety of aroma compounds, namely the aromatic amino acids L-tyrosine and
L-phenylalanine, which are derived from the shikimate pathway and the mevalonate pathway-derived
isoprenoid precursors dimethylallyl pyrophosphate and isopentenyl pyrophosphate.
2. Yeast as a Recombinant Host for Bioflavour Production
Various yeasts—with S. cerevisiae being the model organism—have long been harnessed for
the expression of recombinant genes to enhance endogenous aroma-active metabolites of the host
cells or to produce novel recombinant compounds. The initial reasons why researchers opted for
S. cerevisiae remains true, that is, this yeast species is by far the best-studied unicellular eukaryote
with the genomes of several of its strains fully sequenced [12]; it is a non-pathogen that enjoys GRAS
(generally recognised as safe) status; and it is amenable to genetic manipulation with a wide range
of genetic tools available to alter the genetic make-up of the yeast. S. cerevisiae also possesses an
efficient homologous recombination machinery, which greatly assists stable integration of genetic
elements. This yeast is also the most robust fermenter and laboratory-scale processes can be scaled up
to industrial-level set-ups with relative ease. Some of the abovementioned attributes also hold true
for E. coli. However, as a prokaryote, this bacterium lacks a sophisticated protein-folding mechanism.
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This often leads to the recombinant proteins being insoluble and most likely non-functional and that
might require additional recovery steps for refolding of the protein of interest.
S. cerevisiae is, however, by no means a perfect host; for example, it is not a prolific biomass
producer and the way secreted proteins are glycosylated sometimes lead to pronounced reduction
in bioactivity. There are also reports of recombinant genes that cannot be successfully expressed for
unknown reasons. Regardless of the whether S. cerevisiae turns out to be appropriate as a host to
produce a particular recombinant product, it remains the best starting point to move onwards to
other organisms. A prudent strategy is to examine the expression levels in multiple yeast hosts
and to compare titres of a protein (or metabolite) of interest. Often the methylotrophic yeast
Pichia pastoris (now reclassified as Komagataella phaffii) and Hansenula polymorpha (now reclassified as
Ogataea polymorpha) have shown superior protein and/or metabolite production capabilities owing
to their unusually high biomass production [13]. Many other yeast species with their own special
attributes can (and have) been utilised as a recombinant host with varying outcomes. Examples of such
yeasts include Kluyveromyces lactis, Yarrowia lipolytica and Schizosaccharomyces pombe. The usefulness of
non-Saccharomyces yeasts in the biotransformations of certain substrates into aroma compounds with
whole-cell or resting cell systems are well-documented [14]. This has been a popular way of producing
aroma compounds as it can allow for the assembly of regio- and stereoselective compounds under
mild and mostly solvent-free conditions.
Identification of natural variation within a yeast strains and species has undeniably created a
valuable source of flavour-active strains [15]. The underlying molecular determinants for a particular
phenotype has been elucidated through the advances in ‘omics’ capability. Effective mining of
genes and alternative alleles responsible for a desired phenotype have become common practice,
with access to comprehensive conventional yeast libraries based on mutagenesis, breeding [16],
single gene deletions [17] and overexpression [18]. Yeast libraries have become more sophisticated
and, in many cases, combine the genomic variation generation with a selection for the particular
characteristic of interest. This includes biosensor-enabled directed evolution (discussed in later section
below), rapid genome-wide editing (YOGE) or the complete reconstruction of pathways (VEGAS) and
genomes (Yeast 2.0).
Yeast Oligo-mediated Genome Engineering (YOGE) enables rapid genome engineering by
introducing allele variation by sequential oligonucleotide recombination [19]. Designer synthetic
DNA oligonucleotides allow the combinatorial alteration of pathway genes and, with successive
rounds of transformation, gradually remodel the yeast genome toward the production of a metabolite
or to embody a specific phenotype. Smaller, directed libraries, only altering the pathway(s) of interest,
have been demonstrated with techniques like Versatile Genetic Assembly System (VEGAS). VEGAS
uses the yeast’s innate preference for homologous recombination to assemble complex pathways,
allowing different combinations of the pathway genes to be assembled and subsequently screened for
the best production [20].
A new generation of yeasts might allow us to greatly expand yeast strain diversity beyond what
has resulted to date with directed breeding and natural selection. The revolutionary synthetic biology
initiative known as the Yeast 2.0 project (also known as Sc2.0) was initiated in 2007 [21] to deepen our
understanding of the molecular mechanisms that drives this versatile organism. Upon completion,
the Sc2.0 strain will be world’s first eukaryote with a streamlined chemically-synthesised genome.
In addition to the removal of repetitive sequences, the liberation of a codon and the introduction
of hundreds of watermark sequences, LoxPsym sequences were introduced at the 5′-ends of all
genes considered individually non-essential [22,23]. These sites allow for inducible homologous
recombination downstream of all non-essential genes, mediated by the action of the site-specific
Cre-recombinase. Upon activation of the site-specific Cre-recombinase, homologous recombination
is promoted between these LoxPsym sites, resulting in rapid gene deletion, duplication or inversion.
This process—known as SCRaMbLE (Synthetic Chromosome Rearrangement and Modification by
LoxPsym-mediated Evolution)—allows for the rapid synthetic rearrangement and evolution of
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the yeast genome [24] (Figure 1). In addition to this novel way of producing large libraries of
genomically-divergent yeasts, SCRaMbLE also allows us to produce and explore minimum eukaryotic
genomes for the first time. These libraries will be valuable assets in the screening for interesting
phenotypes, like aroma compound production and the elucidation of the underlying principles
governing these production pathways.
Figure 1. Depiction of aroma compound pathway optimisation through loxPsym-mediated
rearrangement of synthetic chromosomes (SCRaMbLE) in yeast. (A) A yeast containing synthetic
versions of their respective chromosomes with multiple loxPsym sequences would be subjected to the
actions of the loxPsym-specific Cre recombinase. (B) The subsequent insertions, duplications, deletions,
inversions and other genetic alterations will allow for the generation of an instantly-made library of
yeast that have tremendous diversity in their respective genetic backgrounds (C) allowing for the
screening of yeast with preferred phenotypes. By introducing metabolite pathway genes, flanked by
loxP sequences, copy number optimised pathways can be assembled into the generated library. At the
time of writing this review, 6 of the 16 chromosomes have been fully synthesized, with the rest at various
stages of construction and debugging [25]. The strains harbouring these chromosomes (or combinations
thereof) can currently be used for SCRaMbLE-based phenotype generation experiments.
Irrespective of the specific yeast strain used, optimisation of the recombinant production of a given
protein or metabolite would require the systematic improvement of the properties of the recombinant
host using analytical and computational methods to quantify fluxes and their regulation. The following
guiding principle questions, regarding global and pathway-specific metabolic engineering, have been
proposed previously [26]: (i) can the precursor and/or cofactor supply be increased?; (ii) can the
heterologous expression of non-native genes be different or the expression thereof be improved?;
(iii) can pathways that compete for the same precursors and co-factors be blocked or down-regulated?;
(iv) are transcriptional regulators known and what would be the effect if they are overexpressed?;
and (v) can the enzyme specificity be improved? Most of these questions are directly applicable in
improving a yeast’s ability to produce aroma compounds. Below we will discuss the work researchers
have undertaken in addressing these questions in order to increase the levels of phenylpropanoid and
terpenoid production in yeast.
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3. Yeast Precursors Utilised
3.1. Phenylpropanoids
The aromatic amino acids L-phenylalanine, L-tyrosine and L-tryptophan serve as the precursors
to many compounds of commercial interest [27]. More specifically, L-phenylalanine, L-tyrosine
provide the precursors for a large group of compounds called phenylpropanoids—of which many
have aroma-active properties. The biosynthesis of the aromatic amino acids proceeds via the
shikimate pathway [28] (Figure 2). It is a seven-step metabolic pathway leading to the production
of chorismate, the common aromatic precursor to all three amino acids. The shikimate pathway is
initiated with the condensation of phosphoenolpyruvate (PEP)—an intermediate in the glycolysis
pathway—and erythrose-4-phosphate (E4P)—an intermediate in the pentose phosphate pathway—to
generate 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP). Chorismate is the branching node,
where L-tryptophan is separated from the other two amino acids as chorismate is converted to
prephenic acid (the precursor molecule of L-phenylalanine and L-tyrosine) by a chorismate mutase.
Subsequent decarboxylation and transamination events lead to the production of L-tyrosine and
L-phenylalanine. In general, intracellular L-tyrosine levels in S. cerevisiae are about ten-fold higher than
L-phenylalanine with L-tryptophan 10 times less than L-phenylalanine [29].
Figure 2. Biosynthetic pathway for phenylpropanoids. Yeast can synthesize all three aromatic
amino acids (L-phenylalanine, L-tyrosine and L-tryptophan) via the shikimate pathway but have
few processing capabilities beyond utilising them in peptide synthesis or their catabolism via the
Ehrlich pathway (which can produce the aroma compound 2-phenylethanol). S. cerevisiae and other
yeast have been exploited to convert their free aromatic amino acids to compounds with aroma
properties. The recombinant enzymes that have been incorporated in yeast to convert precursors to
aroma compounds of commercial value are shown below each recombinant metabolite.
S. cerevisiae has a limited capacity to process aromatic amino acids beyond using them for protein
synthesis. Pathways involved in using L-tyrosine and L-phenylalanine as precursors have been
8
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incorporated into yeast to produce a multitude of compounds and of these, the phenyl ring structure
represents a central feature (Figure 2). A key aroma compound derived from the shikimate pathway
is that of vanillin (imparting vanilla flavour) and has been the subject of many investigations in the
past due to its high value and wide use. Vanillin is not synthesised from any of the aromatic amino
acids, but from an intermediate in the shikimate pathway, namely dehydroshikimate. The first report
of vanilla production by yeast used three recombinant genes in the fission yeast S. pombe to transform
dehydroshikimate to vanillin [30]. In the same study, S. cerevisiae was also used, but an additional
activation enzyme was needed. Vanillin is moderately toxic to yeast cells (it represses translational
processes [31]). It was shown that adding a glycosyl moiety, by expressing a 1-UDP-glycosyltransferase,
leads to the conversion of vanillin to vanillin-glucoside (VG), which markedly increased production
levels. Remarkable improvements in VG titres have been achieved with rational engineering design
approaches: in silico metabolic engineering algorithms have been implemented to identify yeast target
genes that could enhance productivity [32]. Manipulations of two of the identified targets (PDC1 and
GDH1) led to a five-fold improvement of VG yields and was attributed to the recycling of the supply
of cofactors. Additional modelling-based methodologies underlined the utility of in silico design for
improvement in VG levels [33,34].
The pathway for the production of p-hydroxycinnamic acid (also known as p-coumaric acid),
which imparts a cinnamon aroma, has been incorporated in S. cerevisiae [35]. This simply involved
the incorporation of various phenylalanine ammonia-lyases (PAL)/tyrosine ammonia-lyases (TAL)
which deaminate L-tyrosine. Several metabolic engineering strategies have proven successful in
enhancing p-hydroxycinnamic acid along with the levels of so-called trans-cinnamic derivatives (which
include cinnamaldehyde, cinnamyl alcohol and hydrocinnamyl alcohol) [36]. These strategies involved
removing known feedback-regulated steps of aromatic amino acid biosynthesis and directing the
flux towards the production of these trans-cinnamic compounds by side-tracking the decarboxylation
step of the competing Ehrlich pathway. A phenylacrylic acid decarboxylase (PAD1) is thought to be
responsible for the decarboxylation of trans-cinnamic derivatives, as a pad1 knockout strain showed
no endogenous activity on trans-cinnamic acid and p-hydroxycinnamic acid [37]. Nevertheless,
the trans-cinnamic derivatives are converted to less toxic compounds by the yeast via unknown
mechanisms [36]. It was found, similar to vanillin, that by adding a glycosyl moiety to trans-cinnamic
acid catalysed by an UDP-glucose:cinnamate glucosyltransferase reduces its toxicity and led to
increased levels.
A recent addition to the phenylpropanoid aroma compounds that are recombinantly produced
in yeast is that of raspberry ketone [4-(4-hydroxyphenyl)butan-2-one] [38]. This involved
the incorporation of a four-gene pathway from various organisms into yeast that converted
L-phenylalanine and L-tyrosine to raspberry ketone. Testing various enzyme combinations and
fusions resulted in higher levels of raspberry ketone.
Improving yields of 2-phenylethanol (2-PE)—a compound with a rose-like aroma—has been
investigated extensively. 2-PE is the fusel alcohol of L-phenylalanine and of the four phenylpropanoid
aroma compounds discussed, 2-PE does not require the expression of recombinant genes as
it arises from the catabolism of L-phenylalanine via the Ehrlich pathway. This includes its
deamination, decarboxylation and reduction that are conducted by ARO9, ARO10 and various alcohol
dehydrogenases (ALD1-5) in S. cerevisiae respectively. Metabolic engineering efforts to increase 2-PE
levels included the streamlining the Ehrlich pathway which involved the overexpression of ARO9
and ARO10 with the concomitant removal of a competing phenylacetaldehyde oxidase (ALD3) [39].
A transcription factor (ARO80) is known as an activator of the ARO9 and ARO10 genes and its
overexpression, together with ARO9 and ARO10, led to a four-fold increase in 2-PE levels.
Efforts have also been made to increase the intracellular levels of the precursors of the shikimate
pathway PEP and E4P. Especially targeting E4P, which has lower intracellular concentrations than
PEP [40] would result in an equal balance of the two precursors and could facilitate improved flux
toward aromatic amino acid production. Attempts thus far to increase levels of E4P have involved
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alternations within the pentose phosphate pathway [41]. It was shown that the deletion of the
glucose-6-phosphate dehydrogenase (ZWF1) gene and overexpression of the transketolase (TKL1)
gene reversed the flux from the glycolytic intermediates and led to a higher (~eight-fold) increase in
E4P levels [42].
Some non-Saccharomyces yeasts like Ashbya gossypii [43], Kluyveromyces marxianus [44] and Candida
glycerinogenes [45] have been investigated for 2-PE production with yields reported that were greater
than for S. cerevisiae. Similarly, as with S. cerevisiae, overexpressing the genes involved in the Ehrlich
pathway have led to increased levels in K. marxianus [44], but not A. gossypii [43].
Media composition, especially adding L-phenylalanine, have shown in many cases to enhance the
production of polypropanoids [46,47]. This implies that the yeast precursor is still a major bottleneck
for phenylpropanoid production. High-throughput mass spectrometry experiments conducted on
a yeast gene deletion library, which determined the intracellular concentration of each amino acid,
revealed that certain gene knock-outs resulted in a two to four times higher intracellular concentration
of L-phenylalanine than the wild type [29]. Many of the strains carrying these respective gene deletions
also had an increased level of L-tyrosine and L-tryptophan suggesting that these gene products might
have a putative role in regulating the shikimate pathway, but in most cases no obvious connection has
ever been reported.
3.2. Terpenoids
Terpenoids (also called terpenes or isoprenoids) are the largest and most diverse group of
natural compounds. They are derived from the basic five-carbon (C5) precursor unit isopentenyl
diphosphate (IPP) and its double-bond isomer dimethylallyl diphosphate (DMAPP) that can be
assembled and modified in over 60,000 different types of terpene-like structures. Apart from the
exceptional flavour qualities of many terpenoids, certain terpenoids have promising applications in
biofuel and antimicrobial research [48].
Terpenoids are either produced via the mevalonate biosynthesis pathway (MVA) or the
2-C-methyl-D-erythritol-4-phosphate pathway (MEP) with the former being the best-studied and found
in yeast. In this pathway, acetyl-CoA is condensed to produce the universal isoprene building unit (C5),
isopentenyl diphosphate (IPP). Subsequent condensations conducted by prenyltransferases of IPP
and DMAPP result in terpenoid precursors called polyisoprenoid diphosphates of different lengths:
geranyl diphosphate (GPP) for monoterpenoids (C10), farnesyl diphosphate (FPP) for sesquiterpenoids
(C15), geranylgeranyl diphosphate (GGPP) for diterpenoids (C20), 2 units of FPP for triterpenoids (C30)
and 2 units of GGPP for tetraterpenoids (C40). The C30 and C40 precursors lead to the biosynthesis of
sterols and carotenoids, respectively. Cyclisation of the abovementioned polyisoprenoid diphosphates
are catalysed by a large group of enzymes called terpene synthases to generate terpenoids with single
or multiple ring structures (with some remaining open). These enzymes often display a high level of
promiscuity with regards to their substrate preference leading to the large diversity among terpenoid
structures. In addition, tailoring enzymes like oxygenases, methyltransferases, acetyltransferases and
glycosyltransferases can add functional groups to different positions of the terpenoid structure.
As mentioned, yeast including S. cerevisiae, do possess an MVA pathway but does not have terpene
synthases that are able to produce monoterpenoids, sesquiterpenoids and diterpenoids. S. cerevisiae
implements the MVA pathway to produce sterols (specifically ergosterol) that are structural elements
of the cell membrane and impart modulation to the membrane fluidity. It is an essential pathway for
yeast as strains with mutated genes in this pathway require exogenous sterol for survival [49].
Significant efforts have been made to create a yeast platform that would be able to produce
terpenoids as discussed in multiple papers and reviews [50–54] (Figure 3). A yeast without any
modification within its MVA pathway would produce negligible levels of recombinant terpenoids.
A key strategy to improve levels would be to direct carbon flux away from producing sterols without
the complete elimination of the pathway. On a transcriptional level, the native promoter of the squalene
synthase ERG9 gene (that encodes the enzyme that catalyses the first reaction of converting farnesyl
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diphosphate to ergosterol) was replaced with repressible promoters which led to subsequent lower
concentrations of ERG9, facilitating the increased levels of recombinant terpenoid production [55].
Recently, a degradation tag attached to ERG9 was shown to destabilise the protein, which also led to a
dramatic improvement in recombinant terpenoid production without compromising the cell viability
to any significant extent [56].
The overexpression of a truncated version of the hydroxymethylglutaryl-CoA reductase (tHMG1),
that is devoid of its transmembrane moiety and is thus present in the cytosol, led to an increased
amount of squalene. This confirmed that HMG-CoA reductase, the enzyme that produces mevalonate,
is a rate-limiting step [57]. Many subsequent attempts using yeast to produce recombinant terpenoids
contain this feature [58,59]. Similarly, the overexpression of the ERG20 gene encoding an enzyme with
both dimethylallyltranstransferase and geranyltransferase activities and the sterol regulator upc2-1 [60]
has generally led to improved yields in recombinant terpenoid production.
Improving the intracellular levels of the precursor molecule acetyl-CoA—an intermediate central
to many metabolic pathways—has also been investigated. In one study by Meadows et al. [61],
a S. cerevisiae strain was developed by completely overhauling the native metabolic network involved
in acetyl-CoA supply by incorporating several synthetic pathways which directly resulted in increased
recombinant terpenoid levels.
Figure 3. Manipulations in mevalonate pathway for recombinant terpenoid production.
Enzymes directly involved in the MVA pathway of S. cerevisiae have been upregulated, downregulated
or altered to increase the flux towards the production of various terpenoid-based aroma compounds.
Additional recombinant enzymes needed for the catalysis of the terpenoid production are shown
in orange with the respective aroma compounds being produced. Adapted from [53]. ERG10,
acetyl-CoA C-acetyltransferase; ERG13, hydroxymethylglutaryl-CoA synthase; HMG1/HMG2,
hydroxymethylglutaryl-CoA reductase 1/2; ERG12, mevalonate kinase; ERG8, Phosphomevalonate
kinase; ERG19, mevalonate diphosphate decarboxylase; IPP, isopentenyl diphosphate; DMAPP,
dimethylallyl diphosphate; IDI1, isopentenyl diphosphate isomerase; ERG20, geranyl/farnesyl
diphosphate synthase; BTS1, GGPP synthase; ERG9, squalene synthase; crtYB, phytoene synthase and
lycopene cyclase; crtI, crtE phytoene desaturase; geranylgeranyl diphosphate (GGPP) synthase.
It was shown that by fusing mitochondria signals to sesquiterpenoid synthases, along with the
introduction of a recombinant farnesyl diphosphate synthase, resulted in a marked increase of the
citrus aroma compound valencene [62]. This demonstrates the prowess of compartmentalisation
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approaches where enzymes, substrates and intermediates are close to each other and competing
pathways in the cytosol are avoided.
Other successful attempts to produce terpenoids in yeast include the highly sought-after
nootkatone, which imparts a strong grapefruit aroma [63]. This was achieved in P. pastoris with
a similar engineering strategy which has been proven fruitful for S. cerevisiae to overexpress a truncated
version of its HMG1 gene to improved levels.
Carotenoids (specifically β-carotene) have also been produced in S. cerevisiae by expressing
carotenogenic genes from strains from the ascomycete Xanthophyllomyces dendrorhous (previously
Phaffia rhodozyma) [64]. Increased concentrations of β-carotene were observed when the BTS1 gene
encoding a geranylgeranyl diphosphate synthase was overexpressed. These strains appear bright
orange and although itself not an aroma compound, β-carotenes do serve as a substrate for carotenoid
cleavage oxygenase, which releases compounds known as apocarotenoids. The expression of a
carotenoid cleavage oxygenase from Petunia hybrida in a strain already producing β-carotene, led to
the release of detectable levels of a compound known as β-ionone, which has a highly desired
violet scent [65]. Interestingly, a polycistronic version (genes separated from each other by viral T2A
sequences) of the abovementioned carotenogenic genes was successfully expressed in yeast [66].
Assessing the feasibility of replacing elements of the MVA with that of the MEP
pathway—theorized to yield a higher stoichiometric maximum plus having a lower requirement
for oxygen—has been investigated. The yeast strain was developed where its MVA pathway was
replaced with an MEP pathway. The resulting strain showed a slight growth defect made less biomass
compared to the wild type, implying slight incompatibility [67].
4. Biosensing Aroma Compounds in Yeast
Rational engineering strategies to redistribute carbon flux towards the production of a specific
metabolite or the introduction of novel synthetic biosynthesis pathways, have been successfully
employed in the past to produce the desired molecule of interest [68,69]. Aroma compound production
has also benefitted from these methodologies when ample precursor molecules are available [70].
However, the inherent volatile nature of some precursor molecules have excluded them from
many directed evolution endeavours, as these are mostly limited to growth-selectable phenotypes,
with limited high-throughput possibilities for the rapid screening of mutant libraries [71].
A promising, more recent addition to the synthetic biologist’s toolbox is biosensors [72].
These genetic circuits translate a metabolic ‘input’ into a measurable ‘output’ signal like fluorescence;
decoupling metabolite production from cellular growth. Biosensor designs are becoming increasingly
more complex, with higher order circuits combining multiple interacting components and logic
gate arrays to allow enhanced pathway regulation and output sensitivity. Table 1 shows some
recent examples of biosensors developed for the direct or indirect detection of aroma compounds
produced in yeast.
In one, early biosensor study [73], it was shown how biosensors can be employed to develop
a high-throughput screen for yeast strains producing high concentrations of β-phenylethanol.
This indirect method used the flux through the Ehrlich pathway as an indicator of high end-product
concentrations. Endogenous biosensors have previously been employed to increase the flux toward
the production of precursors of aroma compounds in yeast [74–77]. Synthetic biosensors have been
constructed to allow feedback-regulated evolution of high IPP-producing strains [74].
There is much more scope for the development of aroma biosensors for yeast when compared
to the diversity of available bacterial sensors, with E. coli sensors allowing for the detection of
benzaldehyde, cinnamaldehyde, salicylaldehyde, syringaldehyde and vanillin [78,79]. Attempts have
been made to translate some of these concepts in an endeavour to sense aroma compounds produced
by bioengineered yeast, using encapsulated p-coumaric acid-sensing E. coli to screen for yeast cells
producing p-coumaric acid [80].
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Table 1. Examples of yeast biosensors to detect phenylpropanoids and terpenoids produced in
Saccharomyces cerevisiae.
Aroma Compound Molecule(s) Sensed Description Reference
Shikimate pathway
β-phenylethanol Aromatic amino acids
Allosteric transcription factor sensor. Transcriptional
regulation LacZ reporter gene by the aromatic amino
acid responsive ARO9 promoter. Increased




Enzyme-coupled sensor. Highly yeast-active
heterologous L-tyrosine hydroxylases were
identified, based on increased betaxanthin
fluorescence intensities in yeast expressing the
plant DOPA dioxygenase.
[70]
p-Coumaric acid p-Coumaric acid
Exogenous bacterial sensor. Droplet sorting of
encapsulated p-coumaric acid producing
yeast cells and p-coumaric acid sensing E. coli cells,




Heterologous allosteric transcription factor. Used an
Acinetobacter sp. transcriptional regulator to drive




Recombinant allosteric transcription factor sensor.
Used a bacterial FapR transcription factor and FapO
operator pair to identify strains from a genome-wide




Synthetic transcription factor to allow
feedback-regulated evolution of phenotype. Higher
intracellular IPP concentrations resulted in increased




In only the past decade has research been focussed on incorporating biochemical pathways in
yeast to produce key aroma compounds. Beyond proving the concept—as with all biotechnological
approaches—researchers will always try to find ways to improve the overall yield of a given aroma
compound. Simple fermentation optimisation has proven, on many occasions, to be impactful but the
most profound improvements were achieved with the metabolic engineering of the yeast. Metabolic
engineering can be defined and categorised in many ways, but, it is generally regarded as any kind
of genetic modification applied onto a cell that would cause a preferential change in its phenotype.
It is a cornerstone characteristic of synthetic biology: a confluence of many different streams of science
and engineering with the scope of building artificial biological systems. Elements that appear to be
central to the field of synthetic biology have been part of science for decades: the earliest recombinant
genes that were expressed in E. coli (that of human insulin and the human growth hormone) were
indeed chemically synthesised in the 1970s (before the advent of PCR-based cloning). Even slightly
more complex genetic elements like synthetic promoters have been described to function in yeast
since the late 1980s [81]. Yet, it is well-recognised that the dramatic drop in the cost for synthesising
DNA-sequences in the past decade was the catalyst to jump-start the current wave of synthetic biology.
Large pieces of DNA can now be designed and purchased from a multitude of companies which has
drastically alleviated the often-time-consuming effort of constructing genetic elements.
As has been explained in instructive reviews [82,83], central for the rapid advancement of
synthetic biology is the application of the concept of design-build-test-learn (or DBTL) (Figure 4)
to address biological and/or engineering questions. This idea, adapted from other engineering fields,
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aims to streamline and accelerate the iterative process of improving a biological system as well as
to minimise human input to eliminate bias in the interpretation of the output. As mentioned by
Hollywood et al. [84], the testing part is often reliant on a high-throughput screen which makes this
component—if available—often the most time-consuming and costly. This is particularly true for the
determination of most aroma compounds, as the screening of millions of cells and assessing individual
cells for aroma compound production is not yet feasible. This is why the development of aroma
biosensors with appropriate sensitivity and specificity is most desired. A desired attribute of the
biosensor would be for it to have a ‘dynamic range,’ that is, besides detecting aroma compounds it
would have the ability to provide a differing signal depending on the concentration of the aroma.
This might be achieved, although not yet tested in such a capacity, by coupling either a bioluminescence
resonance energy transfer (BRET)-based sensor [85] or metal oxide [86] sensor, developed to detect
volatile organic compounds, within a high-throughput screening process to test a yeast library.
Figure 4. An example of how DBTL could be applied to build a yeast with increased production levels
of raspberry ketone. During the “design” part of the project, researchers would need to plan all the
experiments with a particular focus on the types of metabolic engineering tactics that will be employed
to alter the target pathway within the yeast. The raspberry ketone synthesis pathway has already
been introduced in S. cerevisiae [29], thus an avenue to follow is to test several similar enzymes from
different organisms to assess their compatibility within the pathway. The “build” part encompasses all
the aspects of constructing the strains that need to be tested. Multiplex CRISPR-based techniques for
yeast have been developed and could easily be adapted to introduce combinations of the recombinant
raspberry ketone pathway genes [76,77]. CRISPR-based techniques enjoy the benefit of its precision in
editing the genome that would lead to minor modifications being made to the genome. The system can
also allow for the strain to be ‘markerless’—free of any antibiotic resistance genes normally used in
conventional genetic manipulations. Additional mutagenesis, ranging from chemical mutagenesis to
using a strain in which one could induce SCRaMbLE, could be included which will add more genetic
diversity to the strains that need to be tested. The ‘testing’ part would, in most cases, involve some level
of culturing of the strains coupled with determining the levels of the metabolite of interest. This would
require high-throughput screening machinery. Raspberry ketone titres will need to be measured with
mass spectrometry-based techniques. Eventual sequencing of high performers would be needed to
ascertain what mutagenesis allowed for the superior production levels. Once the testing is concluded,
the ‘learning’ part—where interpretation of the data (in this case identifying strains with superior
raspberry ketone titres) and assessment of how one could improve upon the titres based on which
strain performed better—is executed before commencing with a new cycle of DBTL. This is a simple
example of a single iteration of DBTL with each step reliant on human intervention. The eventual
goal—especially with the advent of genome or biofoundries—is to curtail human input and allow for
automation and machine learning to dominate proceedings. Adapted from [83,87].
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As has been discussed in this review, nearly all of the reported metabolic engineering approaches
for improvement in aroma compound production have been by way of rational design principles.
This is because the pathways of the precursors have been largely elucidated and known bottlenecks or
rate-limiting steps have been identified. Rational design will continue to be a potent pursuit as we learn
more about relevant pathways and the regulation thereof. However, for fast-tracking improvements
in aroma compound production in yeast, applying a DBTL-type approach holds a lot of potential.
Indeed, it is perfectly suited for such an approach to target the production levels of a single metabolite.
This is in contrast, however, to recent work in aroma compound development in yeast as part of an
alcoholic beverage set-up, where hops flavour (a combination of geraniol and linalool) was introduced
in yeast for beer production [87]. An elegant DBTL approach was followed to build strains with ideal
hops flavour (similar to commercial beer). Although the researchers were eventually successful in
obtaining strains that could ferment malt and impart hops flavour, many of their initial strain building
attempts failed as strains selected for ideal hops flavour could not completely consume the malt sugars.
This was unintentional and not easily explained but emphasised the limitations of employing DBTL
on strains with multiparametric purposes. Nevertheless, to date, no DBTL-like approach has been
performed on yeast for the sole purpose of producing enhanced levels of an aroma compound.
A key element complementary to metabolic engineering within the synthetic biology realm, is that
of individual enzyme engineering in order to alter the catalytic activity and increase the flux toward
the production pathway of a given aroma compound [88]. Few cases exist where mutants of the
enzymes within certain pathways were examined for improved production. Site-directed mutagenesis
in enzymes involved in the MVA pathway has led to the general increase in terpenoids [89] or just
specific classes of terpenoids [90]. Although not studied in yeast, mutants of a sesquiterpenoid synthase
(TPS24) from Syrah grape (Vitis vinifera) produced significantly higher levels of α-guaiene, which is a
non-enzymatic precursor of rotundone, the active compound of black pepper [91].
There are also non-metabolic engineering-based challenges that exist in order to enhance aroma
compound development. The overwhelming majority of interesting aroma compounds are derived
from plants and it would thus make sense to explore the genes relevant to the production of the
given product and assess their suitability within a recombinant yeast host. Yet, genomic data
of many plants are still lacking and even though the enzymes involved in the production of a
certain aroma compound are known, the genes that encode these enzymes have still not been
identified. The complexities in assembling plant genomes explain the current dearth of publicly
available fully-annotated whole genome sequences of plants [92,93] but more options will open up
as more become available. Many recombinant pathways (like with p-coumaric acid and raspberry
ketone) employed Arabidopsis thaliana genes, mainly due its sequence availability as it is a model
organism and hardly because it is the ‘best’ enzyme candidates. Related to this is the mystery of
how certain recombinant genes are expressed in high levels whereas similar ones are expressed
poorly [94]. This underlines the utility of still employing a trial-and-error approach and exploring
many recombinant genes to assess their ability to be expressed in yeast.
Non-Saccharomyces yeast have been shown, on many occasions, to be a more suitable host for
the production of aroma compounds. However, the tools available to manipulate these so-called
“non-conventional” yeast are not as extensive. As discussed in Wagner and Alper [95] tremendous
strides have been made in this field as even CRISPR-based tools have been developed for a number of
species. Further development is required, with a possible aim to incorporate large synthetically
designed genetic elements in the non-Saccharomyces genomes similar to the SCRaMbLE-set-up
developed for S. cerevisiae.
As already shown with the development of a hoppy yeast [87], many of the strategies employed
and discussed here could easily be used to engineer aroma development in strains involved in the
fermented beverage industry [96–98]. The engineering strategies should not, however, interfere with
all other processes involved in fermentation. Strains tailor-made to produce certain aroma compounds
could streamline the fermentation process. An ultimate goal would be to have a winemaker or
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brewmaster use a specific yeast strain to achieve a more predictable outcome in the aroma profile of
the fermented product. An example would be to develop a yeast strain that could synthesise the oak
lactones found in oak barrels. Its biosynthesis pathway is complicated and fine-tuning within the
yeast strain would be necessary but such a strain would eliminate the use of expensive oak barrels in
winemaking and dramatically shorten the production time.
Recombinant aroma compound development in yeast is still in its infancy especially when
compared to chemical synthesis or extraction from plants—both methods in their various incarnations
are centuries old. The field of synthetic biology is primed to evolve by aiming to achieve levels that can
compete with the status quo. An even newer competitor is that of cell-free enzyme pathways [99] and
it would be interesting to witness how each approach would evolve to compete in producing aroma
compounds in a cost-effective manner. A revolutionary step, as one could imagine, would be a large
yeast fermentation set-up producing a given aroma compound eventually replacing the acres and
acres of flower fields and all the required inputs, dedicated for eventual aroma compound extraction.
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Abstract: This proof-of-concept study establishes Yarrowia lipolytica (Y. lipolytica) as a whole cell
factory for the de novo production of long chain dicarboxylic acid (LCDCA-16 and 18) using glycerol
as the sole source of carbon. Modification of the fatty acid metabolism pathway enabled creating
a pool of fatty acids in a β-oxidation deficient strain. We then selectively upregulated the native
fatty acid ω-oxidation pathway for the enhanced terminal oxidation of the endogenous fatty acid
precursors. Nitrogen-limiting conditions and leucine supplementation were employed to induce fatty
acid biosynthesis in an engineered Leu- modified strain. Our genetic engineering strategy allowed a
minimum production of 330 mg/L LCDCAs in shake flask. Scale up to a 1-L bioreactor increased the
titer to 3.49 g/L. Our engineered yeast also produced citric acid as a major by-product at a titer of
39.2 g/L. These results provide basis for developing Y. lipolytica as a safe biorefinery platform for the
sustainable production of high-value LCDCAs from non-oily feedstock.
Keywords: Yarrowia lipolytica; long chain dicarboxylic acid; building blocks; citric acid; glycerol;
genetic and metabolic engineering; fermentation; bioconversion
1. Introduction
Growing demand for petroleum dependent chemicals, in addition to surging environmental
concerns, has inspired increased use of renewable resources. The sustainable production of monomers
and polymers is of particular interest for reducing petroleum feedstock dependency and CO2 emissions.
The environmental cost of using petrochemical polymers can be lowered by replacing them with
bio-based polymers, produced through fermentation using biomass or byproducts as feedstock [1].
Glycerol is the main byproduct of biodiesel production process, and its efficient valorization would
help offset biodiesel production costs. Such bioconversion also decreases the environmental impact of
waste streams. Despite various technological successes, it is still challenging to establish an integrated
bioprocess, at commercial scale, for the valorization of such hydrophilic substrates into desirable
compounds [2]. Nonetheless, the development of high productive strains and high value co-products
advance the commercialization of such bioprocesses.
Bulk monomers of high value are commonly targeted co-products for industrial biotechnology.
LCDCA monomers have a much higher value than regular free fatty acids. These building block
monomers are used to make various polyamides, polyester and, polyurethanes [3] in the bio-plastic
and coating industries. Their use enables the synthesis of various novel polymers with enhanced
Fermentation 2017, 3, 40; doi:10.3390/fermentation3030040 www.mdpi.com/journal/fermentation22
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hydrolytic stability, solvent resistance, optical clarity, and flexibility properties [4]. They can also be
used in the automotive, food, medical, and chemical industries as adhesives, corrosion inhibitors,
lubricants, fragrances, surfactants, antiseptics, and personal care ingredients [5]. Non-renewable
petroleum-derived alkanes or plant-derived fatty acids that compete with food production are currently
the main hydrophobic feedstock for the production of these multi-purpose building blocks [6–8].
A chemical-based approach for the production of these monomers from hydrophobic substrates
has already been established. For instance, the chemical degradation of plant oil fatty acids to
LCDCAs via self-metathesis reaction is one of the major chemical-based production routes [9].
The chemical-based production of LCDCA is an energy-intensive and environmentally unfriendly
process, which requires expensive catalysts and cost intensive purification steps due to the generation
of various by-products. Contrary to chemical approaches, the bio-based approach offers higher
selectivity and sustainability [10]. The microbial production of short to medium chain DCAs has been
reviewed and partly industrialized [10–13]. In terms of LCDCAs, the major producing strain is a
pathogenic yeast, Candida tropicalis [14].
The biosynthetic pathway to LCDCA monomers is mediated by the P450 system. In general,
cytochrome P450 monooxygenases (P450 or CYP) systems are involved in the oxygenation of
various hydrophobic compounds. For instance, the CYP52 family performs terminal ω-oxidation
of alkanes, alcohols, and fatty acids of various chain lengths [15]. This family belongs to yeast
species, including Candida and Yarrowia, and is comprised of members whose products have different
specificities for alkanes versus fatty acids [16,17]. The yeast CYP52 has higher productivity than the
bacterial ω-hydroxylases [18]. Terminal oxidation by P450 is carried out at high regioselectivity and
stereoselectivity. This can result in the synthesis of high value compounds whose production is nearly
impossible through chemical approaches due to the instability of double bonds or the generation of
unwanted byproducts [19]. Several examples of cytochrome P450 monooxygenases with terminal
ω-oxidation activity toward fatty acids have been reported [20–27]. Some are also capable of fatty
acid over-oxidation to their corresponding dicarboxylic acids [23,26,28]. The mechanism of a P450
mediated ω-oxidation process has been discussed [29], and is briefly presented here.
This nicotinamide adenine dinucleotide phosphate (NADPH) dependent reaction takes place
under mild conditions and requires molecular oxygen. In summary, an active intermediate is formed
when the heme group of P450 monoxygenase is coupled to molecular oxygen. As a result, oxygen is
added to the attached substrate, the C-H bond of fatty acid. Subsequently, another atom of oxygen
is released in the form of a water molecule, and a hydrogen atom is transferred from the substrate
to the heme group, leading to the generation of hydroxylated substrates. During this process, the
P450-diflavin reductase partner (CPR) is bound to the NADPH cofactor to derive electrons from
that while positioning the redox active nicotinamide ring and flavin adenine dinucleotide (FAD) at a
close distance. The FAD accepts hydride ions from the NADPH and transfers electrons to the flavin
mononucleotide (FMN) to reduce the heme group of the P450 monooxygenase [30]. This complex
enzymatic system has some limitations, such as low activity and stability, dependency on cofactor
and redox partner proteins, and low product yields for broad industrial usage [19,31]. Moreover,
eukaryotic CYPs are often associated with ER membranes [32] and have lower solubility and stability
compared to bacterial ones. High-density cultivation of P450-carrying cells or modification of the
P450 system for higher expression and stability can help overcome these limitations in a bioreactor
application [15].
Yarrowia lipolytica is an advantageous biorefinery platform for the production of fatty acid-based
bioproducts [33] and for P450 catalytic bioconversion [34]. The P450-dependent hydroxylation of
alkane, fatty alcohol, and fatty acid precursors is predominant in this yeast [35,36]. This assists with
detoxification and degradation of these potentially toxic molecules. The overexpression of homologous
and heterologous P450 has been employed in Y. lipolytica [37] resulting in a remarkable proliferation
of ER [38]. There are at least 17 P450 genes and some electron transfer proteins in this oleaginous
yeast [38]. Among them, twelve P450 Alk genes (YlALK) and a single NADPH P450 reductase gene,
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YlCPR, have been isolated and characterized [32,36,38,39]. They have various substrate requirements
with respect to length, degree of unsaturation, and functional groups [40]. For instance, YlALK 3,
YlALK 5, and YlALK 7 can catalyze the ω-oxidation of fatty acids [41]. The resulting ω-hydroxy fatty
acids undergo further steps of oxidation that could also constitute rate limiting steps in this yeast.
These steps can be carried out by fatty alcohol oxidase (FAO1; YALI0B14014g) and by the alcohol
dehydrogenase genes (FADHs) in the ER and peroxisome [42,43]. The fatty acid precursors and their
corresponding oxygenated fatty acid monomers are susceptible to the effective peroxisomal β-oxidation
degradation in Y. lipolytica, resulting in the generation of energy, water, and CO2. The POX genes are
involved in the degradation of these monomers [44,45]. The disruption of the β-oxidation pathway
via deletion of POX genes is commonly employed to prevent fatty acid and LCDCA degradation
and unwanted chain modification [14,46,47]. In this yeast, the overproduction of fatty acids can be
efficiently achieved in the form of free fatty acids rather than fatty acyl-CoAs, since the production
of the latters are highly regulated by feedback inhibition [48,49]. In fact, the ω-oxidation of free fatty
acids can favor their degradation and alleviate their toxicity. The ω-oxidation pathway acts as a rescue
route in the peroxisome-deficient cell by generating oxygenated fatty acids of higher solubility in
water [50,51].
Engineering Y. lipolytica for the de novo production of LCDCAs enables utilization of various
unrelated feedstock, including sugars, glycerol, and short chain volatile fatty acids, for this process.
Y. lipolytica has a preference for using glycerol as a carbon source [32]. Glycerol and glucose have
a transcription-repressive effect, with various degrees of strength, on background P450 activities
in this yeast [52]. Glycerol has a strong repressor effect, so the overexpression of selected P450
members in the presence of this substrate can enable higher selectivity through the minimization
of background ω-oxidation activity. Y. lipolytica accumulates a larger proportion of endogenous
unsaturated long chain fatty acids when grown on glucose [53]. The preservation of double bonds
through the terminal ω-oxidation results in the generation of multi-functional unsaturated LCDCAs.
These double bonds enable the attachment of additional functional groups [54] and the generation of
cross-linked degradable polymer networks with adjustable properties [55].
In this study, we engineered Y. lipolytica, a “safe-to-use” yeast [56], for the de novo production
of high value LCDCA monomers. This involved a one-step bioprocess, using glycerol as the
sole source of carbon. This was done by inactivating the endogenous cytosolic fatty acyl-CoA
synthetase, YlFAA1 YALI0D17864g, and redirecting the resulting pool of free fatty acids toward
an engineered ω-oxidation pathway, in a deficient β-oxidation background. The ω-oxidation pathway
was engineered by overexpressing P450 reductase (YALI0D04422g), fatty alcohol oxidase YlFAO1, and a
selected member of P450 monoxygenases (YlALK5, YALI0B13838g). After preliminary screening and
shake flask cultivations, we used a 1-L bioreactor for the P450-based biocatalytic system and achieved
a productivity of 0.04 g/L·h, which is more than the process productivity of 0.001 g/L·h acceptable for
P450-based biocatalytic production of pharmaceuticals [19]. Our results demonstrated the promise
of Y. lipolytica for use as an oleaginous yeast cell factory for LCDCA production. The safe status of
this yeast enhances the suitability of the resulting LCDCA monomers for food and pharmaceutical
uses, where high security standards should be met. To the best of our knowledge, this is the first
reported study on the biosynthesis of LCDCAs from glycerol by engineered Y. lipolytica. The findings
of this work present a unique biosynthetic route that is expected to advance Yarrowia platform for the
sustainable production of these multi-purpose long chain building blocks.
2. Materials and Methods
2.1. Strains and Culture Conditions
Escherichia coli top 10 was used for plasmid DNA construction and propagation. According to
the standard protocols, Luria-Bertani (LB) broth or agar medium was made and supplemented with
ampicillin at the concentration of 100 μg·mL−1 [57]. The recombinant Y. lipolytica strains of this study
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were all derived from Y. lipolytica H222 (a potential citric acid-producer wild-type German strain) [42]
and are presented in Table 1
Table 1. Y. lipolytica strains used in this study.
Y. lipolytica Strains
Names
Strain Genotypes Gene Configurations Reference









Same as HP-U, +Δleu2
Δsnf1 Δfaa1 Δsnf1::URA3
loxR-URA3-loxP flanked by SNF1




Same as F, +Δleu2::URA3
YlALK5 YlCPR YFAO1
loxR-URA3-loxP flanked by SNF1
upstream and downstream This study
H222ΔPΔLΔSΔF ΔL
+ALK5 YlCPR YlFAO1
++ALK5 (M) [leu−, ura+]
Same as P, +YlALK5
Multiple-copy integration of YlALK5
using zeta based integrative vector
pINA1291(this strain was selected
after screening of 10–20 transformants
for their growth and
production capacities)
This study
The yeast nitrogen base (YNB) medium with following composition was used to select auxotrophic
Ura− and Leu− transformants and to prepare the seed cultures: 6.7 g/L yeast nitrogen base
(without amino acids w/ammonium sulfate) (Becton, Dickinson and Company, Sparks, MD, USA),
20 g/L glucose, and 1.92 g/L synthetic mix minus uracil (YNB-Ura) or 1.62 g/L synthetic mix minus
leucine (YNB-Leu) (US Biological, Salem, MA, USA). YNB-Leu was also used to grow the strain
carrying the plasmid with the LEU2 marker and CRE gene to restore the uracil auxotrophic derivatives
of the F and P strains. Rich medium (YPD) containing 20 g/L glucose, 20 g/L bacto peptone (BD), and
10 g/L bacto yeast extract (BD) was used for non-selective propagation of strains. Agar (US Biological,
Salem, MA, USA) was added at a concentration of 20 g/L for preparing plates.
Production media in shake flasks and bioreactor were performed in minimal media with the
following defined composition: 1.7 g/L Yeast Nitrogen Base (without amino acids and without
ammonium sulphate) (BD), 1.5 g/L MgSO4. 7H2O, and1.92 g/L drop-out synthetic mix minus uracil.
The (NH4)2SO4 was used as the major source of nitrogen at a concentration of 1.9 g/L. The production
media formulations contained 52 g/L glycerol, to reach the target carbon to nitrogen (C/N) ratio of 50.
The CaCO3 was added to the shake flasks at a concentration of 6 g/L to provide buffering conditions.
This carbonate plays a role in maintaining a stable pH [58]. The shake flask cultivations were carried
out in 250 mL Erlenmeyer flasks containing 50 mL of the medium at an agitation rate of 180 ± 5 rpm
and a temperature of 28 ± 1 ◦C. Fresh colonies from the YNB-Ura plates were precultured in YNB-Ura
broth. Exponentially growing cells were harvested by centrifugation, washed with water, and then
resuspended in water. The production media were inoculated with the resuspended cells to an initial
optical density (OD600) of 0.1.
2.2. Batch Fermentation
Batch cultivation was carried out in a 1-L benchtop fermenter BioFlo 110 (New Brunswick
Scientific, Enfield, CT, USA). Cells from a 24 h-shake flask YNB-Ura culture were harvested, washed
using water, and inoculated into 700 mL of the fermentation medium (with C/N of 50) to reach a
minimum OD600 of 0.1. The temperature was kept at 28 ◦C. The pH was controlled and maintained
at 6 during the biomass propagation (typically for 1 day) and then was increased to 8 during the
production phase using 5 M NaOH. This pH adjustment was also beneficial to lessen the rate of citric
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acid production. A minimum dissolved oxygen level of 50% was maintained by cascading with an
agitation ranging from 250 to 800 rpm, and by supplying sterile air at a flow rate of 2 vvm. Samples
with a volume of 15–25 mL were taken daily during 4 days of fermentation. An antifoam Y-30 emulsion
(Sigma, St. Louis, MO, USA) solution of 10% was made and added at the beginning of each batch
cultivation, as well as during the fermentation, when required.
2.3. Genetic Techniques
Standard molecular manipulation techniques were used to develop the vectors [57]. All plasmids
and their functions are presented in Table 2.
Table 2. Vectors used in this study.
Vector Names Map Features




vector, low-copy CEN plasmids
(1–2 copies/cell~1.6 plasmid
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Table 2. Cont.
Vector Names Map Features
Leu 5cf (L5CF)
Uracil selection marker flanked by






Integrative vector, hp4d- YlALK5
Tlip2, ura3d4 defective marker,
zeta region for multi-copy
integration
LEU (LU)
Uracil selection marker flanked by
LEU2 upstream and downstream
sequences
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Table 2. Cont.
Vector Names Map Features
SNF (SU)
Uracil selection marker flanked by
SNF1 upstream and downstream
sequences
FAA (FU)
Uracil selection marker flanked by
FAA1 upstream and downstream
sequences
The construction of the triple gene expression cassette was carried out by the amplification of
Yarrowia lipolytica cytochrome P450 YlALK5, NADPH-P450 reductase YlCPR, and fatty alcohol oxidase
FAO1 gene segments. Cloning inserts were obtained from polymerase chain reaction (PCR) using
Q5 high fidelity DNA polymerase (New England Biolabs, Ipswich, MA, USA), the gDNA of Po1f
(ATCC MYA-2613) as the template, along with the primers presented in Table 3. The amplicons were
individually digested and inserted into Y. lipolytica plasmid pGR12 (PFBA-Tlip1), pJN44 (PTEFin-Txpr2),
and pGR51 (PGPM1-Tcyc1). These are the constitutive promoters with the following orders of strength:
FBA1 > GPM1~TEF [59]. The segments of PGPM-YlCPR Tcyc1 and PTEFin-FAO1-Txpr2 were separated
from the non-shuttle vectors by digestion with XbaI and SpeI. For a more distinguishable separation
of the plasmid digestion products on the gel, the unique sites of XmnI and ScaI were also used in
a triple digestion process. The target gel recovered fragments were consecutively inserted into the
SpeI-digested and Fast Alkaline Phosphatase treated ALK5–pGR12 plasmid. Gene knock-out was
carried out using the uracil maker containing vectors. The marker was surrounded by LoxP sites. For
knock-out plasmid constructions, the 0.6–1.1 kb 5’- and 3’-flanking regions of the Y. lipolytica LEU2,
SNF1, and FAA1 genes were amplified with the primers listed in Table 3. The amplicons were inserted
into the sites upstream and downstream of uracil gene upon digestion and purification. The triple
gene expression cassette segment was double digested using XbaI and SpeI and purified on gel for
subsequent insertion into the SpeI-digested and Fast Alkaline Phosphatase treated LEU2 knock-out
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vector. The triple gene cassette was successfully integrated into the genomic LEU2 locus, in a one
step site-specific gene knock in/out. This was carried out to reach long-term genetic stability. YlALK5
gene segment was also inserted into a vector under the control of the growth phase-dependent hp4d
promoter. This promoter shows high quasi-constitutive activity [60] at the start of the stationary phase,
and is relatively independent of medium composition and pH [61]. Application of the hp4d growth
dependent promoter lessens the metabolic burden of YlALK5 overexpression during the growth phase.
The corresponding vector contains zeta sequences (Ylt1 retrotransposon LTRs), enabling its multiple
random integration into the genome of strains devoid of Ylt1 retrotransposon, such as the P strain.
This zeta-based vector bears the defective marker, ura3d4 allele, thus allowing a random ectopic
integration of about ten copies into all H222 derivatives, which are devoid of Ylt1 retrotransposon [62].
Table 3. PCR primers used in this study.
No. Name Sequence (5′→3′, Underlined Restriction Site)
1 Alk 5 F HindIII GAGCGAAAGCTTATGCTACAACTCTTTGGCGTCC
2 Alk 5 R PstI CTTAGA CTGCAG CTACGCCTTCTCACCCTTATACA
3 Alk 5 Zeta F A AATGCTACAACTCTTTGGCGTCC
4 Alk 5 Zeta KpnI R TTGCAAGGTACCCTACGCCTTCTCACCCTTATACATCT
5 YlCPR F HindIII GAGCGAAAGCTT ATGGCTCTACTCGAC TCTC
6 YlCPR R SmaI GTTAT CCCGGG CTACCACACATCTTCCTGG
7 FAO1F NdeI CCTCA CATATGATGTCTGACGACAAGCACACT
8 FAO1R SmaI GTTAT CCCGGG AGGATCTCCGACCTCGAATC
9 LEU2 up F ApaI CTATAGGGCCC ACCGGCAAGATCTCGTTAAGACAC
10 LEU2 up R XbaI GATCCTCTAGATGTGTGTGGTTGTATGTGTGATGTGG
11 LEU2 down F SpeI CTGGACTAGTCTCTATAAAAAGGGCCCAGCCCTG
12 LEU2 down R NdeI CCTCACATATG GACAGCCTTGACAACTTGGTTGTTG
13 LEU2 F Ura TACAGTTGTAACTATGGTGCTTATCTGGG
14 LEU2 Ura R CCTTGGGAACCACCACCGT
15 LEU2 Ura F ACTTCCTGGAGGCAGAAGAACTT
16 LEU2 R Ura ATAGCAAATTTAGTCGTCGAGAAAGGGTC
17 SNF1 up F ApaI CAATTGGGCCCGTGATCAAAGCATGAGATACTGTCAAGG
18 SNF1 up R XbaI GATCCTCTAGAGAGGTGGTGGAAGGAGTGGTATGTAGTC
19 SNF1 down F SpeI CTGGACTAGT TCATTAATACGTTTCCCTGGTG
20 SNF1 down R NdeI CCTCACATATGGGAATTCGTGCAGAAGAACA
21 SNF1 F Ura GCGGGAAATCAAGATTGAGA
22 SNF1Ura R CGGTCCATTTCTCACCAACT
23 SNF1 Ura F CCTGGAGGCAGAAGAACTTG
24 SNF1 R Ura ACTACTGGCGGACTTTGTGG
25 FAA1 up F ApaI CAATT GGGCCC CCAGGTCTCAGTTGCACTTGC
26 FAA1 up R XbaI GATCC TCTAGA CAAATTATACCCCTCATCTCTCTAGGACA
27 FAA1 down F SpeI CT GGACTAGTTTGGTGAGCCCACCGC
28 FAA1 down R NdeI CCTCACATATGAACCTCCAGCAGACTAACTAGAACA
29 FAA1 F Ura ACTGTAGCTAGATGGGTGCC
30 FAA1 Ura R CGGTCCATTTCTCACCAACT
31 FAA1 Ura F CCTGGAGGCAGAAGAACTTG
32 FAA1 R Ura ACCAGCCCAGCCGG
33 LEU2 up F Ura TCATGTTCGTGGAGGGGAG
34 LEU2 up Ura R AAAACGCAGCTGTCAGACC
35 LEU2 down F FAO GGAGTCCAAGCCCTTCGA
36 LEU2 down R CACAAGACGTCAACTAAAGCGT
Site-specific gene knock in/out was achieved by transforming the linearized vectors containing
homologous upstream and downstream sequences. Y. lipolytica was transformed with the linearized
plasmids, consisting of NdeI-digested LU, ApaI-digested SU, NdeI-digested FU, and NsiI-digested
L5CF. The zeta-containing vector was linearized using FD NotI enzyme. Transformation was performed
using a Zymogen Frozen EZ yeast transformation kit II (Zymo Research, Irvine, CA, USA) according
to the manufacturer’s protocol. We modified this protocol to enhance the efficiency of multi-copy
integration transformation. The loxR–URA3–loxP modules were rescued for subsequent genetic
modification by the LoxP-Cre system as previously reported [63]. Gene deletions and expression
cassette insertion were confirmed by PCR using the primers listed in Table 3.
Construction of vectors was carried out using standard cloning methods, with FastDigest
restriction enzymes (Thermo Fisher Scientific, Waltham, MA, USA). Yeast genomic DNA was isolated
as described previously [64] and was used for PCR amplification and verification. A DNA Clean &
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Concentrator-5 Kit (Zymo Research, Irvine, CA, USA) was used for the purification of DNA products
from PCR and digestion reactions. A GeneJET Gel Extraction Kit (Thermo Fisher Scientific) was used
for the recovery of nucleic acid fragments from agarose gels.
2.4. Analytical Methods
2.4.1. Dry Biomass
Seven milliliters of culture broth were collected daily for dry cell weight, extracellular metabolites,
fatty acids, and LCDCAs measurements. Five milliliters were centrifuged for 5 min at 13,300 rpm.
The cell pellet underwent two stages of washing with a saline solution (0.9% NaCl) and distilled water.
The biomass yield was measured gravimetrically by drying samples at 105 ◦C to reach a consistent
weight. This was presented in grams of dry cell weight per liter (g·DCW/L).
2.4.2. Glycerol and Citric Acid Concentrations
High performance liquid chromatography (HPLC) with an Aminex HPX-87H column was used
to measure the concentration of glycerol and citric acid. After centrifugation, supernatants were
filtered using 0.22 μm pore-size membranes and eluted with 5 mM H2SO4 at a flow rate of 0.6 mL/min,
at 65 ◦C. Refractive index (RI) and UV (210 nm) detectors were employed for the detection of target
signals. Standards were used for the identification and quantification of glycerol and citric acid.
Our methods did not adequately separate citric acid from its isomer, iso-citric acid. Thus, the reported
concentration corresponds to the sum of these isomers, expressed as citric acid.
2.4.3. Qualitative and Quantitative Analysis of Fatty Acids and LCDCAs
Fatty acid methyl esters (FAME) and dicarboxylic dimethyl esters were made in hexane after lipid
extraction and transesterification, in compliance with the previously described method [65]. Analysis
of esterified compounds was conducted using an Agilent 7890A gas chromatography instrument
coupled with a flame-ionization detector (FID) and a FAMEWAX column (30 m × 320 μm × 0.25 μm)
(Restek Corporation, Bellefonte, PA, USA). The injection temperature and volume were set at 250 ◦C
and 1 μL, respectively. The injection was performed with a split mode (ratio 20:1). The initial
temperature of oven was 190 ◦C and progressed to 240 ◦C at a rate of 5 ◦C/min. The final temperature
was maintained for 20 min. The FID temperature was 250 ◦C. FAME standards were used to identify
the fatty acid peaks in the chromatograms. Quantification of fatty acids and LCDCAs were conducted
by comparison with tridecanoic acid (C13:0) (0.5 mg/mL) (Sigma-Aldrich, St. Louis, MO, USA) as
internal standard and by the calculation of response factor. The supernatant was filtered and used for
possible extracellular metabolite extraction and quantification. Results show that the GC-FID method
did not sufficiently separate C16 and C16:1 fatty acids, C18 and C18:1 fatty acids, LCDCA16 and
LCDCA16:1, and LCDCA 18 and LCDCA 18:1. Therefore, the reported concentration represents the
sum of these acid pairs, expressed as total fatty acid 16, total fatty acid 18, total LCDCA 16, and total
LCDCA 18. LCDCA18:2 was also quantified and added to the category of LCDCA 18. An Agilent
GC-MS was also used for the qualitative analysis of other dicarboxylic acids (DCAs), DCA12 and
DCA14. The initial temperature of 170 ◦C with a holding time of 1 min, was increased to 250 ◦C at a
rate of 3 ◦C/min, and held at the final temperature for 20 min. The split ratio was 30:1.
3. Results
3.1. Screening Process
We developed several single, double, and triple gene expression vectors with different promoters
and terminators carrying homologous P450 monoxygenase (YlAlk 2, 3, 5, 7, and 10), P450 reductase
YlCPR, fatty alcohol oxidase YlFAO1, and fatty aldehyde dehydrogenase YlHFD1 gene segments.
We tested these vectors for their performance in the ω-oxidation of endogenous fatty acids to
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the corresponding LCDCA monomers. YlAlk gene products catalyze the rate-limiting step of the
ω-oxidation pathway. Therefore, it is important to use strong FBA promoter for their overexpression
when replicative vectors with low-copy numbers are used. Among YlALK 2, 3, 5, 7 and 10, we noted
that YlALK3, YlALK 5, and YlALK 7 each have an effect on the production of LCDCA-16 with the
following order of strength: YlALK5 > YlALK7 > YlALK3. We also observed that co-expression
of YlALK5 and YlCPR led to the generation of ω-hydroxy fatty acids of 16 carbons in the F strain.
We selected YlALK5 for single as well as multiple integration because it exhibited the highest activity
toward the ω-oxidation of accumulated fatty acids among the tested monoxygenases. We constructed
the F strain by deleting YlLEU2, YlSNF1, and YlFAA1 in the HP-U (POX-deleted) strain. Then, the P
strain was constructed by performing the site specific single-copy integration of the YlALK5, YlCPR,
and YlFAO1 expression cassette into the locus of the LEU2 gene. It is notable that this single-copy
integration improved the growth behavior of the resulting strain over the F strain in the minimal
YNB-Ura media. Then, the M strain was constructed by random multiple integration of YlALK5 into
the P strain. Ten to twenty colonies were screened for their growth on selective YNB-Ura plate and
LCDCA production. All of the F, P, and M strains were uracil prototrophic and leucine auxotrophic.
The YNB-Ura culture of the M strain was additionally supplemented with an additional 400 mg/L
leucine to study the possible stimulatory effect of this amino acid on the metabolite production by
the M strain. This was labeled as the ML strain/treatment. Preliminary shake flask studies were
conducted to find the best strain for a fermentation scale-up. However the production of LCDCAs in
shake flask cultures is generally challenging due to insufficient aeration, agitation, and poor control
over pH. The next section presents the data from the 6-day shake flask cultivations.
3.2. Preliminary Shake Flask Experiments for Fatty Acid and LCDCA Production
We tested four strains (wild type W and engineered F, P, and M) for fatty acids and monomer
production in shake flask cultures. Glycerol was added to YNB-Ura at a concentration of 52 g/L to
reach a C/N ratio of 50. This medium contained about 0.38 g/L of leucine and was supplemented
with an additional 400 mg/L of leucine for the ML strain/treatment. Results of biomass production in





















Figure 1. Study of 6-day shake flask cultures for biomass production by the W, F, P, M and ML
strains/treatment. Glycerol based media under nitrogen-limiting conditions (C/N = 50). Error
bars represent standard deviation for n = 3. W: H222 wild type strain, F: ΔPOX1-6 ΔLEU2 ΔSNF1
ΔFAA1 ΔSNF1::URA3, P: F + Δ LEU2:: URA3 YlALK5 YlCPR YlFAO1, M: P + YlALK5:: URA3,
ML: M + 400 mg/L leucine. abc Columns with dissimilar letters at the top are significantly different
(p < 0.05).
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The data present a significant (p < 0.05) difference between the wild type (W) strain and all mutant
strains. This can be explained in part by the final pH of media, which can affect the CaCO3 solubility.
Although all shake flask media contained an equal amount of calcium carbonate (6 g/L), their final
pH varied depending on the strain. For example, the final pH of the W strain was above 4.1, while it
was in the range of 3.2 to 3.9 for other strains because of a higher citric acid production. The pH of
media can affect CaCO3 solubility and this interferes with dry biomass measurements. In addition
to this explanation, we also noted that glycerol was almost completely consumed by the end of the
6-day period for all mutant strains. However, we observed a residual glycerol level of 15 g/L for the
W strain. The integration of the fatty acid-oxidizing genes, did not significantly (P > 0.05) enhance the
final biomass level under nitrogen limiting conditions. However, the supplementation of the YNB-Ura
medium with an additional leucine caused the M strain to produce a significantly higher biomass level
than F and P strains.
We also assessed the capability of the strains for citric acid production. Our methods could not


































Figure 2. Study of 6-day shake flask cultures for citric acid production by the H, F, P, M and ML
strains/treatment. Glycerol based media under nitrogen-limiting conditions (C/N = 50). Error bars
represent a standard deviation for n = 3. W: H222 wild type strain, F: ΔPOX1-6 ΔLEU2 ΔSNF1 ΔFAA1
ΔSNF1::URA3, P: F + Δ LEU2:: URA3 YlALK5 YlCPR YlFAO1, M: P + YlALK5:: URA3, ML: M + 400 mg/L
leucine. ab Columns with dissimilar letters at the top are significantly different (p < 0.05).
All mutant strains produced a significantly (p < 0.05) higher level of citric acid than the W strain,
in the range of 21 to 31 g/L. A small amount of the detected acid can be in the form of its isomer,
iso-citric acid because this yeast is able to produce citric and iso-citric acid and their proportion is
mainly influenced by feedstocks and strains [35]. Although the M strain produced the highest level
of citric acid, there was no significant (p > 0.05) difference among the mutant strains. Moreover, the
leucine supplementation did not have a significant effect on citric acid production. Citric acid is
the major by-product of the lipid biosynthesis in Y. lipolytica under nitrogen-limiting conditions [66].
Higher re-direction of carbon flux from citric acid to fatty acid can be achieved by upregulating the
first committed step of fatty acid biosynthesis, controlled by ACC1 [67], and by removing the feedback
inhibition effect of endogenous fatty acyl-CoA through thioesterase overexpression or acyl-CoA
synthetase inactivation [49].
Figure 3 presents the total fatty acid and LCDCA monomer production by the strains from 6-day
shake flask cultivation.
The wild-type W strain accumulated fatty acids at a low concentration of 340 mg/L with oleic
acid (FA18:1) as the main constituent. The concentration of total fatty acids in the mutant strains
33
Fermentation 2017, 3, 40
was significantly (p < 0.05) higher than in the W strain. The deletion of YlFAA1 in the F strain
significantly (p < 0.05) increased the TFA level to 3300 mg/L in the F strain. These endogenous
fatty acids were precursors for the LCDCA production. The LCDCAs were not produced by the W
strain. The production of these monomers was initiated by the deletion of YlFAA1 in the F strain.
This shows the involvement of background ω-oxidation activity in LCDCA-16 and 18 production.
This contribution was higher toward the end of 6-day shake flask cultivations. Single and multiple
copy integration of the fatty acid-oxidizing genes significantly (p < 0.05) increased LCDCA production.
This LCDCA level was similar for the P, M, and ML strains/treatment. Generally, LCDCA production
in shake flasks is not stable and faces several challenges, including inadequate aeration, agitation,
and pH control. Oxygen limitations are typical for shake flask cultures. Moreover, addition of 6 g/L
CaCO3 cannot sufficiently maintain the stability of pH value in shake flask cultures. These limitations
undermine the effect of genetic or cultivation modification on LCDCA production. For instance, we
observed the positive effect of leucine supplementation on biomass and LCDCA production by the
M strain in bioreactor fermentations. However, application of similar treatment did not significantly
change the LCDCA production level of the M strain in shake flask cultivations. Additionally,
an extensive post-screening for choosing the best LCDCA-producing strain is beneficial to reach
the strongest effect of multiple-integration. The preliminary shake flask studies were carried out,
nonetheless, to select the appropriate strain and conditions for bioreactor fermentation. We obtained
a LCDCA titer of 330 to 430 mg/L from the P, M and ML strains/treatment under nitrogen-limiting
conditions. Chromatograms from the F and P culture indicate that a negligible amount of FA-17 was

















































































Figure 3. Study of 6-day shake flask cultures for fatty acid and LCDCA production by the H, F, P,
M, and ML strains/treatment. Glycerol based media under nitrogen-limiting conditions (C/N = 50).
Error bars a represent standard deviation of n = 3. W: H222 wild type strain, F: ΔPOX1-6 ΔLEU2
ΔSNF1 ΔFAA1 ΔSNF1::URA3, P: F + Δ LEU2:: URA3 YlALK5 YlCPR YlFAO1, M: P + YlALK5:: URA3,
ML: M + 400 mg/L leucine. Total FA: total fatty acids of 16 and 18 carbons, Total LCDCA: total long
chain dicarboxylic acids of 16 and 18 carbons. ABC/abc Columns with dissimilar letters at the top are
significantly different (p < 0.05).
In general, the deletion of POX genes prevents the degradation of fatty acid precursors and
monomers. Additionally, the inactivation of YlFAA1 promotes the generation of free fatty acids,
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which do not have the feedback inhibitory effect of acyl-CoA on the fatty acid biosynthesis pathway.
The combination of these genetic modifications with the deletion of YlSNF1 can promote the
re-direction of the carbon flux towards malonyl-CoA and eventually free fatty acid accumulation.
In addition to background ω-oxidation activity, the upregulation of the ω-oxidation pathway can
enhance the transformation of free fatty acid pool into the monomers of less toxicity. Therefore, our
genetic engineering served the dual purpose of enhancing fatty acid accumulation and producing
LCDCA monomers. The ML strain and treatment was selected for further bioreactor fermentation
experiments.
3.3. Batch Fermentation
The batch bioreactor fermentation was carried out using YNB-Ura medium with a C/N of 50.
Glycerol was added to the medium at a concentration of 52 g/L. The production medium was also
supplemented with 400 mg/L leucine. The time course study of biomass and citric acid production as






















































Figure 4. Time course study of glycerol utilization, biomass proliferation, and citric acid production
by the ML strain/treatment. Glycerol based YNB-Ura media under nitrogen-limiting conditions
(C/N = 50). Data from 2 rounds of batch fermentation. ML: ΔPOX1-6 ΔLEU2 ΔSNF1 ΔFAA1 + Δ LEU2::
YlALK5 YlCPR YlFAO1 + YlALK5:: URA3 + 400 mg/L leucine.
Glycerol was consumed rapidly within 2 days of fermentation. During this period, the citric
acid and biomass reached their peak at about 39 and 8.6 g/L, respectively. Afterwards, there was a
slight reduction in the concentration of biomass, possibly due to some cell attachment to the fermenter
vessel. The ML strain and treatment produced citric acid at a yield of more than 0.75 g/g of consumed
glycerol. During the last two days of fermentation, the citric acid concentration did not undergo a
marked change. It is notable that the mutant strains of this study are derived from H222 stain, which
has a strong potential for citric acid production. Additionally, nitrogen-limiting conditions reroute
carbon flux to lipid accumulation for storage and to citric acid for secretion. Both citric acid and fatty
acids compete for the building units of acetyl-CoA [68]. To gain insight into monomers production
conditions, we analyzed the concentration of fatty acids and monomers during the 4-day fermentation.
Results are shown in Figure 5.
Batch fermentation in the 1-L bioreactor significantly enhanced the titer of LCDCA from 0.33 g/L,
which was obtained in the shake flask culture, to 3.49 g/L for the ML strain and treatment. This
corresponds to a minimum yield of 0.067 g/g of consumed glycerol and to a productivity of 0.04 g/L·h.
This significant improvement was mainly due to adequate aeration, agitation, and precise control over
35
Fermentation 2017, 3, 40
the pH. The increase in LCDCA level continued until the last day of the 4-day fermentation at the
expense of fatty acid pool.
The LCDCAs are more soluble than their fatty acid counterparts. This feature facilitates their
transportation across the cell. We also analyzed the concentration of extracellular LCDCA monomers
in cell-free production media to find more about the spatial distribution of LCDCAs. Figure 6 presents
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Figure 5. Time course study of fatty acids and LCDCA production by the ML strain/treatment. Glycerol
based media under nitrogen-limiting conditions (C/N = 50). ML: ΔPOX1-6 ΔLEU2 ΔSNF1 ΔFAA1
ΔLEU2:: YlALK5 YlCPR YlFAO1 + YlALK5:: URA3 + 400 mg/L leucine. FA-16: fatty acid of 16 carbons,
FA-18: fatty acid of 18 carbons, LCDCA-16: long chain dicarboxylic acids of 16 carbons, LCDCA-18:
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Figure 6. Time course study of total fatty acid, total LCDCA, and extracellular LCDCA production
by the ML strains/treatment. Glycerol based media under nitrogen-limiting conditions (C/N = 50).
Data from 2 rounds of batch fermentation. ML: ΔPOX1-6 ΔLEU2 ΔSNF1 ΔFAA1 ΔLEU2::YlALK5
YlCPR YlFAO1 +YlALK5:: URA3 + 400 mg/L leucine. Total FAs: fatty acids of 16 and 18 carbons, Total
LCDCAs: long chain dicarboxylic acids of 16 and 18 carbons. Data from 2 rounds of batch fermentation.
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According to these results, more than half of the LCDCAs were present in the extracellular
medium while the fatty acids were intracellularly used as precursors for the monomer production.
Figure 6 also indicates that the availability of intracellular free fatty acids is the rate limiting step for
de novo LCDCA production in the 1-L bioreactor fermentation. It should be noted that a small amount
of dicarboxylic acids of 12 and 14 carbons was also found in the extracellular medium (less than
0.2 g/L). This can be due to the activity of YlALK5 that was integrated into the genomes at multiple
copies. The composition of metabolites was also determined. Results are presented in Figure 7.
Figure 7 shows that LCDCAs became predominant fatty acid-based metabolites at the end
of the 4-day fermentation. Also, LCDCA-16 accounted for more than 50% of LCDCAs, meaning
that the ω-oxidation rate of 16 carbon-fatty acid was higher than that of 18 carbon-fatty acids.
This rate is influenced by the background ω-oxidation activity, as well as the activity of those genes
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Figure 7. Percentage composition of fatty acids and LCDCAs produced by the ML strain/treatment.
Glycerol based media under nitrogen-limiting conditions (C/N = 50). ML: ΔPOX1-6 ΔLEU2 ΔSNF1
ΔFAA1 ΔLEU2::YlALK5 YlCPR YlFAO1 +YlALK5:: URA3 + 400 mg/L leucine. FA-16: fatty acid of
16 carbons, FA-18: fatty acid of 18 carbons, LCDCA-16: long chain dicarboxylic acids of 16 carbons,
LCDCA-18: long chain dicarboxylic acids of 18 carbons. Data from 2 rounds of batch fermentation.
Table 4. Summary of the production level for biomass, citric acid, and LCDCAs.
DCW (g/L) Citric Acid (g/L) LCDCA Titer (g/L) LCDCA Yield (g/g) LCDCA Productivity (g/L·h)
8.58 ± 0.23 39.2 ± 3.5 3.49 ± 0.14 0.06 0.04
4. Discussion
The de novo production of fatty acid-derived monomeric compounds from unrelated feedstock
has been previously demonstrated. For example, the overexpression of a plant thioesterase and
of an engineered self-sufficient monooxygenase fusion protein in a β-oxidation deficient E. coli
strain resulted in 234 μM ω-hydroxy octanoic acid production in a fed-batch fermentation [69].
In another study, E. coli was engineered for sugar-based hydroxyl fatty acid production [70]. That was
achieved by the coexpression of acetyl-CoA carboxylase and acyl-CoA thioesterase in an inactivated
acyl-CoA synthetase background, followed by the expression of a heterologous fatty acid hydroxylase.
This resulted in the production of different hydroxyl fatty acids with chain lengths of 10 to 18 carbons
at a final titer of 58.7 and 548 mg/L in culture broth and fed-batch fermentation, respectively.
The engineered reversal of the β-oxidation cycle, in combination with the expression of heterologous
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thioesterase and monooxygenase systems, has led to the biosynthesis of medium chain ω-hydroxy
fatty acids and dicarboxylic acids at a titer of 0.8 and 0.5 g/L, respectively, from glycerol in E. coli [71].
This bacterial host has also been engineered for the biosynthesis of long chain hydroxylated fatty acids
at a titer of 117 mg/L [72]. In that study, both thioesterase and fatty acid hydroxylase P450BM3 were
involved in the production of free fatty acids and in their conversion into oxygenated monomers.
Bowen et al. (2015) also engineered E. coli for sugar-based C12 and C14 ω-hydroxy FAs and
α,ω-DCAs production [6]. This was achieved by expressing high-specificity acyl ACP thioesterases
(TEs) to detach free fatty acids from the fatty acid synthase (FAS II). The application of p450 (CYP)
and alcohol/aldehyde dehydrogenases led to the generation of ω-hydroxy FAs and subsequently
α,ω-DCAs at a titer and productivity of 600 mg/L and 0.026 g/L·h, respectively. Figure 8 presents a
summary of aforementioned strategies.
 
Figure 8. Genetic engineering strategies for the de novo production of oxygenated fatty acid monomers:
overexpression of acetyl-CoA carboxylase (ACC) for higher carbon flux re-direction toward fatty
acid biosynthesis pathway, overexpression of length specific thioesterases (TE) for the hydrolysis of
acyl-CoA and consequently mitigation of their feedback inhibition effect, inactivation of the fatty
acyl-CoA synthase (FAA) for the prevention of free fatty acid re-activation, inactivation or reversal of
the β-Oxidation cycle for enhancing fatty acid pool and preventing degradation of fatty acid derivatives,
and selective upregulation of the ω-oxidation pathway for the terminal oxidation of endogenous fatty
acids to their oxygenated counterparts.
The above-mentioned yields and titers are notably less than those reported for whole-cell
biotransformation of exogenously added long chain fatty acids to the corresponding monomers [8,73].
For instance, engineering Y. lipolytica for the production of LCDCA from C18 oil allowed to reach a
titer of 16 g/L. This was accomplished through the blockage of β-oxidation and overexpression of
ALK1,2 together with the CPR gene under the control of pPOX2 [46].
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This study reports the construction of Y. lipolytica as an oleaginous yeast cell platform
for the de novo production of LCDCA monomers from renewable hydrophilic feedstock.
Our LCDCA-producing platform is independent of oily feedstock whose utilization has potential
disadvantages such as toxicity, low solubility, and weaker cellular uptake [7]. Instead, this
sustainability-driven biosynthetic route utilizes hydrophilic substrates for the dual purpose of energy
production and LCDCA biosynthesis under nitrogen-limiting conditions.
We developed our platform through a combinatorial genetic engineering strategy in a β-oxidation
deficient strain. Our strategy involved the inactivation of SNF1 for enhancing malonyl-CoA
biosynthesis, disruption of the major cytosolic acyl-CoA synthetase (FAA1) for generating free fatty
acid precursors, and upregulation of native ω-oxidation pathway for improving oxidation of the
endogenous free fatty acid precursors into the corresponding long chain monomers. This strategy was
developed based on the functions of the targeted genes.
In general, it is necessary to delete the POX genes in order to inactivate the β-oxidation
pathway as the major degradation route. This prevents the degradation of fatty acid precursors and
LCDCAs [45,47]. However, complete disruption of the peroxisome creates unwanted consequences.
Also, defects in peroxisome biogenesis may have an inhibitory effect on the native P450 system [23,74],
and may interfere with the oxidation of various metabolites [75]. SNF2 deletion has been found
to enhance lipid accumulation [76]. Inactivation of the SNF1 gene led to an enhanced constitutive
fatty acid accumulation and citric acid production in Y. lipolytica [66,77]. An alternative strategy to
enhance carbon flux re-direction from citric acid production to fatty acid biosynthesis is to overexpress
ACC1 or use hyperactive Acc1p [67,78]. This strategy can prevent the possible unintended metabolic
consequences resulting from SNF1 deletion. Inactivation of FAA1 can interfere with the re-activation of
released fatty acids that could serve in energy production, membrane maintenance, or triglyceride
(TAG) homeostasis [49,79]. Deletion of the FAA1 and FAA4 genes in S. cerevisiae have been found
to interfere with fatty acid incorporation in phospholipids or TAG, while generating a free fatty
acid-producing phenotype [80].
In Y. lipolytica, the free fatty acids that are activated by YlFaa1p are partially incorporated into
the lipid bodies [81]. In this yeast, several gene products that differ in their substrate specificities
are involved in the activation of fatty acids in different organelles [82]. Faa1p is the major cytosolic
long chain fatty acid activator [83]. This gene plays a crucial role in the utilization of both ex novo
fatty acids and those obtained from the metabolism of n-alkanes [84]. FAA1 also plays a role in
the storage of fatty acids in lipid bodies [81,83]. Besides YlFat1p, which is mainly involved in fatty
acid remobilization, there are at least 10 AAL genes involved in the activation of fatty acids in the
peroxisome and lipid bodies. The inactivation of these genes can prevent the cell from storing fatty
acids in lipid bodies [82]. The deficiency of fatty acid activation systems can also negatively affect
yeast growth in batch cultures with glucose [85], due to either the detergent-like properties of free fatty
acids or metabolic disorder [86].
We observed some residual fatty acids at the end of the 4-day batch fermentation. Since these
fatty acids may occur in the esterified form in lipid bodies, they do not act as substrates for the
ω-oxidation reactions. Our genetic engineering did not involve the disruption of TAG biosynthesis.
This is because the generation of free fatty acids, particularly unsaturated ones, causes toxicity in the
cell with deficient lipid body formation [87]. This occurs for several reasons: the destabilizing effect of
fatty acid overproduction on the cellular membrane [80,88], the harmful effects of oxidative species
derived from the oxidation of unsaturated fatty acids [89], and a lack of protection against excess lipid
intermediates [90].
Free fatty acid accumulation or starvation can also trigger the ω-hydroxylation of fatty
acids [91,92]. The resulting hydroxylated fatty acid monomers may also interfere with the TAG
homeostasis [93]. We propose that ω-oxidation serves as a rescue route to detoxify free acids in the
β-oxidation-disrupted strains, especially when FAA1 is inactivated. The stress relieving effect of fatty
acid oxidizing enzyme has also been observed in plants [23]. In Y. lipolytica, ALK genes are involved
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in the detoxification of fatty alcohol, dodecanol [36]. Thus, this background ω-oxidative activity
processes free fatty acids to oxygenated monomers of higher solubility and less toxicity. This can
explain the stimulatory effect of ω-oxidation upregulation on biomass proliferation in the F strain with
deficient FAA1p activity. In fact, the natural enzymatic machinery of the host cell plays an influential
role in fatty acid over-oxidation [18].
Results show that our combinatorial genetic engineering for the biosynthesis of free fatty acids and
their terminal oxidation to the corresponding LCDCAs served multiple purposes. These included the
reduction of free fatty acid toxicity, increase of product solubility, facilitation of product transportation
across the membrane, and the creation of a pull for further fatty acid flux direction toward ω-oxidation.
We observed that free fatty acids, generated from the FAA1 inactivation, are suitable substrates for
the native ω-oxidation pathway. This accords with a previous study, which reported the hydroxylation
of the free fatty acid pool by a fatty acid hydroxylase (CYP102A1) from Bacillus megaterium [70].
Free fatty acids do not have the feedback inhibition regulatory effect of fatty acyl-CoAs on some genes of
lipid synthesis [48,86]. To obtain free fatty acids, the inactivation of native fatty acid activation systems
or overexpression of heterologous/homologous thioesterases has been suggested in the literature.
For example, inactivation of FAA1 and FAA4 genes in S. cerevisiae was found to mitigate the feedback
inhibition of acyl-CoA on fatty acid synthesis and undermine the β-oxidation upregulating-effect of
fatty acid overproduction [86]. Overexpression of thioesterases has also been employed to release the
free fatty acids of specific chain lengths [6].
Studies show that YlALK3, YlALK5, and YlALK7 exhibit ω-oxidation activity against dodecanoic
acid [36,41]. However none could result in a detactable amount of products from ω-oxidation of
hexadecanoic acid in a Δalk1-12 strain [36]. It was postulated that Alk3, 5, and 7p may prefer shorter
fatty acids, while larger fatty acids are preferrably used for cell maintenance. In this study, the DCAs of
12 and 14 carbons were detected as minor products. Their production can be due to the overexpression
of YlALK5. Additionally, the overexpression of this gene, using the replicative vector with the strong
constitutive promoter, contributed toward LCDCA-16 and ω-hydroxy fatty acid-16 production in our
preliminary shake flask cultivations. In fact, a high gene dosage is necessary to achieve sufficient
P450 expression in Y. lipolytica [94]. This contribution was in addtiton to the background ω-oxidation
activity in the F strain toward LCDCA-16 and 18 production. We also observed the contribution of
YlCPR and YlFAO1 to the multiple-step oxidation of endogenous long chain free fatty acids precursors
to the monomers. In the same fashion, amplification of the P450 reductase gene was found to enhance
LCDCA production from C. tropicalis [14]. Similarly, it was reported that the overexpression of YlFAO1
improves LCDCA production from exogenous hydrophobic substrates [42]. This accords with the
contribution of FAO1 to diacid production observed in C. tropicalis [95]. Various fatty aldehyde
dehydrogenases have been identified in Y. lipolytica that are involved in the detoxification of fatty acid
aldehyde intermediates by oxidizing them to dicarboxylic acids [96–98]. These native genes likely
contribute to the background ω-oxidation activity.
A bioreactor is much more efficient than a shake flask for DCA production [7]. Adequate aeration,
agittion, and control over pH play major roles in the P450-based LCDCA production. The inner pH of the
cell, as well as aeration, both affect the induction of yeast CYP monooxygenase and CYP reductase [10].
Studies show that a higher dissolved oxygen (DO) level can remarkably improve P450 activity [99,100].
This level was kept at 80% saturation for LCDCA production from C. ropiclais [14]. In fact, the native P450
sytem utilizes molecular oxygen that is abundant in a bioreactor fermentation. In our study, fermentation
scale-up to 1-L bioreactor under the DO level of at least 50% significantly enhanced the rate of free fatty
acid oxidation to LCDCAs. The majority of free fatty acids were converted to LCDCA during the four
days of bioreactor fermentation, reaching a titer of 2 g/L for LCDCA-16 and 1.45 g/L for LCDCA-18.
Adjustment of the pH is also required for the biosynthesis of LCDCAs. During the production phase,
the pH was adjusted to 8 since the LCDCAs are completely diasscoiated at this level. For instance, the
diassociation constant of DCA13 is less than 5.8. A higher extracellular pH level increases the solubility
of LCDCAs, improves their transportation efficiency, and consequently mitigates the corresponding
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product inhibition [101]. Adjustment of pH as well as metabolite production in the production media
increases the demand for antifoam addition. Thus, the antfoam was also periodically added to
the media.
Transport of LCDCAs out of the cell can improve P450 activity [100] and simplify recovery for an
enhanced downstream process at a lower cost. Our engineered strain showed good secretion efficiency,
since more than half of the synthetized monomers were found in the media [102]. In fact, DCA of
13 carbons has been found to undergo passive diffusion due to the concentration difference between
the inside and outside cells [101]. At a low intracellular pH, the undissociated form of the carboxylic
acid is expected, which can mitigate their transportation across the cell membrane [103]. In this study,
we showed that LCDCAs are extracellular products. Secretion allows LCDCA production to exceed
the lipid accumulation capacity of the cell, and promotes their recovery from media after cell harvest
at a lower cost. This also can alleviate their inhibitory effect on P450-based hydroxylation reaction due
to their competitive binding to P450 [104].
We supplemented the production media with 400 mg/L leucine to take the advantage of
its possible stimulatory effect on the metabolite produciton, under nitrogen-limiting conditions.
Supplementation of media with leucine had significant effect on biomass level in shake flask cutures.
In addition to that, our preliminary bioreactor fermentation using YNB-Ura, without additional leucine
supplementation, resulted in less biomass and LCDCA production from the M strain (Biomass up to
7 g/L and maximum LCDCA of 3 g/L). Similalrly, addition of leucine was reported to increase the
growth and lipid accumulation in S. cerevisiae devoid of active SNF2 [105].
Although nitrogen-limiting conditions hinder growth, they induce lipid and citric acid production.
The resting cell production of LCDCAs has several advantages, including the dedication of a larger
proportion of supplied oxygen to metabolism and the targeted P450 reaction [106], the repeated
utilization of LCDCA-exporting cells, the use of high cell concentration, particularly for the multi-copy
transformants [107], as well as more strain robustness against fermentation media. In fact, resting cells
consume nearly half of what they typically utilize when they have access to a nitrogen source [106].
We used this strategy for the de novo production of free fatty acids. This strategy also caused our
engineered cell factory to produce more than 36 g/L of citric acid as the major bioproduct which was
nearly stable during the 4-day bioreactor fermentation. The production of this byproduct, which
is extensively used in pharmaceutical industries [108] raises more revenue and offsets the total
production cost.
This Y. lipolytica platform can be tailored to produce LCDCA of higher specificity with respect
to chain length and saturation. This yeast accumulates a higher proportion of unsaturated fatty
acids, oleic and linoleic acids, when it is grown on sugar, due to the strong expression of endogenous
desaturases [53]. Overexpression of these native desaturase genes, including Δ-9 and Δ-12 desaturases,
can increase the proportion of desaturated fatty acids in lipid bodies. Together with FAA1 inactivation,
this can result in a larger pool of unsaturated free fatty acids for higher unsaturated LCDCA
production. In fact, Y. lipolytica predominantly accumulate fatty acids in the form of C16:0 and C18:1.
These fatty acids are more susceptible to remobolization [109]. Disruption of their re-activation in
the ΔFAA1 background, enbales their availibiltiy for the ω-oxidation. Our study confirmed that
this oxidation does not change the configuration of double bonds. As a result, LCDCA16 and
LCDCA18:1 were the predominant LCDCA products of our platform. Moreover, according to the
chromatogram of GC-FID, a smaller portion of LCDCA-18 had two double bonds (less than 10%).
These bonds are dervied from the linolenic acid, FA 18:2, whose concntration was less than oleic
acid. Regarding chain length specificity and selectivity, there is room for improvement. For example,
manipulation of YlYAS genes [110], and selective overexpression of elongase, monooxygenase, and
thioesterase can be employed to modulate background activity and enhance the length-specificity of
the terminal oxidation.
Y. lipolytica has several advantages as a LCDCA-producing platform. This yeast platform has its
own native P450 system that catalyzes terminal oxidation of alkanes and fatty acids [36]. Moreover,
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this platform possesses an endogenous redox partner (cytochrome P450 reductase), has the capability
for large free fatty acid accumulation [111], and can efficiently generates NADPH cofactor mainly
through the pentose phosphate pathway (PPP) [112,113]. This pathway is not tightly regulated
by nitrogen concentration [114]. Together with glycolysis, it can contribute significantly to the
energy supply of resting cells [115]. At the stationary phase, a higher expression of cytochrome
P450 monoxygenases [104] and lipid remobilization [40] are also expected. These features enable
the large-scale application of engineered Y. lipolytica cells without the need for cofactor addition.
Regeneration of NADPH is crucial in whole-cell P450-based biotransformation [116], particularly
in the NADPH- and adenosine triphosphate (ATP)-consuming process of fatty acid biosynthesis
and oxidation. Moreover, whole cells also provide a protected environment for the increased
stability of the P450 enzymes [51]. A whole cell biocatalyst is a cheaper option than the isolated
or immobilized enzyme [106]. The pathogenic yeast, C. tropicalis, has been commonly engineered
for whole cell biotransformation of aliphatic feedstock to LCDCAs [14,25]. However, Y. lipolytica
has safe status, and has been categorized as a GRAS microorganism by the FDA (Food and
Drug Administration) [56,88]. This status, as well as its probiotic properties [117], can pave
the way toward the biosynthesis of LCDCAs that meet the safety requirements of the food and
pharmaceutical industries.
Despite some chemical based-production of LCDCA at large scale, the high price of the LCDCAs,
and their limited commercial availability are still major constraints in expanding the spectrum
of their application [25]. Therefore, researchers should use various renewable resources for the
sustainable production of these multi-purpose building blocks. An alternative sustainable solution
is to establish a P450-based biological approach. However, commercial application of a P450-based
platform has also its own advantages and limitations. For example, the scalability of modified
cytochrome P450 for multi-kilogram scale synthesis remains a challenge [118]. The majority of
P450-based biocatalysts have not met a minimum space-time yield of 0.1 g/L·h in previous studies.
A solution to this limitation would be the production of high-value pharmaceuticals. In this scenario,
a minimum process productivity of 0.001 g/L·h can justify large-scale bioprocessing from an economic
standpoint [19]. The LCDCAs have relatively high selling price, depending on their purity, and
therefore are outstanding targets for white biotechnology [12]. Our study is the first report on
engineering Y. lipolytica for the efficient de novo production of LCDCAs from glycerol. Results from
this study showed a minimum productivity of 0.04 g/L·h, which is more than the foregoing required
productivity. However, the provision of adequate agitation and oxygen transfer in larger fermenters
will be challenging to maintain this minimum productivity. Our biological-based approach has several
advantages over chemically-based approaches, including a broad range of renewable feedstock, milder
process conditions, a more environmentally friendly process, and higher selectivity, particularly toward
long chain unsaturated fatty acids [10,119].
These monomers have superior properties, promising future, and a large global market that is
expected to reach USD $300.3 millions by 2025 [120]. These highly demanding monomers are used in
manufacturing various high-performance polymeric compounds such as nylon and other polyamides.
They have a wide scope of application in the industrial manufacture of automobiles, medicines,
fragrances, adhesives, and macrolide antibiotics [10]. However, pharmaceutical applications exhibit
the quickest growth in terms of revenue [120].
Compared to the shorter diacids, these building blocks and their LCDCA-based polymers have
superior bio-based properties such as improved biodegradability, hydrolytic stability, crystallinity,
melting temperature, optical transparency, dispersion, miscibility, material toughness, and flexibility;
lower moisture uptake, dielectric constant, and surface tension [5]. These long chain monomers are
also the building blocks of naturally occurring polyesters [121]. Additionally, the double bonds of
unsaturated monomers, which are maintained during terminal oxidation, show promise for additional
functional groups and linkages. These features also allow for the production of novel unsaturated
LCDCAs [54] to synthesize cross-linked polymer networks with adjustable properties. Synthesizing
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these unsaturated long chain monomers is difficult via chemical routes due to the reactivity and
participation of the double bonds in unwanted reactions [122].
Our findings suggest that the tunable high-level expression of selected P450 genes, by high copy
and stable integration or by high copy number expression plasmids, can foster LCDCA overproduction.
Application of a lipid responsive strong promoter may provide additional benefit for P450 gene
expression. The multiple-copy integration of a selected gene at random loci is influenced by the
integration site underlining the need for an intensive screening afterwards [62,123]. We recommend an
intensive screening process for choosing the most productive multiple-copy transformants. We selected
the YlALK5 for multiple-copy integration since it exhibited the highest ω-oxidation activity, among
the tested YlALKSs toward the endogenously synthesized fatty acids of 16 carbons. The YlALK5 gene
product is a good candidate for protein engineering, allowing higher selectivity and turn-over rates
for long chain fatty acids. The combination of the YlALK5 and YlFAO1 overexpression can create a
push and pull of fatty acid precursors and oxygenated fatty acids in the ω-oxidation pathway. Further
studies are recommended to identify the major native cytochome monoxygenese member involved
in the temrinal oxidation of 18 carbon-fatty acids. We also suggest modulating the ratio of P450
monoxygenase/reductase overexpression for better performance. Our engineered cell factory can be
further optimized to produce a higher proportion of LCDCAs with specific chain lengths or degrees
of desaturation. This can be achieved in two ways: by introducing heterologous thioesterase-coding
genes that have long chain fatty acid specificity (e.g., Cocos nucifera fatty acyl-ACP thioesterase CnFatB2
and Iris germanica acyl-ACP thioesterase AAG43857 [124]) or by manipulating the native desaturase
and elongase systems. The LEU2 gene was disrupted for enabling a successful site-specific multiple
gene integration and testing various expression systems. However, we suggest targeting other sites
for future multiple-gene integrations, due to the positive role of the LEU2 gene on biomass and
metabolite production. We used a standard minimal medium for production. However, the availability
of rich nutrients, heme containing compounds, and low cost substrates, including lignocellulosic
hydrolysates and crude glycerol, could enhance production level and economy of this bioprocess.
The overexpression of key genes from PPP can promote NADPH availability [113], and this may
serve the NADPH-consuming process of endogenous fatty acid and LCDCA production. We also
recommend the application of immobilized cells and a biofilm reactor for integrated production
and recovery and for efficient use of multi-copy transformants. The de novo production of LCDCA
can be further improved by generating a larger pool of free fatty acids [125], which have stronger
stimulatory effect on the induction of the background ω-oxidation activity. This could be achieved
by overexpressing the upstream and downstream targets of the fatty acid biosynthesis pathway.
Acetyl-CoA carboxylase (ACC1) and thioesterase (TE) are examples of these targets. Disruption of
other acyl-CoA synthetases (e.g., YlFat1) [81] and overexpression of intracellular lipases (e.g., TGL3
and TGL4) [126] may also contribute to a larger pool of free fatty acids. Microscopic examination of
resting cells may reveal more information about the status of remaining fatty acids. Moreover, time
course qualitative analysis of free fatty acids can also provide further insight into their threshold for
the induction of background ω-oxidation activity. Despite the good LCDCA transport efficiency of
our platform, the overexpression of potential heterologous transporters such as CmCDR1 [127], or
homologous transporter like ABC2 [128] could improve LCDCA export to minimize product inhibition.
Optimization of culture conditions was beyond the scope of this study. However, production titer
and yield can be enhanced by optimizing production media and developing fed-batch or continuous
bioprocess. For example, providing a reduced aeration rate [129] or nitrogen as co-feed [130] might
lessen citric acid production in favor of more fatty acid accumulation. Summary of elements for further
improvement is shown in Figure 9.
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Figure 9. Summary of elements for further improvement.
5. Conclusions
Our study presents the construction of Y. lipolytica as a cell factory platform for the de novo
production of LCDCAs from glycerol. We accomplished this by harnessing the native capabilities
of this yeast for endogenous fatty acid accumulation and ω-oxidation. Our combinatorial genetic
engineering mainly involved inactivating the peroxisomal fatty acid degradation, disrupting cytosolic
fatty acid activation, and upregulating fatty acid ω-oxidation. Further enhancement was obtained
through fermentation scale-up to the 1-L nitrogen-limited bioreactor culture. Our engineering strategies
led Y. lipolytica strains to produce about 3.49 g/L LCDCA, with a yield of 0.06 g/g. To the best of
our knowledge, this is the highest de novo production level ever reported for LCDCA monomers.
We envision that this study constitutes a foundational work in developing Y. lipolytica as a safe
oleaginous yeast platform to upgrade low-value, unrelated feedstock to high-value multi-purpose
LCDCAs at a larger scale in the foreseeable future. This work represents a key advance in yeast strain
manipulation and fermentation for the biosynthesis of LCDCAs from renewable non-oily feedstock.
Last, this research paves the way for an industrial process that can supplement the global supply of
LCDCA from a second source, independent of the non-renewable hydrophobic substrates such as
crude oil.
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Abstract: The world market of citric acid (CA) is one of the largest and fastest growing markets
in the biotechnological industry. Microbiological processes for CA production have usually used
the mycelial fungi Aspergillus niger as a producer and molasses as a carbon source. In this paper,
we propose methods for CA production from renewable carbon substrates (rapeseed oil, glucose,
glycerol, ethanol, glycerol-containing waste of biodiesel industry and glucose-containing aspen
waste) by the mutant strain Yarrowia lipolytica NG40/UV5. It was revealed that Y. lipolytica grew and
synthesized CA using all tested raw materials. The obtained results are sufficient for industrial use of
most of the raw materials studied for CA production. Using rapeseed oil, ethanol and raw glycerol
(which is an important feedstock of biodiesel production), a high CA production (100–140 g L−1)
was achieved.
Keywords: yeast Yarrowia lipolytica; citric acid (CA) production; raw materials
1. Introduction
Citric acid (CA) and its salts are widely used as an acidulate, flavoring agent and antioxidant in the
production of beverages and confectionery, in infant formula, as well as in the chemical, pharmaceutical,
electronic, defense, and other industries. The volume of citric acid globally exceeds two million tons
per year and its production is annually increased by 5% [1].
Modern technologies of citric acid (CA) production are based on using various mutant strains of
the mycelial fungi Aspergillus niger as a producer and molasses as a raw material. CA production by
fungi is a complicated and environmentally unsafe process; as a result of its implementation, a large
number of both liquid effluents containing mineral acids, ballast organic substances, cyanides, and
solid wastes, primarily gypsum, are accumulated. Moreover, A. niger is an opportunistic pathogenic
fungi and can cause allergic diseases and aspergillosis [2,3].
Over the past 40 years, the interest of researchers has focused on yeast as a producer of CA;
the yeast Yarrowia lipolytica has been the most used CA producer [1–3]. Initially, this kind of yeast
attracted the attention of researchers due to its ability to grow and synthesize CA in media with
n alkanes—an available and cheap substrate [2]. However, due to changes in the world oil market,
the use of this substrate has become economically unprofitable. In this regard, it is of interest to use
other types of raw materials.
The choice of raw materials for developing CA biotechnology is determined by factors such
as renewability, ability of the producer to assimilate the substrate with a high conversion rate,
consumption value and cost price of the target product. To carry out fermentation processes, in addition
to very expensive food raw materials, such as glucose [4–7] and plant oils [8–10], much cheaper
substrates which are waste products of various industries, such as glycerol-containing waste of the
biodiesel industry [9–17], glucose-containing wood hydrolysates [18,19], olive mill waste-water [20],
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and inulin [21] are used. Ethanol, a water-soluble individual compound which ensures the formation
of a pure product and facilitates the isolation process, is also of great importance [22,23]. In the
works of the above-mentioned researchers it was shown that all these substrates are promising for
CA production and the use of glycerol-containing waste of biodiesel industry and glucose-containing
wood hydrolyzates can increase the profitability of CA production process.
The aim of this work was a comparative study of CA production by the yeast Y. lipolytica on
different types of renewable raw materials.
2. Materials and Methods
2.1. Microorganisms and Chemicals
The mutant strain Y. lipolytica NG40/UV5 was obtained as described previously [9,24].
Chemicals, the manufacturer of the carbon sources, and their characteristics were presented in
our published articles [7,9,15,17].
2.2. Media and Cultivation Conditions
All experiments were done using the same equipment, nutrient medium and cultivation
conditions. Strain Y. lipolytica NG40/UV5 was cultivated in a 10-L ANKUM-2M fermenter (Pushchino,
Russia) with an initial volume of 5 L. The medium contained (g L−1): carbon source: (NH4)2SO4,
6; MgSO4·7H2O, 1.4; NaCl, 0.5; Ca(NO3)2, 0.8; KH2PO4, 2.0; K2HPO4, 0.2; Difco yeast extract (BD
Diagnostic Systems, Sparks, MD, USA), 1.0; trace elements (mg L−1): FeSO4 × 7H2O, 14.9; MnSO4 ×
4H2O, 0.2; ZnSO4 × 7H2O, 8.1; CuSO4 × 5H2O, 3.9. The fermentation conditions were maintained
automatically at a constant level: Temperature 28−0.5 ◦C; pH 4.5.0−0.1; pO2 50% (of air saturation);
agitation rate of 800 rpm. Pulsed addition of carbon source (by 2–20 g L−1) depending on the carbon
source used was performed as the pO2 value changed by 10%. Cultivation was continued for 6 days.
2.3. Assays
Biomass, concentration of CA, isocitric acid (ICA) and other organic acids were determined as
described previously [7].
2.4. Calculations
Earlier, it was found that the mass yield of CA production (YCA), expressed in g of CA per g of
carbon source, and the fermenter productivity, expressed in g (L·h)−1 were influenced by the medium
dilution due to the addition of NaOH solution for maintaining a constant pH value [9,17]. In this
regard, the total amount of CA in the culture broth at the end of the fermentation was used to calculate
YCA and fermenter productivity. Formulas for calculation of YCA value and fermenter productivity
were described earlier [9,17].
All the data presented are the mean values of three experiments and two measurements for each
experiment; standard deviations were calculated (S.D. < 10%).
3. Results and Discussion
The dynamics of nitrogen consumption and the accumulation of biomass and CA by Y. lipolytica
NG40/UV5 grown on rapeseed oil are shown in Figure 1a, while the logarithmic growth curve (μ)
and the specific rate of biosynthesis of CA (qp) are shown in Figure 1b. As it can be seen in the latter
figure, the growth curve had an exponential phase (phase I) lasting for 12 h, growth retardation phase
(phase II) lasting from 12 to 36 h of cultivation, and stationary phase (phase III) lasting from 36 h to
the end of cultivation. The retardation of growth coincided with the exhaustion of nitrogen from the
medium. The specific growth rate attained a maximum (μmax = 0.360 h−1) in the exponential growth
phase (12 h of cultivation). This value of μmax was more than two times higher than that of the other
CA-producing strain Y. lipolytica (0.17–0.22 h−1) [4,8]. After 12 h of cultivation, μ gradually decreased
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to zero after 48 h of cultivation. The excretion of CA did not occur in the exponential growth phase
but became active in the growth retardation and stationary phases. Within this cultivation period,
the specific rate of CA production (qp) was between 0.065 and 0.104 g CA/g·h. At the end of cultivation
(144 h), the strain produced 140 g L−1 CA and 5.3 g L−1 ICA (data not shown) with CA:ICA ratio of
26.4:1. The CA production yield YCA was 1.5 g g−1; the fermenter productivity was calculated to be
1.46 g (L·h)−1 with account for the dilution factor.
Figure 1. Time courses of nitrogen consumption, biomass accumulation, and citric acid production in
Y. lipolytica grown on rapeseed oil (a) and calculated parameters of the process (b): I—the exponential
cell growth; II—the cell growth retardation; III—the stationary phase.
The data of the accumulation of biomass and CA by Y. lipolytica NG40/UV5 grown on other
substrates compared to rapeseed oil are shown in Table 1.












Rapeseed oil 17.0 ± 1.1 140.0 ± 5.0 5.3 ± 0.8 26.2:1 1.46 1.50
Glucose 18.7 ± 1.3 100.8 ± 9.2 4.9 ± 0.9 20.6:1 1.05 0.80
Glucose-containing aspen waste 5.6 ± 0.8 31.2 ± 2.1 7.84 ± 0.9 4:1 0.325 0.50
Glycerol 16.8 ± 1.1 87 ± 6.4 13 ± 1.1 6.7:1 0.906 0.64
Glycerol waste of biodiesel industry 20.0 ± 1.8 100 ± 3.4 15 ± 1.2 7.7:1 1.04 0.90
Ethanol 15.3 ± 1.4 106.7 ± 2.7 15 ± 1.4 7.1:1 1.32 0.87
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As seen in Table 1, at the end of cultivation (144 h), Y. lipolytica NG40/UV5 produced 100.8 g L−1 CA
and 4.9 g L−1 ICA with CA:ICA ratio of 20.6:1 in the medium containing glucose. The CA production yield
YCA was 0.80 g g−1; the fermenter productivity was calculated to be 1.05 g (L·h)−1.
As seen in Table 1, Y. lipolytica NG40/UV5 only produced 31.2 g L−1 CA and 7.84 g L−1 ICA with
CA:ICA ratio of 4:1 in the medium containing glucose-containing aspen waste. The CA production
yield YCA was 0.50 g g−1; the fermenter productivity was calculated to be 0.325 g (L·h)−1.
As it can be seen from the data in Table 1, the mutant grows perfectly and synthesizes CA both in
a medium with pure glycerol and in a medium with biodiesel-derived glycerol. Y. lipolytica NG40/UV5
produced 87 g L−1 CA with a ratio of CA to ICA of 6.7:1. The application of waste glycerol for
Y. lipolytica NG40/UV5 cultivation increased CA production by 15% (up to 100 g L−1) compared
to that obtained from pure glycerol; the CA to ICA ratio was 7.7:1. The fermenter productivity
was high and reached 0.906 and 1.04 (g (L·h)−1) in the media with pure- and biodiesel-derived
glycerol, respectively. The mass yield (YCA) reached 0.64 and 0.9 g/g in the media with pure- and
biodiesel-derived glycerol, respectively.
As seen in Table 1, Y. lipolytica NG40/UV5 produced 106.7 g L−1 CA and 15 g L−1 ICA with
CA:ICA ratio of 7.1:1 in the medium containing ethanol. The CA production yield YCA was 0.87 g g−1;
the fermenter productivity was calculated to be 1.32 g/L·h.
Comparative data on the most efficient processes of CA production by yeasts Y. lipolytica from
various carbohydrate-containing substrates are given in Table 2. As seen in this table, in the experiments
with wild and mutant strains, Y. lipolytica produced CA in industrially sufficient amounts. For instance,
in the mutant strain Saccharomycopsis lipolytica NTG9 grown on rapeseed oil, the CA concentration
reached 152.3 g L−1 with the yield (YCA) of 1.5 g g−1 [25]. Aurich et al. [26] obtained a CA concentration
of 198 g L−1 with the yield (YCA) of 1.16 g g−1, which was achieved after a 300 h fed-batch cultivation
of the wild strain Y. lipolytica H181. The wild strains Y. lipolytica H222 and Y. lipolytica W29, grown
on glucose, produced 41 g L−1 [4] and 49 g L−1 of CA, respectively [27]. Recently, we found that
the wild strain Y. lipolytica VKM Y 2373, cultivated in a medium with glucose under cell growth
limitation using nitrogen, phosphorus and sulfur, produced CA at a level of 80–85 g L−1 with a yield
of 0.70–0.75 g g−1 [7]. The overexpression of gene PYR encoding pyruvate carboxylase in Y. lipolytica,
resulted in the production of CA at a level of 95–111.1 g L−1 with the yield (YCA) of 0.75–0.93 g g−1 [5,6].
Strain Y. lipolytica ACA-DS 50109 cultivated on glucose and olive mill wastewaters produced CA
(28.9 g L−1) with the product yield (YCA) of 0.53 g g−1 [28]. Later, the authors of the last article
improved the process of CA production up to 52.0 g L−1 with the product yield (YCA) of 0.64 g g−1
using strain Y. lipolytica ACA-YC 5033, which was also able to remove harmful phenolic compounds
from olive mill wastewaters [29]. The glycerol-grown yeast Y. lipolytica NRRL YB-423 produced
21.6 g L−1 of CA with mass yield of 0.54 g g−1 [12]; strain Y. lipolytica ACA-DC 50109 synthesized
62.5 g L−1 of CA with mass yield of 0.56 g g−1 from raw glycerol [20], while the recombinant strain
Y. lipolytica NCYC3825 was able to produce 58 g L−1 of CA [30]. Earlier, we indicated that the other
mutant Y. lipolytica NG40/UV7 synthesized, CA (122.2 g L−1) with the yield of 0.95 g g−1. The high CA
production (up to 140 g L−1) has also been reported for acetate-negative mutant Y. lipolytica Wratislavia
AWG7, grown on crude glycerol [13] and recombinant strain Y. lipolytica H222-S4 (p67ICL1), harboring
the invertase encoding ScSUC2 gene of Saccharomyces cerevisiae under inducible XPR2 promoter control
and multiple ICL1 copies, cultivated on sucrose [31].
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Table 2. Comparative data of the processes of CA production from various substrates using
Y. lipolytica strains.





S. lipolytica NTG9 canola oil mutant/nitrosoguanidine 152.3 1.50 [25]
Y. lipolytica H181 sunflower oil wild type 198.0 1.16 [26]
Y. lipolytica H222
glucose
wild type 41.0 0.55 [4]
Y. lipolytica W29l wild type 49.0 0.85 [27]
Y. lipolytica VKM Y 2373 wild type 80–85 0.70–0.75 [7]
Y. lipolytica PG86 PYC gene expression 95.0 0.75 [5]
Y. lipolytica PR32 PYC gene expression 111.1 0.93 [6]
Y. lipolytica ACA-DS 50109 glucose + olive mill
wastewaters
wild type 28.9 0.53 [28]
Y. lipolytica ACA-YC 5033 wild type 52.0 0.64 [29]
Y. lipolytica NRRL YB-423 glycerol wild type 21.6 0.54 [12]
Y. lipolytica ACA-DC 50109 raw glycerol wild type 62.5 0.56 [20]
Y. lipolytica NCYC 3825 raw glycerol multigene expression 58.8 0.17 [30]
Y. lipolytica NG40/UV7 raw glycerol mutant/nitrosoguanidine/UV 122.2 0.95 [17]
Y. lipolytica Wratislavia AWG7 raw glycerol mutant/acetate− 139.0 0.70 [13]
Y.lipolytica H222-S4 (p67ICL1) sucrose ScSUC2/ICL1 127–140 0.75–0.82 [31]
Y. lipolytica XYL+ xylose XYL gene expression 80.0 0.53 [19]
Y. lipolytica Wratislavia K1 inulin INU1 gene expression 105.2 0.53 [21]
Y. lipolytica NG40/UV5 rapeseed oil mutant/nitrosoguanidine/UV 140.0 1.5 Present study
It should be noted that plant raw materials, such as wood, straw, and agricultural products
processing waste, are inexpensive, accessible, renewable, and environmentally friendly substrates for
microbiological synthesis of practically valuable compounds. However, the effective conversion of
these substrates into easily assimilable carbohydrates (glucose, xylose, and higher glucose-containing
polymers) is a difficult task. The traditional technologies of hydrolysis of plant raw materials with
the use of strong acids and alkalis are associated with the formation of by-products that inhibit the
growth of microorganisms and biosynthesis of target substances. Therefore, recombinant producers,
effectively assimilating plant raw materials, were developed. For instance, Ledesmo-Amaro et al.
(2016) engineered Y. lipolytica able to metabolize xylose to produce CA and lipids. The overexpression
of xylose reductase, xylitol dehydrogenase and xylulokinase resulted in a production of 80 g L−1 of
CA from xylose by mutant strain Y. lipolytica [19].
Rakicka et al. (2016) reported the production from inulin by engineered strain Y. lipolytica
Wratislavia K1. The overexpression of the INU1 gene from Kluyveromyces marxianus coding inulinase
resulted in the effective hydrolysis of inulin by mutant and the production of a high amount of CA
(105.2 g L−1 from 200 g L−1 inulin) [21].
4. Conclusions
The results of the experiments indicated that the mutant Y. lipolytica NG40/UV5 was able to
grow and synthesize CA on media containing all types of the investigated renewable raw materials.
However, it should be noted that the accumulation of the by-product of fermentation—ICA—was
even very high in four of the six substrates investigated (glucose-containing aspen waste, glycerol,
glycerol waste of biodiesel industry and ethanol). The best results were obtained using rapeseed oil
(140 g L−1 CA; CA:ICA ratio of 26.2:1; mass yield of CA production (YCA) of 1.5 g g−1, and fermenter
productivity of 1.46 g (L·h)−1). However, economic considerations may lead to the fact that using a
cheaper and less pure substrate (glycerol waste of biodiesel industry; 100 g L−1 CA; CA:ICA ratio of
7.7:1; mass yield of CA production (YCA) of 0.9 g g−1, and fermenter productivity of 1.04 g (L·h)−1)
would be preferable on a production scale.
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Abstract: Cost-effective production of cellulosic ethanol requires robust microorganisms for
rapid co-fermentation of glucose and xylose. This study aims to develop a recombinant diploid
xylose-fermenting Saccharomyces cerevisiae strain for efficient conversion of lignocellulosic biomass
sugars to ethanol. Episomal plasmids harboring codon-optimized Piromyces sp. E2 xylose isomerase
(PirXylA) and Orpinomyces sp. ukk1 xylose (OrpXylA) genes were constructed and transformed into
S. cerevisiae. The strain harboring plasmids with tandem PirXylA was favorable for xylose utilization
when xylose was used as the sole carbon source, while the strain harboring plasmids with tandem
OrpXylA was beneficial for glucose and xylose cofermentation. PirXylA and OrpXylA genes were
also individually integrated into the genome of yeast strains in multiple copies. Such integration was
beneficial for xylose alcoholic fermentation. The respiration-deficient strain carrying episomal or
integrated OrpXylA genes exhibited the best performance for glucose and xylose co-fermentation.
This was partly attributed to the high expression levels and activities of xylose isomerase. Mating a
respiration-efficient strain carrying the integrated PirXylA gene with a respiration-deficient strain
harboring integrated OrpXylA generated a diploid recombinant xylose-fermenting yeast strain STXQ
with enhanced cell growth and xylose fermentation. Co-fermentation of 162 g L−1 glucose and
95 g L−1 xylose generated 120.6 g L−1 ethanol in 23 h, with sugar conversion higher than 99%, ethanol
yield of 0.47 g g−1, and ethanol productivity of 5.26 g L−1·h−1.
Keywords: Saccharomyces cerevisiae; diploid; xylose isomerase; xylose fermentation; glucose and
xylose co-fermentation; biomass hydrolysate; cellulosic ethanol
1. Introduction
Ethanol can be produced from renewable resources such as crops or agricultural waste. It is
therefore a sustainable and clean fuel. Further growth in bioethanol production largely depends on the
effective conversion of lignocellulosic feedstock such as agricultural and forestry wastes to bioethanol
because they are the most abundant polymers of fermentable sugars [1–3].
Saccharomyces cerevisiae is the most effective microorganism for fermenting sugars to ethanol due to
its rapid sugar consumption rate, high sugar and ethanol tolerance, and resistance to biomass-derived
inhibitors [4,5]. Much research has been done to genetically engineer S. cerevisiae strains for xylose
fermentation [6–10].
Two xylose-assimilating pathways were heterologously engineered in S. cerevisiae for
xylose-fermenting yeast construction. One focused on the D-xylose isomerase (XI) pathway [11,12],
the other focused on the D-xylose reductase (XR) and xylitol dehydrogenase (XDH) pathway [10,13–15].
In the XI pathway, xylose is first isomerized into xylulose by XI and xylulose was then phosphorylated
into xylulose 5-phosphate by xylulokinase. Xylulose is subsequently metabolized to ethanol through
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glycolysis in the pentose phosphate pathway [11]. As no xylitol is produced in this pathway,
much research focused on the XI pathway construction in xylose-fermenting yeast [12].
However, for all the engineered strains developed, rapid glucose and xylose co-fermentation
is still challenging, in particular when sugar concentration is high [4,8–10]. Because fermentation
time on mixed-substrate hydrolysates is still not cost-effective, strategies in evolutionary engineering
were used to improve fermentation kinetics [16–18] and much research focused on the search for
new or engineered sugar transporters [19–21]. More recently, robust diploid S. cerevisiae strains were
developed for rapid xylose-fermentation [22–25].
This study aims to develop a recombinant S. cerevisiae strain for rapid glucose and xylose
co-fermentation through metabolic engineering, evolutionary engineering and strain mating. Firstly,
four episomal plasmids containing the two-copy codon-optimized Piromyces sp. E2 XI gene (PirXylA,
GenBank accession number AJ249909.1), one-copy codon-optimized Orpinomyces sp. ukk1 XI gene
(OrpXylA, GenBank accession number EU411046), one-copy PirXylA and OrpXylA in tandem,
and two-copy OrpXylA, were individually constructed. They were subsequently transformed to
an evolved respiration-deficient yeast strain. Four engineered strains with episomal XI genes were
generated and optimal XI functional expression was identified. Afterwards, PirXylA and OrpXylA were
separately integrated into the genome of two evolved S. cerevisiae strains (one respiration-efficient and
the other respiration-deficient) in multiple copies according the methods described previously [26,27].
Four engineered yeasts with integrated XI genes were generated and screened for xylose fermentation
or glucose/xylose co-fermentation. In the end, a diploid recombinant xylose-fermenting S. cerevisiae
was constructed by mating a respiration-efficient haploid strain with a respiration-deficient haploid
strain. To the best of our knowledge, this is the first report on diploid xylose-fermenting yeast strain
construction by such strain mating. The resulted diploid yeast strain displayed superior glucose and
xylose co-fermentation performance, which far exceeded that by engineered S. cerevisiae reported
to-date [28,29].
2. Materials and Methods
2.1. Plasmid Construction
All plasmids used in this work are listed in Table 1. All primers used in this study are listed in
Table S1.
E. coli strain DH5α (Life Technologies, Rockville, MD, USA) were used as the transformation
host for plasmid construction. E. coli were grown in LB medium containing 100 μg/mL ampicillin
at 30 ◦C or 37 ◦C for plasmid maintenance [25]. The PGK1 promoter was amplified from
genomic DNA of S. cerevisiae strain ATCC 24860 and was ligated to pYES2 (Thermo-Fischer
Scientific, Singapore) to replace the GAL1 promoter, resulting in pPY1. PirXylA and OrpXylA
were synthesized by Integrated DNA Technologies Singapore). Cassettes PGK1p-OrpXylA-CYC1t,
PGK1p-PirXylA-CYC1t-PGK1p-OrpXylA-CYC1t, PGK1p-OrpXylA-CYC1t-PGK1p-OrpXylA-CYC1t and
PGK1p-PirXylA-CYC1t-PGK1p-PirXylA-CYC1t were cloned into pPY1 individually, resulting in
plasmids pPYXo, pPYXpXo, pPYXoXo and pPYXpXp (Figure 1A–D).
NTS2-2 partial fragment (pNTS) was obtained by overlap extension polymerase chain reaction
(OE-PCR) of S. cerevisiae ATCC 24860 genomic DNA over 274 bp upstream and 245 bp downstream
homologous regions of NTS2-2. The XXUN plasmid (Figure 1E) is an integrating yeast plasmid based
on pPYXpXp whereby the 2 μ origin was replaced with pNTS. The loxP-KanMX4-loxP cassette was
amplified from the plasmid pUG6 [30]. Cassettes PGK1p-OrpXylA-CYC1t and loxP-KanMX4-loxP-pNTS
were obtained by OE-PCR and then subsequently constructed into plasmid pUC19 [12], resulting in
plasmid XoNK (Figure 1F). Both plasmids were digested with SwaI for XI genome integration using
NTS2-2 homologous recombinant arms.
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Figure 1. Map of plasmids. (A) pPYXo; (B) pPYXpXo; (C) pPYXoXo; (D) pPYXpXp; (E) XXUN;
and (F) XoNK.
2.2. Strain Construction and Adaptive Evolution
All strains used in this work are listed in Table 1. S. cerevisiae haploid strains JUK36α and JUK39a
were isolated from the diploid strain S. cerevisiae ATCC 24860. They were both overexpressed with
the non-oxidative pentose phosphate pathway (PPP) genes and xylulokinase gene, XKS1. URA3 and
GRE3 genes were disrupted in both haploid strains. In addition, the CYC3 gene, encoding cytochrome
c heme lyase, was knocked out in strain JUK39a to eliminate respiration [12].
Plasmid pPYXpXp was transformed into strain JUK39a using the LiAc/SS carrier DNA/PEG
method [31], resulting in recombinant S. cerevisiae 39aXpXp. The respiration-deficient strain 39aXpXp
was evolved by continuous transfer and cultivation in a synthetic medium (SM) containing 6.7 g L−1
yeast nitrogen base without amino acids (YNB) (Difco Laboratories Inc., Detroit, MI, USA) and 20 g L−1
xylose (SMX) under oxygen-limited conditions according to the protocols described in our earlier
report [12]. After 75-day continuous transfer, cell doubling time was reduced from 15.9 h to 6.4 h.
Samples were taken on day 75 and streaked on SMX plates containing 20 g L−1 xylose and 20 g L−1
agar. Fifteen large single colonies were selected. They were then incubated in 50 mL SMX medium in
100 mL Erlenmeyer flasks capped with rubber stoppers, shaken at 200 rpm and 30 ◦C. Weight loss of the
cultures from the 15 colonies was individually measured on Day 4. The best ethanol-producing strain
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was indicated by the highest weight loss [18]. This strain was denoted 39aXpXp2415, and plasmid
pPYXpXp in this strain was removed by streaking the culture on 5-FOA plates [12]. This generated
the background strain 39a2 (Table 1). On the other hand, strain JUK51a_2 (Table 1) was evolved
anaerobically in a chemostat with an increase in the dilution rate from 0.01 to 0.14 h−1 on xylose using
the method described in our earlier report [12]. The fastest growing strain was selected, and the plasmid
pJFX11 was removed according to the above-described method on 5-FOA plates. The background
strain 36α2 was later obtained (Table 1).
Table 1. Strains and plasmids used in this study.
Strains/Plasmid Genotype/Phenotype References
Saccharomyces cerevisiae strains
Saccharomyces cerevisiae ATCC 24860 Obtained from American Type Culture Collection (ATCC)
JUK36α









JUK51a_2 JUK36α derivative; {pJFX11}/(BvuXylA, XK, PPP, gre3Δ) [12]
39aXpXp JUK39a derivative; {pPYXpXp}/(two-copy PirXylA, XK, PPP, gre3Δ, cyc3Δ) This work
39aXpXp2415 39aXpXp derivative; {pPYXpXp}/(two-copy PirXylA, XK, PPP, gre3Δ, cyc3Δ, AE) This work
36α2
Isolate from chemostat anaerobic and adaptive evolution at a dilution rate of 0.15
h−1 on xylose of JUK51a_2 and loss of plasmid pJFX11 This work
39a2 Isolate from 39aXpXp2415 and loss of plasmid pPYXpXp This work
39a2XpXp 39a2 derivative; {pPYXpXp}/(two-copy PirXylA, XK, PPP, gre3Δ, cyc3Δ) This work
39a2XpXo 39a2 derivative; {pPYXpXo}/(OrpXylA, PirXylA, XK, PPP, gre3Δ, cyc3Δ) This work
39a2Xo 39a2 derivative; {pPYXo}/(OrpXylA, XK, PPP, gre3Δ, cyc3Δ) This work
39a2XoXo 39a2 derivative; {pPYXoXo}/}/(two-copy OrpXylA, XK, PPP, gre3Δ, cyc3Δ) This work
36α2XpXpUN 36α2 derivative;NTS2-2::two-copy PirXylA, ura3, XK, PPP, gre3Δ This work
36α2XoNK 36α2 derivative;NTS2-2::OrpXylA-KanMX4, XK, PPP, gre3Δ, ura3Δ This work
39a2XpXpUN 39a2 derivative; NTS2-2::two-copy PirXylA, ura3, XK, PPP, gre3Δ, cyc3Δ This work
39a2XoNK 39a2 derivative; NTS2-2::OrpXylA-KanMX4, XK, PPP, gre3Δ, cyc3Δ, ura3Δ This work
STXQ Isolate from mating of 36α2XpXpUN with 39a2XoNK This work
Plasmids
pUG6 E. coli plasmid with segment loxP–KanMX4–loxP [30]
pJFX11 YEp, TEF1p-BvuXylA-CYC1t [12]
pPY1 pPYES2; GAL1p replaced by PGK1p This work
pPYXo pPY1; PGK1p-OrpXylA-CYC1t This work
pPYXpXp pPY1; 2 copies of PGK1p-PirXylA-CYC1t in tandem This work
pPYXpXo pPY1; PGK1p-PirXylA-CYC1t-PGK1p-OrpXylA-CYC1t This work
pPYXoXo pPY1; 2 copies of PGK1p-OrpXylA-CYC1t in tandem This work
XXUN pPYXpXp-based yeast integration plasmid; 2 μ and ura3 were replaced with ura3and NTS2-2 partial fragment This work
XoNK pUC19-based yeast integration plasmid;loxP-KanMX4-loxP-pNTS-PGK1p-OrpXylA-CYC1t This work
Plasmids pPYXo, pPYXpXo, pPYXoXo and pPYXpXp were individually transformed into 39a2,
resulting in strains 39a2Xo, 39a2XpXo, 39a2XoXo and 39a2XpXp, respectively. Plasmids XoNK and
XXUN were digested with SwaI and linearized. The linearized fragments were integrated into the
genome of 39a2 and 36α2 at the NTS2-2 site, individually, resulting in recombinant strains 39a2XoNK,
39a2XpXpUN, 36α2XoNK and 36α2XpXpUN. For each plasmid transformation, a pool of transformants
were generated. The best transformant was isolated based on its cell growth and ethanol production in
xylose medium as described in the isolation of 39aXpXp2415. Recombinant strains, 36α2XpXpUN and
39a2XoNK, were later mated to obtain strain STXQ through screening on SMX agar plates containing
20 g L−1 xylose at pH 6 followed by fermentation in SMX medium containing up to 250 g L−1 xylose.
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2.3. Enzyme Activity Assay
Cells were grown to the exponential phase in SMX medium containing 20 g L−1 xylose.
After centrifugation, cells were washed twice with chilled distilled water, and then lysed in chilled
extraction buffer (100 mM Tris-HCl, 10 mM MgSO4, pH 7.5) by vortex mixing using a Vortex Mixer
(Mixer UZUSIO, Tokyo, Japan) with 0.5 mg of 0.5 mm glass beads (Sigma-Aldirich, Singapore).
Protease inhibitor cocktail set V (Merck Millipore, Singapore) was added to inhibit serine and cysteine
generated in the lysis process. Cell debris was removed by centrifugation (Microcentrifuge D3024, DR.
LAB Technology Hong Kong, Hong Kong, China) at 4000× g for 10 min at 4 ◦C, and the crude extract
was stored for enzyme activity assay. The protein concentration of the cell extract was determined by
the Bradford Assay using a Coomassie Protein Assay Kit (Thermo Scientific, Singapore), and bovine
serum albumin (BSA) was used as the standard. Extraction of raw proteins from the yeast strains was
performed in duplicate.
The in-vitro XI activity was determined by measuring NADH absorbance using sorbitol
dehydrogenase (SDH) (Sigma Aldrich, Singapore). The assay mixture (1 mL) contained extraction
buffer, 0.15 mM NADH, 1 U SDH, and 50 μL crude extract. It was equilibrated at 30 ◦C for 2 min.
The reaction was started by the addition of D-xylose to a final concentration of 500 mM. The change of
NADH concentration within 3 min was detected using a UV-visible spectrophotometer (Shimadzu,
Tokyo, Japan) at wavelength 340 nm, and the specific activity of XI in the recombinant strains was
determined [32]. A molar extinction coefficient of 6.25 (mM cm)−1 at 340 nm for NADH was used to
calculate specific activity. Specific activity was expressed as units per mg protein. One unit of enzyme
activity was defined as the amount of enzyme required to oxidize 1 μmol of coenzyme/min, under the
specified reaction conditions [12].
2.4. Glucose and Xylose Fermentation by the Recombinant Strains
The preculture of the evolved engineered strains was prepared by growing them in 40 mL SMX
medium containing 20 g L−1 xylose in 100 mL Erlenmeyer flaks at 200 rpm and 30 ◦C for 24 h.
The oxygen-limited conditions in the flasks was maintained by capping the flasks with rubber stoppers
pierced with a needle to allow the release of CO2. Cells in the exponential phase were harvested
by centrifugation (Microcentrifuge D3024, DR. LAB Technology Hong Kong, Hong Kong, China)
at 14,000× g for 1 min. Cell pellets were washed twice and were then inoculated into SM medium
supplemented with 20 g L−1 xylose with (SMGX) or without 20 g L−1 glucose (SMX). The initial optical
cell density at 600 nm (OD600) of the culture was about 2 unless otherwise stated. Fermentation was
conducted in 100 mL Erlenmeyer shaking flasks under oxygen-limited conditions with a working
volume of 40 mL at 200 rpm and 30 ◦C. The pH value was adjusted at 5.0–6.0 using 3 M NaOH
during fermentation. All fermentation experiments were performed in duplicate. Samples were taken
periodically to measure OD600, sugar and metabolite concentration.
2.5. Analytical Methods
Cell densities (OD600) were determined using a UV-visible spectrophotometer (Shimadzu, Tokyo,
Japan). Fifty-mL cell cultures with varying OD600 (1–5) were filtered with 0.22 μm glass fiber
filter membrane (Merck Millipore, Singapore) using Aspirator A-3S (Fisher Scientific, Tokyo, Japan).
Cells were washed twice with distilled water, dried at 105 ◦C in an oven for 24 h, and then weighed.
One OD600 unit corresponded to 0.241 g L−1 dry cell weight (DCW). Concentrations of glucose, xylose,
xylitol, acetate, glycerol and ethanol produced in fermentation were determined by Agilent 1200 series
HPLC system (Agilent Technologies, Santa Clara, CA, USA) equipped with a refractive index detector
RID-10A using an Aminex HPX-87H ion exchange column (Bio-Rad Laboratories, Woodinville, WA,
USA). The column was eluted at 60 ◦C with 5 mM of sulfuric acid as the mobile phase at a flow rate of
0.6 mL min−1.
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2.6. Quantitative Reserve Transcription Polymerase Chain Reaction (RT-PCR)
Recombinant yeast strains 39a2Xo, 39a2XpXo, 39a2XoXo and 39a2XpXp were individually
cultivated in 40 mL SMX medium containing 20 g L−1 xylose under oxygen-limited conditions at
200 rpm and 30 ◦C. The expression of XI gene transcripts was determined by quantitative reverse
transcription polymerase chain reaction (qRT-PCR). Primers for RT-PCR are listed in Table S1. Samples
were taken at 24 h, and cells were harvested by centrifuging 2-mL culture at 14,000× g and 4 ◦C for
1 min. Cell pellets were washed twice using double distilled water and total RNA was isolated by
using the E.Z.N.A™ Yeast RNA Kit (Omega Bio-tek, Norcross, GA, USA). First-strand cDNA was
obtained by using the SuperScript® First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad,
CA, USA). Such cDNA was then used as the template for qRT-PCR using iCycler iQ™ Real-time PCR
Detection System (Bio-Rad Laboratories, Woodinville, WA, USA) and FastStart Universal SYBR Green
Master (Roche Applied Science, Penzberg, Germany). The cycle threshold values were calculated
with the Optical System Software Version 3.1 (Bio-Rad Laboratories, Woodinville, WA, USA), and the
detection threshold over the cycle range was set at 2 to 10. Each PCR was carried out in duplicate.
All kits were used under conditions recommended by the manufacturers. The 2−ΔΔCt method [33]
was used to analyze the relative changes in gene expression using the housekeeping ACT1 gene as
the reference.
2.7. Biomass Hydrolysate Fermentation Using Strain S. cerevisiae STXQ
The diploid recombinant S. cerevisiae strain STXQ (Table 1) was inoculated into YP medium (10
g L−1 yeast extract, 20 g L−1 peptone, pH 5.0) containing 132 g L−1 xylose or mixture of 162 g L−1
glucose and 95 g L−1 xylose at an initial OD600 of about 13. Fermentation was conducted in 40 mL YP
medium in 100 mL shaking flasks under oxygen limited conditions at 200 rpm and 30 ◦C.
Oil palm empty fruit bunch (OPEFB) hydrolysate was obtained using crude cellulase from
Trichoderma reesei Rut-C30 according to the protocols described in our earlier report [34]. OPEFB
hydrolysate was sterilized using 0. 22 μm filter membrane (Merck Millipore, Singapore) and was
supplemented with 7 g L−1 yeast extract 2 g L−1 peptone, 2 g L−1 (NH4)2SO4, 2.05 g L−1 KH2PO4,
and 0.25 g L−1 Na2HPO4. The diploid recombinant S. cerevisiae strain STXQ was inoculated into the
above OPEFB hydrolysate medium with an initial OD600 about 5. Fermentation was carried out in
40 mL fermentation medium in 100 mL shaking flasks under oxygen-limited conditions at 200 rpm
and 30 ◦C with an initial pH of 4.48. Samples were taken periodically for OD600, sugar and metabolite
analysis. Experiments were conducted in duplicate.
3. Results
3.1. Expression of XIs with Various Combinations
XI activities were assayed for 39a2 recombinant strains with episomal XI genes (Table 2). XI activity
of 39a2XoXo was three times higher than that of 39a2XpXp and 2.5 times higher than that of 39a2Xo.
Strain 39a2XoNK presented the highest XI activity among all the yeast strains with integrated XI genes,
followed by 39a2XpXpUN. Quantitative RT-PCR showed that the transcription level of XI gene in
the engineered strains significantly increased compared to that in the parent strain 39a2 (Table 3).
In 36α2XpXpUN and 39a2XoNK, respective 1.04-fold and 1.41-fold increases in XI gene transcription
levels were observed compared to those in 39a2XpXp and 39a2XoXo. Inconsistent XI activity and
transcription level were observed.
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Table 2. Specific activity of xylose isomerase in the recombinant strains.
Strains Specific Activity (U mg−1 Protein)
39a2XpXp 0.10 ± 0.003
39a2XpXo 0.11 ± 0.019
39a2Xo 0.12 ± 0.041
39a2XoXo 0.30 ± 0.079
36α2XpXpUN 0.11 ± 0.007
36α2 XoNK 0.04 ± 0.005
39a2XpXpUN 0.26 ± 0.004
39a2XoNK 0.72 ± 0.006
The results represent the mean ± standard deviation of duplicate independent experiments.




39a2XpXp 50.21 (47.81–52.74) nil
39a2XpXo 29.86 (28.43–31.36) 11.71 (10.62–12.92)
39a2Xo nil 59.71 (51.98–68.59)
39a2XoXo nil 59.71 (55.72–64)
36α2XpXpUN 51.98 (49.50–54.60) nil
39a2XoNK nil 84.45 (59.71–119.43)
a Fold-change of XI mRNA level in the recombinant yeast strains compared to the parent strain 39a2. Results were
based on duplicate independent real-time RT-PCR reactions.
3.2. Glucose and Xylose Fermentation by the Engineered 39a2 Strains Harboring Episomal XI Genes
Fermentation performance of 39a2 recombinant strains with episomal XI genes was tested in SMX
medium containing 20 g L−1 xylose under oxygen-limited conditions. Apparently, strain 39a2XpXp
displayed the fastest xylose utilization rate, followed by 39a2XoXo (Figure 2). Strain 39a2XpXo utilized
xylose more slowly than 39a2XpXp, though it demonstrated almost the same XI activity (Table 2).
On the other hand, strain 39a2XoXo showed a faster xylose utilization rate than strain 39a2Xo; however,
the former displayed much higher activity than the latter. On the contrary, xylose utilization results
accorded quite well with the results of qRT-PCR analysis showing that strain 39a2XpXp had higher XI
gene transcription levels than strain 39a2XpXo (Table 3) and a faster xylose utilization rate (Figure 2).
However, strains 39a2XoXo and 39a2Xo displayed identical XI gene transcription levels (Table 3),
almost the same xylose consumption rate (Figure 2) and xylose conversion (Table 4). Interestingly,
strain 39a2XpXp also exhibited the maximal ethanol yield of 0.472 g g−1 (Table 4). Such results suggest
that expression of two-copy PirXylA is favorable for xylose alcoholic fermentation when xylose is used
as the sole carbon source.
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Figure 2. Sugar fermentation under oxygen-limited conditions by the engineered S. cerevisiae
strains in SM medium containing 20 g L−1 xylose (SMX) or 20 g L−1 glucose and 20 g L−1 xylose
(SMGX). (A) 39a2XpXp SMX; (B) 39a2XpXo SMX; (C) 39a2Xo SMX; (D) 39a2XoXo SMX; (E) 39a2XpXp
SMGX; (F) 39a2XpXo SMGX; (G) 39a2Xo SMGX; (H) 39a2XoXo SMGX. The results represent the
mean ± standard deviation of duplicate independent experiments (p < 0.01).

















39a2xpXp a - 20 98% ± 0.004 0.472 ± 0.013 0.098 ± 0.004 0.014 ± 0.001
39a2XpXo a - 20 89.8% ± 0.011 0.434 ± 0.017 0.098 ± 0.004 0.011 ± 5.89 × 10−6
39a2Xo a - 20 97.3% ± 0.0138 0.428 ± 0.026 0.084 ± 0.001 0.011 ± 0.0003
39a2XoXo a - 20 98.5% ± 0.0057 0.449 ± 0.038 0.108 ± 0.001 0.013 ± 2.29 × 10−5
36α2XpXpUN a - 20 86.4% ± 0.052 0.318 ± 0.01 0.069 ± 0.007 0.014 ± 0.0003
36α2XoNK a - 20 6.42% ± 0.057 ND ND 0.003 ± 0.0006
39a2XpXpUNa - 20 67.0% ± 0.089 0.398 ± 0.048 0.067 ± 0.001 0.013 ± 0.0002
39a2XoNK a - 20 99.0% ± 0.002 0.368 ± 0.029 0.107 ± 0.007 0.0098 ± 0.0003
39a2XpXp a 20 20 22.0% ± 0.003 0.444 ± 0.029 0.221 ± 0.020 0.020 ± 0.0007
39a2XpXo a 20 20 77.5% ± 0.017 0.392 ± 0.001 0.081 ± 0.006 0.022 ± 0.0001
39a2Xo a 20 20 84.3% ± 0.0007 0.428 ± 0.01 0.238 ± 0.003 0.021 ± 0.0004
39a2XoXo a 20 20 96.7% ± 0.011 0.449 ± 0.022 0.213 ± 0.004 0.021 ± 0.001
36α2XpXpUN a 20 20 73.8% ± 0.011 0.348 ± 0.049 0.225 ± 0.007 0.029 ± 0.0006
36α2XoNK a 20 20 2.62% ± 0.000 0.390 ± 0.043 0.222 ± 0.003 0.016 ± 0.0013
39a2XpXpUN a 20 20 25.6% ± 0.097 0.405 ± 0.049 0.213 ± 0.002 0.013 ± 0.0002
39a2XoNK a 20 20 97.3% ± 0.006 0.387 ± 0.002 0.243 ± 0.003 0.020 ± 0.0005
36α2XpXpUN b - 40 75.9% ± 0.041 0.384 ± 0.033 0.108 ± 0.011 0.013 ± 0.0004
39a2XoNK b - 40 81.6% ± 0.004 0.421 ± 0.004 0.131 ± 0.000 0.010 ± 0.0003
STXQ b - 40 93.3% ± 0.019 0.393 ± 0.024 0.146 ± 0.009 0.017 ± 0.0002
STXQ b - 132 100% 0.498 ± 0.006 1.13 ± 0.01 0.014 ± 0.0004
STXQ c 162 95 99.27% ± 0.002 0.475 ± 0.01 5.24 ± 0.02 0.024 ± 0.0001
a Fermentation in SM medium in 72 h; b Fermentation in YP medium in 102 h; c Fermentation in YP medium.
The results represent the mean ± standard deviation of duplicate independent experiments.
Co-fermentation of 20 g L−1 glucose and 20 g L−1 xylose was carried out in SM medium under
oxygen-limited conditions. It can be seen that for all strains, glucose was almost completely consumed
at 24 h (Figure 2). However, xylose utilization varied greatly for the four engineered 39a2 strains.
Noticeably, in the presence of 20 g L−1 glucose, strain 39a2XpXp utilized xylose quite slowly and about
22% xylose was consumed at 72 h (Table 4). On the other hand, xylose utilization was improved to
77.5% by strain 39a2XpXo. Moreover, xylose consumption was improved to 84.3% by strain 39a2Xo
and it was further improved to 97% by 39a2XoXo (Table 4). It is worth noting that strain 39a2XoXo
presented the highest ethanol yield (0.449 g g−1). The above results suggest that the expression of
two-copy of OrpXylA is beneficial for glucose and xylose co-fermentation.
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3.3. Glucose and xylose Fermentation by the Engineered Yeast Strains Harboring Integrated XI Genes
Fermentation performance of 39a2 recombinant strains with integrated XI genes was tested in SM
medium containing 20 g L−1 xylose (SMX) or 20 g L−1 glucose and 20 g L−1 xylose (SMGX) under
oxygen-limited conditions (Figure 3). In SMX fermentation, the specific growth rate of 36α2XpXpUN
on xylose was 0.014 h−1, much higher than that of 36α2XoNK (0.003 h−1), whereas xylose conversion
by strain 39a2XoNK was 99.0%, much higher than that by 39a2XpXpUN (67.0%) (Table 4). In SMGX
fermentation, the specific growth rate of 36α2XpXpUN on xylose was 0.029 h−1, much higher
than that of 36α2XoNK (0.016 h−1), whereas xylose conversion by strain 39a2XoNK was 97.30%,
much higher than that by 39a2XpXpUN (73.8%) (Table 4). In both SMX and SMGX fermentation,
strain 36α2XpXpUN presented the best cell growth, whereas strain 39a2XoNK displayed the best
xylose conversion. Furthermore, strain 39a2XoNK exhibited the highest ethanol productivity in
both SMX and SMGX fermentation. Despite the possible XI gene copy number variation in these
strains, the above results demonstrated that the elimination of respiration was favorable for xylose
fermentation, which corroborated quite well with previous reports [12,14]. Strains 36α2XpXpUN and
39a2XoNK were therefore selected for mating to generate the diploid recombinant strain STXQ to
attain good cell growth and xylose fermentation.
3.4. Glucose and xylose Fermentation by Diploid Recombinant Strain STXQ
Fermentation performance of STXQ was tested in YP medium containing 40 g L−1 xylose under
oxygen-limited conditions. As expected, strain STXQ inherited the advantages of both parent strains,
36α2XpXpUN and 39a2XoNK. It presented 93.3% xylose conversion and a specific growth rate of
0.017 h−1; both were higher than those of its parent strains (Table 4). In addition, ethanol productivity
was greatly improved (Figure 3, Table 4). A very minimum amount of glycerol was produced by
STXQ, although glycerol production was notable for the respiration-deficient parent strain 39a2XoNK
(Figure 3). Moreover, production of xylitol and acetate was almost undetectable.







































































































Figure 3. Xylose fermentation in YPX medium containing 40 g L−1 xylose under oxygen-limited
conditions. (A) 36α2XpXpUN; (B) 39a2XoNK; (C) STXQ. The results represent the mean ± standard
deviation of duplicate independent experiments (p < 0.01).
Fermentation performance of strain STXQ was further invested in YP medium containing
high-concentration sugar. With an initial OD600 of about 13, strain STXQ consumed 100% xylose in
fermenting 132 g L−1 xylose and produced 65.8 g L−1 ethanol at 46 h. The corresponding ethanol yield
was 0.498 g g−1 (Figure 4A, Table 4). In fermentation of 162 g L−1 glucose and 95 g L−1 xylose with
about the same initial OD600, more than 99% glucose and xylose were co-utilized within 23 h (Figure 4B,
Table 4). Ethanol titer reached 120.6 g L−1 corresponding to an ethanol volumetric productivity of
5.26 g L−1 h−1. These are so far the highest values compared to those reported in the literature.
The above results indicate that the strain development strategy elaborated in this study is efficient in
generating a robust S. cerevisiae strain with improved xylose fermentation capabilities.
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Figure 4. High-titer sugar fermentation under oxygen-limited conditions by strain STXQ in YP
media. (A) Xylose fermentation in YPX medium containing 132 g L−1 xylose; (B) Glucose and xylose
co-fermentation in YPGX medium containing 162 g L−1 glucose and 95 g L−1 xylose. The results
represent the mean ± standard deviation of duplicate independent experiments (p < 0.01).
3.5. Oil Palm Empty Fruit Bunch Hydrolysate Fermentation by Diploid Recombinant Strain STXQ
Fermentation performance of strain STXQ was further tested in OPEFB hydrolysate containing
41.81 g L−1 glucose, 30.00 g L−1 xylose, 7 g L−1 yeast extract, 2 g L−1 peptone, 2 g L−1 (NH4)2SO4,
2.05 g L−1 KH2PO4, and 0.25 g L−1 Na2HPO4 under oxygen-limited conditions with an initial OD600
of about 10. Strain STXQ consumed 95.3% glucose and 88.9% xylose (Figure 5). The pH value decreased
from 4.48 to 4.00 within 72 h. Strain STXQ consumed 94.0% total sugar from the OPEFB hydrolysate
without detoxification. The specific cell growth rate (μmax) reached 0.013 h−1 and the ethanol yield was
0.420 g g−1. Glucose was quickly consumed, and glucose-xylose co-fermentation was clearly observed
within 24 h. Subsequently, ethanol concentration kept increasing with almost the sole consumption of
xylose until it reached the final titer of 28.4 g L−1 at 72 h.


































Figure 5. Sugar fermentation under oxygen-limited conditions by strain STXQ in oil palm empty fruit
bunch hydrolysate supplemented with 7 g L−1 yeast extract, 2 g L−1 peptone, 2 g L−1 (NH4)2SO4,
2.05 g L−1 KH2PO4, and 0.25 g L−1 Na2HPO4. The results represent the mean ± standard deviation of
duplicate independent experiments (p < 0.01).
4. Discussion
Episomal plasmids containing OrpXylA, PirXylA and OrpXylA in tandem, two-copy PirXylA and
two-copy OrpXylA expression cassettes (Figure 1) were transformed into the background strain 39a2
individually. Among all the 39a2 strains harboring episomal XI genes, strain 39a2XpXp presented
the fastest rate of xylose utilization when xylose was used as the sole carbon source. However, it did
not exhibit the highest XI activity and transcription level (Tables 2 and 3). Inconsistent XI activity
and transcription level in recombinant xylose-fermenting S. cerevisiae strain was reported and it
could be due to rearrangement of pentose phosphate pathway (PPP) genes, decreased glycolysis
activity, repressed respiration activity, and enhanced gluconeogenesis [35]. Besides XI activity, the
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enhanced xylose utilization and fermentation could be associated with the elevated expression of sugar
transporter genes, non-oxidative pentose phosphate pathway (PPP) genes such as TAL1, TKL1, RKI1,
and RPE1 and xylulokinase gene, XKS1 [19,20,25,36].
For glucose and xylose co-fermentation, strain 39a2XoXo presented the best glucose and xylose
co-utilization (Figure 2) and exhibited the highest xylose conversion (96.7%) (Table 4). S. cerevisiae does
not contain specific xylose transporters. Xylose was therefore transported by glucose transporters.
Xylose affinity for the glucose transporters was very low at a high glucose concentration; however,
it could increase to a similar level of glucose affinity at low glucose concentration [19,20]. As a result,
diauxic lag is still a practical problem associated with mixed sugar utilization by xylose-fermenting
yeasts. However, the diauxic growth was not significant for strains expressing OrpXylA, 39a2Xo and
39a2XoXo (Figure 2). The above results and analysis suggest that expression of OrpXylA is beneficial
for glucose and xylose co-fermentation. This is consistent with a previous report [37].
Chromosomal integration of the XI gene into the S. cerevisiae genome has received a significant
amount of attention in recent years [25,26]. It allows the recombinant strain to retain its physiological
characteristics in nonselective medium. In the present study, multiple copies of XI genes were integrated
at the 18S rDNA sites based on random homologous recombination. Such genome integration led to
stable recombinant yeast strains (Figure S1) and boosted XI activity to 0.72 U mg−1 protein in 39a2XoNK
(Table 2). Such improvement might be associated with the multiple copies of XI integrated in the
yeast genome [25]. This further led to high XI transcription levels (Table 3), high xylose conversion
and ethanol production (Table 4). Such results accorded quite well with earlier reports [25,26,36].
Notably, among these strains, 39a2 strains with integrated XI genes presented higher XI activity and
transcription level than 36α2 strains (Tables 2 and 3). This further confirmed that the elimination of
respiration was favorable for xylose fermentation [12,14].
S. cerevisiae strains are regarded as industrial working horses for ethanol production owing to
their high ethanol titer and sugar tolerance. Mating is one of the traditional yeast breeding methods
to develop improved S. cerevisiae strains without genetic modifications [38]. Through strain mating,
robust diploid S. cerevisiae strains were developed for enhanced xylose-fermentation and inhibitor
resistance [23,24]. In the present work, a recombinant diploid S. cerevisiae strain STXQ was obtained by
mating respiration-dependent strain 36α2XpXpUN with the respiration-deficient strain 39a2XoNK.
Such strain mating enabled strain STXQ to present improved cell growth, xylose utilization and ethanol
production (Figure 4, Table 4).
For glucose-xylose co-fermentation by engineered laboratory S. cerevisiae strains, higher ethanol
concentration of ~60 g L−1 was reported by Ho et al. [39] (Table 5). An ethanol titer of 47.5 g L−1 was
obtained by recombinant S. cerevisiae RWB218 expressing PirXylA [40]. About 53 g L−1 ethanol titer was
reported by Diao and his colleagues using the diploid recombinant S. cerevisiae strain CIBTS0735 [22].
Demeke et al. obtained an inhibitor-resistant recombinant S. cerevisiae through metabolic engineering
and adaptive evolution [18]. It utilized glucose and xylose rapidly with ethanol titer up to 46 g L−1 and
ethanol productivity of 2.58 g L−1·h−1. This is the highest volumetric ethanol productivity reported
to-date in the literature. More recently, about 58 g L−1 ethanol titer was obtained by a diploid
recombinant yeast strain LF1 developed from a wild-type S. cerevisiae strain in YP medium [25]. Strain
STXQ yielded 65.8 g L−1 ethanol with an ethanol yield of 0.50 g g−1 at 56 h in YPX medium containing
132 g L−1 xylose (Figure 4A, Table 4). Further glucose-xylose co-fermentation produced 120.6 g L−1
ethanol with an ethanol yield of 0.48 g g−1 at 23 h in YP medium containing 162 g L−1 glucose and
95 g L−1 xylose. The corresponding volumetric ethanol productivity reached 5.24 g L−1·h−1. (Figure 4B,
Table 4). Both ethanol titer and volumetric productivity far exceeded the results in previous reports.
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The OPEFB hydrolysate fermentation result demonstrated that strain STXQ could co-ferment
glucose and xylose without detoxification, with 95.3% glucose conversion and 88.9% xylose conversion
at 72 h (Figure 5). Ethanol titer reached 28.4 g L−1 at 72 h with an ethanol yield of 0.420 g g−1. Strain
STXQ has potential in the conversion of lignocellulosic biomass hydrolysate to ethanol. These results
suggest that the strain development protocols outlined in this study are effective in obtaining robust
xylose-fermenting yeast strains for industrial applications.
5. Conclusions
A recombinant haploid strain containing plasmids harboring two-copy PirXylA presented the
best xylose utilization among the engineered yeast strains harboring episomal XI genes when xylose
was used as the sole carbon source. On the other hand, the strain containing plasmids with two-copy
OrpXylA exhibited the best glucose and xylose co-fermentation. Respiration-deficient 39a2 strains
harboring the OrpXylA gene were favorable for xylose fermentation and glucose-xylose co-fermentation
in the engineered yeast strains. Chromosome integration of XI genes in S. cerevisiae resulted in high XI
activity, high XI transcription levels, and improved xylose fermentation. Mating the respiration-efficient
strain 36α2XpXpUN with the respiration-deficient strain 39a2XoNK resulted in a diploid recombinant
S. cerevisiae strain STXQ with enhanced cell growth and xylose fermentation. Strain STXQ demonstrated
superior glucose and xylose co-fermentation performance. It produced 120.6 g L−1 ethanol with a
volumetric productivity of 5.24 g L−1 h−1, the highest among those reported to-date. Such superior
performance by strain STXQ is largely associated with its development process, in particular with
strain adaptive evolution, XI gene chromosome integration and strain mating.
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Abstract: Development of a counter-selection method for phenylalanine auxotrophy could be a useful
tool in the repertoire of yeast genetics. Fluorinated and sulfurated precursors of phenylalanine were
tested for toxicity in Saccharomyces cerevisiae. One such precursor, 4-fluorophenylpyruvate (FPP),
was found to be toxic to several strains from the Saccharomyces and Candida genera. Toxicity was
partially dependent on ARO8 and ARO9, and correlated with a strain’s ability to convert FPP
into 4-fluorophenylalanine (FPA). Thus, strains with deletions in ARO8 and ARO9, having a
mild phenylalanine auxotrophy, could be separated from a culture of wild-type strains using FPP.
Tetrad analysis suggests FPP resistance in one strain is due to two genes. Strains resistant to FPA
have previously been shown to exhibit increased phenylethanol production. However, FPP resistant
isolates did not follow this trend. These results suggest that FPP could effectively be used for
counter-selection but not for enhanced phenylethanol production.
Keywords: fluorinated compounds; counter selection; phenylalanine; phenylethanol; yeast
1. Introduction
The phenylalanine biosynthetic pathway is a route to production of the high-value chemical
2-phenylethanol that is used for its rosy scent in cosmetics, foods, and cleaning supplies [1].
Phenylethanol is produced mainly by synthetic chemical processes but also naturally by yeast,
as a degradation product of phenylalanine, moving through the intermediate metabolites of
phenylpyruvate then phenylacetaldehyde (Figure 1). In Saccharomyces cerevisiae, one method of
increasing the production of these chemicals is to select for resistance to the fluorinated phenylalanine
analog 4-fluorophenylalanine (FPA) [2]. One facet of the mechanism of resistance is enhanced
endogenous production of phenylalanine, thus requiring less dependence on exogenously provided
phenylalanine [3]. Hence, FPA can be used to increase production of phenylethanol.
There are numerous counter-selection methods for a variety of genes. One method, the use of
toxic metabolites to counter-select for auxotrophies such as uracil or tryptophan, has been a boon
in yeast genetics, enabling numerous techniques such as the plasmid shuffle and Synthetic Genetic
Array analysis [4–6]. These techniques rely on adding a fluorine to a precursor of the final biosynthetic
pathway product, such that use of the fluorinated precursor results in a fluorinated end-product, which
is toxic to the cell. There are many potential mechanisms of resistance to toxic precursors. One such
mechanism is the prohibition of toxic metabolite import, as in the case of canavanine resistance via
abrogation of the arginine transporter [4]. Another is to decrease endogenous production of the
precursor while relying on exogenous end-product for growth, as in the case of deletion of URA3
and reliance upon external uracil for 5-fluoroorotic acid resistance. In the case of resistance to a toxic
end-product, one mechanism of resistance is via increasing endogenous production of the end-product
so as to decrease exogenous nutrient dependence, such as in the case of increased phenylalanine
production in response to fluorophenylalanine [3].
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We sought to identify toxic precursors to the phenylalanine biosynthetic pathway that could be
used for auxotrophic counter-selection, and that may lead to increased production of phenylethanol.
OH
Figure 1. Diagram of the yeast pathway for biosynthesis of tryptophan, tyrosine, and phenylalanine.
Number of enzymes and steps are indicated by number of arrows.
2. Materials and Methods
2.1. Media and Growth Conditions
Rich medium, or YPD, was made with BactoTM Yeast Extract at 10 g L−1 (Becton Dickinson,
Franklin Lakes, NJ, USA), BactoTM Peptone at 20 g L−1 (Becton Dickinson), and dextrose at 20 g L−1
(Fisher Scientific, Waltham, MA, USA). Minimal medium contains 1.8 g L−1 yeast nitrogen base
without amino acid or ammonium sulfate and 6.2 g L−1 ammonium sulphate and dextrose at
20 g L−1. Synthetic complete medium contains minimal medium with 20 mg L−1 of all the following
compounds: uracil, lysine, tyrosine, tryptophan, phenylalanine, adenine, leucine, histidine, and
methionine. For clarification, the phenylalanine-related chemicals used in this paper are described in
Table 1, their molecular structures are shown in Figure 2.
F
Figure 2. Analogs of phenylpyruvate and phenylalanine tested.
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Table 1. List of phenylalanine-related drugs used.
Chemical Name Abbreviation CAS # Source
4-fluorophenylalanine FPA 1132-68-9 Chem-Impex
4-fluorophenylpyruvate FFP 7761-30-0 Enamine
2-thienylpyruvate 2TP 15504-41-3 Enamine
3-thiolproprionate 3TP 16378-06-6 Enamine
L-3-thienylalnine L3T 3685-51-6 Sigma
Chem-Impex (Wood Dale, IL, USA);Enamine (Monmouth Jct., NJ, USA); Sigma (St. Louis, MO, USA). CAS# refers
to Chemical Abstracts Service registry number for indicated compound.
Experiments using FPA, FPP, 2TP, 3TP, or L3T were performed in MM2 medium, which consists
of minimal medium with 2 mg L−1 of all the following compounds: uracil, tyrosine, phenylalanine,
leucine, histidine, and methionine. Chemicals FPA, 2TP, 3TP, or L3T were suspended in water, while
FPP and FPA were suspended in dimethyl sulfoxide (DMSO).
Culture density was determined by a spectrophotometer reading of the optical density at 600 nm,
which was correlated to cell density via hemocytometer counts. Strains used are listed in Table 2.
Strains mentioned with a dash (e.g., S288c-3) are derivatives of the parental strain named preceding
the dash. Mutation cultures were obtained by exposure to ultraviolet light at 230 nm for 10 s that
resulted in viability between 30–70% as measured by methylene blue.
Table 2. List of yeast strains used.
Strain Genotype Source
26704c MATα ura3 aro8-2 aro9-1 [7]
BY4700 MATα S288c ura3Δ0 ATCC
BY4742 MATα S288c his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 ATCC
A364A MATa ade1 ade2 ura1 his7 lys2 tyr1 gal1 ATCC
AW051 MATa ura3 aro8-2 aro9-1 This study
AW052 MATa ura3 aro8-2 aro9-1 This study
AW063 MATα ade2 pha2 arg8 lys2 This study
AW077 MATα ade2 ura1 This study
AW081 MATa ura1 his7 This study
AW083 MATα lys2 ade1 ade2 This study
AW102 MATa/MATα wild-type This Study
AW108 MATα S288c pha2::G418 This study
AW109 MATα S288c pha2::G418 This study
AW258 MATα ura1 This study
AW259 MATα his7 This study
AW261 MATα met15 This study
IM006 MATα lys2 This study
Calb Candida albicans ATCC 10231 Gift from Darlene Miller
Ctrop Candida tropicalis Gift from Darlene Miller
S288c MATα SUC2 mal mel CUP1 flo1 flo8-1 hap1 ATCC
SPara lys2 Saccharomyces paradoxus Gift from Doug Koshland
SBaya ura3 Saccharomyces bayanus Gift from Doug Koshland
American Type Culture Collection (ATCC)
Drug resistance was measured by calculating the relative viability of cells, which is the number of
viable cells resulting from a drug treated culture divided by the number of viable cells resulting from a
carrier treated (water or DMSO) culture. Viability was measured as colony forming units on a petri
dish by directly plating cells to a plate or by first serially diluting in water, then pinning to drug and
carrier plates (frogging method) or by using the Tadpoling method, discussed below. For timecourse
experiments, relative viability was calculated by using the number of viable cells at timepoint zero as
the denominator in all subsequent timepoints.
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Briefly, the Tadpoling method consists of inoculating 20 μL of yeast containing culture into
180 μL YPD in a well of a 96-well plate and serially diluting 20 μL from this well to subsequent
wells [8]. This plate is incubated until individual colonies can be counted in the most dilute well,






Growth rate was calculated using the following expression: where ODin is the initial A600, ODfin
is the final A600, hours is the number of hours in between A600 readings.
2.2. Determination of Phenylethanol and Phenylalanine
After growth in 2 mg L−1 uracil, tyrosine, phenylalanine, leucine, histidine, and methionine
with 1.8 g L−1 yeast nitrogen base without amino acid or ammonium sulfate with 20 g L−1 dextrose
and 6 g L −1 phenylalanine for 6–8 days at 30 ◦C, culture supernatant was removed and selected
ion monitoring (SIM) was performed to detect phenylethanol and phenylalanine using liquid
chromatography-tandem mass spectrometry (LC-MS/MS). A gradient was run from 100% 50 mM
ammonium acetate to 100% methanol with 0.1% formic acid over the course of 20 min. Phenylethanol
retention time was 12.5 min while that of phenylalanine was 4.5.
2.3. Determination of Fluorophenylalanine
Yeast samples were grown in medium containing FPP at a concentration of 200 mg L−1 for 16 h
then yeast samples were resuspended in 70% ethanol, boiled for 10 min, then the supernatant was
transferred to a new tube and after evaporated in a spinning-vacuum centrifuge. Samples were
fully dissolved in 1 mL of 3:1:1 water:acetronitrile:isopropanol, with 2 min of vortexing and 20 min
sonication. The resulting solutions were 5× diluted (200/1000) in 10 mM ammonium formate in
water (mobile phase A) and was injected in the LC-MS/MS system, an AB Sciex QTRAP 5500
Triple-Quadrupole mass spectrometer, equipped with a Turbospray ESI source. A binary gradient
separation program was employed using a reverse phase HPLC column (Dionex Acclaim 120 C18
Column, 250 × 2.1 mm, 5 μm). Sample injection (20 μL) and LC separation was performed by a
Shimadzu Prominence LC-20AD Ultra-Fast Liquid Chromatograph.
3. Results
First, we sought to identify a toxic phenylalanine analog and work backward to design toxic
phenylalanine precursors. Two promising toxic phenylalanine analogs were identified from the
literature: L-3-thienylalanine (L3T), consisting of phenylalanine with the benzene ring substituted
for thiophene, and fluorophenylalanine (FPA), consisting of phenylalanine with a fluorine attached
to the benzene ring (Figure 2, Table 1). A 2.6 mg L−1 concentration of L-3-thienylalanine has been
shown to inhibit growth of S. cerevisiae by 50% [9]. First, the toxicity of L3-thienylalanine was tested by
plating wild-type strains S288c and AW077 to medium with L3-thienylalanine at 0 or 300 mg L −1 and
determining the relative viability. L3T killed all AW077 cells and nearly all of S288c cells (Figure 3a).
Next the toxicity of FPA was tested by plating strains S288c and AW077 onto medium containing
FPA at 0 or 300 mg L−1 and determining the relative viability (Figure 3b). FPA at both of these
concentrations killed almost all cells of S288c and AW077. Thus, we reconfirmed that L3T and FPA are
toxic to S. cerevisiae.
Next, we sought to design a molecule that may be enzymatically converted to a toxic
phenylalanine analog. By identifying a toxic phenylalanine precursor, we could use this compound to
select for strains that have mutations in the phenylalanine biosynthetic pathway. We considered several
precursors of phenylalanine; chorismate (this precursor is used to synthesize not only phenylalanine,
but also tryptophan, tyrosine, folate, and ubiquinone). Thus, a strain with a chorismate deletion would
have numerous other auxotrophies besides phenylalanine. Next, prephenate—however, this is not
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a good candidate for this particular intervention as adding fluorine or sulfur on the cyclohexadiene
ring could interfere with transformation to a benzene ring. Additionally, there seems to be at least two
mechanisms to convert prephenate to phenylalanine, as we found that deletion of PHA2 does not confer
complete phenylalanine requirement. To test this, strains lacking PHA2 were inoculated alongside a
strain with functioning PHA2 in minimal medium with or without phenylalanine added (Figure 4,
Table 3). The A600 was measured over four days, and maximum growth rate (lowest doubling time)
was calculated. Strains AW108 and AW109 grew much better with phenylalanine added (Table 3),
showing the dependency on phenylalanine; however, they still grew over time. This is in contrast to
previously described observations of strains lacking PHA2. However, it is likely that the extremely
slow growth rate explains this conclusion (Figure 4) [10]. The next candidate is phenylpyruvate,
which does not require modification of its benzene ring prior to becoming phenylalanine, and it is
the substrate for only two essentials molecules: phenylalanine and tyrosine. Use of phenylpyruvate
has one drawback: there are two primary enzymes that can complete the transamination reaction
converting phenylpyruvate to phenylalanine (ARO8 and ARO9) and several others that are predicted









Figure 3. Viability of yeast in response to toxic phenylalanine or phenylpyruvate analogs. Cultures of
yeast strains were serially diluted in water then plated onto medium containing either (a) L3T, 3TP, 2TP
or (b) FPA, FPP, or (c) dimethyl sulfoxide, FPA. Relative viability was obtained by dividing the number
of colony forming units (CFUs) from drug plates by CFUs from YPD plates. Plates were incubated for
2–3 days and CFUs counted. The average and standard deviation of three independent trials is shown.
Table 3. Density of two-day-old cultures.
Strain Genotype MM + U a MM + UP b
AW108 pha2 0.06 3.8
AW109 pha2 0.08 3.6
AW051 aro8 aro9 ura3 0.37 1.1
AW052 aro8 aro9 ura3 1.2 2.2
BY4700 ura3 3.6 3.7
MM: Minimal Medium a Minimal medium with 20 mg L−1 uracil, b Minimal medium with 20 mg L−1 of uracil
and phenylalanine.
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Figure 4. Growth rate of strains in medium lacking phenylalanine. The indicated strains were grown
overnight in synthetic complete medium then washed and inoculated to minimal medium with uracil
and rotated at 23 ◦C. The A600 was measured over subsequent hours. Max growth was the lowest
growth rate calculated for all points tested.
This presents a problem for selection, as strains would need to have deletions in two genes, rather
than just one, in the case of uracil (URA3), lysine (LYS2), or arginine (CAN1) [6,12,13]. To test if ARO8
and ARO9 were required for phenylalanine production, strains lacking ARO8 and ARO9 (AW051,
AW052) were constructed and inoculated alongside a wild-type strain in minimal medium with or
without phenylalanine added (Figure 4, Table 3).
The A600 was measured over four days, and maximum growth rate (lowest doubling time) was
calculated. Strains AW051 and AW052 grew much better with phenylalanine added (Table 3), showing
their dependency on phenylalanine. However, they still grew over time. These strains do grow faster
than the PHA2 mutants but are not completely rescued solely by phenylalanine, as they also require
tyrosine, hence the lower A600 on the second day of growth with phenylalanine added.
Furthermore, to verify there were no residual nutrients in the minimal medium, strains with various
individual auxotrophies were inoculated to minimal medium and were found to not grow (Table 4).




AW108 pha2 3.0 5.8
AW109 pha2 2.8 5.6
AW258 ura1 0.1 3.6
AW259 his7 0.04 0.3
AW261 met15 0.08 5.2
IM006 lys2 0.07 1.4
a Minimal medium with 20 mg L−1 of auxotrophy required for strain.
Nonetheless, multiple enzymes producing phenylalanine could be viewed as a boon, as cells are
less likely to develop spontaneous resistance to a toxic phenylpyruvate analog, as they would have
to delete multiple processing enzymes. Thus we set out to design phenylpyruvate-like derivatives
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that may be catalytically converted into toxic phenylalanine analogs so that these can be used for
counter-selection of phenylalanine auxotrophies.
The first two phenylpyruvate-like derivatives of L-3-thienylalanine tested were 3-thiolproprionate
(3TP) and 2-thienylpyruvate (2TP). Wild-type yeast strains S288c and AW077 were pinned to plates
containing these analogs at 500 mg L−1 and 900 mg L−1, respectively, and relative viability was
calculated (Figure 3a). Despite higher concentrations of the phenylpyruvate derivatives compared to
L3T, S288c and AW077 strains exhibited no decrease in viability on 3TP and 2TP containing medium.
Thus, while the phenylalanine analog was toxic to these strains, the phenylpyruvate analogs were not.
Differences in toxicity could be due to adsorption to the cell wall, decreased uptake, or incompatibility
with enzymes.
The toxicity of the FPA derivative fluorophenylpyruvate (FPP) was next examined. Strains AW077
and S288c were serially diluted in water, then pinned to plates containing 0, 300 mg L−1, or 500 mg L −1
FPP and relative viability was calculated (Figure 3b). At 300 mg L−1 FPP strain S288c showed mild
growth inhibition but no lethality, while strain AW077 was more growth-inhibited. At 500 mg L−1,
no growth was detected from S288c and AW077 strains (Figure 3b). These results indicate that the
phenylpyruvate analog FPP is toxic to S288c and AW077 strains.
Phenylpyruvate is converted to phenylalanine primarily by the proteins Aro8p and Aro9p.
However, there are other proteins that can catalyze this reaction. To test if the mechanism of FPP
toxicity was due to its conversion to FPA, the toxicity of FPP was tested on strains lacking genes ARO8
and ARO9 (Figure 3b). Strains lacking ARO8 and ARO9 (AW051, AW052) are able to grow on this
medium, showing approximately equal growth on YPD. However, these strains are hypersensitive to
FPA, which may reflect the cells increased import of phenylalanine, due to a phenylalanine auxotrophy
(Figure 3c). This result suggests that ARO8 and ARO9 are primarily responsible for affecting the
toxicity of FPP.
For FPP to be of use as an auxotrophic marker, the natural resistance for it should be low.
For example, the frequency of spontaneous resistance to 5-fluoroanthranilic acid or 5-fluoroorotic acid,
for selection of tryptophan or uracil auxotrophs, respectively, was 6 × 10−7 [5]. To test the natural
resistance frequency of S288c and AW077 strains to FPP, we plated 5 × 106 cells on plates containing
500 mg L−1 FPP. We found no resistant cells grew on this medium, indicating natural resistance of
wild-type strains to FPP is below a frequency of 2 × 10−7. As a comparison to this, we also plated
these strains to medium containing 500 mg L−1 FPA. Strains S288c and AW077 formed 240 and 86
colonies giving a frequency of resistance of 3 × 10−5 and 5 × 10−5, respectively. This indicates that
the natural frequency of resistance to FPP is quite low, while that of FPA is higher. This indicates that
resistance to FPP toxicity requires either more mutations or more specific mutations, as compared to
FPA, and that perhaps these molecules do not induce toxicity via the same mechanism.
To further investigate the difference between FPP and FPA resistance, strains that were FPA
resistant were tested for FPP resistance. Isolates that were resistant to FPA were plated onto medium
with or without FPP and relative viability was calculated (Figure 5). Three isolates derived from
strain AW083 and one from AW077 showed resistance to FPA, but no resistance to FPP. This indicates
that FPA resistance is not sufficient for FPP resistance. However, an isolate from a wild-type yeast
wine strain (AW102) and an S288c mutant isolate (S288c-3) were recovered that showed resistance to
FPP and FPA. When the strain S288c-3 was mated to a non-resistant strain (AW081) and sporulated,
the resulting haploid segregants generally showed a pattern of 1:3 resistance to FPP, while resistance
to FPA showed a pattern of 2:2 (Table 5).
Table 5. Tetrad analysis of FPP and FPA resistance.
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Figure 5. Viability of selected strains in response to FPP or FPA. Cultures of parental and
derivative yeast strains were serially diluted in water then plated onto medium containing either
500 mg L −1 of FPA, FPP. Plates were incubated for 2–3 days and colony forming units (CFUs) counted.
Relative viability was obtained by dividing the number of CFUs from drug plates by CFUs from YPD
plates. P indicates the parental strain while D indicates a derivative of that strain. The average and
standard deviation of three independent trials is shown.
A predominance of 1:3 segregation (tetratype) indicates that two genes are segregating
independently, following the pattern of 1:1:4 PD:NPD:TT, while a 2:2 pattern indicates a single gene.
All haploid segregants that were resistant to FPP were also resistant to FPA. The haploid segregants
that were only resistant to FPA generally showed slow growth on FPA. One interpretation of these
results is that detoxification of FPP requires the activity of two genes, either of which will suffice to
detoxify FPA.
To determine if cells converted FPP into FPA or some other compound, we evaluated the presence
of FPA in cells treated with FPP. Strains were inoculated to medium containing FPP and allowed to
incubate for > 12 h, enzymatically digested to recover individual amino acids, and then tested for
the presence of FPA using LC-MS/MS (Figure 6). Strains sensitive to FPP, AW077, and S288c were
observed to accumulate the highest amounts of FPA, while the less sensitive strain AW051 accumulated
less. The modest decrease in FPP conversion of AW051 is not too surprising, as there are other enzymes
capable of converting phenylpyruvate to phenylalanine (Bat1, Bat2, His5), and this strain is capable
of growth without phenylalanine supplementation. Strains S288c-3 and AW102, both of which are
resistant to FPP, had the lowest levels of FPA. This suggests that their mechanism of resistance involves
decreased conversion of FPP to FPA. Thus cells can convert FPP into FPA, and this may be the cause of
some of the toxicity of FPP.
 
Figure 6. FPP is converted by cells to FPA. Yeast cells were inoculated to Synthetic Complete medium
overnight at 30 ◦C, then inoculated to MM2 medium with 200 mg L−1 FPP and incubated at 30 ◦C for
16 h. Cultures were isolated, dried, weighed, and analyzed for the quantity of FPA. FPP resistance is
indicated below each strain corresponding to a qualitative measure of their resistance to FPP with -
signifying little or no resistance, + indicating moderate resistance, and ++ indicating strong resistance.
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For FPP to be an effective selective agent, it should exert its toxic effect amongst diverse genre
of yeast. To test the evolutionary conservation of FPP toxicity, strains from diverse species such as
Candida tropicalis, Candida albicans, Saccharomyces bayanus, and Saccharomyces paradoxus were exposed to
0 or 500 mg L−1 FPP or FPA and their viability was measured over several days, and relative viabilities
were calculated (Figure 7). To test these strains, the FPP and FPA sensitivity test was performed by
inoculating cells into media with said compounds and evaluating culture viability using the Tadpoling
method [8]. All the strains tested retained viability or slightly increased in cell number when inoculated
into media without FPP or FPA, except for AW083. When inoculated to media containing FPA, C.
tropicalis exhibited high resistance while most of the other strains lost viability over the course of four
days. Both C. albicans and S. bayanus exhibited enhanced sensitivity to FPA, as these lost almost all
culture viability within one day. Surprisingly, in media containing FPP, all strains showed greater
sensitivity than in FPA and lost at least four orders of magnitude culture viability within two days.
This result would suggest that FPP may be transported more effectively than FPA, or that FPP can
exert its toxicity through a mechanism distinct from that of FPA. S.paradoxus and AW051 (aro8-2 aro9-1)
showed the least sensitivity to FPP of all the strains tested, but even these cultures succumbed after
four days. This data shows that FPP can act through diverse yeast genre to exert its toxic effect and
may be a more effective fungicide than FPA.
 
Figure 7. Toxicity of FPP and FPA are well conserved. Yeast cells were inoculated to Synthetic Complete
medium overnight, then inoculated to MM2 medium with 500 mg L−1 FPP, FPA, or no drug, and
incubated at 37 ◦C in an immobile 96-well plate. Culture viability was assessed over time using the
Tadpoling method. Relative viability was assessed by dividing the number of CFUs on day 0, 1, 2, or 5
by the number of CFUs on day 0. The average of three independent trials is shown.
One potential mechanism of FPP toxicity is to affect the mitochondria. Phenylpyruvate acts
as an inhibitor of pyruvate transport into the mitochondria where pyruvate would normally be
decarboxylated to acetate [14]. Indeed, accumulation of phenylpyruvate in phenylketonuria patients
becomes toxic as it may disrupt oxidative metabolism by preventing normal pyruvate movement
into the mitochondria. To test if phenylpyruvate alone may exert a toxic effect on yeast, exponential
phase cells were inoculated to 500 mg L−1 phenylpyruvate and culture viability was measured over
several days using the Tadpoling method. The ratio of CFUs of cells exposed to phenylpyruvate
with control cells was calculated over the course of several days (Figure 8). There were no significant
(p < 0.05) deviations from the ideal 1 ratio for all strains tested, indicating that phenylpyruvate
does not significantly affect culture viability. Nonetheless, there were notable deviations in decreased
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viability of S288c cells exposed to phenylpyruvate and an increase in viability of AW052 cells exposed
to phenylpyruvate. Thus, it is likely that fluorine is required for fluorophenylalanine toxicity.
Figure 8. Phenylpyruvate does not affect culture viability. Yeast cells were inoculated to Synthetic
Complete medium overnight, then inoculated to MM2 medium with 500 mg L−1 phenylpyruvate, or
no drug, and incubated at 37 ◦C in an immobile 96-well plate. Culture viability was assessed over
time using the Tadpoling method. To calculate the CFUs PP/CFUs control, the number of CFUs in
phenylpyruvate treated cultures was divided by the number of CFUs in the untreated culture for each
day. The average of three independent trials is shown. Markers are the same as used in Figure 7.
In S. cerevisiae, one method of increasing the production of the valuable chemical phenylethanol
is to select for resistance to FPA [2]. We wanted to test whether FPA resistant strains obtained
herein would produce high amounts of phenylethanol. To do this, we inoculated strains into medium
containing phenylalanine as the source of nitrogen and measured the phenylethanol and phenylalanine























Figure 9. FPP or FPA resistance is not sufficient for increased phenylethanol production. Strains were
incubated in medium containing phenylalanine as the source of nitrogen for three days, and
then phenylethanol and phenylalanine concentration in the medium were measured using GC-MS.
Each strain’s production of phenylethanol or phenylalanine was normalized to 1 using (A) AW083
strain or (B) AW077 strain. The average and standard deviation of three independent trials is shown.
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Resistance to FPA did not induce higher phenylethanol production in the four strains that were
tested. This is not surprising, as previously, the frequency of FPA-resistant mutants with high levels of
phenylethanol production was approximately 20% [15]. Thus, if we had tested five or more isolates
we may have expected to obtain at least one. However, because of the low frequency of obtaining
FPA-resistant strains we did not pursue this further. Because we had seen that FPP resistance was more
difficult to attain than FPA, we predicted that these mutants may produce phenylalanine at a greater
rate than FPA-resistant mutants and thus may have higher phenylethanol production. However, upon
testing FPP-resistant strains, no increase in phenylethanol production was noted (Figure 9B). Thus,
FPA and FPP resistance is not sufficient to induce high levels of phenylethanol production.
4. Discussion
Here, we report that FPP can act as a toxic agent in diverse strains of yeast, and this effect is at
least partially mediated by ARO8 and ARO9 conversion to FPA. Whether FPP exerts its toxic effect
solely by conversion to FPA or via another route rquires further investigation. FPP exhibited higher
toxicity than FPA, suggesting a separate mechanism of toxicity, however this could be due to enhanced
adsorption to cell wall, decreased cell uptake, or other enzymatic activities that decrease the effective
concentration of FPA.
The mechanism of FPP toxicity still remains somewhat of a mystery. It is possible that
there is preferred transport of phenylpyruvate over phenylalanine although evidence for this is
absent. Another hypothesis is that FPP is converted into some other compound that FPA is not,
such as fluoro-phenylethanol. Phenylalanine degradation follows this pathway: phenylalanine >
phenylpyruvate > phenylacetaldehyde > phenylethanol. Phenylpyruvate is one enzymatic step
closer to phenylethanol, and it is possible the fluorine moiety decreases its ability to convert to
fluoro-phenylalanine, but instead allows it to become fluoro-phenylethanol. Phenylethanol has been
shown to be toxic to C. albicans at 20 mg L-l [16].
We observed differences in the sensitivity of strains to FPP and FPA depending on the
method of delivery—solid or liquid medium. Phenylpyruvate shows increased solubility relative to
phenylalanine (112 g L−1 versus 27 g L−1) that may explain its increased toxicity in liquid medium [17].
This observation may be explained by the increased exposure of cells to all toxic molecules in a liquid,
as opposed to a solid medium in which cells are only exposed to toxins within close physical proximity.
Previous groups have reported similar enhanced drug potency in liquid media [18].
The effect of fluorinated phenylalanine metabolites has been observed previously in other fungal
species. Fluorophenylalanine at concentrations as low as 2.5 mM can inhibit growth of fungal species
Cladosporium cucumerinum and Colletotrichum lagenarium [19]. We found that FPP was toxic to a variety
of yeast species at 2.74 mM indicating that it is a more potent fungal inhibitor than FPA.
Interestingly, we also found that PHA2 was not required for slow growth. This is in contrast to
several other works that indicate that PHA2 causes an absolute requirement for phenylalanine in the
medium [10,20]. However, strain growth is typically assayed over a period of up to three days on solid
medium, while in our studies, liquid medium was used which allows for faster growth. PHA2 converts
prephenate to phenylpyruvate, but an alternative method to converting prephenate to phenylalanine is
via the arogenate dehydratase enzyme. This enzyme has not been reported in S. cerevisiae. The closest
species having a putative arogenate dehydratase is Neurospora crassa, which shares the same phylum
with S. cerevisiae. Further investigation is needed to determine the mechanism of slow phenylalanine
generation in strains lacking PHA2.
These observations should be helpful in better understanding phenylalanine metabolism and
may be of interest in identifying potential secondary targets of FPP.
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Abstract: Yeast β-glucan polysaccharide is a proven immunostimulant molecule for human and
animal health. In recent years, interest in β-glucan industrial production has been increasing.
The yeast cell wall is modified during the fermentation process for biomass production. The impact
of environmental conditions on cell wall remodelling has not been extensively investigated. The aim
of this research work was to study the impact of glucose and NaCl stress on β-glucan formation in
the yeast cell wall during alcoholic fermentation and the assessment of the optimum fermentation
phase at which the highest β-glucan yield is obtained. VIN 13 Saccharomyces cerevisiae (S. cerevisiae)
strain was pre-cultured for 24 h with 0% and 6% NaCl and inoculated in a medium consisting of 200,
300, or 400 g/L glucose. During fermentation, 50 mL of fermented medium were taken periodically
for the determination of Optical Density (OD), cell count, cell viability, cell dry weight, β-glucan
concentration and β-glucan yield. Next, dry yeast cell biomass was treated with lytic enzyme
and sonication. At the early stationary phase, the highest β-glucan concentration and yield was
observed for non-NaCl pre-cultured cells grown in a medium containing 200 g/L glucose; these cells,
when treated with enzyme and sonication, appeared to be the most resistant. Stationary is the
optimum phase for cell harvesting for β-glucan isolation. NaCl and glucose stress impact negatively
on β-glucan formation during alcoholic fermentation. The results of this work could comprise
a model study for yeast β-glucan production on an industrial scale and offer new perspectives on
yeast physiology for the development of antifungal drugs.
Keywords: yeast fermentation; glucose stress; NaCl stress; β-glucan production; cell wall remodelling
1. Introduction
Saccharomyces cerevisiae is the model microorganism most commonly used in the study of yeast and
higher eukaryotic cell physiology [1]. A major substrate for its growth is sugars, which are degraded
through an aerobic or anaerobic fermentation process with the production of CO2 or alcohol and CO2,
respectively [2]. Nowadays, the biotechnological research and industrial applications of S. cerevisiae
have extended far beyond food and beverage production to medicine development, molecular biology
and genetics, and environmental protection technologies [3].
In yeast, the plasma membrane is surrounded by the cell wall, a structure of 100–200 nm
width that consists of consecutive layers. The main structural elements of the yeast cell wall are
Fermentation 2017, 3, 44; doi:10.3390/fermentation3030044 www.mdpi.com/journal/fermentation87
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constructed of three groups of polysaccharides: (a) mannoproteins (or mannans): α-mannose polymers,
which account for around 40% of the cell wall dry weight [4]; (b) α- and β-glucans: D-glucose
homopolymers with α- or β-glycosidic bonds between C-1 and C-2, C-3, C-4, and C-6 of glucopyranose
rings; they account for approximately 30–60% of the cell wall dry weight (β-D-glucans are the main cell
wall glucans in which two different types are found: a major β-1,3-D-glucan (85%), which is the main
β-glucan, representing more than 50–55% of cell wall, and a minor β-1,6-D-glucan (15%), representing
5–10% of cell wall dry weight [5–8]); and (c) chitin: β-1,4-D-N-acetyl-glucosamine homopolymers,
equates to around 2% of the yeast cell wall dry weight [8,9]. The plasma membrane is an extension of
the cell wall to the interior of the yeast cell. Its width is 7.5 nm and it consists of lipids and proteins that
are found in much lower proportions compared to the cell wall components [10,11]. Yeast β-glucans
(β-1,3-D-glucan and β-1,6-D-glucan) belong to biological response modifiers (BRMs) due to their
ability to enhance and stimulate the human immune system presenting antitumor, anti-inflammatory,
antimicrobial, wound healing, coronary heart disease prevention, hepatoprotective, weight loss,
and antidiabetic properties [12–14].
Depending on the yeast growth and cultivation conditions, the cell wall dry weight may vary
between 10% and 25% of the total cell dry weight [15]. The cell wall has four main functions: to (1) protect
the cell from osmotic stress by maintaining its turgidity [10]; (2) protect the cell from mechanical stress;
(3) maintain the cell’s shape; and (4) act as a hold for the cell’s surface proteins [15,16].
During yeast cell batch fermentation, the cell wall is modified. These changes are affected by the
yeast strain and cell growth conditions [17–20]. The conditions of cell growth, such as pH, temperature,
aeration, carbon sources, limitation of nitrogen, and the mode of cultivation, affect the cell wall
polysaccharide composition, structure and morphology [21]. Also, the addition of supplements (SDS,
ethylenediaminetetraacetic acid (EDTA), NaCl) in the yeast culture medium and the conditions during
alcoholic fermentation for beer production impact variously on the cell wall β-glucan concentration at
the end of the fermentation process [22] as it also modifies the polysaccharide structure of produced
spent yeast biomass [23].
The remodelling of the yeast cell wall, as a response to various environmental stresses, is controlled
by: (a) the cell wall integrity (CWI) and (b) high osmotic glycerol (HOG) through mitogen-activated
protein kinase (MAPK) signalling pathways that modulate the cell wall gene expression and lead to
the construction of a newly modified cell wall [24,25]. In addition to the HOG pathway, the cell growth,
carbon storage and stress response are regulated by the RAS-cAMP PKA pathway [26], while during
rapid hyperosmotic shocks the yeast cell sensitivity is regulated by the cell wall elasticity increase
through the inactivation of the Crh family of cell wall cross-linking enzymes [25].
The impact of glucose concentration and NaCl osmotic stress on yeast performance during
anaerobic fermentation has been well studied [27–35], but their impact on cell wall β-glucan production
has not been studied until now.
The aim of this work was the investigation of yeast cell wall β-glucan production during the
anaerobic fermentation process under the influence of hyperosmotic stress of fermented media glucose
concentration and NaCl pre-cultured cells used for defined media inoculation. The motivations for
this research study were: (a) the fact that there are few reports concerning yeast growth conditions and
cell wall polysaccharide composition; (b) the lack of studies of the impact of different environmental
stresses on yeast cell wall structure during the fermentation process and the yeast cell osmoadaptation
responses against an osmotic shock; (c) the lack of knowledge of the entire physiological role of
β-glucan in the yeast cell; (d) the fact that the monitoring of the yeast cell wall is a dynamic
and unexplored research field that offers potential biotechnological applications and purposes;
(e) the increasing interest in the industrial production of β-glucan from various yeast sources (medium
cultures, brewery and winery waste yeast biomass) due to its proven immunostimulant properties and
its incorporation in medicines, cosmetics and functional foods; and (f) the potential benefits from the
study of the yeast cell wall in the creation of new antifungal drugs. Furthermore, the study of the yeast
88
Fermentation 2017, 3, 44
cell wall under various conditions can offer new perspectives on the biochemical pathways involved
in the alcoholic fermentation process and the biology of the stressed yeast cell.
2. Materials and Methods
2.1. Yeast Cells and Culture Growth Conditions
Yeast cells S. cerevisiae VIN 13 strain (commercial dry yeast) used for laboratory experiments were
provided by Anchor Yeast (Cape Town, South Africa). Yeast cells were grown in a medium containing
(per litre of deionised water): 100 g D-glucose, 1 g K2HPO4, 1 g KH2PO4, 0.2 g ZnSO4, 0.2 g MgSO4,
2 g yeast extract and 2 g NH4SO4. All the media components were purchased from the Sigma Chemical
Company (St. Louis, MO, USA).
2.2. Yeast Cell Preconditioning and Inoculum Preparation
One gram dry weight of yeast was resuspended in 100 mL of deionised water in an Erlenmeyer
flask of 250 mL volume, at 30–35 ◦C, for 30 min with NaCl 6% w/v. The inoculum for experimental
fermentations was prepared as follows: after 24 h of pre-culturing, 10 mL was collected and centrifuged
at 5000 rpm for 15 min. Cells were resuspended in deionised water and re-centrifuged. This was
repeated twice prior to the determination of total cell number and cell viability in the final washed
inoculum; 2 × 105 of living cells were used to inoculate 1000 mL of medium substrate [27].
2.3. Preparation of Yeast Fermentation Medium
The medium for laboratory batch fermentations consisted of the following: 200, 300, 400 g/L
glucose, 1 g/L K2HPO4, 1 g/L KH2PO4, 0.2 g/L ZnSO4, 0.2 g/L MgSO4, 2 g/L yeast extract and 2 g/L
NH4SO4 (Sigma-Aldrich Co., St. Louis, MO, USA). Mineral components and glucose were sterilised
separately at 120 ◦C, and 2 atm pressure for 20 min. The pH was set to 4.0 with the use of 1 N HCl.
Batch fermentations were carried out in 2000 mL volume flasks containing 1000 mL of growth medium
with NaCl-preconditioned cells without shaking at 25 ◦C [36].
2.4. Cell Wall Treatment with Lytic Enzyme and Sonication
Yeast cells were treated with lytic enzyme Glucanex®200G (β-1,3-glucanase with some β-1,6-glucanase)
(Novozymes, Kobenhavn, Denmark) for the cell wall lysis (pH 4.64/50 ◦C/5 h/10 times higher than the
normal dose of 0.015 g/L, optical density of the resuspended cells with 10 mM citrate buffer adjusted
to approximately 1.0 OD at 600 nm, 15% w/v cell concentration) [18,37,38] and sonication for the
cell disruption at 35 kHz/70 W/6 min (u = 230 V/AC, I = 1.6 A, f = 50/60 Hz) in an ice bath with
a Transsonic 570/H sonicator (Elma, Singen, Germany) [39].
2.5. Determination of Cell Concentration
Yeast cell number was determined by counting using a hemocytometer (Neubauer type) [36].
2.6. Cell Viability Determination
Cell viability was determined using a haemocytometer (Neubauer type) and according to the
methylene blue method: 1 mL of sample medium was taken and diluted in 9 mL of deionised water.
1 mL of this solution was dissolved with 1 mL of 10% v/v methylene blue solution and left for 10 min.
Aliquots of 1 μL were placed on the haemocytometer using a Pasteur pipette. The haemocytometer was
then microscopically observed with an optical microscope (Olympus model CHK2-F-GS microscope).
Yeast cell viability was calculated and expressed as follows:
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Viability (%) = a/n × 100,
where
a: number of metabolically active cells
n: total cell number [27].
2.7. Monitoring of Fermentation Kinetics
OD at 600 nm was determined spectrometrically (phasmatophotometer mini 1240, SHIMADZU,
Beijing, China) and was used for the monitoring of fermentation kinetics and the discrimination of
exponential, lag and death phase of cells growth during the fermentation process [18].
2.8. Determination of Cell Dry Weight
The sediment of yeast cells was frozen (−80 ◦C/24 h), lyophilised (−50 ◦C /vacuum/24 h) using
a Thermo Fischer (Waltham, MA, USA) drying digital unit. The weight of each yeast cells freeze
dried sample was measured gravimetrically with an analytical balance (Kern, Kern and Sohn GmbH,
Balingen, Germany) with an accuracy of four decimal places.
2.9. Determination of β-Glucan Concentration (%)
The determinations of total yeast β-glucan concentration in lyophilised yeast biomass were
performed with the use of Enzymatic K-EBHLG Yeast β-Glucan Assay Kit (Megazyme, Bray, Ireland).
2.10. Determination of β-Glucan Yield (%)
The yield of β-glucan was calculated as the product of yeast cells’ dry weight with β-glucan purity [40].
2.11. Statistical Analysis
Each experiment was carried out in triplicate and the reproducibility was within the range of
±5%. Results are displayed as means of three determinations in all methods with standard deviation.
Experiments were set up in a completely randomised design while for the determination of significant
differences between the different treatments and the tested parameters, all results were analysed using
two-way analysis of variance (ANOVA) run on XLSTAT software (Addinsoft Co., New York, NY, USA),
with significant differences indicated at p ≤ 0.05.
3. Results
3.1. Experimental Design
Yeast cells S. cerevisiae VIN 13 strain were inoculated in a medium containing three different glucose
concentrations: 200, 300, or 400 g/L. The inoculation of each sample of the fermentation batch was
performed according to the instructions of the yeast company (Anchor Yeast, Cape Town, South Africa)
for wine production with 2 × 105 living cells of 0.1 g dry yeast preconditioned in 0% and 6% NaCl
for 24 h before the inoculation according to the procedure described by Logothetis et al. (2013) [41].
The volume of the inoculated substrate was 1000 mL for each sample. During alcoholic fermentation,
for the monitoring of fermentation kinetics, samples of 50 mL from each fermented medium were collected
every 8 h after homogenisation of the fermented medium for the direct determination of cell viability and
optical absorption (OD). In a next step, these 50 mL samples were centrifuged (5000 rpm/10 min) and the
sediment (yeast biomass) was freeze dried for the determination of cell dry weight and the yeast cell
β-glucan concentration. Subsequently, the freeze-dried yeast cells were treated with lytic enzyme and
sonication for the estimation of cell wall resistance and its correlation with cell wall β-glucan amount.
After the centrifugation of the samples and before their freeze drying, they were washed three times
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with distilled water for the removal of the possible glucose that may have remained in the sample.
This was applied in order to avoid glucose weight being taken into account in the determination of
the dry weight of the sample, which might cause subsequent data errors to arise. After 192 h for
the completion of the alcoholic fermentation, the suspension was separated from the yeast biomass
sediment (centrifugal/5000 rpm/10 min) for the determination of various oenological analytical
parameters, while the sediment was freeze-dried for β-glucan determination in yeast cell biomass.
3.2. Cell Viability
For all the samples, cell viability rose during the early exponential phase of fermentation and reached
a first peak after 16 h. At this point, cells of samples (200 g/L glucose, 0% NaCl), (200 g/L glucose,
6% NaCl) and (300 g/L, 6% NaCl) showed the highest viability (%) (97.78 ± 2.04%, 97.36 ± 1.59% and
97.28 ± 1.02% respectively) while NaCl-stressed cells of samples (300 g/L glucose, 6% NaCl) and (400 g/L
glucose, 6% NaCl) had higher viability portions (97.28 ± 1.02% and 93.43 ± 1.44% respectively) compared
to the corresponding (300 g/L, 0% NaCl) and (400 g/L glucose, 0% NaCl) ones (93.94 ± 1.42% and
89.89 ± 1.13% respectively) (Figure 1). The cell viability reached a second, lower peak during the end
of the exponential and the beginning of the stationary phase for all samples. The more viable cells were
counted for samples (200 g/L glucose, 0% NaCl) and (200 g/L glucose, 6% NaCl) (97.84 ± 2.03% and
93.54 ± 1.88% respectively) (Figure 1). At the death phase (48–120 h), the cell viability decreased for all the
samples, with a higher decrease for samples (300 g/L glucose, 6% NaCl) and (400 g/L glucose, 6% NaCl)
(Figure 1). From 120 to 192 h, an increase in cell viability occurred for all samples, but this was more
abrupt for NaCl-stressed cells of samples (300 g/L glucose, 6% NaCl) and (400 g/L glucose, 6% NaCl).
Despite this increase, for all samples, after 192 h of fermentation, cell viability was lower when compared
to values of the second peak. Finally, the viability of NaCl preconditioned and non-preconditioned
yeast cells growing in a medium containing 200 g/L glucose was similar at the end of the fermentation
(85.34 ± 1.3% and 83.44 ± 0.8% respectively) (Figure 1).
3.3. Optical Density (OD) and Cell Count
The results of OD (600 nm) measurements showed that the lag phase was 0–8 h for all the fermented
samples; the exponential phase was between 0–40 h for the samples (200 g/L glucose, 0% NaCl) and
(200 g/L glucose, 6% NaCl) and 0–48 h for the others. The stationary phase for the samples (200 g/L
glucose, 0% NaCl) and (200 g/L glucose, 6% NaCl) was short (40–48 h), while for the other samples it
was longer (48–72 h). The death phase was determined to be between 48 and 192 h for the samples
(200 g/L glucose, 0% NaCl) and (200 g/L glucose, 6% NaCl)) and 72–192 h for the samples (300 g/L
glucose, 0% NaCl), (300 g/L glucose, 6% NaCl), (400 g/L glucose, 0% NaCl), and (400 g/L glucose,
6% NaCl) (Figure 2).
The cell count was used in order to determine the total yeast cell number during the fermentation
process. Our results revealed that during the death phase, the OD (600 nm) and the cell number decreased
for all the samples but, surprisingly, between 120 and 192 h the number of cells grown in 400 g/L glucose
(0% and 6% NaCl) increased considerably (198.75 × 106 and 186.44 × 106 cells/mL respectively) compared
with the other media (200 g/L glucose, 0% NaCl), (200 g/L glucose, 6% NaCl), (300 g/L glucose, 0% NaCl)
and (200 g/L, 6% NaCl) (24.15 × 106, 30.12 × 106, 52.13 × 106 and 45.54 × 106 cells/mL respectively)
(Figure 3). The samples with 200 g/L glucose showed two peaks, at 24 and 48 h, with the first peak
a little higher than the second. The other samples (200 g/L glucose, 0% NaCl), (200 g/L glucose,
6% NaCl), (300 g/L glucose, 0% NaCl), (200 g/L glucose, 6% NaCl) showed one peak at 24 h, which
was significantly higher compared to that of samples (200 g/L glucose, 0% NaCl) and (200 g/L glucose,
6% NaCl), thus indicating a higher cell number (Figure 3).
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Figure 1. (A) Yeast cell viability (%) of non-NaCl-stressed cells during various fermentation times (h)
with three different media containing 200, 300, or 400 g/L glucose (n = 3 replications for each time).
(B) Yeast cell viability (%) of NaCl-stressed cells during the fermentation process (h) with three different
media containing 200, 300, or 400 g/L glucose (n = 3 replications for each time) (): (200 g/L glucose,
0% NaCl), (Δ): (300 g/L glucose, 0% NaCl), (): (400 g/L glucose, 0% NaCl), ( ): (200 g/L glucose, 6%
NaCl), (): (300 g/L glucose, 6% NaCl), (): (400 g/L glucose, 6% NaCl).
92






































Figure 2. (A) OD (600 nm) of non-NaCl-stressed cells during various fermentation times (h) with three
different media containing 200, 300, or 400 g/L glucose (n = 3 replications for each time); (B) OD (600 nm)
of NaCl-stressed cells during the fermentation process (h) with three different media containing 200, 300,
or 400 g/L glucose (n = 3 replications for each time) (): (200 g/L glucose, 0% NaCl), (Δ): (300 g/L glucose,
0% NaCl), (): (400 g/L glucose, 0% NaCl), ( ): (200 g/L glucose, 6% NaCl), (): (300 g/L glucose, 6%
NaCl), (): (400 g/L glucose, 6% NaCl).
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Figure 3. (A) Total cell count (cells/mL) of non-NaCl-stressed cells during various fermentation times
(h) with three different media containing 200, 300, or 400 g/L glucose after cell treatment with sonication
(n = 3 replications for each time and error bars represent standard deviation of the average value of
all replications with each range of fermentation time); (B) Total cell count (cells/mL) of NaCl-stressed
cells during various fermentation times (h) with three different media containing 200, 300, or 400 g/L
glucose after cell treatment with sonication (n = 3 replications for each time and error bars represent
standard deviation of the average value of all replications with each range of fermentation time) ():
(200 g/L glucose, 0% NaCl), (Δ): (300 g/L glucose, 0% NaCl), (): (400 g/L glucose, 0% NaCl), ( ):
(200 g/L glucose, 6% NaCl), (): (300 g/L glucose, 6% NaCl), (): (400 g/L glucose, 6% NaCl).
3.4. Dry Weight and Sample β-Glucan Yield
The freeze-dried yeast cell biomass obtained from a 50-mL sample of fermented medium at
various times was determined gravimetrically. For each of the fermented media, the dry weight of
yeast biomass rose constantly until the early stationary phase and then decreased constantly during
the death phase only for media (200 g/L glucose, 0% NaCl), (200 g/L glucose, 6% NaCl) and (300 g/L
glucose, 0% NaCl). The fermented media (300 g/L glucose, 6% NaCl), (400 g/L glucose, 6% NaCl)
and (400 g/L glucose, 6% NaCl) showed a smaller decline, with a slight increase in yeast biomass for
(300 g/L glucose, 6% NaCl) and (400 g/L glucose, 0% NaCl) and a more significant one for (400 g/L
glucose, 6% NaCl) at the end of the fermentation (144–192 h) (Figure 4). The highest value of yeast
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dry weight (0.1900 ± 0.0066 g) was obtained with 200 g/L glucose, NaCl-stressed cells, with 40 h












































Figure 4. (A) Dry weight (g) of a 50-mL sample of non-NaCl-stressed cells during various fermentation
times (h) with three different media containing 200, 300, or 400 g/L glucose (n = 3 replications for each
time and error bars represent standard deviation of the average value of all replications with each
range of fermentation time); (B) Dry weight (g) of a 50-mL sample of non-NaCl stressed cells during
various fermentation times (h) with three different media containing 200, 300, or 400 g/L glucose
(n = 3 replications for each time and error bars represent standard deviation of the average value of
all replications with each range of fermentation time) (): (200 g/L glucose, 0% NaCl), (Δ): (300 g/L
glucose, 0% NaCl), (): (400 g/L glucose, 0% NaCl), ( ): (200 g/L glucose, 6% NaCl), (): (300 g/L
glucose, 6% NaCl), (): (400 g/L glucose, 6% NaCl).
The β-Glucan yield (g) was optimum for media (200 g/L glucose, 0% NaCl), (200 g/L glucose,
6% NaCl), (300 g/L glucose, 0% NaCl) and (300 g/L glucose, 6% NaCl) at the stationary phase
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(p ≤ 0.05), while for medium (400 g/L glucose, 0% NaCl) it reached a peak at the stationary phase and
remained constant until the end of fermentation and for medium (400 g/L glucose, 6% NaCl) it was
optimum at the end of fermentation (Figure 5). The highest β-Glucan yield (0.1038 ± 0.0073 g) was
obtained with fermented medium (200 g/L glucose/0% NaCl (non-stressed cells)/48 h fermentation


















































Figure 5. (A) β-Glucan yield (%) of a 50-mL sample of non-NaCl-stressed cells during various
fermentation times (h) with three different media containing 200, 300, or 400 g/L glucose (n = 3
replications for each time and error bars represent standard deviation of the average value of all
replications with each range of fermentation time). Mean values between 0–144 h were significantly
different at p ≤ 0.05 level. (B) β-Glucan yield (%) of a 50-mL sample of non-NaCl-stressed cells during
various fermentation times (h) with three different media containing 200, 300, or 400 g/L glucose (n = 3
replications for each time and error bars represent standard deviation of the average value of all replications
with each range of fermentation time). Mean values between 0–144 h were significantly different at p ≤ 0.05
level. (): (200 g/L glucose, 0% NaCl), (Δ): (300 g/L glucose, 0% NaCl), (): (400 g/L glucose, 0% NaCl),
( ): (200 g/L glucose, 6% NaCl), (): (300 g/L glucose, 6% NaCl), (): (400 g/L glucose, 6% NaCl).
3.5. β-Glucan Concentration
For the fermented media (200 g/L glucose, 0% NaCl), (200 g/L glucose, 6% NaCl), (300 g/L
glucose, 0% NaCl) and (300 g/L glucose, 6% NaCl), the highest yeast cell wall β-glucan concentration
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was observed at the stationary phase (p ≤ 0.05) (Figure 6). For media (400 g/L glucose, 0% NaCl)
and (400 g/L glucose, 6% NaCl), the β-glucan concentration rose until the cell culture entered the
stationary phase and remained stable during the death phase (Figure 6). The highest β-glucan yeast
cell concentration was observed for non-NaCl-stressed and NaCl-stressed cells grown in a medium
containing 200 g/L glucose (62.95 ± 3.39 % and 39.49 ± 1.78 % respectively). Also, cells grown in these
media showed a β-glucan concentration higher at the end of the alcoholic fermentation compared to


















































Figure 6. (A) Yeast cell wall β-glucan (%) of non-NaCl-stressed cells during various fermentation times
(h) with three different media containing 200, 300, or 400 g/L glucose (n = 3 replications for each time
and error bars represent standard deviation of the average value of all replications with each range
of fermentation time). Mean values between 0–144 h were significantly different at p ≤ 0.05 level.
(B) Yeast cell wall β-glucan (%) of NaCl-stressed cells during various fermentation times (h) with three
different media containing 200, 300, or 400 g/L glucose (n = 3 replications for each time and error bars
represent standard deviation of the average value of all replications with each range of fermentation
time). Mean values between 0–144 h were significantly different at p ≤ 0.05 level. The stationary phase
is indicated with the vertical line. (): (200 g/L glucose, 0% NaCl), (Δ): (300 g/L glucose, 0% NaCl),
(): (400 g/L glucose, 0% NaCl), ( ): (200 g/L glucose, 6% NaCl), (): (300 g/L glucose, 6% NaCl),
(): (400 g/L glucose, 6% NaCl).
3.6. Cell Wall Treatment with Lytic Enzyme and Sonication
The highest cell wall resistance to the end of exponential phase either to lytic enzyme or to
sonication was observed for sample (200 g/L glucose, 0% NaCl), which had the highest β-glucan
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concentration. A decline in these results was observed for the fermented media (400 g/L glucose,
0% NaCl) and (400 g/L glucose, 6% NaCl) during the death phase (120–192 h of fermentation); despite
their lowest β-glucan cell wall content, they appeared to be more resistant to the action of lytic enzyme
but not to ultrasounds when compared to cells of samples (300 g/L glucose, 0% NaCl) and (300 g/L














































Figure 7. (A) Yeast cell viability (%) of non-NaCl-stressed cells during various fermentation times (h)
with three different media containing 200, 300, or 400 g/L glucose after cell treatment with Glucanex
200G lytic enzyme (n = 3 replications for each time and error bars represent standard deviation of
the average value of all replications with each range of fermentation time); (B) Yeast cell viability
(%) of NaCl-stressed cells during various fermentation times (h) with three different media containing
200, 300, or 400 g/L glucose after cell treatment with Glucanex 200G lytic enzyme (n = 3 replications
for each time and error bars represent standard deviation of the average value of all replications with
each range of fermentation time) (): (200 g/L glucose, 0% NaCl), (Δ): (300 g/L glucose, 0% NaCl),
(): (400 g/L glucose, 0% NaCl), ( ): (200 g/L glucose, 6% NaCl), (): (300 g/L glucose, 6% NaCl), ():
(400 g/L glucose, 6% NaCl).
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Figure 8. (A) Yeast cell viability (%) of non-NaCl-stressed cells during various fermentation times (h)
with three different media containing 200, 300, or 400 g/L glucose after cell treatment with sonication
(n = 3 replications for each time and error bars represent standard deviation of the average value of
all replications with each range of fermentation time); (B) Yeast cell viability (%) of NaCl-stressed
cells during various fermentation times (h) with three different media containing 200, 300, or 400 g/L
glucose after cell treatment with sonication (n = 3 replications for each time and error bars represent
standard deviation of the average value of all replications with each range of fermentation time)
(): (200 g/L glucose, 0% NaCl), (Δ): (300 g/L glucose, 0% NaCl), (): (400 g/L glucose, 0% NaCl),
( ): (200 g/L glucose, 6% NaCl), (Δ): (300 g/L glucose, 6% NaCl), (): (400 g/L glucose, 6% NaCl).
4. Discussion
The impact of various environmental stresses on the yeast fermentation performance has been
well studied and reviewed before [27–32,42,43], but the study of the yeast cell wall composition during
the fermentation process is insufficient, with only a few published works referring to the impact of
fermentation growth conditions and mode of cultivation on the yeast cell wall structure [20,21,44],
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the mode of fermentation on yeast cell wall β-glucan content [18], and the role of additives in the
culture medium in β-glucan production [22,45]. The impact of glucose and NaCl stress on yeast cell
wall remodelling via the study of the fluctuation of β-glucan concentration during the fermentation
process has not been studied until now.
4.1. Cell Viability
Cell viability measurement with the methylene blue method is an established technique for
yeast cell staining [46], used for the estimation of clear viable yeast cells [36,38]. Cell viability
measurements were conducted: (a) for the estimation of the impact of stress conditions on cell
viability during the fermentation process, and (b) for the correlation of yeast β-glucan concentration
with cell biomass dry weight and total cell number, as non-viable and lysed cells were expected to
have a higher β-glucan concentration (expressed as % of the yeast dry weight). In our experiments, cell
viability reached two peaks and then decreased for all the fermented samples (Figure 1). At this point,
the glucose concentration stress seems to be critical as cell viability decreases as glucose increases but
the corresponding values for NaCl-stressed and non-stressed cells were similar for the same glucose
concentration for all fermented samples (Figure 1). At the death phase (48–120 h), the synergistic action
of glucose and NaCl stress seems to impact negatively on the cell viability, with a larger decrease in
viable cell count for fermented samples with NaCl-stressed cells grown in media containing 300 and
400 g/L glucose (Figure 1).
Our results differed from the observations of other researchers under the same glucose (200 g/L)
and NaCl (6%) stress conditions with the use of the S. cerevisiae VIN 13 strain, which observed a constant
decrease of cell viability during the fermentation process [27]. These differences might be due to the
different cell NaCl pre-culturing time (24 h in our experiments, 48 h in their work), the different volume
of fermented medium (1000 mL in our experiments, 250 mL in their work) and the different package
containing dry yeast used for carrying out the fermentations.
Also, at the end of death phase, the NaCl-preconditioned cells grown in the denser glucose
medium had the highest viable cell values. These results cannot be compared with other researchers’
results that used the same yeast strain with salt pre-culturing (NaCl 6% w/v) but in an even denser
glucose medium (550 g/L), as cell viability values are not given [41]. Our results were in accordance
with the observations of other researchers who found that NaCl pre-cultured yeast cells showed
an increased cell viability at the end of the fermentation process [36]. Despite this increase, for all
samples, after 192 h of fermentation, cell viability was lower compared to the values of the second
peak. Lower cell viability was possibly caused by cell autolysis during the death phase of the alcoholic
fermentation and consequently to a rise in the cell’s dry weight due to cytoplasm leaking out from
the cell to the supernatant [43]. Concerning the impact of NaCl 6% (w/v) concentration on yeast
cells, our results with NaCl pre-cultured and non-pre-cultured yeast cells growing in a medium
containing 200 g/L glucose differed from results of other researchers that indicated that higher osmotic
shock conditions (>5% w/v NaCl) resulted in a higher cell viability at the end of the fermentation
compared to the non-NaCl-stressed cells, while the viability value (83.44 ± 0.8%) for NaCl-stressed cells
was in accordance with the corresponding one that previous researchers reported [27,47] (Figure 1).
Concerning all the fermented media with the same glucose concentration, they appeared to have
almost the same cell number at the end of fermentation (Figure 1), thus indicating that NaCl stress for
the same glucose concentration had almost no impact on the cell viability at the end of the fermentation
(Figure 1). As a general rule, the viability results were in accordance with the results reported by
Logothetis et al. (2014), which suggested that salt pre-culturing of yeast S. cerevisiae impacts positively
on cell viability [36].
4.2. Optical Density and Cell Count
Optical density (OD) is used for the estimation of yeast growth and the determination of
exponential, stationary and lag phase during batch fermentations [18,21]. For media (300 g/L glucose,
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0% NaCl), (300 g/L glucose, 6%), (400 g/L glucose, 0% NaCl) and (400 g/L glucose, 6% NaCl) the
three fermentation phases coincided while for media (200 g/L glucose, 0% NaCl) and (200 g/L glucose,
6% NaCl) the fermentation phases also coincided but the exponential and stationary phases were
shorter compared to the other media, thus indicating that NaCl stress had no impact on fermentation
kinetics, while glucose concentration had a slight impact (Figure 2). Our OD results cannot be
compared with those of other researchers who used the same yeast strain and stress conditions, as OD
measurements are not given [27,47]. Also, our OD results differed from the report of Kim et al. (2006),
but these researchers used a different S. cerevisiae strain with no glucose and NaCl-stressed yeast cells,
and also used different media and fermentation times [18].
The cell count was used in order to determine the total yeast cell number during the fermentation
process and correlate it with cell viability [47], but also with dry yeast mass weight (g) and β-glucan
yield (%). During the death phase, the cell number decreased, with a simultaneous decrease in OD
(600 nm) for all the fermented media; surprisingly, though, between 120 and 192 h, the number of
cells grown in 400 g/L glucose increased spectacularly compared to the other samples. This cell
number increase of glucose- and NaCl-stressed cells was not accompanied by a cell dry mass increase.
This probably indicates a smaller yeast cell but further observations with electron microscopy must
be performed in order to validate such a hypothesis (Figure 3). These results differed from other
researchers’ studies that used the same yeast strain, glucose and NaCl stress conditions, which suggests
that NaCl-induced osmotic stress caused growth arrest in yeast cells, while an increase in osmotic
stress with elevated NaCl concentration caused a decrease in yeast growth and total cell number over
time [27]. During the first 40 h of fermentation, the cell count of media (200 g/L glucose, 0% NaCl) and
(200 g/L glucose, 6% NaCl) was lower than that of the other media, while their dry weights appeared
to be higher and their cell walls contained much more β-glucan (Figures 3 and 6), thus indicating
fewer cells but larger ones, those with wider cell walls or both.
4.3. Dry Weight and Sample β-Glucan Yield
The determination of yeast dry weight at the various fermentation phases was done in order
to calculate the β-glucan yield (g) at the different fermentation phases and optimise the phase at
which the cells must be harvested. The highest value of dry weight (g) and β-glucan yield (g) was
obtained with 200 g/L glucose/NaCl-non-stressed and 200 g/L glucose/stressed cells at 48 and 40 h,
respectively, thus indicating that the stationary phase is the most appropriate time for cell harvesting,
a result that is in accordance with the observations of Kim et al. (2006) [18]. From the obtained results,
it is shown that glucose and NaCl stress impacts negatively on yeast dry weight and β-glucan yield
(Figures 4 and 5). Also, for media (400 g/L glucose, 0% NaCl) and (400 g/L glucose, 6% NaCl),
the highest value for yeast dry weight and β-glucan yield appeared at the end of the death phase and,
despite the fact that β-glucan concentration was lowered, the total cell number increased. It seems
that, in this way, the yeast cell maintains homeostasis in order to cope with the conditions of glucose
and NaCl stress during the fermentation process, but this needs further investigation and is proposed
as future research.
4.4. β-Glucan Concentration, Lytic Enzyme and Sonication
The determination of yeast β-glucan concentration was done for the estimation of polysaccharide
and its accumulation in the yeast cell, while furthering the understanding of yeast cell wall
β-glucan modification during the fermentation process under stress conditions, the estimation of
cell wall lysis and disruption resistance against lytic enzymes and sonication was tested with cell
viability measurements.
Generally, for all the fermented media, the β-glucan yeast cell wall concentration rose constantly
during the exponential phase and rose to a peak value at the stationary phase and then decreased
during the death phase (Figure 6). Also, the cell treatment with lytic enzyme and sonication revealed
that the cell’s resistance against lysis and disruption increased as the cell entered the stationary phase.
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Next, as the cell entered the death phase, its resistance against lytic enzymes and sonication lowered,
thus supporting the observations of a constant accumulation of β-glucan in the cell wall during the
exponential phase, with its maximum quantity at the stationary phase and consequently a decrease
during the death phase (Figures 7 and 8). During yeast alcoholic fermentation, the accumulation of
ethanol causes an increase in yeast cell membrane permeability [42]. During the death phase, all the
samples appeared to be more susceptible to lytic enzyme and sonication treatment (Figures 7 and 8)
but for NaCl-stressed cells grown in a medium containing 300 g/L glucose and both NaCl-stressed
and non-stressed yeast cells grown in a medium containing 400 g/L glucose, there was not a direct
correlation between β-glucan concentration and cell wall resistance as these cells appeared to be more
susceptible to lytic enzyme and sonication treatment, probably due to the additional impact of ethanol
toxicity [48] (Figures 7 and 8).
Our results were in accordance with the observations of Kim et al. (2006), according to which,
during the yeast growth in a defined medium, the cell wall resistance to the action of β-glucanase
increases until the yeast cells enter the stationary phase, while their resistance to the enzyme decreases
at the end of the stationary phase [18]. Also, our results support the reports of Klis et al. (2002),
which indicate that as cells enter the stationary phase, they become thicker [49]. This yeast cell wall
resistance is a result of the cell wall increase during the exponential phase [18].
In non-continuous fermentation, during the transition from the exponential to the stationary phase,
the action of β-1,3-glucan synthetase decreases while the action of glycogen synthetase increases [50].
During the exponential phase, the autolytic action of endo β-glucanases is higher compared to that
in the stationary phase of yeast cells’ growth, while a significant increase in endoglucanases’ activity
into the soluble fraction of β-glucan during the stationary phase in non-continuous fermentation of
Saccharomyces exiguus has also been reported [51]. The stationary phase is characterised by carbon
limitation, and as the cell culture enters this, more glucan is necessary for the maintenance of the cell’s
viability [18]. The higher β-glucan concentration at the stationary phase can also be explained by
the decreased action of cell’s glucanases, with the less active cell’s growth at the exponential phase,
which is accompanied by a non-severe carbon limitation, similar to the one at the end of the stationary
phase [18]. During aerobic fermentation, when yeast cells enter the stationary growth phase, the cells
become more resistant to the action of β-1,3-glucanase and are less permeable to macromolecules with
the expression of Sed1p protein [52,53].
In addition to the above, our results show that the increase of glucose osmotic stress in the growth
medium, but also the NaCl hyperosmotic stress in the pre-cultured yeast cells, impacts negatively on the
β-glucan concentration in the yeast cell wall. This negative impact on the β-glucan concentration was
even more intense from the stationary phase until the end of the fermentation (death phase) (Figure 6).
Our results differed from those of other researchers, who reported a β-glucan increase at the end
of fermentation; however, these researchers incorporated NaCl in the fermented medium and did
not pre-culture yeast cells under salt hyperosmotic stress, and also used a different yeast strain [22].
Also, in their work, cell viability and total cell count were not taken into consideration and an increase in
β-glucan concentration may have resulted from cell lysis, cytoplasm efflux and consequently a higher
cell wall:cell ratio [14]. Our results cannot be compared with the results of Aguilar-Uscanga et al. (2003),
who studied the impact of growth conditions and the mode of cultivation on the yeast cell wall structure
and not the impact of stress conditions, with the collection of cell samples (50 mL volume) only in the
early exponential phase [21].
Our β-glucan concentration results differed from the reports of other researchers that suggest that
the cell wall integrity (CWI) pathway, in cooperation with the high osmotic response (HOG) pathway,
regulates the action of zymolyase, the enzyme hydrolysing the β-1,3 glucan network, and thus result
in an increase in the amount of cell wall β-glucan. These researchers used different yeast strains and
different fermented medium components [24], while the data concerning osmotic stress responses
were based on a previous research work in which KCl and NaCl had been diluted in the fermented
substrate [54,55]. Our results are in accordance with the observations of Ene et al. (2015), who reported
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that the cell wall is not rigid but elastic and that sudden decreases in cell volume due to hyperosmotic
conditions result in rapid increases in cell wall thickness, and thus a decrease in β-glucan content [25].
Our results are in accordance with the results of other researchers who used Glucanex 200G for
the estimation of yeast cell wall resistance to lytic enzyme during batch fermentation and reported
a higher cell resistance in the stationary phase [18]. Also, our results differ from other researchers’
results (97 ± 0.18% breaking rate, 10–15% cell concentration), but these differences may arise from the
fact that these researchers used sonication for yeast cell lysis during a β-glucan extraction protocol
in dry yeast first treated with hot water for mannoprotein removal and not in yeast from various
fermentation phases [38].
The yeast cells appeared to be more susceptible to sonication treatment compared to lytic enzyme
treatment. The higher cell wall resistance to lytic enzymes in the various fermentation phases could be
attributed to the variation in cell number during the fermentation process (Figures 3 and 7) and thus to the
enzyme dispersion to a larger volume of cells [56] (e.g., the stable resistance of cells of fermented media
with 400 g/L glucose to the action of the lytic enzyme at the end of the death phase where they appeared
the highest cell number), while cell disruption of yeast cells treated with ultrasounds is independent of
cell concentration but mainly proportional to the acoustic power [57,58] (Figures 3 and 8).
5. Conclusions
In recent years, there has been increasing interest in industrial production of yeast β-glucan and
its incorporation in functional foods and medicines due to its immunological properties in human and
animal health systems. This study could comprise a quantitative indicator for the industrial production
of yeast β-glucan from defined cell cultures but also from other yeast sources like breweries’ [23] and
wineries’ spent yeast biomass [40].
The stationary growth phase appears to be optimal for β-glucan isolation from pure cell
fermentation cultures. NaCl and glucose stress have a negative impact on β-glucan production.
Yeast NaCl-stressed cells have a reduced β-glucan concentration compared to non-stressed for the
same glucose concentrations, while this difference is more significant at the end of the fermentation for
a fermented medium containing 200 g/L glucose, which is close to the wine must concentration
intended for wine production. For the other two glucose concentrations (300 and 400 g/L),
the differences at the end of the fermentation are not statistically significant. In the present study,
it seems that the two different stresses act synergistically, with an additive negative impact on the cell
wall β-glucan concentration; as for the same glucose concentration, the preconditioned NaCl cells
had a lower β-glucan concentration compared to the non-preconditioned ones. Another significant
observation was that for a yeast cell grown in a medium containing 400 g/L glucose, the cell wall
β-glucan concentration remained almost the same from the end of the exponential phase until the end
of the fermentation for both NaCl-stressed and non-stressed cells.
The study of cell wall physiology, which is still a poorly explored research field, and yeast cell
growth under various stress conditions (glucose, ethanol, temperature, SO2, etc.), could comprise
a key tool for the biotechnological development of new products like functional foods and antifungal
drugs for medical and agricultural applications. Further study on the impact of stress conditions on
the immunological properties of the isolated β-glucan from the various fermentation phases, as well
as the study of glycolysis–glycogenesis biochemical pathways in the yeast cell wall under stress
conditions, is proposed as it could offer new perspectives on yeast β-glucan-based drugs, adding
to a deeper understanding of yeast stress biology phenomena and a more comprehensive view of
alcoholic fermentation biochemical pathways. Additionally, the study of the genes encoding β-glucan
accumulation in the yeast cell wall during the fermentation process and under various environmental
stresses is proposed as it could enlighten us as to the molecular mechanisms of the yeast cell.
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Abstract: Ayeast isolate, selected for its lipolytic activity from a meat product, was characterized
as Pichia anomala. Lipolytic activity, determined on p-NPA as esterase, was maximum at 28 ◦C,
pH 6.5, and induced by the short chain triglyceride tributyrin. Fermentations in 2 L and 10 L stirred
tank bioreactors, with 20 and 60 g/L glucose respectively, showed that in the second case lipolytic
activity increased 1.74-fold, while the biomass increased 1.57-fold. Under otherwise identical aeration
conditions, improved mixing in the 10 L reactor maintained higher dissolved oxygen levels which,
along with the elevated glucose concentration, resulted in significant increase of specific rates of
lipolytic activity (51 vs. 7 U/g/L), while specific rates of growth and glucose consumption maintained
lower. The Crabtree-negative yeast (glucose insensitive growth) exhibited a Pasteur effect at lower
dissolved oxygen concentrations while elevated glucose prevented ethanol formation under oxygen
saturation. The particular physiological traits can be exploited to obtain significant lipolytic activity
in a scalable aerobic process.
Keywords: Pichia anomala; characterization; lipolytic activity; esterase; fermentation; metabolism
1. Introduction
The yeast Pichia anomala (syn. Wickerhamomyces anomalus, former Hansenula) has been isolated
from very diverse habitats, including plants, animals, soil, water, food and hospitals [1,2]. In food and
feed, P. anomala has either a beneficial role, as flavor enhancer, biopreservation agent, probiotic, enzyme
producer, or a detrimental role, as spoilage yeast. Biopreservation is due to its unusual-for-a-yeast
broad spectrum antimicrobial activity against several fungal, yeast, bacterial species and viruses.
P. anomala produces several metabolites with potential biotechnological exploitation. Examples,
apart from the antimicrobial agents that make it an attractive biocontrol organism for applications
in the agri-food sector, include bioethanol, isobutanol, enzymes, sophorolipids, γ-aminobutyric acid,
several volatile organic compounds, and beverage starter cultures [2]. Regarding enzyme production,
P. anomala strains have been reported as producers of phytase, amylase, β-glucosidase, peptidase and
lipase [3]. P. anomala is therefore a biotechnologically interesting organism which deserves in-depth
study in view of future commercialization, as several authors have stressed in their reports [4–6].
A preliminary study with yeast isolates from colonies on the surface of traditional Greek sausages
revealed a significant number of Pichia spp. Pichia isolates were tested for lipolytic activity and upon
obtaining positive results, further studies were carried out which are reported in the present work.
A particular Pichia isolate with the highest lipolytic activity was identified as P. anomala and designated
as M1 strain.
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Lipolytic enzyme production is common among yeasts. Only a few yeasts however (mainly
Candida, Yarrowia and Geotrichum spp.) are capable of producing lipases and esterases with interesting
characteristics and in sufficient amounts that allow characterization as industrial products [7,8].
Apart from the established producers, there are several promising lipase-producing yeasts as for
example, Issatchenkia orientalis, Kluyveromyces marxianus and others [9]. To the best of our knowledge,
P. anomala is reported as a lipolytic enzyme producer in only two cases, the works of Banerjee et al. [10]
and Ionita et al. [11], both being screening works. Strains of P. anomala were cultivated in solid media
and shake flask cultures and moderate lipolytic activity, optimum at pH 6.5–7.5, was detected. In
the present work, the P. anomala M1 strain was cultivated in stirred tank bioreactors and produced
significant lipolytic activity compared to known sources. The characteristics of lipolytic enzyme
production were investigated and evaluated.
Lipolytic enzymes share some important characteristics that can be application specific, e.g.,
substrate specificity, regionspecificity and chiral selectivity [12]. Novel applications have been
successfully established using lipases, as for example in the synthesis of biopolymers, flavor
compounds, enantiopure pharmaceuticals, agrochemicals and biosensors [12,13]. Innovations need
novel biocatalysts and a useful approach for obtaining them is the isolation of microorganisms from
natural sources and subsequent screening for the desired enzymatic activity. P. anomala exhibits many
interesting and potentially exploitable characteristics. It can grow under extreme environmental stress
conditions with regard to oxygen, pH, aw and sugar concentration [3,4,14,15]. As a Crabtree-negative
yeast and therefore insensitive to elevated levels of glucose concentrations in its substrate, it can be
grown easily in batch fermenters without the need of fed-batch cultivation. These characteristics show
an organism of practical significance and therefore a potential industrial microorganism in the case of
effective production of a valuable metabolite.
2. Materials and Methods
2.1. Yeast Isolation
Yeast colonies were transferred from the surface of sausages on agar plates containing YP-glucose
medium (YP, yeast-peptone; 1% yeast extract, 2% bacteriological peptone, 2% glucose, 2% technical
agar). The plates were incubated at 28 ◦C for 2 days. Selected colonies were sub-cultured on new plates
and purified by repeated streaking. The isolated colonies were maintained on YP-glucose agar at 4 ◦C.
The isolated yeast colonies were subjected to standard tests and classification procedures according to
Kreger-van Rij [16].
2.2. Molecular Characterization of an Isolated Pichia Anomala Strain
Yeast identification was done by amplification and sequence analysis of the ribosomal
DNA internal transcribed space region (ITS) [17,18]. The following primers were used: ITS1
(5′-CGGGATCCGTAGGTGAACCTGCGG-3′) and ITS4 (5′-CGGGATCCTCCGCTTATTGATATGC-3′).
The amplification mixture was consisted of: 20 pmol of each primer, 300 ng genomic DNA template,
0.2 mM dNTP, 1.5 mM MgCl2, and 1 U Taq polymerase (final volume of 20 μL). Reactions were
run for 40 cycles at 94 ◦C for 1 min, annealing at 55 ◦C for 1 min and extension at 72 ◦C for 2 min,
according to Tao et al. [18]. The polymerase chain reaction products were cloned into the plasmid
vector pMD18T-Simple (2693 bp) and sequenced. PCR derived sequences were compared with the
deposit in the GenBank ITS region (http://www.ncbi.nlm.nih.gov) and the similarity was evaluated
using the BLAST program.
2.3. Yeast Cultivation
Cultures were grown in 250 mL Erlenmeyer flasks containing 50 mL of YP-glucose broth, pH 6.5,
which contained in addition olive oil (1% v/v), tributyrin (1 g/L), or triolein (1 g/L), alternatively.
The flasks containing sterile media were inoculated with a loopful of yeast directly from a plated
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culture. The inoculated flasks were incubated in a shaker incubator at 150 rpm and 28 ◦C for 48 h. 20 h
flask cultures were used to inoculate the bioreactors in volumes giving a final optical density at 600 nm
of 0.1 to 0.15.
Bioreactor cultivations were carried out in two stirred tank bioreactors of different capacities:
a 2 L working volume (BioFlo, New Brunswick Scientific, NJ, USA) and a 10 L working volume
(BIOFLO 410, New Brunswick Scientific, NJ, USA). The agitator of the 2 L reactor had two six-bladed
Rushton-type impellers (52 mm). The reactor vessel was equipped with baffles. The agitation system
of the 10 L reactor consisted of three disc turbine impellers, 8 cm in diameter, with six flat blades.
The reactor vessel was also equipped with baffles. The operating stirrer speed in both reactors was
200 rpm. The airflow rate was adjusted at 1 L of air per liter of reactor working volume per minute
(1 vvm). The temperature was maintained at 28 ◦C, while the pH at 6.5 throughout fermentations by
automatic addition of titrants (1 M NaOH and HCl solutions). Dissolved oxygen tension (DOT) was
monitored in both reactors during fermentations.
Fermentations in the 2 L bioreactor carried out using the above-described media and lasted 72 h.
In the 10 L reactor fermentations, the medium was modified to include 60 g/L glucose and 1 g/L
tributyrin and fermentations lasted 96 h. Samples were taken at regular intervals, cells were removed
by centrifugation at 14,000 rpm for 10 min, and the supernatants were examined for lipolytic activity.
Batch fermentations were repeated at least three times and each sample was analyzed in triplicate.
2.4. Analytical Methods
The reagents used throughout the study were analytical grade by Sigma. Growth was estimated
by measuring the optical density at 600 nm and by measuring the cell dry weight (CDW). Broth samples
were filtered through pre-weighed glass microfiber filters (Whatman, Maidstone, UK), washed twice
and dried in a microwave oven at the defrost setting for 15 min. The filters were placed in a desiccator
for the next 24 h and weighed. The OD600 was correlated with the CDW and 1 unit OD600 equals
0.42 ± 0.3 mg cells/mL.
Lipolytic activity was preliminary evaluated on YP-glucose agar plates to which 1% v/v olive
oil had been added. Formation of a clearer halo around yeast colonies after 5 days of incubation at
28 ◦C was proof of lipolytic activity. The relative enzyme activity (REA) was calculated by dividing the
diameter of the zone of clearance by the diameter of the respective colony (in millimeters). Experiments
were carried out in triplicate and mean values are presented.
In liquid culture filtrates, lipolytic activity was assayed using the esters p-nitrophenyl palmitate
(p-NPP) and p-nitrophenylacetate (p-NPA) as substrates, following the protocol of our earlier work
with molds [19], which was based on the method of Winkler and Stuckmann [20]. The reaction mixture
was consisted of 405 μL buffer and 45 μL of substrate. The buffer was as: 200 mg Triton X-100, 50 mg
gum arabic in 50 mL of 50 mM phosphate buffer, pH 6.5. As substrate, 15 mg p-NPP or p-NPA in 10 mL
2-propanol was used. The reaction mixture was emulsified in an ultrasonic bath for 5 min. 50 μL of the
sample solution containing the lipolytic enzyme was added to the mixture warmed at 40 ◦C and after a
5 min incubation the reaction was terminated by addition of 0.5 mL of 2% Trizma base. Centrifugation
was followed at 12,000 rpm/4 min and the OD of the supernatant was measured at 410 nm. One unit
(U) of lipase activity was defined as the amount of enzyme that released 1 μmol of p-nitrophenol/min
under the specified conditions.
Neutral protease activity was determined in liquid culture filtrates using the casein assay
according to Sigma’s protocol [21]. Alkaline protease activity was determined using the azocasein
assay according to Reichard et al. [22] with the pH of the 0.1 M Tris-HCl buffer adjusted at 9.0 instead
of the suggested 8.0. One unit (U) of protease activity was defined as the absorbance variation in the
assay conditions of the above methods.
Glucose concentrations were determined with the glucose oxidase/peroxidase method of Kunst
et al. [23]. Ethanol, acetate and glycerol concentrations were determined calorimetrically using assay
kits by Sigma-Aldrich (St. Louis, MO, USA) (MAK076, MAK086 and MAK117, respectively).
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All values are given as mean ± standard deviation in triplicate for each point. Kinetic parameters
of growth and production were calculated from raw data using numerical differentiation.
3. Results and Discussion
3.1. Strain Isolation and Identification
The yeast strain P. anomala M1 studied in this work was isolated from colonies developed on the
surface of traditional Greek sausages. Although the yeast population in the sausages is significant,
there are no reports in the literature either on its biodiversity or on its role in the development of
product characteristics. A preliminary study with yeast isolates from colonies on the surface of the
particular type of sausages revealed a significant number of Debaryomyces and Pichia spp. (data not
shown). Studies on Spanish and Italian relevant products show the dominance of Debaryomyces and
significant numbers of Candida, Pichia, Rhodotorula and Torulopsis spp. [24,25]. The yeasts ferment
sugars and have proteolytic and lipolytic activity and therefore, produce a large array of metabolites
that contribute to the development of flavor and aroma [26]. In addition, some yeasts metabolize the
lactic acid produced by lactic acid bacteria and cause an increase in the pH toward neutrality which is
translated in the product as milder taste [25].
Colonies of the M1 strain on agar plates containing YP-glucose medium were off-white in color,
flat, smooth and opaque. Pseudohyphae were not observed, while 1 to 4 ascospores were detected per
ascus (Figure 1). The strain was able to grow in media containing as carbon source glucose, sucrose,
galactose, and maltose. It was not able to grow on lactose. It could assimilate soluble starch, raffinose,
ethanol, glycerol, D-mannitol, as well as lactic and citric acids, but not L-rhamnose. The yeast was able
to grow on substrates containing 1.5 M NaCl (osmotolerant) and in the absence of vitamins, while it
produces ethanol under anaerobic conditions (negative Crabtree effect). The yeast was preliminary
identified as Pichia while possession of traits such as high osmotolerance, fermentation of sucrose,
assimilation of raffinose but not of L-rhamnose, puts it under the species classification of P. anomala
according to Kurtzman [1].
 
Figure 1. Pichia anomala M1 cell morphology (phase contrast microscopy, ×400).
Taxonomic identity of the M1 strain was confirmed through 18s rRNA ITS region
cloning and sequencing. Following PCR amplification, a fragment of about 600 bp was
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Figure 2. PCR product (pointed) of the internal transcribed spacer (ITS) region of P. anomala M1.
A BLAST search for the above sequence showed that it shared almost complete identity (99%)
with a number of Wickerhamomyces anomalus strains-the name preferred by NCBI for Pichia anomala.
The sequence was deposited to GenBank under the accession number BankIt2015357 (MF076893).
3.2. Relative Lipolytic Activity in Solid State Cultivation
Research on P. anomala growth conditions has shown that it is able to tolerate a relatively wide
range of environmental growth conditions, e.g., temperatures ranging from 3 to 37 ◦C; pH values from
2.0 to 12.0; and osmotic conditions as low as aw 0.92 for NaCl and 0.85 for glycerol [15]. Tao et al. [18]
in their work with P. anomala Y1 reported that good growth was obtained in YPD medium with the pH
in the range of 3.5–6.5 and temperature 25–30 ◦C, while optimum growth conditions were reached
at 30 ◦C and pH 5.0. It would be necessary therefore to investigate for lipolytic activity by P. anomala
M1 over a wide range of temperatures and pHs and this was feasible by evaluating first the relative
lipolytic activity in solid media containing olive oil, over a temperature range at pH 6.5, since most of
yeast and fungal lipases are reported to be most active and stable in neutral and alkaline pHs [19,27].
Figure 3 shows the relative lipolytic activity of P. anomala M1 on YP-glucose agar containing olive
oil at various temperatures, ranging from 25 to 40 ◦C. The pH of the medium was adjusted at 6.5.
The highest activity was obtained at 28 ◦C. The lipolytic activity was lower at 30 ◦C but significantly
higher compared to values obtained at 25 and 35 ◦C. The relative lipolytic activity at 40 ◦C was close to
zero. An experiment was also carried out keeping the temperature at 28 ◦C and changing the pH of
the medium in a range from 3.0 to 7.5. As it is shown in Figure 4, the highest lipolytic activity was
obtained at pH 6.5. P. anomala M1 was able to produce lipolytic activity within the pH range 5.0–7.0
but the relative lipolytic activity values obtained at pHs 6.5 and 6.0 were significantly higher. Lipolytic
activity was not detected at pHs 3.0, 3.5, and 7.0, while it was marginally detected at pHs 4.0 and 4.5.
Considering both Figures 3 and 4, it can be concluded that the optimum conditions of temperature
and pH for lipolytic enzyme production by P. anomala M1 are 28 ◦C and pH 6.5, and these conditions
were applied in submerged fermentations.
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Figure 3. The effect of temperature on the relative lipolytic activity of P. anomala M1 grown on
YP-glucose agar supplemented with olive oil at pH 6.5. Experiments were carried out in triplicate and

























Figure 4. The effect of pH on the relative lipolytic activity of P. anomala M1 grown on YP-glucose agar
supplemented with olive oil at 28 ◦C. Experiments were carried out in triplicate and the Y-error bars
represent the standard deviation of the mean value.
3.3. Production of Extracellular Lipase in Submerged Fermentation
Lipases can be distinguished from carboxyl esterases by their substrate spectra, using p-NPP
(cleaved by lipases) versus p-NPA (cleaved by esterases). The lipolytic activity assay produced results
only on the p-NPA substrate and therefore, the activity is due to an esterase enzyme.
Figures 5 and 6 show the time-courses of biomass and lipolytic activity of P. anomala grown in
shaken flasks with olive oil, triburyrin (short chain triglyceride, C15H26O6) or triolein (long chain
triglyceride C57H104O6) added in the medium as enzyme inducer. There is an obvious enhancement
of both growth but mainly lipolytic activity in the case of tributyrin. Comparing results, it appears
that final lipolytic activity with tributyrin was 1.91 times higher than the obtained with olive oil
while 2.43 times higher than the obtained with triolein. The effect on biomass was not as sound
-although results of the same trend were obtained. Biomass yield with tributyrin was 1.16 times higher
compared to the obtained with olive oil and 1.47 times higher than that of triolein. In all cases, lipolytic
activity increased with increasing biomass and resumed in about 40 h when cultures were well into
the stationary phase of growth. Although in shaken flasks cultivation important process parameters
(e.g., the air supply or the culture pH) were not under control, the effect of the inclusion of tributyrin
in the medium was clear.
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Figure 5. Time courses of biomass concentration of P. anomala M1 in shaken flasks cultures (200 rpm).

























Figure 6. Time courses of extracellular lipolytic activity of P. anomala M1 in shaken flasks cultures
(200 rpm). The YP-glucose medium was supplemented alternatively with olive oil, tributyrin
and triolein.
The profile of extracellular lipolytic activity of P. anomala M1 was next evaluated in submerged
bioreactor cultivations of two different scales under the conditions described in the previous section,
using tributyrin as inducer. Concerning oxygen requirements of P. anomala, it is known that it is able
to grow in both oxygen-replete and oxygen-limited conditions (facultative yeast). However, under
aerobic conditions growth rates and biomass yields are significantly higher than those obtained under
anaerobic conditions [14]. Since extracellular lipases are products of the primary metabolism with
growth-associated characteristics, fermentations were carried out under aerobic conditions to ensure
increased growth rates.
Figure 7 shows the time-courses of biomass, lipolytic activity and residual glucose concentrations
in a run in the 2 L stirred tank bioreactor. P. anomala grew exponentially with a maximum specific
growth rate μmax of 0.17 h−1 and a biomass yield Yx/s of 0.43 g of CDW g of glucose−1 (Table 1).
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Only low amounts of ethanol, glycerol and acetate were detected (results at 50 h, Table 1). Dissolved
oxygen tension decreased during growth and the lowest levels monitored were 70% of saturation,
which were high enough to consider oxygen limitation (Figure 7). Maximum biomass concentration
(8.6 g/L) was obtained around 55 h while maximum lipolytic activity (159 U/L) around 50 h of
fermentation. With depletion of glucose (50 h samples), biomass started decreasing and a sharp
fall in lipolytic activity was observed. Running the process for another 24 h after glucose depletion
resulted in a loss of lipolytic activity of the order of 19.2%. This was observed in several cases of
lipase production in fermentation [27] and was attributed mainly to proteolytic degradation. Protease
activity was determined in the present case and as shown in Figure 7, proteases appeared in the broth
after 30 h of fermentation (1.2 U/mL) and proteolytic activity was increasing towards the end of the
process to reach 11 U/mL. Ethanol, glycerol and acetate were not detected beyond 65 h, indicating





























































Figure 7. P. anomala fermentation in a 2 L working volume stirred tank reactor (200 rpm, 28 ◦C, pH 6.5,
1 vvm aeration). The YP-20 g/L glucose medium was supplemented with tributyrin.
Table 1. Kinetic parameters of P. anomala M1 cultures. Values are averages ± standard deviations based
on the results of three independent cultivations.
Parameter 2 L Bioreactor 20 g/L Glucose 10 L Bioreactor 60 g/L Glucose
Maximum Specific Growth Rate (h−1) 0.17 ± 0.02 0.12 ± 0.03
Maximum Specific Consumption Rate
of Glucose (mmol/g/h)
1.9 ± 0.2 1.3 ± 0.3
Specific Production Rate of
Lipolytic activity (U/g/h) 7 ± 0.8 51 ± 1.3
Ethanol (mmol/g/h) 0.12 ± 0.02 0.09 ± 0.03
Acetate (mmol/g/h) 0.14 ± 0.04 0.11 ± 0.01
Glycerol (mmol/g/h) 0.11 ± 0.03 0.10 ± 0.02
Yield on Glucose (g/g)
Biomass 0.43 ± 0.14 0.24 ± 0.02
Ethanol 0.03 ± 0.002 0.05 ± 0.01
Acetate 0.05 ± 0.01 0.04 ± 0.02
Glycerol 0.02 ± 0.009 0.02 ± 0.001
Figure 7 shows the P. anomala M1 fermentation process in the 10 L bioreactor with 60 g/L initial
glucose concentration. Both biomass production and lipolytic activity were higher compared to those
obtained in the 2 L fermentation. The maximum values obtained, were 14.9 g/L biomass and 213 U/mL
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lipolytic activity (75 h), which is 1.57 times higher biomass, and 1.74 times higher lipolytic activity
compared to those obtained from the 2 L reactor fermentation. Comparing the kinetic parameters for
growth in the two reactors it appears that the values for maximum specific growth rateand the yield of
biomass on glucose were lower in the 10 L fermentation: 0.12 compared to 0.17 h−1 and 0.24 compared
to 0.43 g of CDW g of glucose −1 g, respectively (Table 1). The lower biomass levels however produced
the lipolytic enzyme (in terms of activity) at a higher rate: 0.48 U/mL/h compared to 0.06 U/mL/h
and in terms of specific production rate, 51 U/g/h biomass in the 10 L process compared to 7 U/g/h
biomass in the 2 L process (timing: 50 h). Glucose concentration fell to zero in 72 h and the following
24 h of the process were characterized by declining biomass and enzyme activity levels. The loss
of lipolytic activity was 20.1% in the case of the 10 L fermentation. Only low amounts of ethanol,
glycerol and acetate were detected in this case again (results at 50 h, Table 1). Dissolved oxygen
tension decreased during fermentation but higher values were monitored compared to those of the 2 L
bioreactor fermentation: about 85% of saturation at maximum biomass levels.
Since the lipolytic activity is highly dependent on the experimental conditions and the applied
methodology, direct comparisons of the results with those reported for various microbial lipases
become rather difficult. However, the obtained values for kinetic parameters and product titers
are either comparable or even higher. Kar and co-workers [28] obtained maximum specific rates of
extracellular lipase production by Y. lipolytica at around 50 h of fermentation as in the present study,
the values however were expressed per million of cells and not per g CDW and cannot be compared
since it is a different yeast species. With fungal lipases, the production period is longer as for example
with Mucor hiemalis lipase whose maximum activity was obtained at 192 h of fermentation and reached
110 U/mL [29], or a Penicillium nalgiovense lipase with a maximum activity of 82 U/mL at 168 h of
fermentation [19].
The applied culture conditions in the 10 L bioreactor (Figure 8) resulted in a significant increase in
the specific rate of lipolytic activity while the specific rates of growth and glucose consumption were
decreased compared to those of the 2 L bioreactor. The main differences between the two systems were
the concentrations of glucose and the dissolved oxygen tension. P. anomala is a respiratory yeast that
lacks a Crabtree effect and therefore, there is no induction of alcoholic fermentation by high glucose
concentrations. In addition, similarly to the other respiratory yeast K. lactis, P. anomala exhibits minor
fermentation despite the elevated activities of the key fermentative enzymes PDC and ADH [14,30].
This metabolic profile was apparent in the present study. Although the same stirrer speed (200 rpm)
and air supply rate (1 vvm) were applied in the two reactor systems, the dissolved oxygen tension was
maintained at higher levels in the 10 L bioreactor despite the increased biomass concentration. This can
be explained by a more efficient mixing regime in the 10 L reactor that facilitated a smaller mixing
time of the broth, however, mixing studies were not undertaken at that stage to quantify the effects.
The decrease in DOT in the 2 L bioreactor may have acted as the inducing stimulus for the activation
of fermentative metabolism and the increased glucose consumption rate points to an ongoing Pasteur
effect. Glucose availability however, did not induce ethanol formation.
Intensive studies of P. anomala metabolism and physiology in response to oxygen and glucose
availability carried out by Fredlund and co-workers (2004) [14] showed that with the particular
yeast, the signals that induce respiratory and fermentative metabolism are completely different
from those known for Saccharomyces cerevisiae. Respiratory growth was obtained from aerobic
batch cultures with a high glucose concentration and fermentation could be induced by shifting
the cultures to oxygen limitation (shift from 50% to 0% DOT). Oxygen therefore is the main regulator
of the central energy metabolism while glucose does not repress respiration but possibly repress the
ethanol assimilation pathway. Having this metabolic and physiological background, lipolytic enzyme
production by P. anomala appears to be advantageous compared to other sources as it can take place
under oxygen-saturated conditions using substrates with elevated glucose concentrations.
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Figure 8. P. anomala fermentation in a 10 L working volume stirred tank reactor (200 rpm, 28 ◦C, pH 6.5,
1 vvm aeration). The YP-60 g/L glucose medium was supplemented with tributyrin.
From the applications point of view, the non-conventional yeast P. anomala has been extensively
studied mainly as a biopreservation agent for various post-harvest systems. Although it was reported
in the past as lipase-positive yeast, its production potential in fermentation systems was not
evaluated. The current study shows that a wild strain isolated from a rich in fat meat product
can produce significant lipolytic activity in a scalable aerobic process. Further studies will focus on
the characteristics and properties of the produced esterase as well as in the process itself. Factors for
example, identified in this study as controlling process parameters, e.g., the DOT, should be studied in
a scaling-up perspective.
4. Conclusions
This study shows that a wild strain of P. anomala is capable of producing extracellular lipolytic
(esterase) activity in a process with practical significance. Experiments carried out in agar plates,
shaken flasks, a 2 L stirred tank bioreactor and a 10 L stirred tank bioreactor showed that by setting the
appropriate conditions the physiological traits of the particular yeast can be exploited for effective
enzyme production. The Crabtree-negative yeast P. anomala exhibits a Pasteur effect at lower dissolved
oxygen concentrations but elevated glucose concentrations are not inhibitory and depress ethanol
formation in an oxygen-saturated substrate. The main stimulus for the regulation of central carbon
metabolism as it appears from its effects on the specific rates of growth and enzyme production is
oxygen and, therefore, setting an aerobic process with a high glucose concentration in the substrate
advances enzyme production.
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Abstract: Fungi produce a variety of volatile organic compounds (VOCs) during their primary and
secondary metabolism. In the beverage industry, these volatiles contribute to the the flavor and
aroma profile of the final products. We evaluated the fermentation ability and aroma profiles of
non-conventional yeasts that have been associated with various food sources. A total of 60 strains
were analyzed with regard to their fermentation and flavor profile. Species belonging to the genera
Candida, Pichia and Wickerhamomyces separated best from lager yeast strains according to a principal
component analysis taking alcohol and ester production into account. The speed of fermentation and
sugar utilization were analysed for these strains. Volatile aroma-compound formation was assayed
via gas chromatography. Several strains produced substantially higher amounts of aroma alcohols
and esters compared to the lager yeast strain Weihenstephan 34/70. Consequently, co-fermentation of
this lager yeast strain with a Wickerhamomyces anomalus strain generated an increased fruity-flavour
profile. This demonstrates that mixed fermentations utilizing non-Saccharomyces cerevisiae biodiversity
can enhance the flavour profiles of fermented beverages.
Keywords: aroma profiling; solid-phase microextraction–gas chromatography/mass spectrometry
(SPME–GC/MS); yeast; Saccharomycetes; fermentation; volatile organic compound (VOC); aroma
1. Introduction
Beer is one of the most widely consumed alcoholic beverages in the world. In 2003, worldwide
beer production reached around 1.82 billion hectoliters and increased to a volume of 1.93 billion
hectoliters in 2013 according to the Kirin Beer University Report of 2014. Production is divided into
several beer styles of which ale and lager beers are most prominent. Generally, ale is produced by
top-fermenting yeasts at temperatures between 15–30 ◦C. Ales are known for their fruity aromas
which are regarded as a distinctive characteristic of top-fermenting beers. Lager beers, however, are
produced by a distinct group of bottom-fermenting yeasts at fermentation temperatures between
10–15 ◦C. The aroma of lager beers is more neutral compared to ale-type beers as they contain lower
amounts of fruity flavors.
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Top-fermenting yeasts generally are S. cerevisiae strains. At the end of fermentation, these yeasts
rise to the surface of the fermenter, creating a thick cell layer. Bottom-fermenting yeasts belong to two
distinct groups of lager yeasts [1]. Lager yeasts are hybrids between S. cerevisiae and S. eubayanus [2].
Lager yeasts can be divided into two groups, group I or Saaz type, and group II or Frohberg type, that are
distinguished at the molecular level by ploidy differences, characteristic chromosomal rearrangements
and chromosome losses [3,4].
In contrast to lager beers, lambic beers with sometimes exceptional flavor compositions are based
on a larger biodiversity, including acetic and lactic acid bacteria and various yeasts, e.g., S. cerevisiae,
S. pastorianus and Brettanomyces bruxellensis [5].
Beer is a complex product consisting of volatile and non-volatile components that form the final
aroma. The contribution of ale yeasts to the final flavor bouquet is generally higher than that of lager
yeasts. This has been attributed to the greater diversity of ale yeasts compared to the limited diversity
of the two groups of lager yeast [6]. Other process parameters also influence volatile-compound
formation. Specifically, sugar concentration of the wort and different aeration regimes influence the
production of flavor-active esters. These esters mainly contribute to the fruitiness of the product.
Dominant esters are acetate esters such as ethyl acetate (fruity), isoamyl acetate (banana) and 2-phenyl
acetate (rose) and ethyl or medium-chain fatty acid esters such as ethyl hexanoate, ethyl octanoate
and ethyl decanoate, which provide a fruity apple- or wine-like flavor to the beer [7]. Among the
higher alcohols, n-propanol, isobutanol, 2-phenylethanol and isoamyl alcohol are most abundant.
Higher alcohols such as isobutanol can contribute a rum-like aroma which gives a warm mouth feeling,
while 2-phenylethanol and isoamyl alcohol are prevalent for their sweet/rose and fruity/banana-like
aromas, respectively [8].
Not all flavors are desirable. Strecker aldehydes (aged flavour), aldehydes of the Maillard reaction,
e.g., furfural, and aldehydes of fatty acid oxidation, e.g., trans-2-nonenal, are regarded as off-flavors in
beer [9]. The ketone diacetyl (2,3-butanedione) is monitored during the lager beer brewing process,
in particular, as it imparts an undesirable buttery flavor with a low flavour threshold [10]. Given the
low concentration and volatile nature of these aroma compounds, gas chromatography coupled with
mass spectrometry (GC/MS) offers an optimal technique to analyze the flavor profile of beer.
Recently, non-conventional yeasts or non-cerevisiae yeasts have gained importance for fermented
alcoholic beverages [11,12]. They produce various mixtures of volatile compounds and so contribute
to the aroma profile of beverages [6,13]. Mixed fermentations using S. cerevisiae in combination with a
non-conventional yeast strain e.g., belonging to the genera Lachancea, Pichia or Hanseniaspora, could
provide novel beverages with improved ester profiles [14,15]. On the other hand, the synergistic effects
on aromatic compound production were observed in co-cultures with Metschnikowia pulcherrima and
S. cerevisiae [16]. Non-conventional yeasts could contribute to satisfying the demand of novel and
distinctive, yet natural, flavors in fermented beverages [17].
A vast number of non-conventional yeast strains has been isolated from various food sources and
deposited in culture collection such as the CBS yeast collection of the Westerdijk Fungal Biodiversity
Institute (formerly, CBS, Centraalbureau voor Schimmelcultures, Utrecht, Netherlands). In this study,
we aimed at covering a broad spectrum of species isolated from different substrates like berries, fruits,
cheese, fruit flies or even soil and spanning a broad evolutionary distance within the Saccharomycotina in
order to identify species that could contribute with their particular flavour to lager beer fermentations.
2. Materials and Methods
2.1. Strains and Media
Yeast strains used in this study are shown in Table 1, including their CBS reference number. Each
strain was coded based on its coordinates in a 96-well plate. Yeast strains were subcultured in YPD
(1% yeast extract, 2% peptone, 2% glucose) at room temperature overnight.
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Table 1. Strains used in this study. Each selected strain was assigned to a code based on its coordinates
on a 96-well plate.
Position Strain Number Taxon Name Substrate of Isolation Origin
B2 CBS 10151 Candida alimentaria Cured ham Norway
B3 CBS 12367 Candida alimentaria Brie Régalou cheese
B4 CBS 4074 Candida diversa Grape must Japan
B5 CBS 8058 Candida kofuensis Berries of Vitis coignetiae Japan
B6 CBS 1760 Candida versatilis Pickling vat with 22% brine USA
B7 CBS 2649 Candida stellate Grape juice France
B8 CBS 6936 Clavispora lusitaniae Citrus essence Israel
B9 CBS 4373 Debaryomyces fabryi Dry white wine South Africa
B10 CBS 767 Debaryomyces hansenii
B11 CBS 2659 Debaryomyces subglobosus Apple Italy
C2 CBS 8139 Dekkera anomala Netherlands
C3 CBS 615.84 Geotrichum candidum Brie cheese France
C4 CBS 95 Hanseniaspora guilliermondii Fermenting bottled tomatoes Netherlands
C5 CBS 6783 Hanseniaspora occidentalis var. citrica Orange juice Italy
C6 CBS 2585 Hanseniaspora uvarum Sour dough Portugal
C7 CBS 2568 Hanseniaspora vineae Drosophila persimilis (fruit fly)
C8 CBS 2352 Hyphopichia burtonii Pollen, carried by wild bees
C9 CBS 4311 Kazachstania servazii Soil Finland
C10 CBS 3019 Kazachstania spencerorum Soil South Africa
C11 CBS 2186 Kazachstania transvaalensis Soil South Africa
D2 CBS 398 Kazachstania unispora
D3 CBS 7775 Kluyveromyces aestuarii Neotredo reynei (shipworm) Brazil
D4 CBS 8530 Kluyveromyces dobzhanskii Drosophila sp. Canada
D5 CBS 1557 Kluyveromyces marxianus Stracchino cheese Italy
D6 CBS 7005 Lachancea fermentati Alpechín Spain
D7 CBS 3082 Lachancea kluyveri Drosophila pinicola (fruit fly)
D8 CBS 7703 Lachancea waltii Either fruit or leaf of fruit tree
D9 CBS 5833 Metschnikowia pulcherrima Berries of Vitis labrusca (Concord grapes) USA
D10 CBS 2030 Meyerozyma guilliermondii Insect frass on Ulmus americana (elm tree) USA
D11 CBS 8417 Meyerozyma guilliermondii Brine bath in cheese factory Netherlands
E2 CBS 7720 Nakaseomyces bacillisporus Exudate of Quercus emoryi (Emory oak) USA
E3 CBS 2170 Nakaseomyces delphensis Sugary deposit on dried figs South Africa
E4 CBS 8255 Pichia Kefyr
E5 CBS 2020 Pichia farinosa Fermenting cacao Trinidad and Tobago
E6 CBS 2057 Pichia fermentans Brewers yeast
E7 CBS 188 Pichia kluyveri Olives
E8 CBS 5147 Pichia kudriavzevii Fruit juice
E9 CBS 191 Pichia membranifaciens Wine Italy
E10 CBS 429 Saccharomyces cerevisiae Fermenting must of champagne grapes
E11 CBS 1250 Saccharomyces cerevisiae Sherry Spain
F2 CBS 1782 Saccharomyces cerevisiae Super-attenuated beer
F3 CBS 820 Saccharomycodes ludwigii Grape must Germany
F4 CBS 2863 Schwanniomyces occidentalis Soil of vineyard Spain
F5 CBS 6741 Schwanniomyces polymorphus var. africanus Soil South Africa
F6 CBS 133 Torulaspora delbrueckii Ragi Indonesia
F7 CBS 427 Torulaspora microellipsoides Apple juice Germany
F8 CBS 248 Wickerhamomyces anomalus Red currants Netherlands
F9 CBS 249 Wickerhamomyces anomalus Berries
F10 CBS 261 Wickerhamomyces anomalus Ragi Indonesia
F11 CBS 262 Wickerhamomyces anomalus Beer
G2 CBS 4689 Zygosaccharomyces bailii var. bailii Grape must Italy
G3 CBS 1082 Zygosaccharomyces bisporus Tea-beer fungus Indonesia
G4 CBS 726 Zygosaccharomyces mellis Wine grapes Germany
G5 C1030 Saccharomyces pastorianus Brewers’ yeast
G6 C1039 Saccharomyces cerevisiae Wine yeast
G7 C746 Saccharomyces cerevisiae Brewers’ yeast
G8 CBS 1513 Saccharomyces carlsbergensis Brewers’ yeast
G9 C482 Saccharomyces cerevisiae Brewers’ yeast
G10 WS34/70 Saccharomyces pastorianus Brewers’ yeast
G11 C598 Saccharomyces cerevisiae Laboratory strain
To evaluate growth at different temperatures or the utilization of maltose, cells were spotted on
solid media plates in 10-fold dilution series and incubated for 5 days before evaluation. Growth at the
different dilutions was 10-color coded and is presented as a heat map.
2.2. Fermentation Conditions
Lab-scale fermentations were carried out in 50 mL tubes filled with 40 mL nutrient-rich YPD with
the glucose concentration adjusted to 16 ◦Plato at 20 ◦C. Each fermentation (300 rpm, using a triangular
magnetic stirrer) was started with a cell density corresponding to OD600 = 0.2. For co-fermentations,
the amounts of cells used equaled OD600 = 0.1. The fermentation progress was monitored for up to
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14 days by daily measurement of CO2 release. Sugar content was measured by a DMA 35 Anton Paar
densitometer (medium gravity in ◦P). Plato measurements were taken at the beginning and at the end
of each fermentation process. The fermentation was defined as finished when the CO2 loss did not
increase any further and the residual sugar concentration remained constant for 2 days. Ethanol was
measured after the end of fermentation using an Anton Paar DMA 4500 M Alcolyzer. Aroma profiles
were analysed by headspace gas chromatography.
2.3. Sample Preparation for Solid-Phase MicroExtraction–Gas Chromatography/Mass Spectrometry
(SPME-GC/MS) Analysis
2.5 mL of the samples were put in 20 mL vials with the addition of sodium chloride (final
concentration 40 mg/ml), 50 μL NaN3 0.1%, 25 μL of the internal standard (2-octanol final concentration
of 200 μg/L) and ascorbic acid (final concentration of 20 mg/mL).
All samples were incubated for 10 min at 40 ◦C, then the volatile compounds were collected on a
divinylbenzene/carboxen/polydimethylsiloxane fiber (DVB-CAR-PDMS) coating 50/30 μm, and 2-cm
length SPME fibre purchased from Supelco (Sigma-Aldrich, Milan, Italy) for 40 min.
2.4. Analytical Methods for GC/MS
GC analysis was performed on a Trace GC Ultra gas chromatograph coupled with a TSQ Quantum
Tandem mass spectrometer (Thermo Electron Corporation, Waltham, MA USA), with adaptations as
described in Ravasio et al. [18]. GC separation was performed on a 30 m Solgelwax PEG capillary
column with an internal diameter of 0.25 mm and a film thickness of 0.25 m (SGE Analytical Science,
Melbourne, Australia). The GC oven was kept at 40 ◦C for 4 min and then increased by 6 ◦C/min to
250 ◦C and kept at the final temperature for 5 min. The injector and transfer-line temperatures were
kept at 250 ◦C as well. Helium was used as the carrier gas with a flow rate of 1.2 mL/min. The time for
thermal desorption of analytes was 4 min. The MS detector was operated in full scan mode at 70 eV
with a scan range from 35 to 350 m/z. Data analysis was performed using the software ThermoXcalibur
(Version 2.2 SP1.48, Thermo scientific, Waltham, MA, USA). Identification of compounds was based
on comparison with a mass spectral database (NIST version 2.0, Gaithersburg, MD, USA) and with
reference standards when available. The relative amount of each volatile was expressed as μg/L
of 2-octanol.
2.5. Multivariate Data Analysis
Multivariate data analysis was performed using StatSoft, Inc. STATISTICA version 8.0 (data
analysis software system, 2007, StatSoft (Europe) GmbH, Berikon, Switzerland). Principal component
analysis was employed to simplify data interpretation. The matrix initially contained the 60 strains
considered in this study and the average of the relative 62 VOCs detected and was later reduced to the
sub-selection of 19 strains studied further.
3. Results
3.1. Strain Selection and Identification of Representative Isolates
In order to cover a wide range of the biodiversity of non-conventional yeasts, we selected 60 strains
from 48 different species which were obtained from the strain collection of the Westerdijk Institute.
The focus was on strains that were previously isolated from various fermentations, e.g., from fermented
liquids, fruits, vegetables, or meat. These strains, therefore, may have evolved superior or desirable
features, e.g., the production of high levels of ethanol or may have been recognized based on their
contribution to flavors. All strains were run in lab-scale fermentation trials in nutrient-rich broth (YPD
with adjusted glucose content at 16 ◦Plato) to assess their aroma production. Flavor profiles were
analyzed using GC/MS and compared to a set of brewing and wine yeast strains (Supplementary
Table S1).
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3.2. Aroma Profiles of Fermentations
In total, we identified 62 different volatiles in the samples of all strains (Table 2). Major
volatile-aroma compounds that were detected included esters, alcohols, aldehydes, ketones and
acids. Most species harbor the ability to produce a large variety of flavors. Thus, we did not identify
single species that produced only very few compounds or species with a very high diversity, as shown
in Figure 1 for a selection of species. However, there was an enormous difference in the amounts of
specific volatiles produced. Esters were the most prominent group of volatiles. In total, 22 different
esters could be identified and within this group ethyl-esters dominated, such as ethyl hexanoate
and ethyl acetate, associated with fruity wine/apple-like and sweet pear drop flavors, respectively.
Alcohols comprised the second major group of compounds. Besides ethanol, we identified 14 different
alcohols. Yet, only two compounds, 2-phenylethanol, perceived as rose flavor, and isoamyl alcohol,
a banana-like flavor, were produced by all strains analyzed. During anaerobic fermentations the
formation of aroma alcohols is favored over the production of aroma acids [19]. In line with this, we
identified only six acids, of which acetic acid and butyric acid were prominent.









































































Figure 1. Number of volatile organic compounds (VOCs) produced during fermentation of selected
strains. The compounds were grouped, numbered and colored according to their chemical class.
The complete list of compounds is shown in Table S1 (see Table 1 for nomenclature of strains).
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We were most interested in species that separated well from S. cerevisiae or lager yeast strains.
Therefore, we narrowed down the selection of strains to those that showed clear separation in their
flavour profiles to the set of S. cerevisiae and lager yeast strains based on principal component analysis
(Figure 2). This identified species belonging to the genera Candida, Pichia and Wickerhamomyces.
Figure 2. Principal component analysis of the set of selected strains and their chemical compounds
produced. The matrix is based on the set of 19 strains and the VOCs detected. Strains are presented
with their assigned coordinates (see Table 1). Species belonging to the same genus are represented by
the same color.
Based on the GC data, we generated relative quantifications of the volatile aroma compounds
formed. The set of strains was then compared to the lager yeast S. pastorianus/Weihenstephan to
identify strains that produced higher amounts of esters and alcohols (Tables 3 and 4). One strain of
Saccharomyces cerevisiae (CBS 1250; E11) was a very good producer of alcohols, particularly of isoamyl
alcohol, by contrast with lager yeast. Yet, this strain only produced moderate amounts of esters, mostly
ethyl acetate. Its origin from sherry production suggests that it has been selected as the preferred strain
for these fermentations.
The Wickerhamomyces anomalus isolates showed a remarkably high amount of both alcohol
and ester production. Production of higher alcohols was strongly increased in these W. anomalus
strains compared to lager yeast. Interestingly, here mainly isoamyl alcohol and 2-phenyl ethanol
production was increased. These represent two desirable flavors associated with banana and rose
flavours. The sherry isolate (CBS 1250, E11) was found to produce even more isoamyl alcohol than the
W. anomalus strains, but far less 2-phenylethanol than these strains (Table 3). Yet, the W. anomalus strains
produced abundant amounts of esters, particularly ethyl acetate, isoamyl acetate and 2-phenylethyl
acetate. Overall, these strains produced up to 10-fold more esters than the Weihenstephan lager
yeast strain. (Table 4). Another highly aromatic strain identified in this collection of strains was a
Pichia kluyveri strain, CBS 188. This strain produced almost fourfold more esters than lager yeast,
while its aroma alcohols profile was similar to lager yeast with the exception of fourfold higher
2-phenylethanol production.
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3.3. Fermentation Performance
We compared the fermenting capacity of the strains with very strong volatile compound formation
to the lager yeast strain S. pastorianus WS34/70 and other S. cerevisiae strains. All strains were adjusted
to the same optical density prior to the start of fermentation to allow for comparison of the speed of
fermentation between strains. Fermentation rates were followed by measuring the CO2 release daily
(Figure 3). All strains were able to ferment the liquid within one week except for the W. anomalus
strains CBS 248; CBS 249 and CBS 261. However, in contrast to the other strains, the W. anomalus strains
showed an almost linear fermentation curve with equal amounts of CO2 released per day. During
fermentation the W. anomalus strains produced oily top layers and biofilms of cells. This oily phase
may have reduced the CO2 release as we observed the lowest pH in the W. anomalus fermentations
measured among all strains: for strain CBS 261 the pH reached 4.79 and for strain CBS 262 the pH was
4.59, while the liquids fermented by other yeast strains showed a pH of >5. This suggests that the
dissolved CO2 contributed to the acidification of the liquid in the W. anomalus fermentations. The most
rapid fermentations as represented by fast CO2 loss were observed with the S. cerevisiae and lager
beer production strains. Yet, in addition to the Wickerhamomyces strains, several other strains showed
prolonged CO2 loss, including P. kluyveri CBS 188 (Figure 3).
Figure 3. Fermentation profiles of the selected strains representing the detected flavor diversity.
The CO2 release was measured daily for each individual strain (see Table 1 for the nomenclature of
strains). Fermentations were followed for 13 days.
For most of the strains we could observe a correlation between fermentation speed, residual
sugar concentration and ethanol production. The S. cerevisiae and lager yeast strains left 2–2.5% of
sugar in the medium, while the residual sugar in Candida and Pichia strains was between 3–3.5%.
Wickerhamomyces anomalus strains left 4.5–5% of sugars unfermented (Figure 4). Concomitantly,
S. cerevisiae and lager yeast strains produced the highest amount of alcohol (up to 8%) and the
W. anomalus strains only 4%.
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Figure 4. Final sugar content of the selected strains at the end of fermentation. Sugar concentration
was measured in ◦P after 13 days of fermentation.
3.4. Growth on Other Carbon Sources and Temperatures
The selected species were analysed for growth at low (10 ◦C) and high (37 ◦C) temperatures
as well as for their ability to utilize maltose using serial-dilution plate assays. Growth at elevated
temperatures was mainly restricted to Saccharomyces and Zygosaccharomyces strains, while growth
at lower temperatures was often better in non-cerevisiae strains. Typically, all strains grew well
at intermediate temperatures. Lager beer fermentation relies on maltose utilization. However,
in this screening, good maltose utilization was restricted to lager yeast strains, with the exception
of Candida diversa CBS 4074 (Figure 5), which also showed very good growth on maltose plates and
Clavispora lusitaniae CBS 6936.
Figure 5. Heat map displaying maltose utilization and growth at the indicated temperatures of the
selected strains.
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3.5. Utilization of Mixed Fermentations for Flavor Improvement
Co-fermentations are one way to improve the flavour composition of fermented beverages. We
plotted volatile compound formation of several candidate strains against lager yeast (Figure 6a).
This demonstrated the superior flavour-generation capacity of several strains, most notably of
W. anomalus. Therefore, we used the same nutrient-rich high Plato fermentation broth and inoculated
the Weihenstephan lager yeast WS34/70 in a 1:1 ratio with W. anomalus CBS 261. Volatiles of this mixed
fermentation were determined at the end of fermentation. This clearly demonstrated an enhancement
of ethyl hexadecanoate, isoamyl alcohol and 2-phenyl ethanol, improving the fruity flavour perception
of the fermented liquid (Figure 6b). W. anomalus CBS 261 is a very strong producer of ethyl acetate,
which was also pronounced in the co-fermentation.
(A)
(B)
Figure 6. (A) Comparisons of selected volatiles of selected strains that produced exceptionally
high concentrations of organic volatiles with the lager yeast reference. Strains used were: Candida
diversa (CBS 4074, B4); Debaryomyces subglobosus (CBS 2659, B11); Pichia kluyveri (CBS 188, E7);
Saccharomyces cerevisiae (CBS 1250; E11); Wickerhamomyces anomalus (CBS 261, F10); Zygosaccharomyces
mellis (CBS 726, G4); Saccharomyces pastorianus (G10, reference). (B) Concentration of volatiles at the
end of a co-fermentation using Wickerhamomyces anomalus (CBS 261, F10) and the Weihenstephan lager
yeast (WS, Saccharomyces pastorianus G10, reference).
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4. Discussion
In our study we have screened non-Saccharomyces cerevisiae yeast biodiversity in order to identify
strains with more pronounced volatile compound formation than present in lager yeast strains.
Pronounced differences in aroma alcohol production were identified between S. cerevisiae and lager
yeast strains, as expected from a clean pilsner beer produced by lager yeasts versus the more complex
flavors produced by ale and wine yeasts. In our screening, we identified W. anomalus strains as the
most dominant flavor producers, which also included production of substantial amounts of acetic acid.
The formation of floating cell layers such as seen for the W. anomalus strains has been reported as a
typical phenomenon in stored wines [20]. Yeast biodiversity holds a plethora of strains that show useful
characteristics such as ethanol production and flavor formation. This requires a detailed evaluation
of the initially identified favorable strains under different conditions, particularly in co-fermentation
regimes [21]. It will be challenging to identify the most suitable co-fermentation setups, as flavor
profiles will certainly be influenced by different ratios of non-conventional yeasts versus standard
brewing strains.
In earlier studies, W. anomalus strains have been isolated from a range of cereal-based sources.
It has been reported from sourdoughs and was found as the dominating yeast in sourdough microbial
ecosystems next to S. cerevisiae. The prevalence of the fungus was associated with its osmotolerance and
increased acid tolerance in comparison to S. cerevisiae [22]. Furthermore, it was shown that W. anomalus
provides some antimicrobial activity, e.g., mycocin production, that can be used to prolong the shelf
life of bread [23,24]. Other Wickerhamomyces species have been put to use in baking using microbread
baking platforms. Specifically, bread obtained with Kazachstania gamospora and Wickerhamomyces
subpelliculosus provided added broader aroma profiles compared to control baker's yeast [25].
P. kluyveri CBS 188 produced a total of 41 volatiles during our fermentations. Yet, it was
outstanding in its ester profile, e.g., ethyl acetate, isoamyl acetate or phenethyl acetate that was
several folds higher than in the reference lager yeast strain WS34/70. P. kluyveri strains are found in
“wild ferments” of wine but it is also commercially available to boost flavour production through
sequential fermentations. P. kluyveri strains together with strains of K. marxianus were also presented
as potential starter yeasts for controlled cocoa fermentation [26].
Based on increased demand for natural flavors produced from yeasts, the use of non-conventional
yeasts as platform strains for the production of aroma volatile has gained attention. Hence, K. marxianus
was suggested as a cell factory for flavor and fragrance production based on several advantageous
traits, e.g., thermotolerance and the wide array of volatile molecules it produces [27]. We had one strain
of K. marxianus (CBS 1557) in our collection. However, this strain was as low in aroma-compound
production as our lager yeast reference. This indicates the need to obtain a larger collection of strains of
one species and also to analyse volatile compound formation under different nutritional regimes and
fermentation conditions [28]. It further requires the implementation of high-throughput screening tools
and assays to identify suitable strains, which was actually successfully shown for K. marxianus strains
producing ethyl acetate [29]. Additionally, it requires more effort to acquire genomic, transcriptomic
and metabolomic datasets of non-conventional yeasts in order to bridge the knowledge gap about
S. cerevisiae [12,30]. That said, our approach to screening non-conventional yeasts in non-industrial
fermentation broths only provides an initial glance of the volatile production capabilities of the tested
strains. These capabilities will certainly vary with fermentation and process conditions, particularly at
larger scales.
The strong interest in volatile-compound formation by non-conventional yeasts may also open
a new perspective on yeast ecology. Yeasts occur in diverse niches and interact with other microbes,
insects and plants. These interactions may present selective forces for the production of specific
volatile compounds. Interestingly, strains of Debaryomyces hansenii were shown to produce methyl
salicylate (MeS) as a major compound under very specific conditions using pine weevil (Hylobius abietis)
frass broth [31]. This compound essentially acts as a deterrent for pine weevil. In a follow-up case,
2-phenylethanol was identified as a strong anti-feedant compound against the pine weevil [32].
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Several of the strains we analyzed produced large amounts of 2-phenylethanol, including strains from
S. cerevisiae but most prominently the W. anomalus strains. W. anomalus strains are often isolated from
tree habitats, insects and insect frass [33]. Elucidating this fascinating interplay of yeasts, insects and
plants will provide substantial insight into yeast biology and ecology in the future.
The results obtained in this study indicate that yeast biodiversity harbors a large variety of strains
that could enter diverse beverage production pipelines and provide additional all-natural flavor
variants to improve the taste and sensory perception of lager beers and, beyond that, other fermented
beverages. We used a non-industrial platform to assay strains. In future research, more detailed
fermentations using specific industrial fermentation broths, e.g., wort, grape must, and other juices,
should be explored with non-conventional yeasts.
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Acknowledgments: This research was supported in part by the European Union Marie Curie Initial Training
Networks Cornucopia 264717 (http://www.yeast-cornucopia.se/) and Aromagenesis 764364. Yeast strains were
obtained from the Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.
Author Contributions: Davide Ravasio, Andrea Walther, Marizeth Groenewald, Teun Boekhout and
Jürgen Wendland conceived and designed the experiments; Davide Ravasio, Silvia Carlin, Urska Vrhovsek
and Andrea Walther performed the experiments; Davide Ravasio, Silvia Carlin, Urska Vrhovsek, Andrea Walther
and Jürgen Wendland analyzed the data; all authors contributed to writing the paper.
Conflicts of Interest: The founding sponsors had no role in the design of the study; in the collection, analyses,
or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.
References
1. Dunn, B.; Sherlock, G. Reconstruction of the genome origins and evolution of the hybrid lager yeast
Saccharomyces pastorianus. Genome Res. 2008, 18, 1610–1623. [CrossRef] [PubMed]
2. Libkind, D.; Hittinger, C.T.; Valerio, E.; Goncalves, C.; Dover, J.; Johnston, M.; Goncalves, P.; Sampaio, J.P.
Microbe domestication and the identification of the wild genetic stock of lager-brewing yeast. Proc. Natl.
Acad. Sci. USA 2011, 108, 14539–14544. [CrossRef] [PubMed]
3. Nakao, Y.; Kanamori, T.; Itoh, T.; Kodama, Y.; Rainieri, S.; Nakamura, N.; Shimonaga, T.; Hattori, M.;
Ashikari, T. Genome sequence of the lager brewing yeast, an interspecies hybrid. DNA Res. 2009, 16, 115–129.
[CrossRef] [PubMed]
4. Walther, A.; Hesselbart, A.; Wendland, J. Genome sequence of Saccharomyces carlsbergensis, the world’s first
pure culture lager yeast. G3 (Bethesda) 2014, 4, 783–793. [CrossRef] [PubMed]
5. Spitaels, F.; Wieme, A.D.; Janssens, M.; Aerts, M.; Daniel, H.M.; Van Landschoot, A.; De Vuyst, L.;
Vandamme, P. The microbial diversity of traditional spontaneously fermented lambic beer. PLoS ONE
2014, 9, e95384. [CrossRef] [PubMed]
6. Mertens, S.; Steensels, J.; Saels, V.; De Rouck, G.; Aerts, G.; Verstrepen, K.J. A large set of newly created
interspecific Saccharomyces hybrids increases aromatic diversity in lager beers. Appl. Environ. Microbiol. 2015,
81, 8202–8214. [CrossRef] [PubMed]
7. Verstrepen, K.J.; Derdelinckx, G.; Dufour, J.P.; Winderickx, J.; Thevelein, J.M.; Pretorius, I.S.; Delvaux, F.R.
Flavor-active esters: Adding fruitiness to beer. J. Biosci. Bioeng. 2003, 96, 110–118. [CrossRef]
8. Pires, E.J.; Teixeira, J.A.; Branyik, T.; Vicente, A.A. Yeast: The soul of beer's aroma—A review of flavour-active
esters and higher alcohols produced by the brewing yeast. Appl. Microbiol. Biotechnol. 2014, 98, 1937–1949.
[CrossRef] [PubMed]
9. Vanderhaegen, B.; Neven, H.; Coghe, S.; Verstrepen, K.J.; Verachtert, H.; Derdelinckx, G. Evolution of
chemical and sensory properties during aging of top-fermented beer. J. Agric. Food Chem. 2003, 51, 6782–6790.
[CrossRef] [PubMed]
10. Duong, C.T.; Strack, L.; Futschik, M.; Katou, Y.; Nakao, Y.; Fujimura, T.; Shirahige, K.; Kodama, Y.; Nevoigt, E.
Identification of sc-type ilv6 as a target to reduce diacetyl formation in lager brewers' yeast. Metab. Eng. 2011,
13, 638–647. [CrossRef] [PubMed]
132
Fermentation 2018, 4, 15
11. Gamero, A.; Quintilla, R.; Groenewald, M.; Alkema, W.; Boekhout, T.; Hazelwood, L. High-throughput
screening of a large collection of non-conventional yeasts reveals their potential for aroma formation in food
fermentation. Food Microbiol. 2016, 60, 147–159. [CrossRef] [PubMed]
12. Varela, C. The impact of non-saccharomyces yeasts in the production of alcoholic beverages. Appl. Microbiol.
Biotechnol. 2016, 100, 9861–9874. [CrossRef] [PubMed]
13. Steensels, J.; Verstrepen, K.J. Taming wild yeast: Potential of conventional and nonconventional yeasts in
industrial fermentations. Annu. Rev. Microbiol. 2014, 68, 61–80. [CrossRef] [PubMed]
14. Viana, F.; Gil, J.V.; Genoves, S.; Valles, S.; Manzanares, P. Rational selection of non-saccharomyces wine yeasts
for mixed starters based on ester formation and enological traits. Food Microbiol. 2008, 25, 778–785. [CrossRef]
[PubMed]
15. Comitini, F.; Gobbi, M.; Domizio, P.; Romani, C.; Lencioni, L.; Mannazzu, I.; Ciani, M. Selected
non-saccharomyces wine yeasts in controlled multistarter fermentations with Saccharomyces cerevisiae. Food
Microbiol. 2011, 28, 873–882. [CrossRef] [PubMed]
16. Sadoudi, M.; Tourdot-Marechal, R.; Rousseaux, S.; Steyer, D.; Gallardo-Chacon, J.J.; Ballester, J.; Vichi, S.;
Guerin-Schneider, R.; Caixach, J.; Alexandre, H. Yeast-yeast interactions revealed by aromatic profile analysis
of sauvignon blanc wine fermented by single or co-culture of non-saccharomyces and Saccharomyces yeasts.
Food Microbiol. 2012, 32, 243–253. [CrossRef] [PubMed]
17. Canonico, L.; Comitini, F.; Ciani, M. Torulaspora delbrueckii contribution in mixed brewing fermentations
with different saccharomyces cerevisiae strains. Int. J. Food Microbiol. 2017, 259, 7–13. [CrossRef] [PubMed]
18. Ravasio, D.; Wendland, J.; Walther, A. Major contribution of the Ehrlich pathway for 2-phenylethanol/rose
flavor production in Ashbya gossypii. FEMS Yeast Res. 2014, 14, 833–844. [CrossRef] [PubMed]
19. Hazelwood, L.A.; Daran, J.M.; van Maris, A.J.; Pronk, J.T.; Dickinson, J.R. The Ehrlich pathway for fusel
alcohol production: A century of research on Saccharomyces cerevisiae metabolism. Appl. Environ. Microbiol.
2008, 74, 2259–2266. [CrossRef] [PubMed]
20. Alexandre, H. Flor yeasts of Saccharomyces cerevisiae—Their ecology, genetics and metabolism. Int. J.
Food Microbiol. 2013, 167, 269–275. [CrossRef] [PubMed]
21. Viana, F.; Belloch, C.; Valles, S.; Manzanares, P. Monitoring a mixed starter of Hanseniaspora
vineae-Saccharomyces cerevisiae in natural must: Impact on 2-phenylethyl acetate production. Int. J.
Food Microbiol. 2011, 151, 235–240. [CrossRef] [PubMed]
22. Daniel, H.M.; Moons, M.C.; Huret, S.; Vrancken, G.; De Vuyst, L. Wickerhamomyces anomalus in the sourdough
microbial ecosystem. Antonie Van Leeuwenhoek 2011, 99, 63–73. [CrossRef] [PubMed]
23. Coda, R.; Di Cagno, R.; Rizzello, C.G.; Nionelli, L.; Edema, M.O.; Gobbetti, M. Utilization of African grains
for sourdough bread making. J. Food Sci. 2011, 76, M329–M335. [CrossRef] [PubMed]
24. Tay, S.T.; Lim, S.L.; Tan, H.W. Growth inhibition of Candida species by Wickerhamomyces anomalus mycocin
and a lactone compound of Aureobasidium pullulans. BMC Complement. Altern. Med. 2014, 14, 439. [CrossRef]
[PubMed]
25. Zhou, N.; Schifferdecker, A.J.; Gamero, A.; Compagno, C.; Boekhout, T.; Piskur, J.; Knecht, W. Kazachstania
gamospora and Wickerhamomyces subpelliculosus: Two alternative baker's yeasts in the modern bakery.
Int. J. Food Microbiol. 2017, 250, 45–58. [CrossRef] [PubMed]
26. Crafack, M.; Mikkelsen, M.B.; Saerens, S.; Knudsen, M.; Blennow, A.; Lowor, S.; Takrama, J.; Swiegers, J.H.;
Petersen, G.B.; Heimdal, H.; et al. Influencing cocoa flavour using Pichia kluyveri and Kluyveromyces marxianus
in a defined mixed starter culture for cocoa fermentation. Int. J. Food Microbiol. 2013, 167, 103–116. [CrossRef]
[PubMed]
27. Morrissey, J.P.; Etschmann, M.M.; Schrader, J.; de Billerbeck, G.M. Cell factory applications of the yeast
Kluyveromyces marxianus for the biotechnological production of natural flavour and fragrance molecules.
Yeast 2015, 32, 3–16. [PubMed]
28. Urit, T.; Li, M.; Bley, T.; Loser, C. Growth of Kluyveromyces marxianus and formation of ethyl acetate depending
on temperature. Appl. Microbiol. Biotechnol. 2013, 97, 10359–10371. [CrossRef] [PubMed]
29. Lobs, A.K.; Lin, J.L.; Cook, M.; Wheeldon, I. High throughput, colorimetric screening of microbial ester
biosynthesis reveals high ethyl acetate production from Kluyveromyces marxianus on c5, c6, and c12 carbon
sources. Biotechnol. J. 2016, 11, 1274–1281. [CrossRef] [PubMed]
133
Fermentation 2018, 4, 15
30. Masneuf-Pomarede, I.; Bely, M.; Marullo, P.; Albertin, W. The genetics of non-conventional wine yeasts:
Current knowledge and future challenges. Front. Microbiol. 2015, 6, 1563. [CrossRef] [PubMed]
31. Azeem, M.; Terenius, O.; Rajarao, G.K.; Nagahama, K.; Nordenhem, H.; Nordlander, G.; Borg-Karlson, A.K.
Chemodiversity and biodiversity of fungi associated with the pine weevil Hylobius abietis. Fungal Biol. 2015,
119, 738–746. [CrossRef] [PubMed]
32. Axelsson, K.; Konstanzer, V.; Rajarao, G.K.; Terenius, O.; Seriot, L.; Nordenhem, H.; Nordlander, G.;
Borg-Karlson, A.K. Antifeedants produced by bacteria associated with the gut of the pine weevil
Hylobius abietis. Microb. Ecol. 2017, 74, 177–184. [CrossRef] [PubMed]
33. James, S.A.; Barriga, E.J.; Barahona, P.P.; Harrington, T.C.; Lee, C.F.; Bond, C.J.; Roberts, I.N.
Wickerhamomyces arborarius f.A.; sp. Nov., an ascomycetous yeast species found in arboreal habitats
on three different continents. Int. J. Syst. Evol. Microbiol. 2014, 64, 1057–1061. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Novel Wine Yeast for Improved Utilisation of Proline
during Fermentation
Danfeng Long 1,2, Kerry L. Wilkinson 2, Dennis K. Taylor 2 and Vladimir Jiranek 2,*
1 School of Public Health, Lanzhou University, 199 Donggang West Rd, Lanzhou 730000, China;
longdf@lzu.edu.cn
2 School of Agriculture, Food and Wine, the University of Adelaide, PMB 1, Glen Osmond, SA 5064, Australia;
kerry.wilkinson@adelaide.edu.au (K.L.W.); dennis.taylor@adelaide.edu.au (D.K.T.)
* Correspondence: vladimir.jiranek@adelaide.edu.au; Tel.: +61-8-8313-6651
Received: 24 December 2017; Accepted: 2 February 2018; Published: 6 February 2018
Abstract: Proline is the predominant amino acid in grape juice, but it is poorly assimilated by wine
yeast under the anaerobic conditions typical of most fermentations. Exploiting the abundance of
this naturally occurring nitrogen source to overcome the need for nitrogen supplementation and/or
the risk of stuck or sluggish fermentations would be most beneficial. This study describes the
isolation and evaluation of a novel wine yeast isolate, Q7, obtained through ethyl methanesulfonate
(EMS) mutagenesis. The utilisation of proline by the EMS isolate was markedly higher than by the
QA23 wild type strain, with approximately 700 and 300 mg/L more consumed under aerobic and
self-anaerobic fermentation conditions, respectively, in the presence of preferred nitrogen sources.
Higher intracellular proline contents in the wild type strain implied a lesser rate of proline catabolism
or incorporation by this strain, but with higher cell viability after freezing treatment. The expression
of key genes (PUT1, PUT2, PUT3, PUT4, GAP1 and URE2) involved in proline degradation, transport
and repression were compared between the parent strain and the isolate, revealing key differences.
The application of these strains for efficient conduct for nitrogen-limited fermentations is a possibility.
Keywords: proline; nitrogen; wine fermentation; yeast
1. Introduction
Amino acids, ammonium, peptides and proteins represent the main forms of nitrogen present
in grape must. The relative abundance of each class of nitrogen-containing compound has
been found to vary considerably according to grape variety, vintage, region, the extent of berry
development/maturation or even the clarification time [1–4]. The nitrogen-containing compounds
utilised by yeast during wine fermentation are referred to as yeast assimilable nitrogen (YAN),
with amino acids and ammonium contributing between 60% and 90% of YAN [2]. When available,
yeast will typically utilise up to 400 mg N/L, i.e., their “maximum requirement” [5]. At lower YAN
levels, which become exhausted some time during fermentation, the risk of excessive hydrogen sulfide
production increases [6] and the fermentation may slow, whereas below the minimum requirement of
120 to 140 mg N/L, fermentation does not finish [2,5,7–10].
The incidence of stuck or sluggish fermentations due to nitrogen deficiencies is of great concern to
winemakers around the world. To avoid such problems, winemakers often employ supplementation
strategies, e.g., the addition of diammonium phosphate prior to or during fermentation or the use
of YAN-rich rehydration additives. However, this practice can also influence yeast metabolism and
therefore impact wine quality; for example due to the accumulation of ethyl carbamate, a known
carcinogen [11,12] or changes to wine aroma profile [13].
In some grapes, proline is typically the most abundant amino acid and represents a potentially
significant source of nitrogen. Proline accumulation in the berry begins just after veraison [14],
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with concentrations up to 3800 mg/L reported for grape juice from different varieties [15].
The winemaking yeast Saccharomyces cerevisiae has been shown to be capable of metabolizing proline
when present as the sole nitrogen source [16]. However, proline is not considered to be an assimilable
nitrogen source under typical winemaking conditions. In the presence of preferred nitrogen sources,
the Put4p proline-specific transporter is repressed and inactivated and so proline uptake is largely
prevented [17]; however, once these nitrogen sources have been exhausted, its uptake is possible,
but oxygen is no longer present (i.e., fermentations have become anaerobic), so catalysis by proline
oxidase cannot occur [16,18,19]. As well as being a nutrient, accumulated proline can also act as
an osmo- and cryo-protectant, with an improved ethanol stress-protective effect [19,20]. Greater
utilisation of proline by winemaking yeast could alleviate the need for nitrogen supplementation,
enhance microbial stability by removing this potential nutrient for spoilage organisms and thus, help
reduce production costs and secure wine quality. Previous attempts to enhance proline utilisation
include mutagenesis of yeast or the addition of oxygen to fermentations [21–25].
This study describes the use of ethyl methanesulfonate (EMS) random mutagenesis to develop
novel wine yeast with an improved capacity to utilize proline. Such a strain was sought as a means of
overcoming nutrient-related fermentation problems, thereby improving fermentation reliability and
overall wine quality.
2. Materials and Methods
2.1. Yeast Strains and EMS Mutagenesis
A common commercial Saccharomyces cerevisiae strain (QA23) was obtained from Lallemand
(Blagnac, France) as an agar slope stock culture and subjected to EMS mutagenesis [26]. Briefly,
QA23 was cultured overnight in 100 mL of yeast extract peptone dextrose (YEPD) nutrient medium
(containing 20 g/L D-glucose, 10 g/L yeast extract and 20 g/L Bacto peptone) at 28 ◦C with shaking
at 120 rpm. Aliquots of 50 mL were washed (twice) with 0.1 M sodium phosphate buffer (pH 7) and
cells re-suspended in 15 mL of the same for microscopic determination of cell number. A sub-sample
(1 mL) was retained as a blank and the remaining sample (14 mL) exposed to 45 μL/mL of EMS
(Sigma Aldrich, St. Louis, MO, USA). Aliquots (1 mL) were collected every 10 min (for 2 h) and plated
on YEPD plates (after appropriate serial dilution). The reminder of the sample from each time point
(~2 mL) was kept in glycerol and stored at −80 ◦C. Colony counts were performed to determine
viability at each time point; with approximately 42% survival observed after 40 min of exposure to
EMS treatment. Sporulation of strains, when required, was performed using standard protocols [27].
2.2. Selection of Isolates
EMS-treated samples (collected at t = 40 min) were spread onto YEPD medium and cultured overnight
at 28 ◦C yielding approximately 10,000 colonies. The colonies were transferred to a yeast nitrogen base
(YNB) agar selection medium containing 4.8 g/L methylamine (Sigma Aldrich, St. Louis, MO, USA) and
2.5 g/L proline [28] with a sterilised velvet pad, and cultured for 24 h according to methodology described
previously [29]. The ammonium analogue, methylamine, elicits Nitrogen Catabolite Repression [30] but
cannot serve as a nitrogen source, thus only colonies derepressed for proline utilisation will grow on
the selective medium. Ninety three such colonies were observed after 2 days, checked by re-streaking
individually onto YNB selection media and incubated as before. This resulted in the isolation of 8 putative
mutant strains that exhibited growth. Proline utilisation by the isolates during fermentation was tested
in CDGJM [2], containing 50 g/L of sugar and 500 mg/L proline. Proline consumption was determined
according to the isatin method [31] and isolates found to consume significantly more proline than the wild
type strain were chosen for further study.
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2.3. Influence of N Source on Growth of QA23 and EMS Isolate Q7
The growth of wild type strain QA23 and EMS isolate Q7, in the presence of ammonium ions or
proline was investigated. YNB medium plates (as above) with either 2.5 g/L ammonium or proline
added, each with or without 4.8 g/L methylamine as a non-metabolisable repressor were used to
investigate strain growth. Starter cultures of QA23 and Q7 were prepared from single colonies of
each cultured in 25 mL of YEPD broth at 28 ◦C until the desired cell number (2 × 107 cells/mL) was
achieved. A dilution series (5× ten-fold dilutions) of the cultures was spotted onto each plate (10 μL),
and incubated at 28 ◦C. Plates were photographed after 3 days.
2.4. Yeast Performance during Fermentation
Small-scale fermentations (100 mL) were conducted in both CDGJM and Chenin Blanc grape
juice to investigate yeast performance. The CDGJM contained 450 mg N/L, comprising 50 mg N/L
of YAN (nitrogen components of CDGJM) and 3.3 g/L of proline (400 mg N/L). Chenin Blanc juice
was prepared from grapes harvested in 2012 (Adelaide Hills, Adelaide, Australia). The juice initially
contained 105 g/L of sugar, 40 mg/L of proline and 102 mg/L YAN, before the juice was adjusted to
200 g/L of sugar and an added 1.5 g/L proline. The media were sterilised (0.22 μm filtration) before
use. Starter cultures were prepared in the appropriate medium diluted 50% with sterile water and
incubated overnight at 28 ◦C with shaking (120 rpm).
Triplicate fermentations were carried out under both aerobic and self-anaerobic conditions,
at 28 ◦C with shaking (120 rpm). Samples were collected at regular intervals to determine fermentation
progress and proline utilisation. Culture density was monitored at 600 nm with a TECAN Infinite 200®
PRO microplate reader (Männedorf, Switzerland). Sugar consumption was monitored with an ATAGO
hand-held refractometer (Tokyo, Japan) until approx. 6◦ Brix before enzymatic determination [32].
Proline content was determined as above.
2.5. Extraction of Intracellular Proline from Yeast Cells
In order to investigate whether proline was metabolised or just accumulated by yeast cells,
proline was extracted from the cytosolic and vacuolar compartments of cells after (i) 24 h in
starter culture (i.e., prior to fermentation), (ii) 24 h of fermentation in CDGJM, (iii) mid-fermentation
(i.e., sugar ≈ 100 g/L) and (iv) post-fermentation (i.e., sugar content < 2.5 g/L). Cells (approx. 3 × 108)
were harvested at each time point, twice washed with sterile de-ionised water, then re-suspended in
1.5 mL of 2.5 mM potassium phosphate buffer (pH 6.0) containing 0.6 M sorbitol, 10 mM glucose and
0.2 mM CuCl2, and incubated for 15 min at 30 ◦C. Aliquots (1 mL) of each cell suspension were washed
twice (12,000 rpm, 3 min) with 0.5 mL of the buffer solution (as above but without glucose). The combined
2 mL supernatants gave the cytosolic extract while the remaining cells were suspended in 3 mL of
de-ionised water, boiled for 15 min, the resulting supernatant afforded the vacuolar extract after 5 min
centrifugation (5000 rpm) [33,34].
Culture samples were collected following 24 h growth in each of YEPD, starter and CDGJM
(as described above), and cell numbers quantified before determination of dry cell weight. In each
case, 3 × 108 cells were collected on a pre-weighed Whatman GF/C glass fibre filter, washed with an
equal volume of sterile de-ionised water, dried and reweighed.
2.6. Freeze Tolerance Tests
To further confirm whether proline was accumulated by yeast cells or not, freeze tolerance tests were
performed. After 24 h of fermentation, the viability of the different strains was similar (close to 100%),
thus the potential benefit of strains with altered intracellular proline content was estimated via a freeze-thaw
test. Approximately 1 × 108 cells were diluted in 1 mL of CDGJM. Approximately 1 × 107 cells (0.1 mL)
were transferred to a 1.7 mL microfuge tube and stored at −20 ◦C or −80 ◦C. After 3 days, samples were
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thawed at room temperature, diluted with 0.9 mL 0.9% (w/v) NaCl solution, and dilutions spread onto
YEPD agar plates (28 ◦C, 24 h) to determine residual viability [19].
2.7. Real-Time Quantitative PCR
The primers used for real-time quantitative PCR are listed in Table 1. Primers for PUT3 and URE2 were
designed by Primer3 software (SourceForge, La Jolla, CA, USA. http://bioinfo.ut.ee/primer3-0.4.0/) and
Primer-BLAST (NCBI, Bethesda, MD, USA. http://ncbi.nlm.nih.gov/tools/primerblast). Netprimer was
used for analysis of secondary structures (hairpins and self-dimers) and cross-dimers (PREMIER Biosoft,
Palo Alto, CA, USA. http://www.premierbiosoft.com/netprimer/). Primers were designed for annealing
at around 60 ◦C.
Table 1. Primers used in this study.


















Cell samples (2 mL) were collected after 24 h growth in starter media containing either: (i) 450 mg/L of
YAN, without proline or (ii) 450 mg/L of nitrogen comprised of 50 mg/L of YAN (nitrogen components of
CDGJM) and 400 mg/L of nitrogen (as proline, 3.3 g/L). RNA was extracted according to Chomczynski and
Sacchi (2006) [38]. Yeast cultures (50 mL) were grown in YEPD at 30 ◦C until they reached 1 × 107 cells/mL.
Samples were harvested (14,000 rpm, 5 min), washed in sterile de-ionised water and then transferred
into a 2 mL screw cap microfuge tube. Cells were again pelleted and resuspended in 500 μL Trizol
(Invitrogen, Carlsbad, NM, USA) and kept in −80 ◦C before use. Glass beads were used for cell breakage,
after incubation at 65 ◦C for 3 min, 100 μL of chloroform was added per 500 μL Trizol, followed by vigorous
shaking for 15 s, then incubation at room temperature for 5 min. After centrifugation (14,000 rpm, 10 min,
4 ◦C), the top clear phase was removed to a new tube and supplemented with 250 μL of isopropanol
per 500 μL Trizol. After 10 min incubation at room temperature, tubes were centrifuged as before,
the supernatant discarded and the pellet washed in 500μL of 75% cold ethanol, vortexed and re-centrifuged.
Purified RNA extracts were dissolved in 100 μL PCR water (Bioline, Melbourne, Australia) and RNA
concentrations determined via 260/280 nm absorbance (TECAN Infinite 200® PRO spectrophotometer;
Männedorf, Switzerland).
2.7.2. Reverse Transcription and Real-Time PCR
Real-time PCR was used to analyse gene expression involved in proline metabolism. Turbo DNase
(Invitrogen) was used for DNA-free treatment of all the RNA extracts. Thereafter, cDNA was synthesized
with iScript cDNA Synthesis Kit (Bio-Rad, Gladesville, New South Wales, Australia). Real-time PCR
was performed with the SsoFast EvaGreen Supermix (Bio-Rad) in a 96-well plate on a Bio-Rad CFX96
138
Fermentation 2018, 4, 10
instrument. cDNA (1 μL, 200 ng) was added to a 10 μL PCR reaction volume including 0.5 μL of each
primer (5 pmol/μL), 5 μL of EvaGreen Supermix and 3 μL of RNase-free water. The PCR conditions
were: initial enzyme activation at 95 ◦C for 30 s, followed by 39 cycles of denaturation at 95 ◦C for 5 s
and annealing/extension at 60 ◦C for 5 s. A melting curve was prepared at the end of each run from
65 to 95 ◦C. All samples were amplified in duplicate. Efficiency of amplifications was determined by
running a standard curve of each run with serial dilutions of cDNA. The means of Ct values (the number
of PCR cycles required for the fluorescent signal to cross the threshold detection) obtained were used
for gene expression analysis conducted using qbase+ software (Biogazelle, Zwijnaarde, Belgium) and
GraphPad Prism, version 6.6 (GraphPad Software, La Jolla, CA, USA).
2.8. Gene Sequencing
Sequencing of genes of interest, i.e., those related to proline metabolism, was achieved through
a contract service (Australian Genome Research Facility, Waite Campus, Adelaide, Australia).
2.9. HPLC Analysis of Fermentation Metabolites
Fermentation metabolites including organic acids (malic, citric, lactic, acetic and succinic), glycerol
and ethanol were determined with an Agilent Series 1100 HPLC, equipped with a vacuum degasser,
a quaternary pump, a thermostatted column oven, and a refractive index detector (RID) and diode
array/multiple wavelength detector (DAD). Separation was achieved using an HPX-87H # 125-0140
column (300 mm × 7.8 mm; Aminex, Bio-Rad, Gladesville, New South Wales, Australia) at an
operating temperature of 60 ◦C. The injection volume was 20 μL and the mobile phase was 2.5 mM
aqueous H2SO4 at a flow rate of 0.5 mL/min run in isocratic mode. Quantitation was performed
using a standard curve prepared with standards of known concentration. Data were analyzed with
Agilent ChemStation software (Version # 3.0.1 B, Agilent Technologies, Palo Alto, CA, USA).
3. Results and Discussion
3.1. Comparison of Growth of QA23 and its EMS Isolate Q7
From the EMS-treated aliquots of a population of QA23, several isolates were identified that were
able to grow on proline (as sole nitrogen source) in the presence of methylamine. The growth of QA23
and EMS isolate Q7 in the presence of ammonium and proline (with or without methylamine) was
further compared via a dilution series on YNB containing ammonium or proline as sole nitrogen sources
with or without methylamine (Figure 1). The influence of pH was also examined. When ammonium
was the only nitrogen source and in the presence of methylamine, there was no difference between the
growth of the wild type strain and Q7 (Figure 1A). In the case of media containing proline as the sole
nitrogen source at pH 3.5, all strains grew equally well (Figure 1B). With inclusion of methylamine in
the medium, growth by QA23 was reduced by two orders of magnitude. Methylamine appeared to be
inducing NCR and thereby preventing utilisation of the only nitrogen source, proline, hence reducing
the growth of the wild type strain, QA23 [39,40]. Instead Q7 remained unaffected with a high level of
growth, implying it was depressed for proline transport and utilisation, confirming it warranted further
investigation. Similar results were seen in proline-only or proline with methylamine media at pH 4.8.
However, at pH 6.0, growth of QA23 was markedly reduced even in the absence of methylamine.
Strain Q7 maintained high levels of growth on proline-only media at pH 6.0, suggesting that QA23
exhibited an interesting property i.e., an inability to grow on proline as sole nitrogen source at high
pH values (not relevant to wine making), or possibly due to the closeness to the PI of proline (6.48).
At the same pH value, the added presence of methylamine greatly restricted growth of Q7. To the
best of our knowledge, methylamine shares a common transport system with ammonia in S. cerevisiae,
and methylamine uptake is pH dependent, with approximately 25%, 60% and 100% of maximum
activity being retained at pH 3.5, 4.8 and 6.0, respectively [30]. This report suggests that methylamine
is more potent at high pH values, because its uptake by the cell becomes more effective. On the other
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hand, proline accumulation also can reduce cellular growth rates [41], which might explain the reduced
cell growth observed for QA23 (Figure 1).
 
Figure 1. Growth of QA23 and EMS isolate Q7 on: (A) YNB with ammonium (±methylamine);
(B) YNB with proline (±methylamine) at pH 3.5, 4.8 and pH 6.0. Five × ten-fold serial dilutions of
yeast cell suspensions (initially at OD 0.08) were applied to each plate. Plates were photographed after
3 days incubation at 28 ◦C.
3.2. Fermentation Performance of QA23 and EMS Isolate Q7 in CDGJM.
Isolate Q7, apparently derepressed for proline utilisation, was examined in fermentations carried
out in CDGJM. The trials were carried out with air-locks or loosely fitted foil to close the flasks to
achieve self-anaerobic or aerobic fermentations, respectively. In the presence of 50 mg/L YAN, isolate
Q7 consumed sugar at a higher rate than QA23, and completed fermentation sooner under either
aerobic or self-anaerobic conditions (Figure 2). Aerobic fermentations completed about 30 h earlier
than the self-anaerobic fermentations (170 h). The wild type strain QA23, however, exhibited sluggish
sugar consumption under aerobic conditions, incomplete even after 370 h (Figure 2a). The reason for
this is not known. It may be related to increased concentrations of some compounds, which negatively
affect the fermentation [42].
140
Fermentation 2018, 4, 10
 
Figure 2. Sugar consumption (circles) and growth (triangles) of QA23 (open symbols) and Q7
(closed symbols) during fermentation conducted in CDGJM initially containing glucose + fructose at
200 g/L, 450 mg N/L (50 mg/L mixed amino acids and ammonia + 3.3 g/L proline). Fermentations were
carried out in (a) aerobic (i.e., vessels were covered with loosely-fitted foil) or (b) self-anaerobic (i.e., vessels
were fitted with air locks) conditions. Culture optical density (OD600) was measured at 600 nm. Results are
the mean of triplicate cultures (±standard error).
Strain Q7 achieved about twice the culture density (estimated by OD600) of QA23 (Figure 2).
These findings are supported by the observed trends in proline utilisation, namely that QA23 utilised
300 mg/L of proline, regardless of oxygen availability, whereas, Q7, which achieved higher culture
densities, assimilated significantly more proline: approximately 370 mg/L (self-anaerobic) or 730 mg/L
(aerobic) (Figure 3). The latter results suggest that dissolved oxygen improved fermentation rates,
as well as proline utilisation, which is consistent with previous studies [21,22,43]. At this stage, it is not
possible to state whether the increase in growth in the presence of oxygen, is due to enhanced sterol
and unsaturated fatty acid biosynthesis, and thereby improved cell condition [22], and/or enhanced
proline catabolism by proline oxidase [21]. Further work will be required to differentiate between
these two mechanisms.
Figure 3. Proline consumption by QA23 and Q7 following fermentation in CDGJM as described in
Figure 2, under aerobic and self-anaerobic conditions. The medium initially contained 3.3 g/L proline.
Results are mean of three culture replicates (±standard error). Histograms identified with different
letters were significantly different within a given condition.
3.3. Cell Morphology, Dry Weight and Intracellular Proline Content
Given the differences seen between QA23 and the Q7 in terms of fermentation kinetics, proline
uptake and growth, we sought to determine what other features might be changed in the isolate, such as
cell morphology. Prior to fermentation, yeast cells were inoculated into YEPD, followed by growth
in starter CDGJM and then CDGJM (aerobic and self-anaerobic). After 24 h in YEPD, the vacuoles
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appeared large and well-defined in each strain. In subsequent growth conditions, vacuoles appeared
more granulated. Cells of Q7 appeared to be smaller, particularly in starter CDGJM and CDGJM.
This notion is supported by the fact that despite all strains producing similar dry cell weight in YEPD
(approximately 5 mg/3 × 108 cells; Figure 4), and QA23 increasing by ~2-fold in either CDGJM, Q7 was
about 40% lighter (smaller) per same number of cells.
 
Figure 4. Comparison of dry cell weights 24 h after inoculation of QA23 and EMS isolate Q7 in yeast
extract peptone dextrose (YEPD), starter, and fermentation media (as described in Figure 2). Results are
the mean of three replicates. Values identified with different letters were significantly different.
To investigate whether or not proline was accumulated in the cells, culture samples were harvested
at different stages of fermentation for extraction of intracellular proline. The growth medium used
was starter CDGJM (100 g/L sugars) followed by experimental cultures in CDGJM (200 g/L sugars)
each containing 3.3 g/L proline. Samples were taken after 24 h and at the mid and end stages of
fermentation. As a reference, cultures grown in starter CDGJM without proline produced cells with no
detectable intracellular proline. By comparison, QA23 cells contained readily detectable amounts of
proline in the cytosolic and vacuolar fractions for all cultures and time points (Table 2). In the starter
culture, most proline was localised in the vacuole rather than the cytosol (17 vs. 132 ng/108 cells).
In subsequent QA23 cultures, highest proline contents were found at 24 h or the mid phase of
fermentation, before only trace levels remained at the end of fermentation. Elevated levels of proline
persisted to a greater extent in the vacuolar compared to the cytosolic fractions for QA23.
The tendency for QA23 to possess higher levels of intracellular proline compared to Q7 (Table 2),
is in direct contrast to the relative amount of proline removed from the medium (Figure 3). There may
be several reasons for this paradox. QA23 may take up but not metabolise proline thereby retaining
higher intracellular amounts, whereas Q7 takes up higher amounts of proline, which is also catabolised
or incorporated to a greater extent thereby depleting intracellular pools. The higher culture densities
for Q7 (Figure 2) combined with the suggested smaller cell size (Figure 4) indicate markedly higher
cell numbers for the isolates. As a consequence, the lower intracellular proline content of the isolates
(expressed on a per cell basis) may be indicative of a greater dilution of accumulated proline amongst
a greatly increased number of cells. Under aerobic condition, yeast cells of QA23 might respond to
oxidative stress and accumulate more proline in the vacuole. Proline accumulation in the vacuole
has been reported to provide a stress protective effect [20,34]. But the excess accumulation of proline
in the cytosol might also be toxic to yeast cell [44], and might contribute to the slow growth of
the wild type strain and slowing of the fermentation under aerobic conditions. Previous research
has linked morphology and proline uptake indicating that proline accumulation can produce
cytological differences and increased cell size [41], however the opposite was found for cell size
in the present experiments.
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3.4. Freeze Test
In this study, the highest intracellular proline levels were observed after 24 h of fermentation.
At this time point, cell viability was also high, close to 100%, thus freeze tests were applied to
gain an insight into the properties of the isolates. Cell tolerance to freezing for 3 days followed
by thawing at room temperature and plating onto YEPD was used to determine residual viability
(Table 3). The highest cell viability was observed for QA23 for all fermentations and under both
freezing conditions. When the storage temperature was −80 ◦C, cell viability tended to be higher.
This might be because at −80 ◦C, freezing occurs quicker than at −20 ◦C, likely related to the rates of
ice formation and changes in solute concentration [45]. Previous studies have found that proline has
cryoprotective effects in S. cerevisiae and is equivalent to glycerol or trehalose [46]. The significantly
higher cell viability of QA23 (Table 3) may be attributable to the higher intracellular proline levels of
this strain (Table 2).
Table 3. Cell viability (%) after freezing for 3 days at −20 ◦C or −80 ◦C.
Strain
−20 ◦C −80 ◦C
Aerobic Self-Anaerobic Aerobic Self-Anaerobic
QA23 63 ± 6 a 57 ± 5 a 66 ± 6 a 63 ± 5 a
Q7 20 ± 2 b 29 ± 5 b 29 ± 2 b 37 ± 5 b
Values are the means of three fermentation replicates (n = 3) ± standard error. Values followed by a different letter
within columns are significantly different.
3.5. Analysis of Gene Expression
An investigation into the expression of the key genes involved in proline transportation and
metabolism was performed to help explain the properties of the isolates. Cells were cultured in
high nitrogen media without proline and in low nitrogen media containing high levels of proline.
Proline is imported into yeast cells mainly by the proline specific permease Put4p and the general
amino acid permease Gap1p [40]. Proline degradation occurs in the mitochondria and is assisted by
two enzymes, proline oxidase and Δ1-pyrroline-5-carboxylate dehydrogenase, encoded by PUT1 and
PUT2, respectively [16]. The PUT3 protein binds to the upstream activation sequences in the promoter
of PUT1 and PUT2, and induces their expression, but transcription is only activated in the presence of
proline [47,48]. When preferred nitrogen sources are present, the expression of PUT genes is inhibited
by the URE2 gene product [49]. These genes were targeted in a gene expression analysis.
When proline was present in the medium, PUT1 and PUT2 were not induced in QA23; but expression
decreased to approximately one quarter and one third, respectively. Instead up-regulation was observed
for PUT1 and PUT2 in Q7 (Figure 5). PUT1 expression paralleled that of PUT2, for the two strains.
PUT3 was up-regulated in the presence of proline, consistent with previous studies, which have shown
transcription is only induced in the presence of proline [47,48]. It is noteworthy that the gene that
encodes the high-affinity proline transporter PUT4, was up-regulated 2-fold in Q7, but significantly
down-regulated in QA23 when proline was present in the medium. The opposite trend was observed in
the expression of GAP1. Thus when the media contained low YAN (+proline), PUT4 was repressed in
the wild type strain, but not in Q7. In contrast, GAP1 was repressed in Q7, but not in QA23. This may
indicated that proline was mainly transported into the cell via the low affinity Gap1p in QA23, but via
Put4p in Q7. The reduced expression of PUT1, PUT2 and PUT4 in QA23 may be a reflection of the higher
expression of URE2 regulatory gene in the presence of proline in this strain.
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Figure 5. Normalized relative expression of key genes involved in proline transportation and
metabolism in QA23 and Q7, cultivated overnight in media containing: 450 mg/L of nitrogen with
mixed amino acids and ammonium, but without proline (−proline); or 50 mg/L mixed amino acids
and ammonium, supplemented with 3.3 g/L proline (+proline). Initial sugar content of each medium
was 100 g/L of glucose: fructose 1:1. The mRNA level of each gene was normalized against TAF10
and ALG9 levels in the same sample. Values are mean (± standard error) of duplicate determinations
from duplicate cultures. Data analysis was performed using qbase+ software. Significant differences in
relative expression are indicated by: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.
3.6. Gene Sequencing
To identify the difference between the parent strain and the isolate, the key genes involved
in proline transportation and metabolism PUT1, PUT2 (proline metabolism), PUT3 (inducer
gene) and PUT4 (proline transporter gene) were sequenced in these two strains (Figures S1–S4).
Nucleotide sequences were aligned using Geneious 7.1.7 software (Biomatters Limited, Auckland,
New Zealand). Following alignment the sequences were analysed for single nucleotide polymorphisms
(SNPs) (Table 4). The sequence of PUT1 (proline oxidase) including 81 base pairs of promoter region
was examined. In Q7, PUT1 had a SNP in the promoter at position −55. This may have led to
differences in interactions with regulatory gene products, partly addressing the loss of NCR for proline
metabolism. Additionally, Q7 showed substitutions at S60N (serine to asparagine) and L167V (leucine
to valine). The PUT3 gene showed no differences between QA23 and Q7, whilst the PUT4 sequence
revealed a likely conservative change from a heterozygosity, Thr/Ser, to Thr at amino acid position 70.
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Table 4. Summary of mutation positions in the sequence of PUT1 and PUT4 in QA23 and Q7.
Gene Strain 55 (Promoter) 260 (ORF) Amino Acid 580 (ORF) Amino Acid
PUT1
QA23 G G Ser C Leu
Q7 T A Asn G Val
45 (Promoter) 465 (ORF) Amino Acid
PUT4
QA23 - W Thr/Ser
Q7 - T Thr
Nucleotide code: W (A or T); Sequence numbers refer to nucleotide bases in the relevant gene sequences in
Supplementary Materials. The position of the feature as being either in the promoter or ORF is indicated.
Protein variation effect analyser (PROVEAN: http://provean.jcvi.org/index.php, accessed on:
22 October, 2014) was applied to analyse the impact of the SNPs on the encoded proteins for PUT1.
No deleterious effect was suggested for mutations in the ORF. Thus, the mutation in the promoter
region (55) might be a factor influencing the strain’s performance during fermentation and gene
expression. However, this position is different from the reported UASNTR sequences in the PUT1
promoter region (−293 to −186) [47], thus the lack of repression could be due to modification of PUT
gene regulatory regions to inhibit binding by repressor gene products, or alternatively that the repressor
genes themselves are modified such that their gene products no longer bind to the regulatory regions
of the PUT genes. Thus, whether the alteration could influence regulator effectiveness, e.g., URE2 or
DAL80 [50], still needs to be confirmed. Further work is required to determine the genetic basis for the
differences between QA23 and Q7.
3.7. Fermentation in Chenin Blanc Grape Juice
To test the performance of the isolate in real juice fermentation, Chenin Blanc (2012) containing
1540 mg/L proline and 102 mg/L YAN from the Adelaide Hills was used for the same trials as
described in CDGJM. In the aerobic fermentations, QA23 became stuck after 192 h with residual sugar
at about 20 g/L (Figure 6a). Isolate Q7, however, completed the fermentation in about 60 h (Figure 6a).
Under self-anaerobic conditions, Q7 completed fermentations about 60 h earlier than the wild-type
strain QA23 (Figure 6b). The isolate also showed significantly different growth kinetics compared to
QA23, by achieving high OD600 values, thereby greater biomass yields. Proline was depleted by Q7
within 48 h in the aerobic fermentation and up to 1000 mg/L was consumed under the self-anaerobic
condition at between 120–144 h (Figure 7).
Figure 6. Sugar (circles) and cell growth (triangles) during fermentation of Chenin Blanc grape juice (2012)
by QA23 (open symbols) and Q7 (closed symbols). Juice initially contained 105 g/L glucose + fructose,
102 mg N/L and 40 mg/L proline, but was modified (glucose + fructose) to give 200 g/L sugar and
1.5 g/L of proline were added. Fermentations were carried out in aerobic (a) (vessels were covered with
loosely-fitted foil) or self-anaerobic (b) (vessels were fitted with air locks) conditions. Culture optical
density was estimated at 600nm. All results are the mean of triplicate fermentations.
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Figure 7. Proline consumption during fermentation in aerobic (a) and self-anaerobic conditions (b).
Fermentation conditions as described in Figure 6. The open and closed symbols represent QA23 and
Q7, respectively. Results are the mean of triplicates.
Overall Q7 fermented faster, achieved greater growth and used proline more quickly. This is not
exactly the case seen in CDGJM (Figures 2 and 3). Such differences are presumably reflective of the
different response of Q7 to the compositional differences between CDGJM and juice. Further trials with
the isolate in a range of media would provide a greater sense of the most representative performance
of the isolate.
The final self-anaerobic fermentation samples were also analyzed by HPLC to determine if there
were any major differences in composition. For all strains, no significant difference in the acid, glycerol
and ethanol content in the wine were observed (Table 5).
Table 5. Major fermentation metabolites derived in the final samples for Chenin Blanc fermentations
by QA23 and Q7.
Metabolites (g/L) QA23 Q7
Malic acid 3.1 ± 0.08 3.5 ± 0.22
Citric acid 3.5 ± 0.03 2.9 ± 0.36
Lactic acid 0.9 ± 0.05 0.9 ± 0.21
Acetic acid 0.2 ± 0.04 0.2 ± 0.07
Succinic acid 2.7 ± 0.04 3.2 ± 0.22
Glycerol 8.0 ± 0.08 7.7 ± 0.81
Ethanol 92.2 ± 0.41 85.7 ± 6.24
In summary, the aim of this research was to develop novel wine yeasts capable of exploiting
the abundance of proline present in grape juice, so as to overcome the issues of stuck/sluggish
fermentation, thereby reducing production difficulties and quality losses to benefit both the wine
industry and consumers. This study reports on a novel yeast strain that utilises proline constitutively
(i.e., in the presence of preferred nitrogen sources). The wild type strain also utilised proline as
a nitrogen source, but at much lower rates than the EMS isolate. Further evaluations of the isolate in
various juices will more fully define its potential applicability to industry.
Supplementary Materials: The following are available online at http://www.mdpi.com/2311-5637/4/1/10/s1.
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Abstract: Acetic acid is undesired in Icewine. It is unclear whether its production by fermenting
yeast is linked to the nicotinamide adenine dinucleotide (NAD+/NADH) system or the nicotinamide
adenine dinucleotide phosphate (NADP+/NADPH) system. To answer this question, the redox
status of yeast cytosolic NAD(H) and NADP(H) were analyzed along with yeast metabolites to
determine how redox status differs under Icewine versus table wine fermentation. Icewine juice and
dilute Icewine juice were inoculated with commercial wine yeast Saccharomyces cerevisiae K1-V1116.
Acetic acid was 14.3-fold higher in Icewine fermentation than the dilute juice condition. The ratio of
NAD+ to total NAD(H) was 24-fold higher in cells in Icewine fermentation than the ratio from
the dilute juice condition. Conversely, the ratio of NADP+ to total NADP(H) from the dilute
fermentation was 2.9-fold higher than that in the Icewine condition. These results support the
hypothesis that in Icewine, increased NAD+ triggered the catalysis of NAD+-dependent aldehyde
dehydrogenase(s) (Aldp(s)), which led to the elevated level of acetic acid in Icewine, whereas, in the
dilute condition, NADP+ triggered NADP+-dependent Aldp(s), resulting in a lower level of acetic
acid. This work, for the first time, analyzed the yeast cytosolic redox status and its correlation to
acetic acid production, providing a more comprehensive understanding of the mechanism of acetic
acid production in Icewine.
Keywords: Icewine; Saccharomyces cerevisiae; hyperosmotic stress; redox status; NAD(H); NADP(H);
acetic acid; aldehyde dehydrogenase
1. Introduction
Icewine is a sweet dessert wine produced from grapes naturally frozen on the vine. The low
temperature during harvesting and pressing (below −8 ◦C in Canada), traps the water crystals in
grape berries, resulting in Icewine juice that is extremely concentrated in soluble solids including sugar,
acids, and nitrogen compounds [1]. In Canada, the minimum concentration of soluble solids in Icewine
juice for fermentation must reach 35 ◦Brix [2], but juice between 38 and 42 ◦Brix is commonly used for
Icewine production [3]. Such a high concentration of sugar in Icewine juice places yeast cells under
extreme hyperosmotic stress, resulting in prolonged fermentation times and a high concentration of
volatile acidity (mainly in the form of acetic acid) [4].
Acetic acid present at high levels is a spoilage compound in wine. In Canada, the maximum
allowed acetic acid concentration in Icewine is 2.1 g L−1, whereas in table wines it is 1.3 g L−1 [2].
The average acetic acid concentration in commercial Canadian Icewines was found to be 1.30 g L−1,
but ranged from 0.49 to 2.29 g L−1 [5]. Acetic acid also contributes to the formation of another undesired
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aromatic compound, ethyl acetate, which is described as having a solvent-like aroma such as that found
in nail polish remover [6,7]. Nurgel et al. reported that the ethyl acetate concentration in commercial
Canadian Icewines ranged from 0.086 to 0.369 g L−1 , with an average value of 0.240 g L−1 [5], and some
wines testing over the sensory threshold in Icewine of 0.198 g L−1 [6].
Acetic acid production appears linked to the osmotic stress yeast are placed under. During Icewine
fermentation, the highly concentrated juice places yeast cells under extreme hyperosmotic stress.
In response, Saccharomyces cerevisiae produces glycerol as an intracellular osmolyte to counteract
the high osmolarity [8]. During glycerol formation, the oxidized cofactor NAD+ is produced,
while dihydroxyacetone phosphate is reduced to glycerol-3-phosphate, leading to a potential redox
imbalance for the NAD+/NADH cofactor system. Because of the lack of transhydrogenase in yeast to
convert reducing equivalents between the NAD(H) system and the NADP(H) system, yeasts must
rely on metabolite formation to maintain the redox balance [9,10]. Acetic acid has been suggested as a
potential metabolite that yeast cells can produce to balance the excess NAD+ produced during glycerol
formation under hyperosmotic stress [8,11,12]. The high level of acetic acid present in Icewine may also
be due to the downregulation of ACS genes encoding for acetyl-CoA synthetases [13]. In S. cerevisiae,
acetic acid is an intermediate to form the central metabolite, acetyl-CoA, catalyzed by acetyl-CoA
synthetases in the pyruvate dehydrogenase (PDH) pathway [14]. Heit et al. found that ACS1 and ACS2
were downregulated 19.0-fold and 11.2-fold, respectively, in S. cerevisicea K1-V1116 yeasts fermenting
Icewine juice compared to diluted juice, suggesting that the lower consumption of acetic acid to
form the downstream metabolites during Icewine fermentation contributes to elevated acetic acid
production in Icewine [13].
The results from current literature are not in agreement concerning which Aldp isoform is
responsible for acetic acid production during sugar fermentations, as different Aldps have distinct
cofactor specificities and play different roles for acetic acid production in yeast metabolism [11–13,15].
S. cerevisiae contain five aldehyde dehydrogenases [16]. Two cytosolic isoforms are NAD+-dependent
(Ald2p and Ald3p) [16], and one is NADP+-dependent (Ald6p) [17]. Ald2p oxidizes 3-aminopropanal
to β-alanine, required for pantothenic acid production [18]. Ald6p has been identified as the main
cytosolic aldehyde dehydrogenase responsible for acetic acid production in S. cerevisiae strains during
the fermentation of glucose [15,19–21], although both mitochondrial NADP+-dependent Ald5p [22] and
NAD+/NADP+-dependent Ald4p [23] have been reported to contribute. Ald6p was linked to acetic
acid generation under osmotic stress to NADPH production to compensate for the downregulation of
genes in the pentose phosphate pathway [15], thus questioning the linkage of acetic acid production
under osmotic stress to glycerol formation and NADH requirements. However, Noti et al. found
ALD6 to be only slightly upregulated in some strains during the first two hours of exposure to 235 g/L
sugar [21]. Contrary to these reports, additional studies have linked acetic acid to ALD3 expression
and the NAD+/NADH cofactor system during fermentation [11,12,24] with a temporal relationship
between acetaldehyde increase, ALD3 expression, and acetic acid production when fermenting juice
at 401 g/L sugar [11,12]. ALD3 was the only isoform upregulated by acetaldehyde stress during
fermentation [12]. To reconcile these differences, we hypothesize that the main Aldp responsible for
acetic acid production throughout fermentation relates back to the starting sugar concentration in the
juice, and the ongoing redox requirements of the cell throughout fermentation.
In S. cerevisiae, the NAD(H) and NADP(H) cofactor systems play important roles as electron
donors/acceptors in more than 300 biochemical oxidation and reduction reactions [25]. NAD(H) is
mainly involved in catabolic reactions such as glycolysis, glycerol production, and nitrogen uptake
and consumption [26,27]. NADP(H) is predominantly involved in anabolic processes including the
pentose phosphate pathway, which provides substrates for the synthesis of nucleic acids (RNA and
DNA) and some amino acids [28], and has been indicated to be growth rate-dependent [29,30].
This study monitored daily changes in the two cofactor systems, NAD(H) and NADP(H),
during the first week of fermentation when acetic acid is rapidly produced by S. cerevisiae K1-V1116.
The fermentations were conducted in both Icewine juice and dilute Icewine juice, which mimics a table
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wine fermentation. The different ratios of oxidized cofactor to total cofactor for these two systems
provides further evidence of which aldehyde dehydrogenases are involved in acetic acid production
during Icewine versus dilute juice fermentation.
2. Materials and Methods
2.1. Yeast Strain and Juices
The commercial wine yeast S. cerevisiae K1-V1116 (Lalvin, Montreal, QB, Canada) was
used for fermentations. Vidal Icewine juice was purchased from Huebel Grapes Estates Ltd.
(Niagara-on-the-Lake, ON, Canada) and stored at −35 ◦C until required for use. The juice was
thawed at 7 ◦C for 24 h, and racked off, followed by filtration through coarse, medium, and fine
pore size pad filters using the Bueno Vino Mini Jet filter (Vineco, St. Catharines, ON, Canada).
The juice was then filtered through a 0.45-μm membrane cartridge filter (Millipore, Etobicoke, ON,
Canada). Sterile filtered Icewine juice (39.4 ◦Brix, 433 ± 5 g L−1 reducing sugars) was used for Icewine
fermentation, and diluted to 20.0 ◦Brix (201 ± 1 g L−1 reducing sugars) for dilute juice fermentations,
which mimics table wine fermentation.
2.2. Fermentation Setup and Sampling
Dried wine yeast K1-V1116 was prepared using the stepwise acclimatization procedure described
in Pigeau and Inglis [11]. A volume of 30 mL of the acclimatized starter culture was used to inoculate
2 L of Icewine juice (39.4 ◦Brix) and dilute Icewine juice (20.0 ◦Brix), reaching a final yeast inoculation
rate of 0.5 g dry weight L−1. Fermentations were incubated at 17 ◦C in triplicate and continued until
sugar consumption stopped for three consecutive days for Icewine fermentations, or until the sugar
level was below 3 g L−1 for dilute juice fermentations. After stirring the fermentations for 5 min to
ensure homogeneity, 100 mL of sample was removed daily and analyzed for cofactors in the first
week of fermentation. Samples (5 mL) were also taken for metabolite analysis every day during the
first week, every other day in the second week, and every third day in the following weeks until the
fermentations stopped. Samples were centrifuged and the supernatants were stored at −30 ◦C until
metabolite analysis was performed.
2.3. Analysis for Metabolites
Soluble solids were determined by ABBE bench top refractometer (model 10450; American Optical,
Buffalo, NY, USA). Acidity was determined by pH measurement using a sympHony pH meter
(model B10P; VWR, Mississauga, ON, Canada), and titratable acidity by titration against 0.1 mol L−1
NaOH to an endpoint of pH 8.2 [31]. Reducing sugars, ammonia nitrogen, amino nitrogen, glycerol,
acetaldehyde, and acetic acid were determined with Megazyme assay kits (K-FRUGL, K-AMIAR,
K-PANOPA, K-GCROL, K-ACHD, K-ACET; Megazyme International Ireland, Ltd., Bray, Co. Wicklow,
Ireland). Ethanol was determined by gas chromatography (model 6890; Agilent Technologies Inc.,
Palo Alto, CA, USA) with a flame ionization detector and a capillary column (Agilent 122-7032 DB-Wax,
30 m × 250 μm diameter, 0.25 μm film thickness), using 0.1% 1-butanol as an internal standard.
All metabolite measurements were performed in duplicate on each fermentation replicate. Metabolite
production during the course of fermentation was calculated by the difference in the respective
metabolite concentration measured between the time zero point (immediately after inoculation) and at
each sampling time point during the course of fermentations. Normalized metabolite production was
determined by dividing the final metabolite production by the final sugar consumed. Metabolite daily
production rate was calculated as: daily production rate = (metabolite concentration on the sampling
day − metabolite concentration on the previous day) / (sugar concentration on the previous day −
sugar concentration on the sampling day).
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2.4. Analysis for Enzyme Cofactors
To collect yeast cells, 100 mL of sample was centrifuged at 5108× g for 10 min at 4 ◦C; the pellet
was washed once with 2 mL sterile deionized water and re-centrifuged. The pellet was re-suspended
in 2 mL g−1 (yeast wet weight) of Tris-dithiothreitol (DTT) buffer (100 mM Tris-H2SO4, pH 9.4;
10 mM DTT; sterile filtered) and incubated for 30 min at 30 ◦C with gentle shaking at 0.059× g.
The treated cells were then collected by centrifugation at 1464× g for 5 min at 4 ◦C. The pellet
was re-suspended in 2 mL spheroplast buffer (1.2 M sorbitol; 20 mM potassium phosphate, pH 7.4;
sterile filtered) and centrifuged as in the previous step. Cells were then added to a mixture containing
10 mg of Zymolyase-100T g−1 of yeast wet weight and 4 mL spheroplast buffer. The mixture
was incubated for 60 min at 35 ◦C with shaking at 0.059× g. Following Zymolyase digestion, the
spheroplasts were collected by centrifugation at 1464× g for 5 min at 4 ◦C, washed twice in spheroplast
buffer, and pelleted as before. The spheroplasts were then re-suspended in ice-cold cell lysis buffer
(0.6 M mannitol; 20 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES)-KOH, pH 7.4;
1 mM phenylmethylsulfonyl fluoride (PMSF); 0.1% w/v fatty acid free-bovine serum albumin (BSA);
sterile filtered) and disrupted using a pre-chilled Dounce homogenizer on ice. The volume of cell lysis
buffer applied was 3.5 mL for yeast samples from diluted fermentation, and 2.0 mL for samples from
Icewine fermentation. The lysate was then quickly transferred to pre-chilled centrifuge tubes and
fractionated at 9682× g for 10 min at 4 ◦C to separate the cytosolic fraction. A small portion (200 μL) of
the supernatant was immediately mixed with 200 μL of Component E from the Amplite Fluorimetric
NAD/NADH or NADP/NADPH Ratio Assay Kits (15263, 15264; AAT Bioquest Inc., Sunnyvale, CA,
USA) and incubated for 10 min to extract NAD+ or NADP+. This sample was also diluted serially by a
mixture of cell lysis buffer and Component E (at a 1:1 ratio) to ensure that the sample concentration
would be within the linear range of the calibration curves of both kits. The rest of the supernatant was
kept on ice for the measurement of the sum of NAD+ and NADH or the sum of NADP+ and NADPH,
and serial dilution was also performed for this sample using cell lysis buffer. All samples were then
tested by the abovementioned fluorimetric kits in duplicate on each fermentation replicate according
to the manuals. The percentage of oxidized cofactor of either the NAD(H) or NADP(H) system was
calculated as: percentage of oxidized cofactor = concentration of oxidized cofactor / (concentration of
oxidized cofactor + concentration of reduced cofactor) × 100%.
2.5. Statistical Analysis
XLSTAT-Pro by Addinsoft (New York, NY, USA) was used for statistical analysis. Analysis of
variance (ANOVA) with Fisher’s Least Significant Difference (LSD) test (p < 0.05) was used to evaluate
differences between variables and mean separation, respectively.
3. Results
3.1. Fermentation Kinetics
The composition of Icewine juice in comparison to the dilute juice indicates that the starting
sugar concentration is over 400 g L−1 in the Icewine juice and concentrated in all other juice
components including acidity, yeast assimilable nitrogen, glycerol, acetaldehyde, and acetic acid
(Table 1). Yeast cells exposed to a greater level of hyperosmotic stress from fermentable sugars in the
Icewine fermentation consumed sugar very slowly in the first week and stopped before half of the
original sugar concentration was consumed on Day 39 (Figure 1). Conversely, in the diluted condition,
yeast cells rapidly consumed sugar right after inoculation with only 1 g L−1 of sugar left in the final
wine on Day 21 (Figure 1 and Table 2).
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Table 1. Vidal Icewine juice and diluted juice initial parameters (mean ± SD).
Parameter Icewine Juice Diluted Juice
Glucose + fructose (g L−1) 433 ± 5 201 ± 1
Titratable acidity (g L−1) 6.4 ± 0.0 3.1 ± 0.0
pH 3.76 ± 0.01 3.88 ± 0.01
Free amino nitrogen (mg N L−1) 238.4 ± 2.4 114.8 ± 3.0
Ammonia nitrogen (mg N L−1) 14.8 ± 0.1 6.6 ± 0.8
Glycerol (g L−1) 8.76 ± 0.06 4.04 ± 0
Acetaldehyde (mg L−1) 5.3 ± 0.8 2.7 ± 0.2
Acetic acid (g L−1) 0.04 ± 0 0.02 ± 0
Ethanol (% v/v) 1.3 ± 0 0.6 ± 0
Table 2. Final wine parameters in Icewine and diluted juice fermentation (mean ± SD).
Parameter Icewine Juice Fermentation Diluted Juice Fermentation
Glucose + fructose (g L−1) 252 ± 3 1 ± 1
Titratable acidity (g L−1) 8.3 ± 0.2 5.5 ± 0.1
pH 3.92 ± 0.01 3.63 ± 0.02
Free amino nitrogen (mg N L−1) 188.5 ± 1.4 7.4 ± 0.4
Ammonia nitrogen (mg N L−1) 3.5 ± 0.1 † ND
Glycerol (g L−1) 17.44 ± 0.19 9.43 ± 0.06
Acetaldehyde (mg L−1) 48.5 ± 0.8 23.0 ± 0.8
Acetic acid (g L−1) 1.48 ± 0.10 0.12 ± 0.01
Ethanol (% v/v) 12.0 ± 0.2 13.9 ± 0.1
† ND indicates that no concentration was detected.
Figure 1. Sugar concentration during fermentation. Fermentations of Icewine juice ( ) and diluted juice
() were inoculated with K1-V1116 and monitored for sugar concentration throughout fermentation.
Fermentations were performed in triplicate and samples from each trial were tested in duplicate.
Sugar values represent the average ± standard deviation.
3.2. Yeast Metabolite Production
Metabolite production was monitored as a function of time (Figure 2a,c,e), but because yeast
consumes sugar at different rates, these metabolites were also plotted as a function of sugar consumed
(Figure 2b,d,f) for direct comparison between the two conditions. Yeast produced higher levels of
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glycerol and acetic acid during Icewine fermentation as a function of sugar consumed, showing a
1.9-fold increase in glycerol and 16.5-fold increase in acetic acid when normalized to sugar consumed
(Table 3). The peak concentration of acetaldehyde production was 4.7-fold higher in the Icewine
fermentation compared to the dilute fermentation, and then declined when acetaldehyde was
consumed for the formation of either ethanol or acetic acid (Figure 2c,d).
Figure 2. Metabolite production during fermentation. Fermentations of Icewine juice ( ) and diluted
juice () were analyzed for the production of (a) glycerol, (c) acetaldehyde, and (e) acetic acid, and
the generation of metabolites were also plotted out as a function of sugar consumed for (b) glycerol,
(d) acetaldehyde, and (f) acetic acid. Fermentations were performed in triplicate and samples from
each trial were tested in duplicate. Metabolite values represent the average ± standard deviation.
Table 3. Normalized metabolite production by yeast measured at the end of fermentation (mean ± SD).
Fermentation
Glycerol
(mg g−1 of Sugar
Consumed) *
Acetaldehyde
(mg g−1 of Sugar
Consumed) *
Ethanol
(g g−1 of Sugar
Consumed) *
Acetic Acid
(mg g−1 of Sugar
Consumed) *
Diluted juice 27.44 ± 0.30 0.23 ± 0.01 0.53 ± 0 0.49 ± 0.06
Icewine Juice 50.92 ± 0.74 0.10 ± 0 0.47 ± 0 8.10 ± 0.50
* Significantly different as determined by Fisher’s Least Significant Difference test (p < 0.05).
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3.3. Ratio of Coenzyme Concentration
The cytosolic coenzymes from both the NAD(H) and NADP(H) systems were analyzed in the
first week of fermentation, when yeast cells adapted to the hyperosmotic stress under the two different
sugar concentrations. The percentage of the cofactors in their oxidized form were plotted against
time (Figure 3). The percentages were then linked to the daily production rate of glycerol and acetic
acid (Figure 4) to understand the correlation between redox status and metabolite production under
hyperosmotic stress.
During the dilute fermentation, the percent of cytosolic NADP+, which ranged from 30.2–57.2%
over the course of fermentation, was consistently higher than the percent of cytosolic NAD+, which was
only 3.6% from Day 1 onward (Figure 3a). The percent of the cytosolic NADP+ was consistently lower
in the Icewine condition (between 19.9–31.6%, Figure 3b) compared to the dilute juice condition
(between 30.2–57.2%, Figure 3a), showing a 2.9-fold higher level in the dilute juice condition on Day 1.
It appears that the cytosolic NADP+-dependent Ald6p has a larger contribution to the low acetic acid
production in the dilute juice condition over NAD+-dependent forms of Aldp (Figure 4b).
However, a very different redox profile resulted during the Icewine fermentation (Figure 3b).
During Icewine fermentation, the percent of cytosolic NAD+ increased over the first two days of
fermentation, peaking on Day 2 at 60.1% and remaining much higher over the remainder of the
fermentation (Figure 3b) in comparison to the dilute juice fermentation (Figure 3a), showing a 24-fold
increase in the Icewine condition. This spike in NAD+ corresponded to the increased production rate of
glycerol in the Icewine condition (Figure 4a) and the increased production rate of acetic acid (Figure 4b).
The redox profile supports the hypothesis of cytosolic NAD+-dependent Aldp(s) contributing to the
elevated acetic acid in Icewine fermentation along with the cytosolic NADP+-dependent Ald6p.
 
Figure 3. Percentage of NAD+ and NADP+ in the first week of fermentation. (a) The percentage
of NAD+ to total NAD(H) () was compared to the percentage of NADP+ to total NADP(H)
() in diluted fermentation; (b) the percentage of NAD+ to total NAD(H) ( ) was compared to
the percentage of NADP+ to total NADP(H) () in Icewine fermentation. Fermentations were
performed in triplicate and samples from each trial were tested in duplicate. Data points represent the
average ± standard deviation.
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Figure 4. Metabolite production rate during fermentation. The daily metabolite production rate of
(a) glycerol and (b) acetic acid was calculated during the first week of Icewine juice fermentation ( )
and diluted juice fermentation (). Fermentations were performed in triplicate and samples from each
trial were tested in duplicate. Metabolite values represent the average ± standard deviation.
4. Discussion
Increased acetic acid production during high sugar fermentation in S. cerevisiae may be due to
metabolic regulation driven by the redox status of the cell, substrate availability, or product usage,
or due to the transcriptional regulation of genes altering enzyme concentrations involved in the
synthesis or usage of acetic acid, or a combination of all these factors.
Past studies have linked acetic acid production during fermentation to either the NADP+ cofactor
system [15] or the NAD+ cofactor system [11–13] based on ALD gene expression patterns encoding
aldehyde dehydrogenases that have different cofactor requirements. We report here, for the first time,
the cytosolic redox status of both cofactor systems during fermentation at two different sugar levels.
We have previously reported increased substrate availability for the aldehyde dehydrogenases
during high sugar fermentations (acetaldehyde levels quickly rise during Icewine fermentation) [11–13],
which was also found in this present study, along with increased expression of ALD3 encoding a
cytosolic NAD+-dependent isoform over that found during dilute juice fermentation [11–13]. ALD3 was
also the only ALD expression stimulated by acetaldehyde stress during fermentation [12]. We now
report that the percent of oxidized cofactor NAD+ on Day 2 of fermentation was 24-fold higher in the
Icewine condition versus the dilute juice condition and 2.1-fold higher than the percent of oxidized
cofactor NADP+ on Day 2 of Icewine fermentation. Taken together, our results further confirm a
role for NAD+-dependent Aldp isoforms along with NADP+-dependent Aldp isoforms in producing
elevated levels of acetic acid during the high sugar fermentations of Icewine production.
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In evaluating the cytosolic redox status of fermenting yeast at two different sugar levels
(201 versus 433 g L−1 of sugar in our present study), the discrepancy in the literature in reporting the
Aldp responsible for acetic acid production during fermentation may have been due to the starting
sugar concentration in the media used for fermentation. Our data supports other published work where
the NADP+-dependent isoform Ald6p was identified as the main aldehyde dehydrogenase responsible
for acetic acid production when sugar concentrations were at or below 200 g L−1 sugar [15,19–21].
However, under high sugar conditions of 400 g L−1, Erasmus et al. linked acetic acid generation
to NADPH production via Ald6p to compensate for the downregulation of genes in the pentose
phosphate pathway [15], questioning the linkage of acetic acid production under osmotic stress to
glycerol formation and NADH requirements. Based on the cytosolic redox status of yeast fermenting
Icewine juice at 433 g L−1 sugar, as well as our previous ALD expression analysis during Icewine
fermentation [11–13], it appears that both Ald6p and Ald3p contribute to acetic acid during Icewine
fermentation. Our data supports a linkage of acetic acid production under the high osmotic stress of
Icewine fermentation to NADH requirements and glycerol production.
We have also previously reported that elevated acetic acid levels appear due to lack of conversion
to acetyl-CoA from the down-regulation in gene expression of cytosolic and mitochondrial acetyl-CoA
synthetase [13]. This was further substantiated by 2-fold lower ethyl acetate levels in the Icewines
(60 mg/L) compared to that found in the dilute juice fermentations (120 mg/L), whereby acetyl-CoA
is required for the esterification to ethanol by alcohol acetyltransferases [13].
We have provided further evidence to support the concept that cytosolic NAD+-dependent
aldehyde dehydrogenase(s) are responsible, in part, for increased levels of acetic acid during Icewine
fermentation stimulated by substrate availability through an increase in NAD+ and acetaldehyde,
whereas the NADP+-dependent isoform plays the dominate role in acetic acid production in table
wine fermentation stimulated by an increase in NADP+. Although substrate availability [11–13],
redox status, and gene expression [11–13] have been evaluated, enzyme activities for the aldehyde
dehydrogenases and downstream acetyl CoA synthetases represent missing information that could
further confirm the enzymes and cofactor system involved in the high acetic acid accumulation during
high sugar fermentations such as that of Icewine.
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Abstract: Yeasts involved in veil formation during biological ageing of Sherry wines are mainly
Saccharomyces cerevisiae, and they have traditionally been divided into four races or varieties:
beticus, cheresiensis, montuliensis and rouxii. Recent progress in molecular biology has led to
the development of several techniques for yeast identification, based on similarity or dissimilarity
of DNA, RNA or proteins. In view of the latest yeast taxonomy, there are no more races. However,
molecular techniques are not enough to understand the real veil-forming yeast diversity and dynamics
in Sherry wines. We propose a reliable method, using a microtiter reader, to evaluate the fermentation
and assimilation of carbon and nitrogen sources, the osmotolerance and the antibiotic resistance,
using 18 S. cerevisiae and 5 non-Saccharomyces yeast strains, to allow correct identification and
classification of the yeast strains present in the velum of flor complex.
Keywords: flor yeast; microplate; fermentation; assimilation; Saccharomyces cerevisiae; non-Saccharomyces;
velum of flor
1. Introduction
Several types of wines are characterized by growing of a yeast film on its surface,
which is known as “veil or velum of flor”. Two of these wines are Fino Sherry and Manzanilla,
both produced from Palomino Fino (Vitis vinifera cv. vinifera) in the Jerez-Xérès-Sherry D.O.,
in Southern Spain [1,2]. The production of these types of wines consists of two successive processes.
First, alcoholic fermentation, an anaerobic process in which sugars are converted in energy, produces
as a result, ethanol and carbon dioxide gas. After the process is finished, wine is fortified to 15% (v/v)
and it is put into oak barrels for storage. The process of biological ageing begins at this moment,
using the “Solera” system [3].
Yeasts involved in veil formation during biological ageing are mainly Saccharomyces cerevisiae,
and they have traditionally been divided into four races: beticus, cheresiensis, montuliensis and rouxii.
The early methods related to taxonomy involved morphological studies and biochemical analyses of
differences on fermentation and assimilation tests, where the substrates used were mainly dextrose,
lactose, maltose, melibiose, raffinose, galactose and sucrose. These physiological properties were
traditionally tested using Durham tubes in a liquid medium, which filled up with gas if fermentation
occurred [4]. Nevertheless, both morphological and physiological characteristics may be influenced
by culture conditions and spoilages and can provide ambiguous results. Using classical techniques
can lead, in some cases, to incorrect classification of species or misidentification of strains. Moreover,
Fermentation 2017, 3, 58; doi:10.3390/fermentation3040058 www.mdpi.com/journal/fermentation162
Fermentation 2017, 3, 58
the methodology often requires evaluation of different parameters by a complex, laborious and
time-consuming process that does not include the most important characteristics of the yeasts from
an industrial point of view. On the other hand, sugar fermentation and assimilation tests using Durham
tubes are not too reliable because some of the yeast strains do not released CO2 immediately (these are
known as slow fermentative yeasts). These yeasts were considered for a long time as non-fermentative,
but they have been recently re-classified [5]. In recent years, new methods have been developed,
such as rapid kits, for yeast identification (API® strips), analyses of total cell proteins and long-chain
fatty acids, using gas chromatography or the determination of chemical compounds formed by the
yeasts [6,7], but their cost, reproducibility and suitability to veil-forming yeast strain classification can
lead to mistakes [8,9]. Therefore, it is necessary to use other identification methods to analyse them.
Recent progress in molecular biology has led to the development of several techniques for
yeast identification based on similarities or dissimilarities of DNA, RNA or proteins. These include
electrophoretic karyotyping [10], RFLP (Restriction Fragment Length Polymorphism) of mitochondrial
DNA [11], random amplified polymorphic DNA analysis (RAPD), PCR-based techniques such as
ribosomal internal transcribed spacers (ITS-PCR) [8], surveys of simple sequences repeats
(SSR-Multiplex PCR) [12] or genomic DNA sequencing of the D1/D2 region of 26S rDNA. Some of these
methods have been found to be of great interest in enology, due to the high level of resolution in
yeast strain characterization, and for making it possible to establish a correlation between the genetic
variability and the most important industrial properties of the strains.
A study carried out by [8] showed that S. cerevisiae flor yeasts responsible for the biological
ageing of Sherry-type wines present a 24-bp deletion, located in the ITS1 region. These results
have extended the analysis of this DNA region to flor yeast isolated in the Montilla-Moriles D.O.
region [9]. Both studies corroborated that this deletion is fixed in flor yeast of the species, S. cerevisiae.
By using molecular analysis techniques, different properties of industrial interest have been detected,
such as physiologic, genetic and metabolic properties in the different identified veil-forming yeast
strains. Moreover, in view of the latest yeast taxonomy, it is important to underline that there are
no more races. S. cerevisiae (beticus) and S. cerevisiae (cheresiensis) are no longer considered as races
or subspecies of S. cerevisiae, according to the last taxonomic study. Indeed, all these previously
named races or subspecies are now considered as S. cerevisiae synonyms, based on nuclear DNA
relatedness [13]. The former race, S. cerevisiae (rouxii), has been classified as Zygosaccharomyces rouxii
and S. cerevisiae (montuliensis) is now considered as Torulaspora delbrueckii [14]. These latter ones are
now classified as ethanol-tolerant non-Saccharomyces species and they also should contain the 24-bp
deletion in the 131–154 ITS1 region. Other yeast species of genera different to Saccharomyces have
been isolated and identified by molecular and/or sequencing methods from Sherry-type wines (from
the initial phase of the fermentation until the ageing phase), such as Wickerhamomyces anomalus,
Pichia membranaefaciens, Zygosaccharomyces bailii or the undesirable species Dekkera bruxellensis
(anamorph Brettanomyces bruxellensis) [3,8,15]. However, the identification strategy should be used
more precisely because many database sequences of these species have identical D1/D2 sequences [16].
The comparison of the D1/D2 sequences and ITS sequences between the isolated strains and those
of the type strains of the species (most can be found in the CBS database). However, many authors
have simply used the first hit in the blast search as the proof of taxonomic affiliation of their
isolate. This strategy can be misleading because database curators do not check submissions for the
correctness of taxonomic affiliation. In this case, using classical biochemical analyses, in conjunction
with molecular methods, can help us to identify and classify the yeast diversity forming the velum
of flor in Sherry wines. Therefore, we propose a reliable, reproducible, inexpensive and efficient
biochemical test, using polysterene 96-well plates that could reinforce the identification of the different
veil-forming yeast strains.
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2. Materials and Methods
2.1. Yeast Strains
Six hundred yeast strains were isolated previously from the veil of flor of “Manzanilla” and
“Fino” wines, from the Sanlúcar de Barrameda and Jerez wineries (Cádiz, Spain), respectively [2,17].
After a first screening, using a Mitochondrial DNA restriction analysis and electrophoretic karyotyping
by pulsed-field-gel electrophoresis (PFGE) and SSR-Multiplex PCR, eighteen different profiles of
Saccharomyces strains were shown and then grouped according to their similarities—eight from
“Manzanilla”, denoted as MI to MVI, MX and MXVIII, and ten from “Fino”, coded as FI to FX,
respectively. Additionally, five potential non-Saccharomyces, isolated from “Fino” veils, which showed
different karyotypes to S. cerevisiae, were subjected to identification by ITS-PCR and sequencing of the
D1/D2 region of 26S rDNA, as stated in [18]. At least two representative members from each ITS-RFLP
genotype group were randomly selected for sequencing of the LSU sRNA gene D1/D2 domain.
2.2. Mitochondrial DNA (mtDNA) Restriction Analysis
Total DNA extraction and mtDNA restriction analyses of the Saccharomyces yeast strains were
performed by the method of [11]. Yeast DNA was digested with a Hinf I restriction enzyme, by
incubation at 37 ◦C, for 3 h. Fragments were separated by electrophoresis on a 1% agarose gel in 1×
TBE buffer (45 mM tris-borate, 1 mM EDTA) and with 0.5 μg/mL of ethidium bromide. The image
of the gel was digitalized in a Molecular Imager apparatus (Gel-Doc XR, Hercules, CA, USA) and
analyzed using Quantity One 1-D software (Bio-Rad, Hercules, CA, USA).
2.3. Electrophoretic Karyotype
Electrophoretic karyotypes of the Saccharomyces and non-Saccharomyces yeast strains were obtained
by PFGE. The colonies were embedded in agarose plugs and treated following a procedure based
on the protocol of [19], and chromosomes were separated using a CHEF-DR III apparatus (Bio-Rad).
Gels were made of 1% pulsed-field certified agarose (Bio-Rad, Hercules, CA, USA) in 0.5× TBE
electrophoresis buffer. The electrophoretic conditions were as follows: an initial pulse of 60 s and
a final pulse of 120 s, during 22 h, at 14 ◦C and 6 V/cm, with an angle of 120◦. Gels were stained
with ethidium bromide solution (0.5 μg/mL ethidium bromide, 0.5× TBE buffer) after electrophoresis,
and the image was captured under UV light with a camera (Bio-Rad Imaging System, Hercules, CA,
USA). The image of the gel was digitalized in a Molecular Imager apparatus (Gel-Doc) and analyzed
using Quantity One-1D software (Bio-Rad). Results were analyzed by comparing the electrophoretic
mobility of the chromosomes with a reference strain (Saccharomyces cerevisiae YNN195).
2.4. Multiplex PCR-Microsatellite (SSR) Analysis
To perform multiplex PCR of microsatellite loci, three loci were simultaneously amplified,
using the primers SC8132X (Fw: CTGCTCAACTTGTGATGGGTTTTGG; Rv: CCTCGTTACTATC
GTCTTCATCTTGC), YOR267C (Fw: GGTGACTCTAACGGCAGAGTGG; Rv: GGATCTACTTGCA
GTATACGGG) and SCPTSY7 (Fw: AAAAGCGTAAGCAATGG TGTAGAT; Rv: AAATGATGCC
AATATTGAAAAGGT) (MWG Biotech AG, Ebersberg, Germany), proposed by Vaudano and
García-Moruno [12]. PCR amplifications were performed in an Applied Biosystems SimplyAmp
Termal Cycler in 50 μL volumes, constituted by: 2 μL of DNA solution (30–90 ng of DNA), 2.5 mM
MgCl2, 200 μM dNTPs, 10 μL of 5× PCR buffer, 2 U of GoTaq® Flexi DNA Polymerase (Promega) and
10 pmol of primers for loci, SCYOR267C and SC8132X, and 40 pmol of primers for locus SCPTSY7.
By using the protocol—4 min at 94 ◦C, 28 cycles of 30 s at 94 ◦C, 45 s at 56 ◦C and 30 s at 72 ◦C,
and 10 min at 72 ◦C—PCR products were separated on an agarose gel (2.5% w/v) with 5 μg/mL of
ethidium bromide in 1× TBE buffer at 115 V for 45 min. DNA fragment sizes were determined by
comparison with a molecular ladder marker of 50 bp (Biolab, London, UK). The gel was digitalized in
a Molecular Imager apparatus (Gel-Doc XR) and analyzed using Quantity One 1-D software (Bio-Rad).
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2.5. Physiological and Biochemical Tests
To perform a quantitative analysis of carbon fermentation and assimilation, nitrogen assimilation,
osmotolerance, and resistance to cycloheximide, different solutions, filtered through 0.22-μm
Stericup filters (Millipore, Burlington, MA, USA) prior to their addition, were incorporated into
the wells of polysterene 96-well microplates (Nunc™ 96-well polystyrene conical bottom Microwell™,
Thermofisher, Denmark). The basal medium for carbohydrate fermentation and assimilation tests
(BMC) was as follows: sterile deionized water 100 mL, 1 g yeast nitrogen base (YNB, Difco) was
prepared with 2 g (w/v) solutions of fructose, glucose, maltose, lactose and sucrose and 4 g (w/v) of
raffinose for fermentation tests, and 0.78 g of glucose, galactose, sorbose, glucosamine, ribose, xylose,
arabinose, rhamnose, sucrose, maltose, α-threalose, cellobiose, salicin, arbutin, melibiose, lactose,
raffinose, melezitose, inulin, starch, erythrytol, ribitol, xylitol, L-arabinitol, D-glucitol, D-mannitol,
myo-inositol, D-Glucono-1,5-lactone, 5-Keto-D-gluconate, D-gluconate, D-galacturonate, DL-lactate,
succinate, citrate and L-tartaric acid, and 0.78 mL of glycerol, propane 1,2-diol, butane 2,3-diol,
Tween 20, Tween 80 for assimilation tests. Nitrogen sources for assimilation were prepared by
supplementing 100 mL of an autoclaved basal assimilation medium yeast carbon base (YNB, DIfco)
(0.17 g YNB without amino acids, 0.5 g ammonium sulphate, 2 g glucose) with filter-sterilized solutions
containing 0.5 g of ammonium sulphate, 0.18 g of ammonium citrate, 0.11 g of nitrate, 0.04 g of
nitrite, 0.1 g of ethylamine and creatine, 0.087 g of creatinine, 0.11 g of glucosamine, 0.1 g of urea, and
D-proline. Then, 180 μL of each substrate was dropped into the wells of the trays. Also, 180 μL of
2%, 20%, 30%, 40% and 50% of a 1:1 mixture of glucose and fructose solution were incorporated into
the wells as an osmotolerance test. Wells for testing the resistance to cycloheximide were prepared
by adding 180 μL of a sterilized 0.1% w/v cycloheximide solution. The medium in each well can be
dehydrated by drying the plate with the lid in a Speed-Vac vacuum oven (Eppendorf), which forms
a small visible residue at the base of the well. After drying, individual trays can be sealed by heat with
a polypropylene-aluminium sealing sheet and can be stored at 4 ◦C for six months, or at −20 ◦C for
one year until subsequent use, rehydrating them with the corresponding basal medium.
The selected yeast strains were previously grown for 24–48 h in 15 mL of YPD (1% yeast extract,
2% peptone, 2% glucose) at 28 ◦C overnight; when achieved, these were washed twice with sterile,
distilled-water. Twenty microliters of inoculum (McFarland standard 2, diluted by a factor of 10) were
introduced into each well using a multi-channel pipette. McFarland standards are used as a reference
to adjust the turbidity of yeast suspensions, so the number of yeast will be within a given range,
to standardize biochemical tests. A 0.5 McFarland standard was prepared by mixing 0.05 mL of
1.175% barium chloride dehydrate with 9.95 mL of 1% sulfuric acid. The standards can be compared
by eye to a suspension of yeasts in sterile water. If the yeast suspension is too turbid, it can be diluted.
If the suspension is not turbid enough, more yeasts can be added (Table 1).
Table 1. McFarland standard values used as a reference to adjust the turbidity of yeast suspensions.
McFarland Standard 0.5 1 2 3 4
1% Barium chloride (mL) 0.05 0.1 0.2 0.3 0.4
1% Sulfuric acid (mL) 9.95 9.9 9.8 9.7 9.6
Cell density ± 108 cells/mL 1.5 3 6 9 12
Absorbance (610 nn) 0.1 0.25 0.45 0.60 0.67
Microplates were sealed with Breathe-Easy membranes (Sigma, Sant Louis, MI, USA) and placed
into an automatic microplate reader (Multiskan go reader, Thermo Fischer Scientific, Waltham, MA,
USA). The optical density of the mix was read at 610 nm every hour (one minute of shaking just
before automatic reading by the microplate reader) at 25 ◦C over 72 h. Data were collected and
processed with the software, SkanIt RE for Multiskan GO 3.2. The absorbance data were exported to
MS Excel for processing. A reading of optical density (OD610) = 1, measured by the microtiter reader,
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corresponds to 6–7 × 107 cells/mL. Absorbance values at 610 nm were transformed into negative
values when OD < 0.4 and positive when OD > 0.4, after 72 h.
2.6. Validation and Reproducibility of the Tests in Microtiter Plates
The yeast strains used in this study were also subjected to a standard test in Durham tubes,
following the protocol proposed by [20] and under the same conditions of temperature and time.
These tests were repeated with the microplate tests six times with each yeast strain. The stability of the
carbon and nitrogen medium of the microtiter plates in storage was also examined. The same yeast
species were analyzed for their reactions in microtitre trays that had been freshly prepared and in
those that had been stored for six months at 4 ◦C and for one year at −20 ◦C.
3. Results
A total of 18 strains belonging to Saccharomyces cerevisiae species were characterized using
the pulsed-field-gel electrophoresis (PFGE) technique and mitochondrial DNA restriction analysis.
Moreover, analyses of polymorphic microsatellite loci and the proposed biochemical test, using 96-well
plates, were used. Chromosomal profiles, obtained from the studied strains, showed fourteen different
patterns. Specifically, strains FII and FIII, FV and FVI, FVIII and FIX, MX and MXVIII showed common
patterns. In regard to the SSR analysis, fourteen different patterns were also obtained, which complied
with the results obtained in the PFGE (Figure 1).
Figure 1. Patterns obtained by the simple sequences repeats (SSR)-Multiplex PCR of the S. cerevisiae
flor yeasts, selected after the first screening. Strains FII and FIII, FV and FVI, FVIII and FIX, MX and
MXVIII showed common patterns.
On the other hand, using mitochondrial DNA restriction analyses with the enzyme Hinf I, three
different patterns were obtained. The most common pattern was H1 (corresponding to FIV, FV, FIX,
MI, MII, MIII, MVIII and MX), the second was H2 (corresponding to FI, FII, MIV and MV) and the
pattern H3 only corresponded to one strain (MVI).
Fifteen different strains were determined by establishing the correspondence between the three
patterns obtained from the analysis of mtRFLP with Hinf I—coded as H1, H2 and H3—and fourteen
patterns were obtained from the polymorphism study of the tested karyotypes and microsatellite
loci. These fifteen different strains are FI, FII, FIII, FIV, FV, FVI, FIX, FX, MI, MII, MIII, MIV, MV, MVI
and MX, according to the different combinations observed. The potential five non-Saccharomycces
species, analyzed by the molecular method mentioned in the material and methods section (Figure 2)
and after sequencing of the D1/D2 region, have been identified as Zygosaccharomyces bailii (NsI),
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Torulaspora delbrueckii (NsII), Zygosaccharomyces rouxii (NsIII), Rhodotorula mucilaginosa (NsIV) and
Rhodotorula minuta (NsV). However, the species, Z. bailii and Z. rouxii, and R. mucilaginosa and R. minuta
showed very similar (less than 1%), or identical, D1/D2 sequences to those found in the databases.
Figure 2. Karyotypes obtained by pulsed-field-gel electrophoresis (PFGE) of the non-Saccharoymyces
veil-forming yeasts isolated in “Fino” Sherry wines. The species were identified as Zygosaccharomyces
bailii (NsI), Torulaspora delbrueckii (NsII), Zygosaccharomyces rouxii (NsIII), Rhodotorula mucilaginosa (NsIV)
and Rhodotorula minuta (NsV).
The selected strains were also analyzed to determine their fermentation and assimilation abilities,
to evaluate if they shared physiological characteristics. Tables 2 and 3, show the results of those which
reached a positive result, among all tested carbon and nitrogen sources.
Table 2. Fermentation of different carbohydrates by selected S. cerevisiae flor yeasts, analyzed with
microtiter technology. Values are expressed as (+) if yeast strains were able to ferment the




Fructose Glucose Lactose Maltose Rafinose Sucrose
FI − + − − − −
FII + + − − + +
FIII + + − − − −
FIV + + − − − +
FV + + − − − +
FVI + + − − + +
FIX − + − − + +
FX − + + − − −
MI + − − − − +
MII + + + − + +
MIII − − + − − −
MIV + + + − + −
MV − + − + − −
MVI + + − − + +
MX + + − − + +
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Table 3. Assimilation of different carbon/nitrogen compounds by selected S. cerevisiae flor yeasts,
analyzed with microtiter technology. Values are expressed as (+) if yeast strains were able to assimilate




Ammonium Citrate Glucose Inulin Melibiose Nitrite Starch Urea
FI + − − − − − −
FII + − − − − . −
FIII + − − − − − −
FIV + − − − − − −
FV + − − − − − −
FVI − − − − − − −
FIX − + + − − − −
FX − − − − − − −
MI + − − − − − −
MII + − + − − − +
MIII + − + − − − +
MIV + − − − − − −
MV − + − + + − −
MVI + − − − − + −
MX − − + − − + −
These tests, repeated six times, were also carried out in Durham tubes, obtaining the same results
in all cases, with the exception of a couple of cases (fermentation of raffinose by yeast strain FII
and fermentation of sucrose by yeast strain MVI), in which Durham tubes showed questionable
results. However, these results obtained by the standard method, had positive results in the
microtiter-read assay (OD > 0.4). Although molecular analyses have shown similarities between
some strains, the diversity of the fermentation and assimilation abilities were significantly higher
(Tables 2 and 3). In the case of the sequenced non-Saccharomyces yeast strains, Z. bailii did not grow on
maltose, which is usually assimilated by Z. rouxii and R. mucilaginosa isolates grew on maltose, sucrose,
lactose, which are not assimilated by R. minuta. These results are in accordance with those published
in [14,21]. Thus, by applying the biochemical tests, we have ensured that these yeast strains have been
satisfactorily identified (Table 4).
Table 4. Assimilation of different carbon/nitrogen compounds by non-Saccharomyces species, isolated
from “Fino” Sherry wine, analyzed with microtiter technology. Values are expressed as (+) if yeast





Raffinose Galactose Inulin Melibiose Maltose Lactose L-Sorbose Ethanol
NsI − + − − − − − +
NsII + + + − + − − +
NsIII − + − − + − − +
NsIV + + − − + − − +
NsV − − − − − + + +
Regarding the results obtained for osmotolerance, only two isolates grew in the media
supplemented with 50% of glucose:fructose, but neither belonged to the Saccharomyces species (Table 5).
The most osmotolerant species was Torulaspora delbrueckii. The tests for cycloheximide resistance gave
the same results when tested by either the standard or microtitre method (Table 5).
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Table 5. Osmotolerance and cycloheximide resistance of the veil-forming yeasts used in this study and
analyzed by microtiter technology. Values are expressed as (+) if yeast strains were able to growth in
a particular concentration of glucose/fructose solution and (−) if yeast strains were not able to growth.
Strain
Designation
Osmotolerance: Growth on Media Supplemented with 1:1 (Glucose:Fructose) and Cycloheximide Resistance
2% 20% 30% 40% 50% Cycloheximide 0.01% Cycloheximide 0.1%
FI + + + − − − −
FII + + − − − − −
FIII + + + − − − −
FIV + + + − − − −
FV + + + − − − −
FVI + + + − − − −
FVII + + − − − − −
FVIII + + − − − − −
FIX + + + − − − −
FX + + + − − − −
MI + + + − − − −
MII + + + − − − −
MIII + + + − − − −
MIV + + + − − − −
MV + + + − − − −
MVI + + + − − + −
MX + + + − − + −
MXVIII + + + − − − −
NsI + + − − − − −
NsII + + + + + − −
NsIII + + + + + − −
NsIV + + − − − + −
NsV + + − − − + −
The reproducibility of the tests in microtiter plates was assessed, using the selected Saccharomyces
and non-Saccharomyces identified in this study. They were examined six times in microtiter plates.
Responses to the identification tests for each species were the same in all replications. Moreover,
the stored 96-well plates gave the same reaction responses, indicating that the multiplates could be
stored for at least one year at −20 ◦C without affecting identification results.
4. Discussion
In recent years, multiplex microsatellite analysis has been implemented as one of the most
decisive techniques in determining polymorphisms within the same species, but it has not often
been applied to flor yeast analyses, since it could show few different patterns. However, in our
study microsatellite analysis have shown fourteen different patterns, obtaining the same results as
electrophoretic karyotyping. In any case, by combining multiplex microsatellite and RFLP of mtDNA
analyses, when required, it is possible to obtain the same number of patterns as using electrophoretic
karyotyping; these results are in agreement with those found in [9].
Pulsed-field gel electrophoresis (PFGE) has a good reproducibility and high discriminatory
power, but it is an expensive and time-consuming technique. On the other hand, multiplex PCR of
microsatellite loci [12] also has a high discriminatory power, sample preparation is easier and it is
faster than PFGE.
Results obtained in the characterization of flor strains are highly variable, since some authors [8]
have identified a higher degree of polymorphism between flor strains in mtDNA restriction than
karyotyping. However, our study revealed the opposite: mtDNA restriction showed only three
different patterns and PFGE showed fourteen different patterns. These results are similar to [9].
Mitochondrial DNA restriction analysis showed less polymorphisms due to the conditions of
the wineries, since these DNA could be subjected to positive selection pressure based on their
ethanol tolerance (15% v/v) [22] and other environmental factors, such as nutrient composition,
growth temperature, and presence of toxic drugs, heavy metals, oxidizing agents, and osmotic/ionic
stresses [23]. This might be the reason why the mtDNA restriction analysis showed only three different
patterns of all the strains that we analyzed.
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Biochemical tests offer supplementary information for characterizing flor strains. Traditionally,
veil-forming yeast strains have been classified into four races belonging to the S. cerevisiae species,
currently considered synonyms of the S. cerevisiae species [14]; another race, previously referred to
as S. cerevisiae var. montuliensis, that has recently been reclassified as Torulaspora delbrueckii [14,24],
and a last race named S. cerevisiae rouxii, is now Zygosaccharomyces rouxii [14]. This classification was
based on morphological and metabolic studies of fermentation and assimilation of different carbon
and nitrogen sources that differentiate these four main breeds [25]. The studies of assimilation and
fermentation of sugars that we have carried out in this work have shown a high variability, so we
were not able to differentiate races within S. cerevisiae strains. We can conclude that biochemical
tests are necessary for identifying and classifying the different yeast strains that form the veil of
flor of Sherry wine, because we believe that each yeast strain brings to the Sherry wines a different
organoleptical characteristic. Thus, the application of this simplified method, using polysterene 96-well
plates, is an inexpensive, low-time consuming and efficient technique, that can be used in combination
with the molecular methods described above, to ensure veil-forming yeast diversity in Sherry wines.
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Abstract: Yeasts are ubiquitous microbes found in virtually all environments. Many yeast species can
ferment sugar into ethanol and CO2, and humans have taken advantage of these characteristics to
produce fermented beverages for thousands of years. As a naturally abundant source of fermentable
sugar, honey has had a central role in such fermentations since Neolithic times. However, as beverage
fermentation has become industrialized, the processes have been streamlined, including the narrow
and almost exclusive usage of yeasts in the genus Saccharomyces for fermentation. We set out to identify
wild honey- or honey-bee-related yeasts that can be used in honey fermentation. Here, we isolated
two strains of Torulaspora delbrueckii from the gut of a locally collected honey bee. Both strains were
able to ferment honey sugar into mead but failed to metabolize more than a modest amount of wort
sugar in trial beer fermentations. Further, the meads fermented by the T. delbrueckii strains displayed
better sensory characteristics than mead fermented by a champagne yeast. The combination of
T. delbrueckii and champagne yeast strains was also able to rapidly ferment honey at an industrial
scale. Thus, wild yeasts represent a largely untapped reservoir for the introduction of desirable
sensory characteristics in fermented beverages such as mead.
Keywords: yeast; mead; fermentation
1. Introduction
Mankind has been fermenting foods and beverages for thousands of years [1–4], which certainly
predates our knowledge that yeasts were the microbial agents responsible for metabolizing sugar
into alcohol. Honey, which is produced by honey bees such as Apis mellifera, is a natural source of
abundant, readily fermentable sugar and has been found as an ingredient in some of the earliest known
fermented beverages [2]. When a dilute honey solution is fermented on its own without the addition
of fruit/fruit juice or other additives, this creates a traditionally strong (8–18% alcohol by volume,
ABV) beverage called mead (reviewed in [5]).
Much like craft brewing, mead making is currently experiencing a renewed interest at the amateur
and professional levels worldwide. Indeed, one average, a new meadery opens in the United States
every 3 days, and one opens every 7 days in the rest of the world [6]. With this proliferation of mead
making has come experimentation with the traditional methods, including aging mead in oak or
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previously used spirit barrels and fermentation with non-Saccharomyces microbes to generate sour and
“funky” meads [6]. In many ways, this again mirrors the craft brewing scene and current popularity of
sour beer [7–9].
Another factor driving innovation in fermented beverage production is the “local
movement” [10,11], i.e., the push to use locally sourced ingredients. In the case of mead, it is often
relatively simple to utilize locally produced honey, but few meaderies use indigenous microbes unless
they rely on those naturally found in the honey itself. Such microbes are naturally resistant to high
osmotic stress from concentrated sugar in honey and typically come from pollen/flower, bee gut
microbiome, and dirt/dust contamination of the honey (reviewed in [12,13]). These organisms include
multiple species from dozens of different genera of bacteria (e.g., Bacillus, Citrobacter, and Lactobacillus),
yeast (e.g., Saccharomyces, Schizosaccharomyces, and Pichia), and molds.
Here, we describe the bio-prospecting for novel yeasts to use in honey fermentation.
We concentrated on ultra-local strains by attempting to enrich for ethanol-tolerant yeasts in honey, the
hive, and honey bees themselves. Ultimately, we recovered two strains of the yeast Torulaspora
delbrueckii from the honey bee microbiome and characterized them for their ability to ferment
honey. Many T. delbrueckii strains have previously been examined for their fermentative abilities
and were found to improve wine quality (see [14] and references therein) and create distinct beer
flavors in beer [15–17]. Compared to S. cerevisiae, T. delbrueckii is generally found to generate lower
levels of ethanol [16] but a wider range of fruity aromas [18,19]. However, in many of these cases,
T. delbreuckii is used in combination with S. cerevisiae for sequential fermentations [14] or mixed culture
fermentations [15].
Currently, there are no reports of T. delbrueckii being used to make mead and how this species
may impact the sensory qualities of the final product. Here, we found that, compared to a traditional
Saccharomyces cerevisiae control strain (WLP715), the mead produced by the T. delbrueckii strains YH178
and YH179 scored more favorably during sensory analysis. Further, T. delbrueckii YH178 and YH179
were successfully used in mixed honey fermentations with S. cerevisiae WLP715 on a production scale.
These data suggest that T. delbrueckii YH178 and YH179 have beneficial honey fermentation profiles
and are suitable for mead production by homebrewers and professional mead makers.
2. Results and Discussion
2.1. Isolation of T. delbrueckii Strains YH178 and YH179
We initially set out to isolate ethanol-tolerant yeasts from multiple bee-related sources. Samples
of honey, honeycomb, propolis, and fragments of a wooden beehive were surveyed for yeasts, but no
microbes were recovered using our wild yeast enrichment protocol [7]. This failure was likely not
due to the stringency (e.g., high ethanol and osmotic stress tolerance) of the method used because we
previously recovered hundreds of wild ethanol-tolerant yeasts from a variety of environmental sources.
However, as only small volumes of samples were surveyed from a single hive, a more extensive search
may have yielded suitable yeasts. Alternatively, the lack of ethanol-tolerant yeasts may be attributed
to the well-characterized hygienic behavior of honey bees, which are known to keep their hives clean
in order to avoid disease [20–23].
We next focused our bio-prospecting efforts on the bees themselves. We again failed to isolate
ethanol-tolerant yeast from the outer surface of several bees via a quick rinse with yeast enrichment
medium or prolonged incubation of a bee submerged in the same medium at 30 ◦C with aeration.
However, when a bee was submerged in yeast enrichment medium and its abdomen was ruptured,
microbial growth was visible in the culture after 24 h. Plating for single colonies on Wallerstein
Laboratories nutrient (WLN) agar revealed that two distinct strains of yeast were present, which
differed in color (Figure 1A). These strains were designated YH178 (darker green on WLN agar) and
YH179 (pale green) as part of our larger yeast hunting efforts and were identified as T. delbrueckii
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isolates by rDNA sequencing (Figure 1B). For comparison, the S. cerevisiae strain WLP715 is shown,
which attains an even lighter shade of green than YH179 on WLN agar (Figure 1A).
 
Figure 1. YH178 and YH179 are both strains of T. delbrueckii. (A) Colony morphology of YH178,
YH179, and S. cerevisiae WLP715 on YPD (left) and WLN (right) agar plates. The indicated strains were
streaked for single colonies and grown at 30 ◦C for 2 days prior to capturing images of the plates with
a flatbed scanner. (B) Sequence alignments revealed that YH178 and YH179 are isolates of T. delbrueckii.
A portion of the 26S rDNA of YH178 and YH179 was PCR-amplified and sequenced, and the sequences
are aligned to the closest related strain in the NCBI nucleotide database. T_del_K23 denotes the 26S
rDNA gene of T. delbrueckii strain K23 (GenBank accession KP852445.1). The ellipsis at the end of each
line represents the missing sequence that was truncated due to spatial constraints. The full alignment is
shown in Figure S1. Green: fully conserved; yellow: conserved among two sequences; blue: similarity
(pyrimidines); dashes: sequence gaps due to indels.
Although no colony size variation was noted on either YPD or WLN plates at the end of a 2-day
incubation (Figure 1A), YH178 attained this colony size faster than YH179 when observed prior to
the end point of growth (data not shown). This suggested that YH178 has a faster doubling time
than YH179. However, plotting growth curves for these strains grown in YPD medium revealed that
YH178 had a shorter lag phase (<4 h; Figure 2A) to exponential growth than YH179 (>6 h; Figure 2B).
Otherwise, these strains displayed similar doubling times and final cell densities.
Figure 2. Cont.
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Figure 2. YH178 and YH179 grow poorly in the presence of maltose. YH178 (A), YH179 (B),
and S. cerevisiae WLP715 (C) were grown to saturation overnight in YPD medium, back-diluted into
YPD (black) or YPM (red) medium, and grown overnight in a 96-well plate. Growth was monitored by
recording the OD660 of each culture and is plotted vs. time. The plotted points are the averages of three
independent experiments, and the error bars are the standard deviations.
2.2. YH178 and YH179 Can Use Honey as a Carbon Source during Fermentation
To determine if YH178 and/or YH179 could ferment honey, we inoculated a diluted honey
solution with an equivalent number of cells from the T. delbrueckii strains, singly and in combination.
As a positive control for fermentation, we also used S. cerevisiae WLP715, which is marketed as an
appropriate yeast for wine, mead, and cider fermentations [24]. The fermentations were monitored for
20 days, and the results are shown in Figure 3A. At approximately 12 h after inoculation, all cultures
displayed signs of fermentation, and WLP715 quickly attenuated the honey solution to a final alcohol by
volume (ABV) of 11.5% in 2 weeks (Table 1). The t1/2 (time necessary for 50% attenuation) was <2 days.
In contrast, YH178, YH179, and the combination thereof fermented the honey solution at a much
more modest pace. The t1/2 for these fermentations was ~4–4.5 days, and while the final ABV for YH178
was identical to that of WLP715 (11.5%), the YH179 and YH178/YH179 combination fermentations
only reached 11% and 11.2%, respectively (Table 1). Subsequent experiments did, however, reveal that
additional incubation time of the YH179 and YH178/YH179 cultures led to the same terminal ABV of
11.5% by 35 and 28 days, respectively.
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Figure 3. The T. delbrueckii isolates can ferment honey into mead. (A) The indicated strains were
used to inoculate a honey solution, and fermentation of the honey was monitored with a digital
hydrometer. The amount of alcohol produced is plotted vs. time. These results are representative of
three independent fermentations for each strain or combination of strains (178/179 = a 1:1 mixture
of YH178 and YH179 cultures). (B) Production-scale honey fermentations using a combination of
YH178, YH179, and WLP715 yeasts. These fermentations were conducted in April (3 April 2017) and
September (18 September 2017) of 2017 under similar conditions but with slightly different starting
gravities of the honey solution.
Table 1. Experimental fermentations with Saccharomyces cerevisiae, Torulaspora delbrueckii,
and Hanseniaspora vineae strains.
Strain
Honey Fermentation 1 Beer Fermentation
Final Gravity ABV 2 Final pH 3 Final Gravity ABV Final pH
S. cerevisiae WLP001 N.D. N.D. N.D. 1.011 4.33% 4.40
S. cerevisiae WLP715 0.992 11.5% 4.25 N.D. N.D. N.D.
T. delbrueckii YH178 0.992 11.5% 4.15 1.041 0.39% 5.40
T. delbrueckii YH179 0.996 11.0% 4.23 1.042 0.26% 5.40
YH178 + YH179 0.994 11.2% 4.20 N.D. N.D. N.D.
H. vineae YH72 1.018 8.2% 3.31 1.016 3.68% 3.26
1 The original gravity of the honey solution was 1.080, and that of the wort was 1.044. 2 Abbreviations: ABV: alcohol
by volume; N.D.: not determined. 3 The initial pH of the honey solution was 4.62, and that of the wort was 5.43.
It is perhaps unsurprising that gut microbiota from the honey bee can metabolize honey, as this
is a food source for A. mellifera itself. Honey is mainly composed of the hexose monosaccharides
glucose and fructose, and most yeast species can utilize one or both as carbon sources for cellular
metabolism [25]. Conversely, unadulterated honey contains no maltose [26], which is a glucose
disaccharide and the primary sugar in beer wort [27]. We tested YH178 and YH179 for their ability
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to ferment wort and found that attenuation of the beer was extremely poor after two weeks of
fermentation (Table 1). In contrast, the S. cerevisiae WLP001 ale yeast attenuated to expected levels.
The basal level of fermentation displayed by YH178 and YH179 is likely attributable to the T. delbrueckii
cells consuming the limited quantities of glucose, fructose, and/or sucrose found in typical worts [27].
Indeed, growth curves in YP medium supplemented with 2% maltose (YPM medium) rather than
glucose (YPD medium) demonstrate that YH178 grows much more poorly in the YPM than YPD
medium (Figure 2A). Similarly, YH179 displayed only minimal growth in YPM medium (Figure 2B).
The WLP715 strain is able to utilize maltose though, showing only a modest decrease in growth rate
in YPM medium compared to YPD medium and no reduction in final cell density (Figure 2C). While
others have successfully isolated yeasts from wasps [28] that can ferment wort into beer, not all yeasts
from hymenoptera gut microbiomes are capable of this feat. Thus, individuals interested in isolating
yeasts for a particular fermentation milieu are cautioned to select for crucial phenotypes (e.g., maltose
utilization) early in the bio-prospecting process.
2.3. YH178 and YH179 Produced Superior Meads Compared to WLP715
We next compared the sensory characteristics of the meads produced via the above fermentations.
This analysis was performed by 10 panelists using a method developed to quantify eight organoleptic
qualities of mead [29] on a 20-point scale. Table 2 shows the results of our sensory analysis of mead
fermented with YH178, YH179, the combination of YH178 and YH179, and S. cerevisiae WLP715.
Overall, the meads fermented with YH178 or YH179 were scored more highly than that produced
by WLP715 (though not significantly preferred, p ≥ 0.052). The WLP715 mead was notable for its
very forward ethanol heat, which was more pleasantly masked by YH178 and YH179 despite having
comparable ABVs. However, the sensory panel also detected obvious differences in the meads made
with YH178 and YH179. For instance, the aroma of the YH178 mead was more reminiscent of honey
than YH179 mead, which some panelists reported as “funky” or simply lacking in honey character.
This again corroborates our findings that YH178 and YH179 are distinct strains of T. delbrueckii.
The mead fermented with the combination of YH178 and YH179 scored highly on aroma but had a
grassy flavor that some panelists did not enjoy. Regardless, all of these meads received a “standard”
score (12–16 points) [29], indicating that YH178 and YH179 are suitable for home and commercial
brewing of mead.
Table 2. Sensory evaluation of mead samples.




YH178 2 ± 0 2 3.7 ± 0.9 1 ± 0.5 1 ± 0.5 0.9 ± 0.7 1.5 ± 0.3 1.3 ± 0.5 1.4 ± 0.2 12.8 ± 2.4
YH179 2 ± 0 3.7 ± 1.2 1.1 ± 0.7 1.7 ± 0.4 1.4 ± 0.5 1.8 ± 0.4 1.8 ± 0.4 1.8 ± 0.4 15.3 ± 2.4
178/179 2 ± 0 4.5 ± 1.2 0.8 ± 0.6 0.9 ± 0.2 0.8 ± 0.6 1 ± 0.5 1.1 ± 0.2 1.2 ± 0.2 12.3 ± 1.9
WLP715 2 ± 0 4.3 ± 0.8 0.8 ± 0.6 1.3 ± 0.4 0.6 ± 0.2 1.2 ± 0.6 1.1 ± 0.4 1.4 ± 0.3 12.7 ± 2.2
YH72 2 ± 0 5.2 ± 0.7 1.5 ± 0 2 ± 0 0.7 ± 0.2 2 ± 0 2 ± 0 2 ± 0 17.4 ± 0.8
1 YH178 and YH179 are Torulaspora delbrueckii isolates, 178/179 is a mixture of both T. delbrueckii strains, WLP715 is
a Saccharomyces cerevisiae strain, and YH72 is a lactic acid-producing isolate of Hanseniaspora vineae [8]. 2 The values
presented are the averages ± standard deviations.
Knowing that acidity would be ranked, we also fermented mead with Hanseniaspora vineae strain
YH72 (Table 2), which produces lactic acid during fermentation [8], as an additional control. As in beer
fermentation, the final pH of the H. vineae YH72 mead dropped to pH = 3.31 due to the lactate created
by this strain. Surprisingly, during our sensory analysis, the YH72 mead was ranked highest in all
categories except one (Body) and achieved a quality score defining it as a “superior” (16–20 points)
mead [29] (p ≤ 0.017 vs. all other meads). This was in part due to its assertive peach aroma, pleasant
acidic finish, and good balance. It should, however, be noted that the final gravity of this mead was
only 1.018, yielding an ABV of 8.2%. Thus, comparing it to dryer meads across all sensory categories
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can be misleading. Indeed, previous large-scale sensory analysis of sweet and dry meads indicates
that consumers prefer sweet meads [30].
2.4. YH178 and YH179 Were Used in the Creation of Honey Schnapps
Based on the performance of YH178 and YH179 in mead fermentation, we sought to determine
how well these strains functioned in production-scale (>20 hL) fermentations. Two large, independent
fermentations of diluted honey were conducted as described in the Materials and Methods. A mixed
yeast culture containing approximately equal cell counts of YH178, YH179, and WLP715 was used in
both cases. As shown in Figure 3B, this yeast blend was able to ferment the solution to a specific gravity
of ~1.000 in <10 days during both trials. This is consistent with the kinetics of fermentation displayed
by these strains individually in laboratory-scale fermentations (Figure 3A), indicating that YH178 and
YH179 can be used for industrial honey fermentations without any additional “domestication” or
adaptation, at least in the presence of WLP715. Future experiments with YH178 and YH179 alone
are planned, as well as trials of serial re-pitching of these strains into fermentations to select for an
increased fermentation rate. Indeed, the desirable rapidity with which WLP715 ferments honey is
one of the reasons that it was added to the production-scale fermentations performed in this work.
Regardless, the fermented honey solutions were distilled into a schnapps that was back-sweetened
with honey and were well received by consumers [31].
3. Materials and Methods
3.1. Strains and Culture Conditions
T. delbrueckii strains YH178 and YH179 were supplied by Wild Pitch Yeast, LLC (Bloomington,
IN, USA), and S. cerevisiae strains WLP001 and WLP715 were purchased from White Labs (San Diego,
CA, USA). All strains were routinely grown on yeast extract, peptone, and dextrose (YPD; 1% (w/v)
yeast extract, 2% (w/v) peptone, and 2% (w/v) glucose) plates containing 2% (w/v) agar at 30 ◦C and
in YPD liquid culture at 30 ◦C with aeration unless otherwise noted. WLN agar contained 4 g/L yeast
extract, 5 g/L tryptone, 50 g/L glucose, 0.55 g/L KH2PO4, 0.425 g/L KCl, 0.125 g/L CaCl2, 0.125 g/L
MgSO4, 2.5 mg/L FeCl3, 2.5 mg/L MnSO4, 22 mg/L bromocresol green, and 15 g/L agar. All strains
were stored as 15% (v/v) glycerol stocks at −80 ◦C. Media components were from Fisher Scientific
(Pittsburgh, PA, USA) and DOT Scientific (Burnton, MI, USA). All other reagents were of the highest
grade commercially available.
3.2. Yeast Isolation
Yeasts YH178 and YH179 were isolated from a honey bee sample as described [7]. Briefly, honey
bees were collected into sterile glass jars and stored at 4 ◦C before being processed in the laboratory.
The bee containing YH178 and YH179 was submerged in 5 mL of YPD8E5 (1% yeast extract, 2% peptone,
8% glucose, and 5% (v/v) ethanol), crushed with a sterile pipet, and the culture was incubated at 30 ◦C
with aeration for 24 h. A small volume of the culture was then streaked onto a WLN agar plate and for
36–48 h at 30 ◦C. To isolate pure strains, single colonies were picked and restreaked onto fresh WLN
agar plates until a uniform colony morphology was obtained.
3.3. Strain Identification
YH178 and YH179 were identified as T. delbrueckii using the procedure described in [8]. Briefly,
100 μL of saturated overnight culture was mixed with an equal volume of lysis solution (0.2 M LiOAc
and 1% SDS) and incubated in a 65 ◦C water bath for ≥15 min to lyse the cells. The genomic (gDNA)
was precipitated with 300 μL of 100% isopropanol and vortexing, and it was pelleted with cell debris
for 5 min at maximum speed in a microcentrifuge. The supernatant was removed, and the gDNA
was resuspended in 50 μL TE buffer (10 mM Tris-HCl, pH 8, and 1 mM EDTA). The variable D1/D2
portion of the eukaryotic 26S rDNA was then amplified by PCR from the gDNA templates using oligos
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NL1 (GCATATCAATAAGCGGAGGAAAAG) and NL4 (GGTCCGTGTTTCAAGACGG) [32] and the
following cycling conditions: 98 ◦C for 5 min; 35 cycles of 98 ◦C for 30 s, 55 ◦C for 30 s, and 72 ◦C for
30 s; and 72 ◦C for 10 min. The amplified DNA was purified using a PCR Purification Kit (Thermo
Scientific, Waltham, MA, USA) and sequenced by ACGT, Inc. (Wheeling, IL, USA) using primer NL1.
The sequence was used to query the National Center for Biotechnology Information (NCBI) nucleotide
database with the Basic Local Alignment Search Tool (BLAST; http://blast.ncbi.nlm.nih.gov/Blast.cgi?
CMD=Web&PAGE_TYPE=BlastHome) to identify the most closely related species.
3.4. Growth Curves
The yeast strains were grown by inoculating 5 mL of YPD liquid medium with single colonies
from YPD plates and incubation overnight at 30 ◦C with aeration. The optical density at 660 nm
(OD660) of each culture was determined using a Beckman Coulter DU730 UV/Vis Spectrophotometer.
Then, the cells were diluted to an OD660 ≈ 0.1 in 200 μL of YPD medium or YPM medium (1% (w/v)
yeast extract, 2% (w/v) peptone, and 2% (w/v) maltose) in round-bottom 96-well plates, overlaid with
50 μL of mineral oil to prevent evaporation and incubated at 30 ◦C with shaking in a BioTek Synergy
H1 plate reader. The OD660 of every well was measured and recorded every 15 min for ~20 h, and the
normalized values (i.e., OD660 reads minus the initial OD660 value) were plotted vs. time to generate
growth curves. All growth experiments were repeated three times, and the plotted points represent
the average OD660 values (error bars represent the standard deviation).
3.5. Laboratory-Scale Honey Fermentation
Wild flower honey from Fort Wayne, IN was provided by Creek Ridge Honey, LLC and Cardinal
Spirits. The honey was diluted approximately 1:5 with sterile deionized water and YP medium to
a gravity of 1.080 and final concentrations of yeast extract and peptone of 0.25% and 0.5% (w/v),
respectively. Fermentations of this honey solution were performed as described in [8]. Briefly, the yeast
strains were grown to saturation (~200 × 106 cells/mL) in 50 mL of YPD liquid medium at 30 ◦C with
aeration and used to inoculate ~800 mL of honey solution (1.080 original gravity) in 1 L glass cylinders
(30 cm tall, 7.5 cm inner diameter). Control fermentations were likewise set up in parallel using the
same reagents but inoculating with 50 mL (~200 × 106 cells/mL) WLP715. These fermentations were
incubated at an average temperature of 23.4 ± 0.3 ◦C, and the gravity and alcohol by volume (ABV)
were monitored in real time using BeerBug digital hydrometers (Sensor Share, Richmond, VA, USA)
for 4 weeks.
3.6. Laboratory-Scale Wort Fermentation
Laboratory-scale wort fermentations were performed as described [8]. Briefly, blonde wort was
prepared by mashing 65.9% Pilsner (2 Row) Bel and 26.9% white wheat malt at 65 ◦C (149 ◦F) for 75
min in the presence of 1 g/bbl CaCO3 and 1.67 g/bbl CaSO4. During the subsequent boil, 7.2% glucose
and Saaz hops (to 25 international bittering units) were added. The original gravity (OG) of this wort
was 1.044. The yeasts were grown to saturation (~200 × 106 cells/mL) overnight at 30 ◦C with aeration
in 5 mL YPD medium, and these starter cultures were used to inoculate approximately 400 mL of
blonde ale wort in glass bottles capped with rubber stoppers and standard plastic airlocks. Control
fermentations were set up identically but inoculated with 5 mL (~200 × 106 cells/mL) WLP001 culture.
The fermentation cultures were incubated at room temperature for 2 weeks, and their final gravity was
measured using a MISCO digital refractometer (Solon, OH, USA).
3.7. Mead Sensory Analysis
Sensory analysis was performed using the method developed by the University of California,
Davis as described by [29]. Briefly, each mead was sampled in a blinded fashion by 10 or more
individuals and immediately scored for appearance (2 points), aroma (6 points), and acidity, balance,
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body, flavor, finish, and overall quality (2 points each). Using these criteria, a score of 17–20 is superior,
13–16 is standard, 9–12 is below standard, and 1–8 is not acceptable.
3.8. Production-Scale Honey Fermentation and Distillation
Two large honey fermentations were performed at Cardinal Spirits, LLC (Bloomington, IN).
The first was performed on 3 April 2017 with a solution of 378 L honey and 23.2 hL H2O, which had
an initial specific gravity of 1.0569 (14.02 Brix) and an initial pH of 4.4. Diammonium phophate (DAP,
1.05 kg; BSG Wine, Napa, CA, USA) and Fermax (587 g; BSG HandCraft, Shakopee, MN, USA) were
added to this solution as yeast nutrients, and then a 1:1:1 mixture of YH178, YH179, and WLP715
was added to inoculate the medium. The culture was maintained at a temperature of 28.5–30 ◦C in
a stainless steel fermenter, and gravity and pH were monitored daily. After 1 day of fermentation,
1.05 kg DAP and 587 g Fermax were again added to the fermentation, and when the gravity decreased
to <6 Brix, 587 g Fermax was added one last time. The fermentation proceeded for ~9 days, reaching a
terminal gravity of 0.13 Brix (7.35% ABV) prior to distillation to approximately 150 proof.
The second large-scale fermentation was performed on 18 September 2017 with a solution of 549 L
honey and 29.2 hL H2O, which had an initial specific gravity of 1.0708 (17.24 Brix) and an initial pH
of 5.04. The same nutrient addition schedule and yeast blend as above was used. The culture was
maintained at a temperature of 28.5–31 ◦C in a stainless steel fermenter, and gravity and pH were
again monitored daily. The fermentation proceeded for ~7 days, reaching a terminal gravity of 0 Brix
(9.14% ABV) prior to distillation to approximately 150 proof. In both this and the previous cases,
the distillate was diluted to ~80 proof and back-sweetened with 0.45 kg honey/3.78 L distillate. After
resting this liquid for 1 month on a fining agent to precipitate out proteins and pollen, the final product
was a yellow-tinted clear liquid (visually reminiscent of white wine) and marketed as a 74.2 proof
honey schnapps. Further details are available upon request.
3.9. Statistical Analysis
All statistical analyses were performed using GraphPad Prism 6 software. Differences between
values were compared using Student’s t-test, and p-values <0.05 were considered statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/2311-5637/4/2/ 22/s1.
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Abstract: Clinical needs for novel antifungal agents have increased due to the increase of people
with a compromised immune system, the appearance of resistant fungi, and infections by unusual
yeasts. The search for new molecular targets for antifungals has generated considerable research,
especially using modern omics methods (genomics, genome-wide collections of mutants, and proteomics)
and bioinformatics approaches. Recently, micro- and nanoscale approaches have been introduced in
antifungal drug discovery. Microfluidic platforms have been developed, since they have a number
of advantages compared to traditional multiwell-plate screening, such as low reagent consumption,
the manipulation of a large number of cells simultaneously and independently, and ease of integrating
numerous analytical standard operations and large-scale integration. Automated high-throughput
antifungal drug screening is achievable by massive parallel processing. Various microfluidic antimicrobial
susceptibility testing (AST) methods have been developed, since they can provide the result in a short
time-frame, which is necessary for personalized medicine in the clinic. New nanosensors, based on
detecting the nanomotions of cells, have been developed to further decrease the time to test antifungal
susceptibility to a few minutes. Finally, nanoparticles (especially, silver nanoparticles) that demonstrated
antifungal activity are reviewed.
Keywords: antifungal drug discovery; microfluidics; nanobiotechnology; omics-based approaches;
antifungal susceptibility testing; nanomotion detection; nanoparticles
1. Introduction
Fungal infections are an extremely important health problem. Fungi infect about 1.2 billion
people every year, yet their contribution to the global burden of disease is largely unrecognised [1,2].
Over 600 different fungi have been reported to infect humans. Most are “relatively” minor infections,
but millions contract diseases that kill at least as many people as tuberculosis or malaria. More than
300 million people are affected by serious fungal infections worldwide. Invasive fungal infections are
responsible for about 1.5 million deaths per year. Fungi are present everywhere in our environment
and are, usually, harmless for people with a normal immune system. Fungal infections can be topical
and local, such as infections on the skin or in the vaginal tract. Systemic infections arise when the
fungi enter and proliferate in the bloodstream. Systemic fungal infections affect people with an
altered immune system due to medical interventions (such as cancer therapy, organ transplantation,
and immune-modulatory medications), immunosuppressive diseases (such as Acquired Immune
Deficiency Syndrome (AIDS)) [3], or malnutrition (under- and overnutrition) [4–6].
The choice of available antifungal drugs to treat invasive fungal infections is limited, since
only three structural classes of compounds are available, i.e., polyenes, azoles, and echinocandins.
Antifungal therapy has become progressively more effective since the 1990s, however, no new
antifungal classes have been reported since 2006 [7]. Current antifungal drugs show some limitations:
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Amphothericin B (a polyene antibiotic) displays a considerable toxicity and undesirable side
effects [8,9], issues with pharmacokinetic properties (such as a short half-life of echinocandins)
and activity spectrum, a small number of targets [10,11], and they can interact with other drugs,
such as chemotherapy agents and immunosuppressants [12,13]. The last approved antifungal (i.e.,
anidulafungin) by the European Medicines Agency and the Food and Drug Administration (FDA)
dates back to 2006 [14]. There is an urgent need for safer and more effective antifungal drugs. Multiple
types of antifungal compounds are in clinical development and these new agents have been recently
reviewed [15–17].
Over the last 20 years, several approaches to antifungal discovery have been explored.
The traditional approach seeks, first, to identify active compounds from large compound libraries
using a panel of fungal pathogens in standardised assays when possible. In the genetic, genomic, or
bioinformatics approach, the objective is, initially, to identify broadly represented targets in fungal
pathogens and non-pathogens [18]. In this “target-centric” genomic approach, up-front genetic,
bioinformatics, and biochemical target prioritisation is performed and, subsequently, an in vitro-based
screening of individual targets is achieved. However, an exceedingly high rate of failure has been
observed when applying this approach [19]. Additionally, not all bioactive compounds act through
a target-specific mechanism of action (MoA). Various compounds act non-selectively as alkylating
agents, intercalators, detergents, etc. Therefore, an integrated approach has been recently proposed for
antimicrobial lead discovery that is rooted in empirical whole-cell screening for small molecules with
intrinsic bioactivity whose MoA may be determined using a variety of forward or reverse genomic
platforms to identify and, subsequently, validate their target [20]. In this “compound-centric” strategy,
it is proposed to use existing genetic methods to evaluate the therapeutic effect of inactivating the target
(both in vitro and in vivo). These methods often use the principles of genetic interaction, relying on the
idea of genetic modifiers (enhancers or suppressors) to generate target hypotheses. Direct biochemical
methods or computational inference have also been used for target identification. In many cases,
however, a combination of approaches may be required to fully characterise on-target and off-target
effects, and understand the mechanisms of small-molecule actions [21].
Recently, micro- and nanoscale approaches have been introduced in the field of antifungal drug
discovery. In this paper, microfluidic approaches for antifungal screening and antifungal susceptibility
testing (AFST), nanosensor development for AFST, and antifungal nanoparticles are reviewed.
2. Emerging Fungal Diseases and Antifungal Drugs
The epidemiology of invasive fungal infection is evolving [22–25]. A growing population of
immunosuppressed patients have been diagnosed with invasive fungal infections. The epidemiology
of candida infections has shifted over the last decade [26]. Non-albicans Candida species, with a reduced
susceptibility to antifungals, are becoming more and more responsible for invasive candidiasis [27].
Several species, such as Candida glabrata and C. krusei, which are less susceptible to azole antifungal
therapy, are increasing in some settings. C. auris has emerged in hospitals as a global concern, since the
strains demonstrated multidrug resistance. Trichosporon species infections are the second most common
cause of fungaemia in patients with haematological malignant disease and they were the third most
commonly isolated non-candida species from patients in the ARTEMIS Global Antifungal Surveillance
Program [28]. These species show resistance to amphotericin and echinocandins. Rhodotorula species
are emerging opportunistic yeasts that are responsible for catheter-related fungaemia and sepsis, and
invasive infections, particularly in immunosuppressed or -compromised patients [24]. The incidence
of infections with non-neoformans crytococci has increased over the past 40 years, especially in patients
with advanced HIV infection or cancer who are undergoing transplant [29]. Since the 1990s, there have
been a growing number of reports about Saccharomyces cerevisiae invasive infections and novel strains
continue to be identified [24,30,31].
Aspergillus species have, historically, been one of the most common causative organisms associated
with invasive mould diseases [32]. Aspergillus fumigatus species were responsible for most of infections.
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Recently, the epidemiology has changed towards non-A. fumigatus species and other moulds, such as
Zygomycetes [33–36], Fusarium [37,38], and Scedosporium [38,39] species. This is due to the occurrence
of azole resistant Aspergillus species [40,41].
Antifungal development is challenging, since, apart from the fungal cell wall, fungi are
metabolically similar to mammalian cells and, therefore, offer few pathogen-specific targets [42].
As explained above, only three molecular classes that target three different fungal metabolic pathways
are commonly used in clinical practice to treat, essentially, systemic fungal infections: Polyenes, azoles,
and echinocandins (Table 1) [43]. The fluoropyrimidine analog 5-fluorocystosine is also used, but only
in combination with amphotericin B.
Table 1. Overview of the mostly used antifungal agents, mechanism of action (MoA), and spectrum of
activity [43–50].
Class Compound MoA Spectrum of Activity Comment
Polyenes
Amphotericin B
Selective binding to ergosterol
cause the formation of pores in
the membrane.












indirectly affects action of
many drugs.
Nystatin/Nyotran
Selective binding to ergosterol
cause the formation of pores in
the membrane.
Candidiasis Nyotran is a liposomal formulationof nystatin with lowered toxicity.
Natamycin









Selective inhibition of fungal
cytochrome P450-dependent
lanosterol-14-α-demethylase.






Fluconazole resistant C. albicans and
non-albicans strains increasing.
Itraconazole




P. brasiliensis, H. capsulatum,
Blastomyces dermatitidis,
Aspergillus fumigatus, A. niger,
Penicillium marneffei.
Better than fluconazole in the
treatment of cocciodioido-mycosis,
not reaching the central nervous
system; numerous drug interactions
due to inhibition of CYP 3A4.
Voriconazole




C. krusei, S. cerevisiae.
More potent than fluconazole; very
rapid metabolism in children;
numerous drug interactions due to
inhibition of CYP 3A4.
Econazole






Is an immidazole antifungal for the
treatment of tinea pedis and crusis,
pityriasis versicolor.
Tioconazole
Selective inhibition of fungal
cytochrome P450-dependent
lanosterol-14-α-demethylase.
C. albicans, Trichophyton sp.,
Epidermophyton sp.
Is an immidazole antifungal for
topical treatment of superficial
mycoses (ringworm, jock itch,
athlete’s foot, tinea versicolor.
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Table 1. Cont.
Class Compound MoA Spectrum of Activity Comment
Echinocandins
Caspofungin Fungal β-1,3-glucansynthase inhibitors.
Candida species,
Aspergillus species.
Fungicidal for Candida, fungistatic
for Aspergillus; modest efficacy as
first-line agent for invasive
aspergillosis; intravenous
formulation only; interacts with
ciclosporin and rifampicin.
Anidulafungin Fungal β-1,3-glucansynthase inhibitors.
Candida species,
Aspergillus species.
Fungicidal for Candida, fungistatic
for Aspergillus; licensed for the
treatment of invasive and
esophageal candidiasis.
Micafungin Fungal β-1,3-glucansynthase inhibitors.
Candida species,
Aspergillus species.
Fungicidal for Candida, fungistatic
for Aspergillus; licensed invasive
and esophageal candidiasis.
5-Fluoropyrimidine
5-Fluorocystosine Selective conversion of toxicintermediate (5-fluorouridine).
Cryptococcosis, candidiasis,
chromoblastomycosis; high MIC




5-Fluorocystosine is always used in
combination with amphotericin B.
Recently, a lot of effort has also been made in analysing the antifungal action of natural compounds
or natural bioactive compounds. The discovered natural antifungal derivatives or compounds derived
from natural origins have been recently reviewed [17,51]. Some examples of these compounds
include chitosan [52]; herbal compounds, such as thymol, carvacrol, eugenol, and menthol [53];
and extracts from plants, such as Hypericum carinatum [54], Stenachaenium megapotamicum [55], and
Acca sellowiana [56].
3. Omics-Based Antifungal Drug Discovery Approaches
The traditional approach seeks, first, to identify active compounds (generally from large libraries
of synthetic small molecules or natural products) that inhibit the growth of the fungus. The most
commonly used assay to identify antifungal leads is liquid growth inhibition assay in which microbial
growth is measured by optical density (OD) of the culture. These assays have some limitations, such
as, sometimes, a poor correlation between growth and OD for fungi that grow as filaments, and
these assays are unable to distinguish between molecules that inhibit growth (fungistatic) from those
that kill the organism (fungicidal), a feature that is very important for the treatment of some fungi
(e.g., Cryptococcus) [57]. Recently, cell viability screening assays based on other readouts have been
developed. The most widely adopted approach is the use of the dyes, Alamar Blue and tetrazolium
salt (XTT), as reporters for metabolic activity. These dyes are converted to fluorescent molecules when
metabolised by viable molecules and can be used for high-throughput multiwell screening [58,59].
The dye, resazurin, was used to develop an assay for high-throughput screening of A. fumigatus [60].
An Alamar-Blue-based high-throughput protocol was devised to identify molecules with fungicidal
activity against C. neoformans [61]. A second type of viability assay that was recently developed is
based on the detection of extracellular adenylate kinase (AK) as a reporter of cell lysis [62]. AK is a
conserved enzyme that has been used as a cytotoxicity reporter in mammalian cell culture assays and
as a reporter of brewing yeast autolysis in the beverage industry [63].
Another approach is referred to as genetic, genomic, or bioinformatics in which the objective
is, initially, to identify broadly represented targets in fungal pathogens and non-pathogens.
The operational code for this strategy consists of three basic rules for identifying potential targets:
(i) A bioinformatics-driven approach is used to identify pathogen-specific genes with the desired
conservation and spectrum, and the absence of a human ortholog; (ii) genetic analyses are performed to
confirm that loss-of-function mutations result in a nonviable growth phenotype and/or a nonvirulent
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phenotype under standard laboratory conditions and/or a nonvirulent phenotype in a relevant animal
model of infection; and (iii) there should be some evidence, derived from sequence, structure, or
biochemical information that the target is druggable [64]. This operational code was used to guide
genomic and target-based antimicrobial discovery. Forward and reverse chemical-genetic methods
have been used to identify the target of drug-like bioactive compounds and MoA. Target-based
approaches have been pursued using high-throughput screening for inhibitor of enzymes and/or
proteins that perform essential functions in microbes. Molecular target-based screening has provided
mediocre to poor results in the field of anti-infective drug discovery, suggesting that cell-based
screening for antimicrobials remains the most effective strategy [19]. Gene knockout microorganisms
and small molecules with well-defined mechanisms can each be used to alter the functions of putative
targets, uncovering dependencies on activity. Reverse chemical screens that exploit genome-wide
collections of mutants have been employed to map susceptibility phenotypes to specific genes by
systematically screening antimicrobial agents against a defined (ideally) comprehensive mutant
collection [20]. Mating of laboratory and wild yeast strains can reveal patterns of small-molecule
sensitivity with specific loci [65]. In another method, molecularly barcoded libraries of open reading
frames have been used to detect small-molecule-resistant clones that are then identified by microarray
analysis [66].
A proteomic profiling approach, based on two-dimensional difference gel electrophoresis and
mass spectrometric identification of the proteins, has been used to predict the target protein of small
molecules of interest [67]. It was demonstrated that this proteomic profiling system could discriminate
small molecules by their mechanism of action. Omics methods have also been used successfully
to identify the MoA of compounds that were discovered using traditional screening approaches.
A key illustrative case is the discovery of the orotomide F901318 compound [68]. A combination
of genetic and biochemical approaches revealed the target of F901318 in A. fumigatus, which was
initially discovered in a high-throughput screen of compound libraries. It was found that F901318
acts via the inhibition of the pyrimidine biosynthesis enzyme, dihydroorotate dehydrogenase, in a
fungal-specific manner.
Although only around 1100 of the 6000 genes of S. cerevisiae are essential under nutrient-rich growth
conditions [69], almost all genes become essential in specific genetic backgrounds in which another
non-essential gene has been deleted or otherwise attenuated, an effect termed synthetic lethality [70].
Genome-scale surveys suggest that over 200,000 binary synthetic lethal gene combinations dominate
the yeast genetic landscape [71]. The genetic buffering phenomenon is also manifested as a phalanx of
differential chemical-genetic interactions in the presence of sublethal doses of bioactive compounds [72].
These observations highlight the inherent redundancy of genetic networks and frame the problem of
interdicting network functions with single agent therapeutics [73]. This genetic network organisation
suggests that judicious combinations of small molecule inhibitors of both essential and non-essential
targets may elicit additive or synergistic effects on cell growth [74,75]. Compounds that enhance the
activity of known agents in yeasts have been identified by small molecule library screens [76–79].
Direct tests of synergistic compounds have successfully yielded combinations that are active against
pathogenic fungi, such as the combination of fluconazole with chemical inhibitors (such as 17-AAG and
17-DMAG) of Hsp90 [80], calcineurin (such as miconazole, ketoconazole), or adenosine diphosphate
(ADP) ribosylation factor (ARF) (such as brefeldin A [81], the antibiotic polymyxin B [78]), and
compounds selected from an off-patent drugs library [79]. Combinatorial antifungal therapies
have many advantages, including a decrease in the rate of selection of resistant strains, a lower
required dosage of individual drugs, a decrease in host toxicity, and enhanced antifungal activity [82].
Syncretic combinations of drugs with improved antifungal properties can be readily identified in both
model fungal species and highly pathogenic clinical isolates [83]. Additionally, it was shown that
synergistic combinations usually yield enhanced selectivity without adverse side effects [84].
These, recently developed, omics-based approaches require expensive, automated, robotic
screening platforms when applied in high throughput. Additionally, these platforms are usually
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based on multiwell screening, which has some limitations. As discussed in the next section, further
improvements can be achieved by integrating these methods in microfluidic screening platforms.
4. Micro- and Nanoscale Approaches
4.1. Microfluidic High-Throughput Antifungal Drug Discovery
Growing cells in 96-, 384-, or 1536-well plates has miniaturised cell assays for drug discovery.
These experiments with multiwell plates are typically integrated in a robotic analysis platform.
Major drawbacks of robotic platforms are the expense of the instrumentation, the cost of experimental
consumables, the systems are closed (no flow through of reagents or cell culture medium), and
still a relatively high consumption of reagents compared to recent developed microfluidic chips.
Additionally, as cell collections are growing, there is a need to further miniaturise the assays to increase
the parallelism of analyses.
In microfluidic lab-on-a-chips, fluids are manipulated at the micrometer length scale [85].
Reducing the scale evidently reduces the reagent consumption and, consequently, the cost to perform
assays, which becomes significant for high-throughput drug screening. The physics at micro/nano
scale are exploited in microfluidic chip designs for drug discovery. Other physical phenomena
dominate at this small length scale compared to the macroscale [86]. Fluid flow in microchannels
is characterized by a low Reynolds number (a dimensional criterion that determines the relative
importance of inertial and viscous effects). The dominant role of viscous forces results in laminar flow
behavior and mass transport by diffusion between two adjacent fluids, resulting in the generation of
stable concentration gradients [87]. Also, fast media and temperature changes can be obtained using
the laminar flow [88]. Mass transport by diffusion becomes a fast mixing method when the length
scale is reduced in small channels or wells. It has been demonstrated that, at these small length scales,
time-resolved reactions have been conducted with millisecond resolution due to the extremely rapid
diffusive mixing [89,90]. Surface tension plays an important role in the formation of small droplet
emulsions in immiscible fluids in microfluidic channels [86]. Surface tension and viscous stresses
destabilize the interface and create droplets when water is injected into a stream of oil at a T-junction
or two perpendicular crossing microchannels [91]. Based on this principle, droplet-based microfluidic
platforms have been developed to encapsulate and screen single cells [92].
Due to the ease of controlling the cellular environment, microfluidic technology has been used to
perturb cellular physiology in screening arrays. Additionally, the cell number and density of a given
area or volume can be controlled, which allows monitoring of a high spatial and temporal resolution
and observation of the dynamic behavior of many cells [93,94]. Parallellisation of experimental
conditions and automatization in microfluidic chips has resulted in designs for high-throughput cell
screening [95], such as living cell microarrays [96–101]. Microfluidic parallelization and single-cell
monitoring allows the measurement and averaging of parameters on hundreds of individual cells,
compared to measuring parameters of a whole cell population. New insights can be obtained by
observing single cells, such as the monitoring of certain classes of proteins, using fluorescently tagged
proteins [102,103] and give information about the cell-to-cell variation in a heterogeneous microbial
population [104–106]. Automation of microfluidic cell culture systems also leads to standardized
manipulation and monitoring, which allows the perfect timing of protocols to characterize dynamic
processes at high temporal resolution to be performed [94].
Cellular microarray platforms have been developed for high-throughput antifungal drug
discovery based on the screening of nanoliter biofilms that are created in hydrogels (Table 2).
Robotic printing is used to fabricate the cellular arrays. The formation of biofilms complicates antifungal
therapy, since the ability of fungal cells to form biofilms is an important reason for the emergence of
severe resistance to most clinically available antifungal agents [107–110]. A better understanding of
fungal biofilms provides new opportunities for the development of urgently needed novel antifungal
agents and strategies.
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Table 2. Examples of microfluidic platforms for high-throughput antifungal drug discovery.
High-Throughput
Technology
Application Microorganism Characteristics References
Cellular microarray Antifungal biofilm screening Candida albicans
Cells robotically printed,
768 (48 × 16 array) cultures of
50 nL biofilms in collagen.
[111,112]
Cellular microarray Antifungal biofilm screening C. albicans
Cells robotically printed,
1200 (60 × 20 array) cultures of
30 nL biofilms in alginate.
[113]




Robotically printing of mono-
and polymicrobial biofilms,
576 (48 × 12 array) cultures of
30 nL biofilms in alginate.
[114]
Droplet microfluidics Antifungal drug screening Phytophthora sojae
The plant pathogen spores and
the drug were encapsulated in
liquid droplets. Phenotypic




4.2. Microfluidics for Antifungal Susceptibility Testing
Resistant microbial infections are becoming a major threat to public health, causing increasing
mortality worldwide. The fast emergence of multiresistant pathogens is caused by extensive, and
sometimes unnecessary, use of antimicrobials and the lack of interest in developing new variants.
The cost of antimicrobial resistance (AMR) is projected to increase significantly as some models predict
a rise in global casualties from the present figure of one million to 10 million in 2050 [116]. A survey of
antimicrobial susceptibility test (AST) methods available demonstrated a need for new approaches
that would enable rapid, inexpensive, and sensitive tests that can quickly provide physicians with
antibiotic profiles [117]. A quick diagnostic method is necessary to prescribe a patient that is infected
by a life-threatening microbe with an effective antimicrobial [118]. AST is widely applied to determine
antimicrobial resistance profiles of the microbial isolates and to help in the selection of an antimicrobial
treatment option [117,119–121]. Currently, AST is usually not performed in the clinic, but in a clinical
microbiology lab, which necessitates transportation of the patient samples [122]. Current susceptibility
tests, that are based on cell culturing of the pathogen, can take several days (especially for slow growing
microbes) and extends the time to make the correct diagnosis and decisions for appropriate and
effective antimicrobial therapy. This leads to increased patient mortality and the use of broad-spectrum
antimicrobials that promote resistance [120]. To survive this evolutionary war against microbial
pathogens, we must pursue technologies that can rapidly perform AST to enable personalized therapies
(narrow-spectrum antimicrobial administration) at the earliest possible treatment stage [122].
Standard antifungal susceptibility (AFST) methods rely on measuring fungal growth in the
presence of antifungals over a few days. The broth microdilution (BMD) is the standard method
for the evaluation of susceptibility to antifungal agents in Candida species [123–126]. Standardized
micro-dilution-based procedures by the Clinical and Laboratory Standards Institute (CLSI) and the
European Committee on Antibiotic Susceptibility Testing (EUCAST) are universally accepted for
performing AFST [127]. However, these procedures are complex, time-consuming, and not intended
for routine use.
Commercially available tests, such as Sensititre YeastOne (broth microdilution method),
Etest (agar-based disk diffusion method), and the fully automated Vitek 2 (broth microdilution
method) yeast susceptibility system, all easy-to-use modifications from CLSI/EUCAST reference
methods, are widely used for testing antifungal susceptibility of relevant Candida and Aspergillus
species [10]. New diagnostic approaches based on emerging technologies, such as flow cytometry,
MALDI-TOF mass spectroscopy, and isothermal microcalorimetry, have been developed to expand, and
potentially improve, the capability of the clinical microbiology laboratory to yield AFST results [126].
Flow cytometry is used to determine the effect of an antifungal compound by measuring changes in the
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viability of fungal cells that are fluorescently labeled [128,129]. A simple and rapid AFST assay based
on MALDI-TOF was developed [130]. This approach facilitated the discrimination of the susceptible
and resistant isolates of C. albicans after a 3-h incubation in the presence of “breakpoint” level drug
concentrations of the echinocandin caspofungin (CSF). A microcalorimetry-based AFST assay has
been developed for real-time susceptibility testing of Aspergillus spp. [131]. The method is based on
measuring changes in growth-related heat production in the presence of the antifungal compound.
Semi-automated susceptibility systems (such as VITEK and MicroScan) decrease the turn-around-time
and operator touch-time (culture and colony isolation are still required) compared to traditional
culture-based methods, but can add significant cost to the tests [132]. The fastest test still requires 9 h and,
therefore, these semi-automated systems do not provide information in time to influence initial treatment
decisions [133,134].
Since microfluidics promises several advantages over existing macro-scale methods, several
microfluidic platforms that can perform rapid antimicrobial susceptibility tests have been developed
during the last years (Table 3) [132,135]. The recent development of microfluidic platforms was mostly
focused on devices for antibiotics susceptibility testing and much less on antifungals susceptibility
testing, although the same designs could, usually, be used for both (e.g., see [136,137]). Most systems
rely on microscopic transmission or fluorescence observation of cells to quantify the effect of the
antimicrobial on the cell growth or viability. The microorganisms are confined to a small volume (wells,
channels, chambers, or droplets). In many systems, the cells are immobilized in a hydrogel, such as
agarose or alginate (Table 3) (Figure 1).
Table 3. Examples of microfluidic platforms for antimicrobial susceptibility testing.
Microorganism Measurement Principle Description Reference
Fungi
Candida strains Fluorescence-based distinctionbetween living and dead cells.
Cell Chip kit 1 used as cell sorter and the
determination of fluorescence histograms
of previously labelled cells.
[138]
Candida albicans ImmunosorbentATP-bioluminescence assay.
The microfluidic device employs a
fiberglass membrane sandwiched
between two polypropylene components,
with capture antibodies immobilised on
the membrane. Cells immobilised in
alginate hydrogel.
[136]
Saccharomyces cerevisiae Fluorescence staining and imagingafter incubation.
Cell seeding and diffusive medium
supply is provided by phase-guide




Escherichia coli Optical imaging of single cell growth(number of cells).
Growth of cells in channels, with a large
surface-to-volume ratio. [139]
E. coli
Magnetic bead rotation, which is
inversely proportional to
bacterial mass.
Droplet microfluidics where single cells
are entrapped in liquid drops. [140]
E. coli Optical imaging of single cell growth(number of cells).
Individual cells grow in gas permeable
(PDMS) microchannels, with dimensions
comparable to a single cell.
[141]
E. coli Fluorescence imaging of cells thatexpress green fluorescent protein.
Growth of cells in 12 sets of quadruplicate
microfluidic chambers. Quantification of





spectroscopy of pH-sensitive chitosan
hydrogel measured the accumulation
of metabolic products.





Growth in microfluidic chambers. [144]
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Table 3. Cont.
Microorganism Measurement Principle Description Reference
Bacteria
E. coli Optical imaging.
The standard broth microdilution method
was miniaturised in a microfluidic chip
that generates an antibiotic concentration
gradient and delivers
antibiotic-containing culture media to
eight 30-nL chambers for cell culture.
[145]
E. coli Fluorescence imaging.
The microfluidic chip allows the carrying
out of commonly executed antibiotic







The use of biofunctionalised silicon
micropillar arrays to provide both a
preferable solid-liquid interface for
bacteria networking and a simultaneous
transducing element that monitors the
response of bacteria when exposed to
chosen antibiotics in real time.
[147]
E. coli Spectral absorbance ofcell suspensions.
An automated linear gradient generator
based on centrifugal microfluidics. [148]
E. coli, Nitrosomas europaea Optical imaging of single cell growth(number of cells).
The cells grow in a layer of agarose upon
which a gradient of the antibiotic
is applied.
[149]
Enterobacter cloacae, E. coli,




A solid-phase microwell growth surface
in a 384-well plate format was used, with
inkjet printing–based application of both
antimicrobials and bacteria at any
desired concentrations.
[150]
Enterococcus faecalis, E. coli Fluorescence staining and imagingafter incubation.
Cell seeding and diffusive medium
supply is provided by phase-guide
technology, enabling operation of
continuous culturing.
[137]
Mycobacterium tuberculosis Optical imaging of single cell growth(number of cells).
Cells were immobilized in an agarose
matrix, which was molded in a
microfluidic chip.
[151]
Pseudomonas aeruginosa Fluorescence imaging ofGFP-expressing cells.
The microfluidic chip generates a
logarithmic concentration gradient
through semidirect dilution in a zero-flow
condition and cells grow in
nanoliter reactors.
[135]
Staphylococcus aureus Fluorescence imaging ofviability indicator.
Stochastic confinement of individual cells
into liquid plugs (droplet microfluidics);
distinction between sensitive and
resistant bacteria.
[152]
S. aureus Optical imaging of single cell growth(number of cells).
Antibiotics diffuse into a microfluidic
channel containing the cells. [153]
S. aureus Fluorescence imaging for dead cells(rates of killing).
Cells are covalently bound to the bottom
of the channels and fluid flow shear stress
activation of pathways that are targets
of antibiotics.
[154]
S. aureus Optical imaging of single cell growth(number of cells). Chip with 32 individual fluidic channels. [155]
S. aureus, E. coli, K. pneumoniae,
P. aeroginosa
Optical imaging of single cell growth
(number of cells).
Antibiotics diffuse into a microfluidic
agarose channels in 96-well format. [156]
S. aureus, S. epidermitis,
S. saprophyticus, E. coli,
K. pneumonia, P. aeruginosa,




The microfluidic device employs a
fiberglass membrane sandwiched
between two polypropylene components,
with capture antibodies immobilised on
the membrane. Cells immobilised in
alginate hydrogel.
[136]
Salmonella thyphimurium, E. coli,
S. aureus
Optical imaging of single cell growth
(number of cells).
Cells immobilised in agarose with a
gradient of the antibiotic in the gel slab. [157]
P. aeruginosa Optical imaging of single cell growth(number of cells). Growth of cells in four parallel channels. [158]
1 Agilent Technologies.
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Figure 1. (A) An automated linear concentration gradient generator based on centrifugal microfluidics
for antibiotic susceptibility testing (AST). The operation is based on the use of multi-layered
microfluidics in which individual fluidic samples to be mixed together are stored and metered in
their respective layers before, finally, being transferred to a mixing chamber. Reprinted with permission
from [148]; (B) (a) The microfluidic microchip design: Black and red channels represent 149-μm and
4-μm tall features, respectively; (b) A photograph of the fabricated PDMS chip. Blue food dye solution
and water were injected to upper (1) and lower (2) inlet ports. (a) Reprinted with permission from [145];
(C) Schematic diagram of the AST process for the microfluidic agarose channel (MAC) system. (a) The
MAC chip was fabricated with PDMS on glass. An agarose–bacteria mixture solution was injected
into the center of the chip, which flowed synchronously into the six main channels. Each interface
between the agarose with the bacteria and antibiotic solutions was monitored microscopically to
analyse bacterial cell growth. (b) (1) The empty channel before AST. (2) The bacteria were mixed with
agarose and then injected into the main channels. (3) A sharp interface was generated due to the
anchors and then liquid medium with different concentrations of antibiotic. (4) Time-lapse microscopic
observation of a bacterial cell. Reprinted with permission from [153]; (D) The structure of the AST
microfluidic device for MIC determination of five drugs. (a) Design. (b) Actual image. (c) Precise
structure of one set of fluids. (d) Microscopic image of Pseudomonas aeruginosa grown in the presence of
piperacillin. Reprinted with permission from [158]; (E) Stochastic confinement of bacteria into plugs.
(a) Schematic drawing illustrates the increase in cell density, resulting from the stochastic confinement
of an individual bacterium in a nanoliter-sized plug. (b) Screening of many antibiotics against the same
bacterial sample. Antibiotics: Ampicillin (AMP), levofloxacin (LVF), vancomycin (VCN), and oxacillin
(OXA). Reprinted with permission from [152].
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4.3. Nanomotion Analysis for Evaluating Antifungal Suscessibility
Recently, very new sensitive sensor technologies based on microcantilevers have been
developed [159–161]. Nanomechanical oscillators are being used for the detection of very small
masses [162,163], for measuring buoyant mass, and determining the “instantaneous” growth rates
of individual cells [164] for the quantitative time-resolved membrane protein (vancomycin)—ligand
(mucopeptides) on cantilever arrays with 10 nM sensitivity and at clinically relevant concentrations in
blood serum [165]. Cantilever nanosensors have been used to measure mass differences in the pico- to
femtogram ranges in air [166] and liquid [167,168]. Many of the available systems are limited by the
need to perform the measurements in air or in a humid environment [161].
Microcantilevers have been explored as nanosensors for living cell studies, since they offer many
advantages, such as being highly sensitive, selective, label-free, performed in real time, and provide
in situ detection capabilities [169]. Single cell detection and monitoring on the cantilever sensor
has been reported for S. cerevisiae cells [164,170,171], E. coli [164,171,172], Bacillus subtilis [164,172],
Enterococcus faecalis [171], HeLa cells [173], mouse lymphoblasts [164], and human lung carcinoma
and mouse lymphocytic leukemia cells [171,174], and mouse and human T cells [171]. Cell growth
detection has been demonstrated by monitoring resonance frequency changes of cantilevers as the
mass increases from immobilized S. cerevisiae and fungal A. niger spores on the surface of the cantilevers
in humid air [175]. S. cerevisiae cells were deposited onto the cantilever surface and its bending as a
function of time and corresponded to the yeast growth behaviour [169]. Recently, serial microfluidic
mass resonator arrays were used to measure single-cell growth of yeast, bacterial and mammalian cells
in liquid and a higher throughput [171].
Recently, a nanomechanical detector, that can be used to assess the effects of chemicals on living
organisms in a timeframe of minutes, was developed. In this technique, the living microorganisms are
adsorbed to the surface of a nanomechanical sensor, i.e., an AFM cantilever, and its fluctuations are
measured as a function of time (Figure 2). This approach requires only a few minutes without
cell growth, since the decrease in cell activity in the presence of the antimicrobial is measured.
Moreover, it is a label-free technique. These are major advantages compared to current methods.
Antimicrobials can be introduced in the measuring chamber, allowing a rapid identification of the
antimicrobial to which the microorganism is susceptible. The sensor position detection is similar to
the one used in Atomic Force Microscopy (AFM): A laser beam is focused onto the sensor (cantilever)
and ends its path onto a multisegment photodiode. Numerous proof-of-concept experiments have
been performed involving several species of bacteria and fungi. By comparing this method with the
traditional techniques in double-blind experiments, a success rate close to 90% could be achieved [176].
The variation of the nanovibration signal is directly proportional to the metabolic activity of the
microbial cell. It allowed estimating with unpreceded speed (15 min per ampicillin dose), the minimum
inhibitory (MIC) and bactericidal concentrations (MBC) for the effect of the antibiotic ampicillin on
E. coli [177]. The high sensitivity of the nanosensor allowed differentiation between bacteriostatic
(kanamycin) and bactericidal (ampicillin) effects when exposed to a resistant E. coli. The high sensitivity
of the nanosensor made it possible to differentiate between bacteriostatic and bactericidal effects.
Recently, this method was successfully applied to blood culture pellets to determine the antibiotic
susceptibility against agents of bloodstream infection [178]. AFM-nanomotion detection (NMD) has
also been applied for AFST, where the effect of a low (10 μg/mL) and high (40 μg/mL) caspofungin
concentration on C. albicans was evaluated [179]. It was recently demonstrated that AFM-cantilever
NMD is so sensitive that single-cell activities of S. cerevisiae cells could be detected [179], and even cell
cycle progression could be observed [180].
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Figure 2. (A) Outline of experimental setup and description of experiments. (a) Schematics of
nanomotion detector setup with a cantilever sensor; laser beam is focused on the surface of the
sensor and reflection is used to monitor movements of the cantilever. (b) Representation of a typical
nanomotion susceptibility test. When microorganisms are not attached to the sensor, fluctuations are
driven only by thermal motion and are relatively low. After attachment of living cells, fluctuations
are linked to their metabolic activity and are high. Finally, after exposure to an antimicrobial drug,
the cells are nonviable and fluctuations return to low levels. Reprinted with permission from [178].
(B) (a) C. albicans deposited onto a cantilever. (b) Reprinted with permission from [161].
4.4. Antifungal Nanoparticles
Due to the development of antimicrobial resistance, pharmaceutical companies and researchers
are searching for new antimicrobial agents. Nanoscale materials have emerged as novel antimicrobial
agents, owing to their high surface area to volume ratio and their unique chemical and physical
properties [181,182]. By definition, nanoparticles are structures that have dimensions in the
1–100 nm [183]. Silver nanoparticles (Ag-NPs) are one of the most commonly used nanomaterials in
consumer and medical products because of their antimicrobial activity [184,185]. It is increasingly
used in a variety of both medical and consumer products, resulting in an increase in human
exposure [183,186]. A large number of in vitro studies indicate that Ag-NPs are also toxic to mammalian
cells derived from the skin, liver, lung, brain, vascular system, reproductive organs, and the immune
system. Although significant progress has been achieved on the elucidation of the antimicrobial
mechanism of silver nanoparticles, the exact mechanism of action is still not completely known [187].
It has been demonstrated that non-cytotoxic doses of Ag-NPs could induce genes that are associated
with cell cycle progression [188,189] and apoptosis in human hepatoma cells [189]. DNA damage by
Ag-NPs in mammalian cells has also been reported [188,190]. The mechanisms for Ag-NP induced
toxicity include the effects of this particle on cell membranes, mitochondria, and genetic material. It has
been recently demonstrated that bacteria (E. coli, P. aeruginosa) can also develop resistance to silver
nanoparticles after repeated exposure [191]. The biosynthesis of silver nanoparticles is now considered
to be the most environmentally friendly and cost-effective method [185]. It can be achieved using a
variety of organisms, such as by the fungi, A. flavus [185], A. terreus [192], Arthroderma fulvum [193],
Penicillium fellutanum [194], and P. expansum [192].
Other nanostructures have been discovered that also show antifungal activity. It was demonstrated
that cationic terephthalamide-bisurea molecules showed excellent microbial selectivity, with
minimal host toxicity [195]. The terephthalamide-bisurea recognition motif facilitated spontaneous
supramolecular self-assembly, with the formation of fibres in water. Antifungal activity against
clinically isolated, drug-sensitive, and drug-resistant Cryptococcus neoformans strains was observed.
These antifungal agents showed effectively dispersed C. albicans biofilms and excellent in vivo
biocompatibility. Homogeneously dispersed copper nanoparticles (originating from n-Cu sepiolite
fibres) in soda-lime glass powder showed high antibacterial properties against gram-positive
(Micrococcus luteus) and gram-negative bacteria (E. coli), and antifungal (Issatchenkia orientalis)
activity [196]. The observed high activity of the n-Cu glass powder was explained by the inhibitory
synergistic effect of the Ca2+ lixiviated from the glass on the growth of the cells, since n-Cu sepiolite
had no significant antifungal activity. Another approach of obtaining nanoparticles with antifungal
activity is to immobilize, covalently, the antifungal amphotericin into nanomaterials, such as silica
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nanoparticles [197]. These antifungal nanoparticle conjugates demonstrated fungicidal activity against
several strains of Candida sp., mainly by contact. In addition, they could be reused for up to five cycles
without losing their activity. The results showed that the antifungal nanoparticle conjugates were more
fungistatic and fungicidal than 10 nm colloidal silver.
5. Conclusions
Fungal infections continue to appear as the population of people with an altered immune system
increases. An impaired immune system arises due to medical intervention, immunosuppressive
diseases, or malnutrition. The infections become life-threatening for systemic infections. The therapeutic
options for invasive fungal infections are limited, since a very limited number of structural classes
of drug compounds are available and some demonstrate significant limitations. The discovery
of new antifungals is mostly achieved by the screening of natural or synthetic/semisynthetic
chemical compounds [16,17]. Using the genomics approach, substantial progress has been made
in antifungal drug development for a multitude of potential drug targets [198] and inhibitors [199,200].
Recent advances that could support and refine the antifungal pipeline were focused on elucidating
fungal pathways, targets, and mechanisms of action that could lead to new antifungal therapies;
antifungal compounds and immune strategies currently in development that could become new
antifungal therapies; improved formulations of existing compounds; and the repurposing of drugs
approved for other indications and could show potential antifungal activity [16]
Surely, there is a need for novel antifungal discovery approaches. The current antifungal tools
that are available to tackle the invasive fungal epidemic occurring in clinics and hospitals have
improved, but are still inadequate for use in all patient groups [16]. Recently, micro- and nanoscale
approaches have been introduced in antifungal drug discovery. It has become increasingly clear
in trends in antimicrobial drug discovery that microfluidic approaches will have an increasing
role. The capability of manipulating fluids, flexibility on geometries and materials, manipulation
of a large number of cells simultaneously and independently, and ease of integrating numerous
analytical standard operations and large-scale integration makes microfluidic devices a versatile
tool for antifungal drugs. One of the future challenges lies in the construction of extended cell
microarrays, or single-cell droplet arrays, and integration in the microfluidic chip [100], since the
recently developed bioinformatics approach for antifungal discovery could be further improved by
integrating these methods in a microfluidic screening platform. Living cell arraying methods, based on
closed microchambers arrays in microfluidic bioreactors, could increase throughput significantly
compared to classical multiwell-plate cell assays, with significantly reduced amounts spent on
expensive test reagents, cells, and chemical compounds, and without the need for expensive robotic
multiwell-plate screening facilities.
Significant progress has been made in the development of microfluidic platforms for antimicrobial
susceptibility testing (AST). Recent efforts are focused on the development of AFST methods that
are independent of cell growth and can provide susceptibility results in a very short time frame.
These methods rely on measuring the cell death in the presence of the antifungal. A promising
technique is the AFM-based nanomotion detection, which can give an answer about the susceptibility
in a few minutes. Further parallelization of this method is required to introduce it in the clinic.
Nanoscale materials have emerged as novel antimicrobial agents. One of the most extensively
studied nanoparticles are silver nanoparticles and this is for their antifungal, but also antibacterial
and antiviral, activities. In minute concentrations, it was found not to be toxic to humans and
microorganisms [185]. Further research should focus on a better understanding the toxicity and
determining the exact mechanism of the interaction between nanoparticles and cells.
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